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 Abstract 
 
Protein tyrosine phosphatases represent a family of signalling enzymes with emerging 
therapeutic potential. The cytoplasmic protein tyrosine phosphatase SHP2, encoded by the 
PTPN11 gene, plays a central role in the activation of downstream signalling events at 
multiple growth factor and cytokine receptors, and was the first oncogenic protein tyrosine 
phosphatase to be discovered. Aberrant SHP2 signalling underlies the pathology of 
numerous developmental disorders such as Noonan and LEOPARD syndrome, and is a 
known driver of breast cancer and myeloproliferative disease. To gain a deeper insight into 
ligand interactions with the SHP2 catalytic domain in solution, NMR backbone resonance 
assignments of  the  34  KDa  SHP2  catalytic domain  were  determined  and  utilised  in 
conjunction with 
15
N-
1
H HSQC NMR spectroscopy to map the structurally undisclosed 
 
binding site of the previously reported SHP2 inhibitor, NSC-87877. In addition, use of a 
fragment-based screening approach to accelerate the discovery of novel SHP2 inhibitors 
has enabled the identification of two novel and distinct chemical scaffolds, both of which 
now serve as validated chemical precursors for the development of more potent SHP2 lead 
inhibitors. 
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CHAPTER 1: INTRODUCTION 
 
 
 
 
1.1 Phosphorylation as a key cellular signal 
 
Cells have evolved elaborate mechanisms for continuously surveying their internal and 
external environment, and function by converting these stimuli into a series of chemical 
messages which programme the appropriate cellular response to a particular stimulus. 
Reversible protein phosphorylation plays a central role in this process and is a principal 
mechanism for linking extracellular signal recognition to intracellular signal transduction 
in higher eukaryotes 
[1-6]
. The balance of protein phosphorylation is controlled by the co- 
 
ordinated and reciprocal activities of protein kinases and protein phosphatases which 
function synergistically to maintain homeostatic levels of cellular phosphorylation. In 
higher organisms, approximately one third of the total cellular proteome is phosphorylated, 
mainly on serine, threonine and tyrosine residues 
[7]
. Interestingly, while the dominant 
contribution  to  cellular  phosphorylation  arises  through  serine  and  threonine 
phosphorylation (~98%), tyrosine phosphorylation 
[8]  
comprises a mere 2% of the entire 
phosphoproteome, despite being a fundamental regulatory mechanism underlying a broad 
spectrum of physiological processes 
[9-17]
. In addition to the critical regulation of normal 
cellular physiology, disruption of tyrosine phosphorylation levels through perturbing the 
balance  of  kinase  
[18]    
and  phosphatase  activity  
[19]    
is  a  hallmark  underlying  the 
pathogenesis of numerous human disease states, highlighting the importance of tightly 
regulated tyrosine phosphorylation in both physiological and pathophysiological contexts 
[9, 13, 19]
. Historically, research centred on protein phosphorylation has placed considerable 
focus on the study of protein tyrosine kinases (PTKs). PTKs function by catalysing the 
transfer of a phosphate group onto a particular substrate, and were once considered as the 
2 
 
 
dominant players in shaping signal responses to external stimuli, with the prevailing notion 
suggesting that their opposing catalytic partners, protein tyrosine phosphatases (PTPs), 
functioned  merely as simple “housekeeping” enzymes with indiscriminate mechanisms of 
action and broad substrate specificities 
[20]
. However, the roles of protein tyrosine 
phosphatases are now known to exhibit far greater functional complexity, and along with 
their protein kinase counterparts play equally important roles in shaping and regulating 
cellular signalling responses. Far from being considered merely as passive housekeeping 
enzymes, it is now acutely apparent that protein tyrosine phosphatases are a highly specific 
family of enzymes with significant degrees of spatiotemporal regulation 
[9, 13]
. 
 
1.2 The PTP superfamily 
 
The PTP superfamily is encoded by the largest group of phosphatase genes and are defined 
by the structurally conserved active site-signature motif HCX5R ((H)His, (C)Cys, and 
(R)Arg) in which the cysteine residue functions as a key nucleophile to instigate catalysis. 
The superfamily of PTP genes can be divided into three discrete protein families based on 
the sequence similarities of the PTP domains 
[21]
. These include class I PTPs (107 genes), 
class II PTPs (1 gene), and class III PTPs (3 genes) (Figure 1.1) 
[9]
. The class I PTPs 
 
comprise the large majority of human PTP genes and are divided into the classical, 
phosphotyrosine (pTyr)-specific PTPs and the dual specificity phosphatases (DUSPs). The 
p-Tyr-specific PTPs (37 genes) are further separated into the transmembrane receptor-like 
PTPs (RPTPs) and the intracellular non-receptor-like PTPs (NRPTPs) 
[9, 13, 21]
. The DUSP 
subfamily (~63 genes) are a heterogeneous group of phosphatases exhibiting a greater 
diversity of substrate specificity and generally have poor sequence similarity beyond the 
catalytic signature motif. The DUSP phosphatase subfamily share the same catalytic 
mechanism as the classical PTPs, but the structural architecture of the PTP active site 
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allows these enzymes to accept phosphoserine (pSer)/phosphothreonine (pThr) as well as 
pTyr residues 
[22]
. This group also includes the phosphothreonine pThr/pTyr-specific 
mitogen-activated protein kinase  (MAPK) phosphatases, the atypical pThr/p-Tyr- mRNA- 
specific DUSPs, the phosphoserine (pSer)-specific slingshots, the pTyr-specific 
phosphatases of regenerating liver (PRLs), the pSer/pThr-specific CDC14s, the PTENs 
which exhibit specificity for the 3’-phosphate moiety of the inositol ring component of 
phosphatidylinositol-(3,4,5)-triphosphate, the myotubularin enzymes which catalyse the 
dephosphorylation of both phosphatidylinositol-3-phosphate and phosphatidylinositol-3,5- 
bisphosphate, as well as the inositol 4-phosphatases, which mediate hydrolysis of the 4’- 
phosphate of phosphatidyl inositol-3,4-bisphosphate, inositol-(1,3,4)-trisphosphate, and 
inositol(3,4)-bisphosphate   
[9,  21,  22]
. Global analysis of the structures of class  I PTPs 
suggest that these enzymes emerged from the evolution of a common ancestor based on 
the similarities and conserved features of their respective structural folds 
[20]
. The class II 
family of PTPs appear to conceal a more ancient evolutionary history than their class I 
PTP family counterparts, and comprise a single gene encoding the pTyr-specific low 
molecular weight PTP (LMPTP) 
[23] 
that contains structural similarities to the overall folds 
exhibited by the bacterial arsenate reductases. Class II PTP family members are 
ubiquitously expressed in plants, prokaryotes, and archaea 
[9]
. The class III family of PTPs 
contain the pThr/pTyr-specific CDC25s, which are suggested to have evolved from 
bacterial rhodanese-like enzymes (See Table 1.1 for compilation of all known PTP 
families.) 
[20]
. 
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Figure 1.1 Structural classification of the PTP superfamily. A schematic representation 
of the PTP superfamily. The classical phosphotyrosine-specific PTPs (shown on the left) 
have been further divided into their respective sub-groups: non-transmembrane PTPs and 
receptor-like  PTPs.  The  right  hand  side  represents  the  dual-specificity  phosphatases 
(DSPs). PTP catalytic domains are depicted as large and small ovals for classical PTPs and 
DSPs, respectively. The various signalling modules associated with each phosphatase 
including regulatory and non-catalytic domains are represented in the box (bottom right) 
associated with each phosphatase (Figure taken from 
[24]
). 
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Table 1.1 Genetic classification of the Human Protein Tyrosine Phosphatome 
 
Gene name 
 
A. Class I Cys-based PTPs 
A. 1. Classical PTPs 
A. 1. 1. Transmembrane Classical 
PTPs 
 
1. PTPRA 
2. PTPRB 
3. PTPRC 
4. PTPRD 
5. PTPRE 
6. PTPRF 
7. PTPRG 
8. PTPRH 
9. PTPRJ 
10. PTPRK 
11. PTPRM 
12. PTPRN 
13. PTPRN2 
 
14. PTPRO 
 
15. PTPRQ 
16. PTPRR 
 
17. PTPRS 
18. PTPRT 
19. PTPRU 
 
20. PTPRZ 
 
A. 1.2. Non-receptor PTPs 
 
21. PTPN1 
22. PTPN2 
23. PTPN3 
24. PTPN4 
25. PTPN5 
26. PTPN6 
 
27. PTPN7 
28. PTPN9 
29. PTPN11 
 
30. PTPN12 
 
31. PTPN13 
 
32. PTPN14 
33. PTPN18 
34. PTPN20 
35. PTPN21 
 
36. PTPN22 
37. PTPN23 
 
 
A. 2. DSPs or VH1-like 
A. 2. 1. MKPs 
 
38. DUSP1 
 
39. DUSP2 
40. DUSP4 
41. DUSP5 
42. DUSP6 
43. DUSP7 
44. DUSP8 
45. DUSP9 
46. DUSP10 
47. DUSP16 
48. MK-STYX 
 
A. 2. 2. Atypical DSPs 
 
49. DUSP3 
50. DUSP11 
 
Protein, Synonyms 
 
 
 
 
 
RPTPα 
RPTPβ 
CD45, LCA 
RPTPδ 
RPTPε 
LAR 
RPTPγ 
SAP1 
DEP1, CD148, RPTPη 
RPTPκ 
RPTPμ 
IA-2, Islet cell antigen 
PTPRP, RPTPπ, IA-2β, phogrin 
 
GLEPP1/PTP-U2/PTPRO 
isoforms A/B/C 
PTPS31 
PTP-SL, PCPTP, PTPBR7, 
PC12-PTP1 
RPTPσ 
RPTPρ 
PTPJ/PTP-U1/PTPRomicron 
isoforms 1/2/3 
RPTPς 
 
 
PTP1B 
TCPTP, MPTP, PTP-S 
PTPH1 
PTP-MEG1, TEP 
STEP 
SHP1, PTP1C, SH-PTP1, 
HCP 
HePTP, LCPTP 
PTP-MEG2 
SHP2, SH-PTP2, Syp, 
PTP1D, PTP2C, SH-PTP3 
PTP-PEST, PTP-P19, 
PTPG1 
PTP-BAS, FAP-1, PTP1E, 
RIP, PTPL1, PTP-BL 
PTP36, PEZ, PTPD2 
PTP-HSCF, PTP20, BDP 
TypPTP 
PTPD1, PTP2E, 
PTP-RL10 
LYP, PEP 
HD-PTP, HDPTP, PTP- 
TD14, KIAA1471, 
DKFZP564F0923 
 
 
 
MKP-1, 3CH134, PTPN10, 
erp, CL100/ HVH1 
PAC-1 
MKP-2, hVH2/TYP1 
hVH3/B23 
PYST1, MKP-3/rVH6 
PYST2, B59, MKP-X 
hVH5, M3/6, HB5 
MKP-4, Pyst3 
MKP-5 
MKP-7, MKP-M 
MK-STYX 
 
 
VHR, T-DSP11 
PIR1 
 
Chromosomal location 
 
 
 
 
 
20p13 
12q15-q21 
1q31-q32 
9p23-p24.3 
10q26 
1p34 
3p21-p14 
19q13.4 
11p11.2 
6q22.2-23.1 
18p11.2 
512 2q35-q36.1 
7q36 
 
12p13.3-p13.2 
 
12q21.31 
12q15 
 
19p13.3 
20q12-q13 
1p35.3-p35.1 
 
7q31.3 
 
 
20q13.1-13.2 
18p11.3-11.2 
9q31 
2q14.2 
11p15.1 
12p12-13 
 
1q32.1 
15q23 
12q24.1 
 
7q11.23 
 
4q21.3 
 
1q32.2 
2q21.2 
10q11.22 
14q31.3 
 
1p13.3-p13.1 
3p21.3 
 
 
 
 
 
5q34 
 
2q11 
8p12-p11 
10q25 
12q22-q23 
3p21 
11p15.5 
Xq28 
1q41 
12p13 
7q11.23 
 
 
17q21 
2p13.1 
   
Mouse 
 
 
 
 
 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
 
 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
 
 
 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
 
 
YES 
YE 
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Table 1.1 Continued 
 
Gene name 
 
51. DUSP12 
 
 
52. DUSP13A 
 
53. DUSP13B 
 
54. DUSP14 
55. DUSP15 
56. DUSP18 
57. DUSP19 
 
58. DUSP21 
 
59. DUSP22 
 
60. DUSP23 
 
61. DUSP24 
62. DUSP25 
63. DUSP26 
 
64. DUSP27 
 
65. EPM2A 
66. RNGTT 
67. STYX 
 
A. 2. 3. Slingshots (3 Genes) 
 
68. SSH1 
69. SSH2 
70. SSH3 
 
A. 2. 4. PRLs (3 Genes) 
 
71. PTP4A1 
72. PTP4A2 
73. PTP4A3 
 
A. 2. 5. CDC14s (4 Genes) 
 
74. CDC14A 
75. CDC14B 
76. CDKN3 
77. PTP9Q22 
 
A. 2. 6. PTENs (5 Genes) 
 
78. PTEN 
79. TPIP 
 
80. TPTE 
81. TNS 
82. TENC1 
 
 
A. 2. 7. Myotubularins (15 Genes) 
 
83. MTM1 
84. MTMR1 
85. MTMR2 
86. MTMR3 
87. MTMR4 
88. MTMR5 
89. MTMR6 
90. MTMR7 
91. MTMR8 
92. MTMR9 
93. MTMR10 
94. MTMR11 
95. MTMR12 
96. MTMR13 
97. MTMR14 
 
Protein, Synonyms 
 
HYVH1, GKAP 
LMW-DSP4 
 
BEDP 
 
TMDP, TS-DSP6 
 
MKP6, MKP-L 
VHY, Q9H1R2 
DUSP20 LMW-DSP20 
DUSP17, SKRP1, LDP-2, 
 
TS-DSP1 
LMW-DSP21, BJ-HCC-26 
tumor antigen 
VHX, MKPX, JSP1, LMW- 
DSP2, TS-DSP2, JKAP 
MOSP, similar to RIKEN 
cDNA 2810004N20 
MGC1136 
VHZ, FLJ20442, LMW-DSP3 
VHP, “similar to RIKEN 
cDNA 0710001B24” 
DUPD1, FMDSP, “similar to 
cyclophilin” 
Laforin 
mRNA capping enzyme 
STYX 
 
 
SSH1, slingshot 1 
SSH2, slingshot 2 
SSH2, slingshot 3 
 
 
PRL-1 
PRL-2, OV-1 
PRL-3 
 
 
CDC14A 
CDC14B 
KAP 
PTP9Q22 
 
 
PTEN, MMAC1, TEP1 
TPIPα, TPTE and PTEN 
Homologous 
PTEN-like, PTEN2 
Tensin 
C1-TEN, TENC1, 
KIAA1075 
 
 
myotubularin 
MTMR1 
MTMR2 
MTMR3, FYVE-DSP1 
MTMR4, FYVE-DSP2 
MTMR5, SBF1 
MTMR6 
MTMR7 
MTMR8 
MTMR9, LIP-STYX 
MTMR10 
MTMR11CRA α/β 
MTMR12, 3-PAP 
MTMR13, SBF2, CMT4B2 
FLJ22075, hJumpy, 
hEDTP 
 
Chromosomal location 
 
1q21-q22 
 
 
10q22.2 
 
10q22.2 
 
17q12 
20q11.21 
22q12.2 
2q32.1 
 
Xp11.4-p11.23 
 
6p25.3 
 
11p11.2 
 
8p12 
1q23.1 
2q37.3 
 
10q22.3 
 
6q24 
6q16 
14 
 
 
12q24.12 
17q11.2 
11q13.1 
 
 
6q12 
1p35 
8q24.3 
 
 
1p21 
9q22.33 
14q22 
9q22.32 
 
 
10q23.3 
13q12.11 
 
21p11 
2q35-q36 
12q13.13 
 
 
 
Xq28 
Xq28 
11q22 
22q12.2 
17q22-q23 
22q13.33 
13q12 
8p22 
Xq11.2 
8p23-p22 
15q13.1 
1q12.3 
5p13.3 
11p15.3 
3p26 
   
Mouse 
 
YES 
 
 
YES 
YES 
YES 
YES 
YES 
YES 
 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
 
 
YES 
YES 
YES 
 
 
YES 
YES 
YES 
 
 
YES 
YES 
YES 
YES 
 
 
YES 
YES 
YES 
YES 
YES 
YES 
 
 
 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
YES 
NO 
YES 
NO
d 
YES 
YES 
YES 
YES 
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Table 1. Continued     
 
Gene name 
 
B.  Class  II  Cys-Based  PTPs  (1 
Gene) 
 
98. ACP1 
 
 
C. Class III Cys-Based PTPs (3 
Genes) 
 
99.   CDC25A 
100. CDC25B 
101. CDC25C 
 
D. Asp-Based PTPs (4 genes) 
 
102. EYA1 
103. EYA1 
104. EYA1 
 
Protein, Synonyms 
 
 
 
LMPTP, low Mr PTP, 
LMWPTP, BHPTP 
 
 
 
CDC25A 
CDC25B 
CDC25C 
 
 
Eya1 
Eya2 
Eya3 
 
Chromosomal location 
 
 
 
2p25 
 
 
 
 
3p21 
20p13 
5q31 
 
 
8q13.3 
20q13.1 
1p36 
  
Mouse 
 
 
 
YES 
 
 
 
 
YES 
YES 
YES 
 
 
YES 
YES 
YES 
 
 
 
 
Table 1.1. A compilation of all known PTPs currently cited in the scientific literature. 
Current data indicate that there are 104 genes encoding PTPs in humans, including 100 
class I, 1 class II, and 3 class III PTP genes. The earlier predicted human OST-PTP has 
been omitted here. Although previously reported as a functionally active PTP in mouse 
and rat, the human OST-PTP cDNA sequence contained numerous disablements and upon 
closer examination was classified as a pseudogene 
[25]
. The earlier predicted myotubularin- 
related phosphatase MTMR15 
[10] 
has also been omitted here. This protein 
(KIAA1018/FAN1) was functionally assigned as a DNA repair nuclease 
[26]
. 
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1.3 The PTP catalytic mechanism 
 
The universally conserved mechanism of catalysis exhibited by all PTPs was first 
elucidated by a combination of site-directed mutagenesis, kinetic analysis 
[27-29]  
and high 
resolution structural information enabling complementary insights into the biochemical 
machinery driving PTP catalysis 
[30-34]
. This uncovered the structural and biochemical 
basis underpinning PTP activity, and revealed that PTP family members share a highly 
conserved catalytic mechanism centred on a nucleophilic cysteine residue acting as the 
initial mediator of phospho-substrate hydrolysis. The highly unstable transition state of the 
PTP reaction is stabilised by a key arginine residue, with hydrolysis of the phospho- 
intermediate  mediated  by  a  catalytic  acid-base  aspartate.  The  overall  reaction  is 
orchestrated by a number of conserved residues optimally positioned in a series of 
conserved loop regions which together form a pre-organised and catalytically competent 
active site primed for the acceptance and turnover of phospho-containing substrates. The 
first step of phospho-substrate hydrolysis features the initial cleavage of phosphorous- 
oxygen bond via a nucleophilic attack on the phosphorous atom by the catalytic cysteine 
residue in the phosphate-binding loop (P-loop). During this process, the catalytic aspartate 
residue present in the WPD-loop functions as a general acid by readily donating a proton 
to stabilise the OH
-  
leaving group. This step generates a phospho-cysteine intermediate 
along with the concomitant release of the dephosphorylated substrate. The second rate 
limiting step of the reaction features the hydrolysis of the thiophosphate intermediate 
assisted by the catalytic aspartate in the WPD-loop which acts as the general base by 
facilitating deprotonation of a key water molecule. Abstraction of the water proton creates 
the hydroxyl nucleophile which cleaves the phospho-sulphur bond to regenerate the 
catalytic cysteine, release free phosphate and perpetuate the catalytic cycle. In classical 
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PTPs, the nucleophilic water molecule is co-ordinated and positioned by a conserved 
glutamine located in the Q-loop. An additionally important feature concerns the 
guanidinium side chain of a conserved arginine residue located in the P-loop which plays a 
crucial  role  in  both  stages  of  the  phosphatase  catalytic  mechanism.  Firstly,  the 
guanidinium side chain acts by stabilising the transition state of the reaction by co- 
ordinating the phosphate group during substrate recognition and nucleophilic attack, and 
also stabilises the phospho-cysteine intermediate during the second nucleophilic attack 
which liberates the free phosphate (Figure 1.2). Although essential for stabilisation of the 
transition state, mutational studies have revealed that PTPs lacking both aspartate and 
arginine retain catalytic activity, but mutation of the critical cysteine results in complete 
abrogation of phosphatase activity 
[35]
. Despite exhibiting a highly conserved active site, 
 
different PTPs in the same subfamily demonstrate different catalytic turnover rates toward 
the generic phosphatase substrate p-nitrophenyl phosphate. Interestingly, the Yersinia PTP 
YopH 
[36]  
is approximately 10-fold more active than human hematopoietic PTP (HePTP) 
[37]
. Thus, despite the highly conserved active site architecture and chemistry, modest shifts 
 
in  the  active  site  microenvironment  can  significantly  perturb  the  efficiency  of  PTP 
catalysis. The efficiency of PTP catalysis is also greatly influenced by the conformational 
flexibility of the WPD-loop, which transitions between an open conformation in the apo- 
form of the enzyme, and a closed conformation upon substrate and ligand binding to the 
active site  
[38]
.  Indeed,  both  targeted mutations and  ligands  which  reduce WPD-loop 
conformational dynamics result in compromised PTP catalytic activity 
[39, 40]
. 
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Figure 1.2 The conserved catalytic mechanism of protein tyrosine phosphatases. The 
nucleophilic cysteine residue present in the P-loop instigates the cleavage of the 
phosphorous-oxygen bond in the phosphorylated substrate. At the same time, the catalytic 
aspartate residue located in the WPD loop acts as a general acid catalyst by donating a 
proton to the hydroxyl leaving group. This step generates a phosphocysteine intermediate 
and the unphosphorylated substrate is ejected from the PTP active site. The phosphorous 
sulphur bond then undergoes hydrolysis via a hydroxyl ion which was generated with the 
assistance of the WPD-loop catalytic aspartate which abstracts the proton from a water 
molecule to create the hydroxyl nucleophile. Figure taken from 
[19]
. 
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1.4 Structural architecture of the PTP domain 
 
Over the past two decades significant progress has been made in unravelling the functional 
importance of phosphatase activity in signal transduction. A large part of this effort has 
focussed  on  dissecting  the  structural  architecture  of  the  phosphatase  active  site  and 
mapping the key determinants of PTP specificity at the molecular level. Multiple atomic 
resolution structures of human PTP catalytic domains have now been solved spanning 
several different families and subfamilies. The archetypal PTP, PTP1B, was the first 
structure solved at high resolution and provided the first atomic-level insights into the 
structural architecture of the PTP catalytic pocket 
[31]
. The overall fold of classical PTP 
 
domains is extremely well conserved and comprises of approximately 280 amino acid 
residues interspersed with a series of defined short sequence motifs (Figure 1.3). These 
short sequence motifs are characterised by several loop regions which collectively form 
the canonical active site architecture of all classical PTPs. Such loop regions include: (1) 
the phosphate-binding loop (P-loop), which contains the PTP signature motif harbouring 
the catalytically critical cysteine and arginine residues; (2) the WPD-loop which contains 
the catalytic acid/base aspartate; (3) the Q-loop which harbours the conserved glutamine 
residue for co-ordination of the water molecule prior to nucleophilic attack of the phospho- 
cysteine and ejection of free phosphate from the PTP active site; (4) the   for pTyr in 
classical PTPs; and 5) the E-loop, which harbours several conserved residues that play a 
key role in controlling the dynamics of the catalytically critical WPD-loop (Figure 1.3). 
Interestingly, the pTyr recognition loop is only found in classical pTyr-specific PTPs, 
where  it  functions  by  defining  the  deep  catalytic  cleft  which  enables  the  essential 
discrimination between pTyr and pSer/pThr residues 
[41]
. 
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1.4.1 The P-loop 
 
 
The base of the catalytic cleft present in all classical PTPs is formed by the P-loop, which 
harbours the essential PTP signature motif HC(X5)R. The P-loop is structurally and 
chemically optimised for accepting pTyr substrates, with backbone amide nitrogen atoms 
and the guanidinium side chain of the conserved P-loop arginine residue providing a 
complementary  positively  charged  microenvironment.  The  evolution  of  the  catalytic 
pocket toward favouring a positively charged microenvironment is critical for maximising 
the affinity for the phosphate anion, and also serves to maintain the nucleophilicity of the 
catalytic cysteine by stabilising the thiolate anion (Cys-S
-
). While the sulphydryl side 
chains of cysteine residues are not typically nucleophilic under physiological conditions 
(with pKa values of ~8.5), the positively charged microenvironment of the phosphatase 
active site creates an unusually low pKa value (typically between 4.5-5.5) allowing the 
reaction to proceed under physiological conditions 
[42]
. However, the low pKa renders the 
catalytic cysteine exquisitely sensitive to oxidation 
[43]
, nitrosylation 
[44]
, and sulfhydration 
 
[45] 
which can lead to both reversible and irreversible modifications that perturb 
nucleophilicity and lead to overall cessation of enzyme activity. 
 
1.4.2 The WPD-loop 
 
 
The WPD-loop is a structural motif present in many PTPs (the exception being the 
myotubularins and the CDC25 family), and is located approximately 30-40 residues 
upstream of the PTP signature catalytic motif in pTyr-specific PTPs. Both the tryptophan 
and proline residues are 100 and 97% conserved across the classical pTyr-specific PTPs, 
and play critical roles in governing WPD-loop dynamics and facilitating PTP catalysis. In 
classical PTPs, the tryptophan residue in the WPD loop has been identified as an essential 
13 
 
hinge residue and thus appears to be an essential determinant of WPD-loop flexibility 
[46,
 
 
47]
.  In  contrast,  the  aspartate  residue  functions  as  the  general  acid/base  during  PTP 
catalysis. The central role of the WPD-loop in PTP catalysis is to act as a flexible gate 
which regulates substrate access to the active site. As such, the WPD-loop has been 
observed in both closed (active) conformations as well as open (inactive) conformations 
[35]
.  In  the  absence  of  pTyr-containing substrates,  the  WPD-loop continuously cycles 
between active and inactive conformations 
[48]
. However, substrate binding is only possible 
 
when the loop adopts an open conformation. Upon recognition of pTyr-containing 
substrates, the WPD-loop transitions to the closed conformation which positions the 
catalytic aspartate residue in close proximity to the catalytic cysteine in order to facilitate 
catalysis. Indeed, mutational studies investigating targeted mutations of the tryptophan 
hinge residue in the WPD-loop result in impaired conformational mobility which leads to 
compromised PTP catalytic activity. Interestingly, PTPs with a different amino acid 
substituted in position of the aspartate, including the receptor protein tyrosine phosphatase 
(RPTP) IA-2 (PTPRN; D->A) 
[49]  
exhibit very low activity levels, and in some cases are 
 
inactive. 
 
 
1.4.3 The p-Tyr recognition loop 
 
 
The p-Tyr-loop, often referred to as the substrate-binding loop, is a conserved structural 
feature of all classical PTPs, and plays a central role in defining the depth of the 
phosphatase catalytic pocket. The structural elements forming the architecture of p-Tyr 
loop determine the selectivity and specificity necessary for optimal recognition of p-Tyr- 
containing substrates, and provide the mechanistic basis for discriminating p-Tyr and 
pSer/pThr-containing  substrates.  These  structural  elements  include  the  loop  region- 
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containing p-Tyr-recognition KNRY motif, which features a highly conserved tyrosine 
residue optimally positioned to provide the appropriate 9Å depth critical for pTyr 
recognition. Aside from its role in priming the catalytic pocket for optimal p-Tyr 
specificity, the conserved tyrosine residue plays a secondary role in forming pi-pi stacking 
interactions with the p-Tyr moiety on substrate engagement, thus consolidating substrate 
interaction in the active site 
[31]
. The conserved arginine residue in the KNRY motif 
 
appears to stabilise the overall loop dynamics and serves to anchor the substrate through 
side-chain  interactions  between  the  guanidinium  group  and  nearby  backbone oxygen 
atoms. Interestingly, despite the essential nature of the tyrosine residue for KNRY motif 
function and overall substrate specificity, a total of six phosphatases including PTPRN, 
PTPRN2, PTPRQ, PTPRU and PTPN21 have replaced tyrosine for an alternative amino 
acid at this position 
[21]
. Furthermore, the phosphatases for which these substitutions are 
apparent also exhibit alterations in their WPD motifs, which may reflect a change in the 
functional  trajectory  of   these   enzymes  throughout  the   course   of   evolution.  For 
conventional  KNRY  motif-containing  phosphatases,  additional  structurally-conserved 
features include aspartate or asparagine residues positioned two-residues from the C- 
terminal end of the conserved tyrosine. The functional importance of this residue hinges on 
the formation of a dual hydrogen bond interaction between the backbone amide nitrogen 
atoms of the pTyr substrate and adjacent residue providing additional stabilisation of the p- 
Tyr substrate interaction. 
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1.4.4 The E-loop 
 
 
The functional significance of the E-loop is defined by the presence of key glutamate and 
lysine residues which are universally conserved across all classical PTPs. In approximately 
85% of all determined structures of classical PTPs, the E-loop is found as a tight β-hairpin 
motif with the critical glutamate residue forming a dual hydrogen bonding interaction with 
the guanidinium side chain of the invariant arginine residue present in the P-loop. This 
interaction is thought to provide sufficient stabilisation of the guanidinium group, thus 
creating  a  geometrically  favourable  orientation  for  phosphate  binding  to  the  P-loop. 
Although the E-loop exhibits a spectrum of conformational flexibility 
[50-52]
, and in some 
 
cases appears intrinsically disordered 
[53]   
the glutamate-arginine interaction remains a 
highly conserved feature found in almost all reported crystal structures of classical PTPs. 
In addition to the functional role exhibited by the conserved glutamate residue, the 
conserved E-loop containing lysine residue forms a hydrogen bonding interaction with the 
closed-conformation of the WPD-loop, specifically through the catalytically critical 
aspartate residue, which likely serves to stabilise the WPD in its substrate bound 
conformation. Mutational studies probing the functional significance of the lysine residue 
confirmed that creating the alanine mutant reduces the catalytic activity of HePTP 
[54]
. 
Despite  the  key  functional  contribution  of  the  E-loop  in  the  overall  mechanism  of 
phosphate binding, observations of similar functions outside the classical PTP family have 
been surprisingly elusive. Although the E-loop is similarly positioned across all PTP 
subfamilies, the conserved positions and mechanisms of action of glutamate and lysine 
residues are only found in pTyr-specific PTPs. 
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1.4.5 The Q-loop 
 
The Q-loop is a conserved structural element underpinning all classical PTPs, and 
comprises a highly conserved glutamine residue which plays a fundamental role in the PTP 
catalytic mechanism. In particular, a combination of kinetic 
[55-57]  
and structural analyses 
[27-29, 31, 44] 
of PTPs revealed that the glutamine side chain extends into the central cavity of 
the  catalytic  pocket,  serving  to  co-ordinate  and  position  the  key  nucleophilic  water 
 
molecule prior to phospho-thioester hydrolysis. Substitution of the conserved glutamine 
with a residue devoid of hydrogen bonding capacity with the nucleophilic water molecule 
results in phosphotransferase activity as opposed to strict hydrolysis of phosphoester 
substrates exhibited by classical PTPs. Therefore, the Q-loop imparts the strict and specific 
hydrolytic activity manifested by classical PTPs, preserving PTP activity and thus 
preventing the acquisition of phosphotransferase activity exhibited by kinases. In addition 
to maintaining the strict hydrolytic activity reminiscent of classical PTPs, the nucleophilic 
water molecule (positioned by the conserved Q-loop glutamine residue) has also been 
proposed as a key player in WPD-loop closure prior to nucleophilic attack of the pTyr- 
containing substrate 
[33]
. 
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Figure 1.3 Ribbon diagram of the classical architecture exhibited by a class I PTP 
catalytic domain. Structural representation of a class I PTP catalytic domain with a 
tungstate ion bound in the active site (PTP1B; PDB: 2HNQ). Conserved amino acid 
residues are highlighted as ball-and-stick representation and are identified in accordance 
with  their  location  within  key  structural  loops.  These  residues  include:  the  catalytic 
cysteine (C215) and conserved arginine (R221) of the P-loop; the acid-base aspartate 
residue (D181) of the WPD-loop; a conserved glutamine (Q262) residing in the Q-loop; an 
essential tyrosine (Y46) present in the pTyr-recognition loop, and a conserved glutamate 
(E115) of the E-loop. Figure taken from 
[41]
. 
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1.5 The Protein Tyrosine Phosphatase SHP2 
 
1.5.1 Discovery of SHP2 
 
 
The protein tyrosine phosphatase SHP2 was initially identified by several groups as a Src- 
homology 2 (SH2)-domain containing protein tyrosine phosphatase 
[58-62]
. Following its 
biochemical classification, further genotypic analysis revealed that the Src homology 2 
domain-containing protein tyrosine phosphatase (SHP2) belonged to a relatively small 
sub-family of non-receptor protein-tyrosine phosphatases which comprised two human 
members,  Src  homology  1  domain-containing  protein  tyrosine  phosphatase  (SHP1; 
encoded by the PTPN6 gene) and SHP2 (encoded by the PTPN11 gene). Interestingly, 
global analysis of the prevalence of SHP genes across higher organisms revealed that all 
vertebrate organisms have ortholog copies for both SHP genes, whereas invertebrates such 
as Drosophilia and Caenorhabditis elegans contain single variants of the SHP gene known 
as csw and ptp-2, respectively. Both csw and ptp-2 exhibit SHP2-like functions suggesting 
that SHP1 may have undergone evolutionary divergence to facilitate a more specialised 
functional role. This is supported by the restricted expression pattern of SHP1 to 
haematopoietic cells, whereas SHP2 displays a more ubiquitous expression pattern across 
multiple tissues 
[63, 64]
. 
 
The  disease-linked  propensities  of  SHP2  were  first  highlighted  by  observations  of 
germline mutations in the PTPN11 gene. These genetic aberrations were first identified in 
Noonan Syndrome (NS) 
[65]
, a common autosomal dominant developmental condition 
characterised by a spectrum of phenotypic alterations, including facial abnormalities, 
defective cardiac function, retarded growth patterns and severe learning difficulties 
[66-69]
. 
NS has been estimated to affect around 1 in 1000-2000 patients, with germline PTPN11 
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mutations reported in 40-50% of NS patients 
[70]
. Similar germline PTPN11 mutations also 
underlie related but much rarer genetic disorders, including Noonan-like disorder with 
multiple giant lesion syndrome and LEOPARD syndrome 
[66]
. In addition to germline 
mutations, somatic mutations in PTPN11 have been identified in ~35% of cases of juvenile 
myelomonocytic leukaemia (JMML) 
[71, 72]
, an aggressive childhood neoplasm defined by 
excessive and deregulated production of monocytic cells that drive invasion of the GI tract, 
lung, liver and spleen. Further somatic mutations have also been found in solid tumours 
 
[70]
, as well as other types of myeloproliferative neoplasm 
[73-75]
. 
 
 
Collectively, the prevalence of both germline and somatic mutations across a broad range 
of SHP2-linked pathologies culminated in the identification of SHP2 as the first proto- 
oncogenic PTP 
[71]
. 
 
1.5.2 Molecular structure and regulation of SHP2 
 
 
The domain organisation and overall structure of SHP2 is composed of two SH2 domains 
(N-SH2 and C-SH2), a globular PTP domain, a disordered C-terminal tail containing 
tyrosine phosphorylation sites (Y542 and Y580), and a proline-rich motif 
[61] 
(Figure 1.4) 
While the majority of the PTP family are generally considered as negative regulators of 
signalling pathways, due to their ability to reverse phosphorylation by PTKs and terminate 
the lifetime of a signal, a large body of genetic and biochemical evidence suggests that 
SHP2 plays a central role in the propagation and activation of signalling cascades at a 
diverse range of receptor tyrosine kinases (RTKs) 
[76]  
and cytokine receptors 
[71]
, and is 
thus required for full activation of the RAS/MAPK pathway 
[24, 77]
. Furthermore, almost all 
 
signalling capabilities and biochemical functions of SHP2 are acutely dependant on the 
presence  of  functional  and  intact  SH2  and  PTP  domains  
[14,   61]
.  Despite  extensive 
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characterisation of SH2 and PTP domain structure and function in the overall context of 
SHP2 signalling, the structural significance of the disordered C-terminus of SHP2 remains 
comparatively underexplored. However, at a functional level, the phosphorylation state of 
the C-terminal tyrosine residues has been shown to arise in response to receptor-specific 
SHP2-signalling. In particular, C-terminal tyrosine residues are transiently phosphorylated 
upon activation of fibroblast growth factor (FGF) and platelet-derived growth factor 
(PDGF) receptor signalling, but exist in the unphosphorylated form in response to 
epidermal growth factor (EGF) and insulin-like growth factor (IGF) receptor signalling, 
suggesting an alternative modulatory mechanism in EGF and IGF-mediated signalling 
pathways 
[78]
. Although relatively uncharacterised, the proline-rich motif has been shown 
 
to bind the SH3-domain of Src kinase enabling transient increases in Src kinase activity 
[79]
 
 
 
Under basal conditions, in the absence of mitogenic stimuli, SHP2 adopts an autoinhibited 
conformation mediated by an intramolecular interaction between the N-SH2 domain and 
the PTP domain 
[80, 81]
. Upon mitogenic stimulation by growth factors or cytokines, the 
autoinhibition of SHP2 is relieved through interaction of the tandem SH2 domains (Figure 
1.5) with pTyr residues in the cytoplasmic domains of RTKs or scaffolding adaptors, such 
as insulin receptor substrates, fibroblast growth factor receptor substrate, or GRB2- 
associated  binders  (GAB)  proteins.  Engagement  of  pTyr  instigates  a  conformational 
change which dislodges the occluding N-SH2 domain and facilitates substrate access to the 
exposed catalytic site 
[78,  79]
. The molecular basis underlying this auto-inhibitory 
mechanism  of  SHP2  was  first  illuminated  by  structural  studies  revealing  the  high 
resolution crystal structure of full-length SHP2. The crystal structure of full length SHP2 
revealed an overall compact structure with the SH2 domains organised around the PTP 
domain with  the  phosphopeptide binding  sites  exposed  in  the  correct  orientation  for 
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substrate recognition 
[78]
. This intricate catalytic mechanism of SHP2 can thus be thought 
of as a molecular switch which, under appropriate extracellular cues and through 
localisation to the correct signalling receptors, can efficiently couple catalytic activation to 
the propagation of a specific physiological stimulus 
[72]
. The physiological significance of 
the intrinsic regulatory mechanism of SHP2 was confirmed by mutational studies targeting 
the residues lining the SH2-PTP interface. Engineering these mutations to disrupt the 
interface and destabilise the SH2-PTP interaction generated mutants with enhanced and 
deregulated catalytic activity 
[82]
. 
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Figure 1.4 Domain organisation of full length SHP2. Schematic representation of the 
modular domain architecture of full length SHP2 (amino acids 1-597). The structure of 
Shp2 consists of two N-terminal SH2 domains designated as n-SH2 (highlighted orange; 
amino acids 6-102) and c-SH2 (highlighted dark teal; amino acids 112-216), a globular 
catalytic (PTP) domain (highlighted blue; amino acids 247-541) and a largely unstructured 
C-terminal tail harbouring a proline-rich region (highlighted red) and two phosphorylation 
sites (Y542 and Y580). The amino acid sequence of full length SHP2 has been coloured to 
highlight individual domains. Black triangles indicate phosphorylation sites present within 
the C-terminal tail. 
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Figure 1.5 Mechanism of auto-inhibition of SHP2. A. Molecular structure of SHP2 in 
the auto-inhibited conformation (PDB: 2SHP) 
[80]
. The structural basis for SHP2 auto- 
inhibition was first identified from a crystal structure of full length SHP2 with a truncated 
C-terminal tail. This revealed the primary role of the N-SH2 which mediates auto- 
inhibition of SHP2 activity via conformational occlusion of the PTP catalytic site. In 
particular, the DE loop of the N-SH2 domain projects into the PTP catalytic site and forms 
multiple contacts with residues present in the catalytic motif and WPD loop which help to 
stabilise the auto-inhibited conformation. B. The release of SHP2 auto-inhibition is 
mediated by a diverse cascade of physiological stimuli. At basal levels of cellular 
stimulation, SHP2 exists primarily in the auto-inhibited conformation. Upon mitogenic 
cellular stimulation, the auto-inhibition of SHP2 is relieved through engagement of the N- 
SH2 and C-SH2 domains and subsequent dephosphorylation of phosphorylated tyrosine 
motifs present the cytoplasmic tails of activated growth-factor receptors. Disengagement 
of the N-SH2 domain through phosphotyrosine binding exposes the SHP2 catalytic site 
and promotes SHP2 activation and downstream propagation of growth factor signalling 
pathways. 
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1.5.3 SHP2 signalling and substrates 
 
 
Although catalytically active SHP2 is required to initiate downstream activation of the 
RAS/MAPK pathway (Figure 1.6), identification of the precise mechanism and key 
signalling targets driving activation of Ras signalling has, until recently, remained unclear, 
with various pathways proposed 
[83, 84]
. One proposed signalling mechanism for SHP2- 
mediated dephosphorylation was the pTyr sites on RTKs involved in binding either p120 
RasGAP or the phosphorylation sites on the p120 RasGAP binding protein, Gab1 
[85-88]
. In 
 
this instance, SHP2-mediated dephosphorylation would abrogate GTPase activity and thus 
act  to  promote  Ras  activation.  An  additional  signalling  mechanism  postulated  for 
triggering RAS/MAPK signalling concerns the SHP2-mediated activation of Src family 
kinases through inhibition of C-terminal Src kinase 
[89]
. This indirect mechanism is 
suggested to occur via the dephosphorylation of the C-terminal Src kinase binding protein 
or paxillin. Other signalling targets postulated as sites for SHP2 dephosphorylation include 
RASGAP binding sites on a selection of RTKs 
[90, 91]  
and the tyrosine phosphorylation 
sites on SPROUTY proteins 
[92, 93]
. In addition, SHP2 may also facilitate Ras activation 
 
through the regulation of transcription factors responsible for downregulation of the Ras 
 
GTPase activating protein, NF1, which acts as a negative regulator of Ras signalling 
[60]
. 
 
 
More recently, however, an alternative mechanism of Ras/MAPK pathway regulation has 
been demonstrated through Src kinase-mediated phosphorylation on the conserved Y32 
residue located in the switch I region of the Ras GTPase. Furthermore, Src-mediated 
phosphorylation at Y32 promotes uncoupling of the Ras-Raf interaction leading to 
enhanced GAP recruitment, increased GTPase activity and inactivation of Ras 
[94]
. 
Interestingly, SHP2 has been identified as a key mediator of direct Ras activation through 
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dephosphorylation of Y32, thereby reversing the negative regulation of Ras activity 
imposed by Src-phosphorylation and promoting continuation of the Ras-GTPase cycle 
[95]
. 
 
In addition to its established and emerging roles in Ras/MAPK pathway regulation, SHP2 
also appears to exert cell-type specific effects on a myriad of other signalling pathways. In 
particular, SHP2 has been implicated in negative regulation of the PI3K/AKT pathway in 
response to EGFR stimulation 
[96,  97]
, and also plays central roles in PDGF and IGF- 
mediated AKT activation 
[94]
. Furthermore, observation of the signalling activities of SHP2 
 
also extend to the regulation of JNK, NF-kB 
[98]
, Rho 
[99, 100] 
and NFAT 
[101] 
activation, as 
well as additional studies implicating contrasting inhibitory and activatory roles for wild 
type SHP2 in JAK/STAT signalling 
[61, 75]
. 
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Figure 1.6 SHP2-mediated signalling pathways. SHP2 plays a central role in the 
transduction of mitogenic signals downstream from multiple growth factor (and cytokine) 
receptors. Ligand-mediated activation of receptor tyrosine kinase activity promotes 
sequential tyrosine phosphorylation of intracellular receptor tails. Phosphorylated tyrosine 
residues serve as docking sites for the engagement of SHP2 via its SH2 domains. This 
promotes activation of SHP2 by release of the autoinhibited conformation, allowing the 
propagation of intracellular signal transduction leading to transcriptional activation and 
expression of genes driving cellular proliferation, development and differentiation. Figure 
obtained from 
[102]
. 
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1.6 Aberrant SHP2 signalling in disease 
 
1.6.1 Noonan syndrome, LEOPARD syndrome and leukaemias 
 
 
In addition to the key regulation of signalling pathways controlling normal cellular 
physiology, dysregulation of SHP2 signalling has been frequently linked to a spectrum of 
myeloproliferative neoplasms and developmental disorders. In particular, germline 
mutations in the PTPN11 gene have been identified in approximately 40-50% of cases of 
NS. Despite clear links establishing the development of NS with defective PTPN11 gene 
function,  gain  of  function  mutations  in  K-ras,  Sos1  and  Raf1  genes  have  also  been 
identified in NS patients devoid of PTPN11 mutations, strongly suggesting that 
dysregulation of the Ras/MAPK pathway is a key biochemical hallmark underlying this 
disorder  
[103]
.  Germline  mutations  in  the  PTPN11  gene  have  also  been  identified  in 
 
LEOPARD syndrome (LS), a rarer but related condition to NS, with approximately 200 
cases known to have been reported 
[104]
. Somatic defects in the PTPN11 gene have been 
characterised in approximately 35% of JMML patient cases, and exhibit a reduced 
prevalence in related myeloproliferative disorders, such as myelodysplastic syndrome 
(MDS) 
[101]
. Unfortunately, despite advances in our understanding of the genetic origins 
driving  JMML,  frontline  therapies  including  stem  cell  transplantation  provide  only 
adequate symptomatic relief, with high relapse rates reported after treatment 
[105]
. The 
identification of novel therapeutic targets driving JMML-like symptoms is therefore an 
urgent requirement for the effective control of this aggressive disease. Indeed, a deeper 
understanding of the biochemical consequences of JMML mutations in controlling SHP2 
catalytic activity may offer a novel avenue for the development of more efficacious 
therapeutics with novel modes of action. At a biochemical level, the onset of NS is driven 
by the defective regulatory properties exhibited by mutant SHP2. More specifically, a 
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combination of structural, enzymatic and computational modelling studies suggest that 
these mutations, which are often found in the N-SH2 or PTP domain, exert their effect by 
destabilising the native auto-inhibitory mechanism of SHP2 leading to the aberrant control 
of  functional  phosphatase  activity  
[106]
.  Similar  mechanistic  defects  in  SHP2  auto- 
inhibition are also exhibited by leukaemia-specific mutations located in the SHP2 N-SH2 
domain leading to hyper-activation of MAPK signalling and marked cytokine sensitivity in 
myeloid-derived progenitor cells 
[107]
. In contrast, LS-associated mutations typically reside 
in the phosphatase domain of SHP2 and manifest their effects by dramatically reducing 
phosphatase catalytic activity leading to an overall reduction in Ras/MAPK signalling 
[108]
. 
This raises an interesting scientific paradox concerning how biochemically opposing 
mutations (e.g. activating mutations in NS versus inhibitory mutations in LS) ultimately 
lead to similar phenotypic observations. A number of potential explanations and key 
insights have been reported in an attempt to rationalise this apparent scientific quandary. 
One potential rationale suggests that overlapping Noonan and LEOPARD syndrome 
phenotypes may be driven by the propensity of mutant SHP2 to exert differential effects 
on Ras-MAPK signalling at temporally distinct phases of the developmental process 
[108]
. 
In   addition,   structural   insights   from   LS   mutants   reveal   that   despite   exhibiting 
compromised catalytic activity, the presence of the mutation encourages longer lasting 
duration of a conformationally open state which is more amenable to interaction with 
upstream signalling activators  and  thus  leads  to  an  overall  enhancement of  catalytic 
activity 
[109, 110]
. Alternatively, the capacity of SHP2 to perform PTP-independent functions 
as part of other signalling networks, or mutation-specific effects driving altered substrate 
recognition may also constitute a plausible biochemical rationale underlying the clinically 
similar phenotypes presented by Noonan and LEOPARD syndrome patients 
[72].
 
29 
 
 
Although mutant SHP2 has been extensively linked to the onset of multiple 
myeloproliferative neoplasms, overexpression of wild-type SHP2 has also been observed 
as a pathological signature underlying chronic myelomonocytic leukaemia (CML) and 
systematic mastocytosis, both of which have been linked to oncogenic mutations in the 
KIT gene. Indeed, oncogenic activating mutations in the KIT receptor (specifically D816V 
mutations) stimulate aberrant activation of receptor signalling and promote 
hyperproliferation of  bone  marrow  cells  in-vitro  and  in-vivo  leading to  the  onset  of 
myeloproliferative  disease  
[111,   112]
.  Interestingly,  recent  studies  have  identified  an 
 
emerging role of SHP2 as a critical driver of oncogenic KIT activation in 
myeloproliferative disease 
[113]
. These reports exposing the transforming ability of SHP2 in 
driving diverse myeloproliferative pathologies suggest that targeted SHP2 inhibition may 
provide  a  viable  therapeutic avenue  for  the  treatment of  JMML  and  other 
myeloproliferative neoplasms driven by aberrant SHP2 expression or KIT hyper-activation 
[114]
.
 
 
1.6.2 Breast cancer 
 
 
With an estimated 1.38 million cases documented annually worldwide, breast cancer 
represents the most frequently diagnosed cancer in women 
[115]
. Like many cancers, breast 
cancer exhibits considerable inter-and intra-tumoural heterogeneity with a diverse 
mutational profile that acts to sustain the oncogenic phenotype 
[116]
. Interestingly, although 
aberrant SHP2 signalling has been reported in breast cancer, observations of specific 
mutations  in  the  PTPN11  gene  have  remained  elusive.  Indeed,  recent  studies  have 
identified that up-regulation and overexpression of a key SHP2 docking protein acts a 
primary driver of SHP2-linked breast cancers 
[69]
. In particular, the gene encoding the 
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SHP2 adaptor protein, GRB2-associated-binding protein 2 (Gab2), is amplified in 
approximately 10-15% of breast malignancies, with multiple studies linking up-regulation 
of SHP2 expression through amplified Gab2 as a key factor underlying the metastatic 
progression of breast cancer cells 
[117-119]
. However, recent lines of evidence have 
demonstrated that SHP2 plays a central and previously unappreciated role in the initiation 
and maintenance breast tumour cells driving the metastatic phenotype underlying both 
human epidermal growth factor receptor 2 (HER2)-driven and triple negative breast 
tumours 
[120]
. More specifically the study generated by Aceto et al. identified a distinctive 
genetic fingerprint that was consistently up-regulated in response to upstream activation of 
SHP2 signalling. Furthermore, this genetic signature was reported in approximately 50% 
of both primary breast malignancies and triple-negative breast cancers 
[117]
. These key 
findings provide robust biological validation in redefining the therapeutic value of SHP2 
as a potential oncology drug target and uncover novel mechanisms that could be exploited 
therapeutically as part of future breast cancer treatment strategies. In particular, patients 
harbouring tumours showing consistent up-regulation of this gene cluster in response to 
hyper-activated SHP2 could be stratified for treatment with a specific SHP2 inhibitor, 
thereby providing a possible therapeutic avenue for overcoming the resistant phenotype 
that frequently undermines current therapeutic regimes 
[121]
. 
 
1.6.3 Gastric cancer 
 
 
The infectious agent Helicobacter pylori has been suggested to underlie approximately 5% 
of all cancer cases in the UK 
[122]
, with around 30% of all stomach cancer cases linked to 
the primary etiological role of this pathogen in gastric carcinoma. More specifically, the 
onset of gastric carcinoma which represents one of the most commonly presented forms of 
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stomach cancer has been increasingly linked to cytotoxin-associated gene A (CagA)- 
specific strains of Helicobacter pylori. In particular, these strains exert their pathogenicity 
by injecting CagA into cells of the gastric epithelia via the evolutionarily conserved 
bacterial type IV secretion system, which functions as a “molecular syringe” by attaching 
to and puncturing the target cell membrane and injecting the CagA secretory factor directly 
into the cells. Following injection into cells of the gastric epithelia, CagA localises to the 
inner cytosolic leaflet of the plasma membrane where it undergoes phosphorylation on a 
number of key tyrosine residues by Src kinase family members Fyn and Lyn 
[123]
. Tyrosine 
 
phosphorylation  of  CagA  creates  docking  sites  which  invokes  recruitment  of  SHP2 
through binding of its tandem SH2 domains. This triggers constitutive activation of Ras- 
MAPK signalling leading to uncontrolled cellular proliferation and transformation. 
Therefore, the functional activation of SHP2 via its direct engagement of tyrosine 
phosphorylated CagA recapitulates the deregulated signalling responses exhibited by 
hyperactivated SHP2 signalling in multiple different cancers 
[120] 
(Figure 1.7). 
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Figure 1.7 CagA-mediated hyper-activation of SHP2 signalling leads to sustained Ras 
activation. CagA is injected into gut epithelial cells via the Bacterial type IV secretion 
system of Helicobacter Pylori. CagA localises to the cytosolic leaflet of the plasma 
membrane and undergoes tyrosine phosphorylation by Src family kinases. The newly 
created phosphotyrosine residues act as docking sites for SHP2 recognition via its SH2 
domains. This leads to hyperactivated SHP2 signalling and sustained Ras activation. CagA 
therefore serves to functionally mimic the gain of function mutation phenotype exhibited 
by hyper-activated SHP2. Figure taken from 
[124]
. 
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1.7 Protein tyrosine phosphatases as therapeutic targets 
 
1.7.1 Modulation of phosphorylation signalling as a therapeutic strategy 
 
 
 
Perturbing the balance of phosphorylation signalling results in compromised regulation of 
signal transduction networks, and serves as a biochemical hallmark underlying a range of 
critical human diseases. In this way, selective and functional modulation of 
phosphorylation-based signalling networks holds considerable therapeutic appeal. Indeed, 
many of the frontline drugs developed to specifically modulate protein tyrosine kinase 
function have entered the clinic and represent outstanding breakthroughs in the field of 
cancer therapeutics. In particular, the development of Gleevec (STI-571), a potent and 
targeted inhibitor of the p210 BCR-ABL oncogenic protein tyrosine kinase (PTK) was a 
significant therapeutic  breakthrough  for  the  treatment of  CML  
[125]
.  Alongside  small 
 
molecule inhibitor development, antibody-based therapies have also emerged as key 
therapeutic  candidates,  most  notably  Herceptin  (Trastuzumab)  which  targets 
overexpression of the HER2 PTK receptor and is frequently overexpressed in 
approximately 25% of breast malignancies 
[126]
. Despite advances in the range of 
therapeutic options available for the treatment of these human cancers, the development of 
chemotherapeutic resistance in patients administered with these treatments poses a robust 
barrier to the long-term treatment of these conditions 
[127, 128]
. This suggests that identifying 
alternative approaches to targeting tyrosine phosphorylation based signalling pathways 
may have profound implications for the future development of novel therapeutics. 
 
Over the past decade, considerable efforts have been devoted to the development of 
therapeutic  candidates  which  selectively  modulate  PTK  function.  Although  this  has 
resulted in great success, and has led to a surge in the approval of PTK inhibitors for 
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clinical development 
[129]
, other equally important components of phosphorylation 
dependant signalling pathways, such as PTPs, have remained largely unexplored. The 
process of protein phosphorylation is a fundamentally reversible process that is critically 
dependant on the synergistic and competing activities of PTKs and PTPs, both of which 
function to maintain the cellular phosphoproteome. Given the multiple successful drug 
discovery initiatives targeting PTKs, and that the maintenance of homeostatic levels of 
protein tyrosine phosphorylation are governed by the highly co-ordinated activities of PTK 
and  PTPs,  PTPs  could  represent  a  class  of  signalling  enzymes  with  considerable 
therapeutic potential
.[13, 74]
. 
 
1.7.2 The “undruggable” nature of protein tyrosine phosphatases 
 
 
 
PTPs comprise a family of 107 signalling enzymes and play a central role in catalysing the 
dephosphorylation of phosphotyrosine-containing substrates 
[13]
. Despite PTPs being 
considered as possible therapeutic targets, and the publication of several phosphatase 
inhibitors,  phosphatases  have been  largely posited as  an  “undruggable” class  of drug 
targets 
[130]
. The proposed undruggability of phosphatases particularly refers to more 
conventional methods of drug discovery involving the development of traditional active- 
site   directed   inhibitors.   For   phosphatases,   these   conventional   active-site   directed 
approaches to drug discovery are often intractable. In particular, targeting phosphatases for 
inhibitor development presents several technical challenges which arise principally from 
the highly conserved and shallow active site architecture, the highly polar catalytic pocket, 
and the catalytically critical and redox-active cysteine. Owing to these challenges, the 
development of potent, selective and cell-active phosphatase inhibitors has been fraught 
with difficulties, often due to the charges and high reactivity of the final optimised ligands 
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that render them poorly cell permeable and of inadequate selectivity. This has led to 
suggestions that targeting phosphatases through active site-directed mechanisms represents 
an intractable approach and that alternative approaches centred on the identification and 
discovery of allosteric pockets may yield greater therapeutic value 
[131]
. 
 
1.7.3 Current landscape of SHP2 inhibitors 
 
 
Since its  discovery as  the  first  oncogenic PTP  
[74]
,  the  past  decade has  witnessed a 
concerted effort towards the development of potent and selective inhibitors for modulation 
of SHP2 function. Indeed, the development of high quality chemical probes is an exciting 
and rapidly growing area of drug discovery 
[132]
. In the context of SHP2, the need for 
potent, selective and cell permeable inhibitors is urgently required both for functional 
annotation and exploration of SHP2-specific signalling pathways, and for enhancing the 
biological validation of SHP2 as an oncology therapeutic target. 
 
In the infancy of SHP2 inhibitor development, one of the earliest reported compounds with 
demonstrable activity against SHP2 was the organometallic-based compound sodium 
stibogluconate (Compound 1; Figure 1.8; Table 1.2). Despite being used clinically for over 
40 years as a treatment for the infectious parasitic-born disease, leishmaniasis, the precise 
mechanism  of   action   remains  unclear  
[133]
.   Interestingly,  it   is   now   known   that 
stibogluconate exerts its inhibitory activity through the potent and irreversible inhibition of 
SHP1, SHP2 and PTP1B in vitro, which elicits activation of a broad spectrum of cytokine 
signalling cascades 
[134]
. Further interrogation of the mechanistic basis of stibogluconate 
action revealed potent anti-tumour activity mediated through IFN-α2b activation in an in 
vivo mouse model. This has now led to initiation of clinical trials investigating the efficacy 
of stibogluconate for the treatment of melanoma and several other human cancers 
[135]
. 
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However, administration of stibogluconate is now widely known to elicit multiple harmful 
side effects including cardio and hepatotoxicity. Despite these undesirable side effects, the 
design of alternative chemical inhibitors with novel scaffolds could still hold therapeutic 
benefit for the treatment of various cancers 
[133]
. 
 
Screening  of  the  chemical  library  belonging  to  the  National  Cancer  Institute  (NCI) 
diversity set led to the observation of inhibitor NSC-87877 (Compound 2; Figure 1.8; 
Table 1.2) 
[136]
. NSC-87877 demonstrates reasonable potency in vitro with an IC50 of 0.3 
μM against SHP2, but lacks selectivity over the closest homolog of SHP2, SHP1. Despite 
 
the lack of SHP1 selectivity, NSC-87877 displays a reasonable selectivity profile over 
other PTPs and has also been reported as an effective inhibitor of DUSP26 signalling 
[102]
. 
Interestingly, despite possessing a core disulphonic-acid based moiety which carries a high 
density of negative charge, NSC-87877 demonstrated in cell activity by inhibiting EGF- 
stimulated activation of SHP2 signalling in HEK293 cells at a concentration range of 10- 
50 μM. Although no clear structural evidence has been reported to unequivocally confirm 
the binding mode of NSC-87877, a combination of in silico modelling and mutational 
analysis suggested an active-site directed binding mode for this compound. Furthermore, 
in vivo analysis of NSC-87877 activity has demonstrated that inhibitor treatment is 
sufficient to reverse the development of experimental autoimmune encephalomyelitis in a 
mouse model of chronic relapsing-remitting multiple sclerosis 
[137]
. Although NSC-87877 
 
has reported demonstrable activity in vivo, whether the phenotypic effects observed are a 
result of specific inhibition of SHP2 or mediated through off target effects (i.e. through 
polypharmacology) remains unclear. 
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Interestingly screening the same NCI-diversity set chemical library also resulted in the 
identification of inhibitor NSC-117119 (Compound 3; Figure 1.8; Table 1.2). Compared to 
NSC-87877, NSC-117119 exhibits modest potency with an IC50 = 47 μM, and also cross- 
inhibition of SHP1 and PTP1B. Similarly, although the existence of structural evidence 
confirming the binding mode of NSC-117119 has yet to be reported, modelling and ligand 
docking studies in conjunction with synthetic chemistry led to the evolution of two related 
chemotypes which both exhibited improved potency and selectivity. These include 
compound 14a (Compound 4; Figure 1.8; Table 1.2) which has a SHP2 IC50 of 0.8 μM and 
exhibits approximately 15-fold greater selectivity over SHP1, and compound  SPI-112 
(Compound  5;  Figure  1.8;  Table  1.2)  which  has  an  IC50   of  1  μM  and  exhibits 
approximately 18-fold selectivity over SHP1 and 14-fold selectivity over PTP1B 
[138]
. 
 
Further modification of the previously cell-impermeable compound SPI-112 to the 
corresponding methyl ester analog SPI-112Me (Compound 6; Figure 1.8; Table 1.2) 
generated a SHP2 inhibitor with in-cell activity at concentrations of 20 μM. Screening of a 
natural product library also identified inhibitor 2a (Compound 7; Figure 1.8; Table 1.2) as 
a relatively potent inhibitor with an IC50 = 2.5 μM and which also exhibited approximately 
20-fold selectivity for SHP2 and PTP1B over a broad panel of other PTPs in a biochemical 
 
assay 
[139].  
Interestingly, in the absence of a negatively charged anionic handle which is 
usually  a  common  structural  feature  of  many  phosphatase  inhibitors,  it  would  be 
interesting to observe the performance of this inhibitor and establish its activity and cell 
permeability using a cell-based assay system. 
 
Virtual screening of a 2.7 million compound collection against the SHP2 catalytic domain 
led to the identification of the inhibitor PHPS1 (Compound 8; Figure 1.8; Table 1.2) which 
exhibits an IC50  of 0.7 μM with 15-fold selectivity over SHP1 and a panel of other 
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phosphatases. Although structural evidence confirming the binding mode of PHPS1 to the 
SHP2  catalytic  domain  remains  elusive,  in  silico  modelling  suggested  an  active-site 
directed binding mode. In addition, PHPS1 exhibited in-cell activity through blocking 
HGF-induced ERK phosphorylation in a range of tumour cell lines 
[140]  
and has been 
shown to inhibit cardiac hypertrophy driven by hyperactivated gain of function SHP2 
mutants in cultured cardiomyocytes 
[141]
. 
 
One of the more well validated SHP2 inhibitors was reported by Zhang et al., where 
screening of a combinatorial library using a salicylic acid based scaffold enabled the 
identification of inhibitor IIB08 (Compound 9; Figure 1.8; Table 1.2), which has an IC50 of 
5.5 μM against the SHP2 catalytic domain and a modest 3-fold selectivity over SHP1 and 
 
PTP1B. Kinetic analysis of compound IIB08 inhibition demonstrated that the compound is 
a reversible non-competitive inhibitor of the SHP2 catalytic domain. Furthermore, 
compound IIB08 demonstrates activity in a cell-based assay by blocking EGF-stimulated 
activation of ERK signalling leading to proliferation of haematopoietic cells in response to 
GM-CSF cytokine signalling. A thorough in vivo analysis of IIB08 activity demonstrated 
reversal of tumour xenograft growth in mouse models of non-small cell lung cancer 
[142]
. 
 
Interestingly, compound IIB08 has also demonstrated activity in mast cell models of 
leukaemia where administration of the compound effectively reduced the growth of cells 
harbouring oncogenic forms of the protein tyrosine kinase KIT. The positive anti- 
myeloproliferative promoting effects of IIB08 led to extended survival of mice in models 
of leukaemia. In addition to the wealth of in vitro and cell-based activity demonstrated for 
compound IIB08, structural studies interrogating the mode of compound binding to the 
SHP2 catalytic domain have provided key insights into the interactions formed between 
active site residues of the enzyme and the salicylic acid moiety. This crystal structure 
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provides a basis for the rational design of more potent and efficacious inhibitors of the 
 
SHP2 catalytic domain based on the salicylic acid scaffold 
[143]
. 
 
 
Multiple other SHP2 inhibitors have been identified through combinations of in silico 
docking, compound library screening and medicinal chemistry. For example, the 
oestrogenic-based compound estramustine phosphate (Compound 10; Figure 1.8; Table 
1.2) which harbours a nitrogen mustard moiety and is used as a therapeutic agent in the 
treatment of prostate cancer is a SHP2 inhibitor with a relatively moderate potency of 17 
μM  [144].  Kinetic  characterisation  of  estramustine  phosphate  suggests  the  compound 
displays mixed enzyme inhibition, with in silico docking analysis suggesting that the 
compound binds with an active-site directed mode of inhibition. Interestingly, the chemical 
scaffold of estramustine phosphate is structurally similar to the PTP1B inhibitor MSI- 
1436, which has recently been identified as an allosteric inhibitor of PTP1B that 
simultaneously targets the disordered C-terminus as well as an additional secondary pocket 
in close proximity to the active site 
[145]
. Thus, although the structural resemblance to MSI- 
1436 may indicate a similar binding mechanism for inhibition of SHP2, this has yet to be 
 
established. 
 
 
More recently, natural product inhibitors have been identified as specific inhibitors of the 
SHP2 catalytic domain. In particular, the compound cryptotanshinone (Compound 11; 
Figure 1.8; Table 1.2) derived from the Salvia miltiorrhiza plant 
[146]  
was observed to 
inhibit both SHP1 and SHP2 with a similar IC50  value of 23 μM. Cryptotanshinone also 
exhibits cell-based activity through effective repression of SHP2 activated IL-3 signalling. 
Profiling the activity of cryptotanshinone in an enzymatic assay revealed an irreversible 
mechanism of inhibition, which has been linked to generic mechanisms identified for 
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quinone-based phosphatase inhibitors that include oxidation of the redox sensitive catalytic 
cysteine residue of PTPs 
[147]
. Despite exhibiting promising activity in cell-based assays, 
the reactive oxygen species generated as a by-product of inhibition would be likely to 
induce toxicity and suggest that side effects of this nature would be difficult to avoid if 
these classes of inhibitors were pursued for further development of more potent SHP2 
inhibitors. Another natural product inhibitor demonstrating specific inhibition of the SHP2 
catalytic domain is tautomycetin (Compound 12; Figure 1.8; Table 1.2), which exhibits 
potent inhibition of serine-threonine phosphatases PP1 and PP2A, with IC50 values of 1.6 
nM and 62 nM, respectively. Recently, tautomycetin was discovered as an in vitro active 
SHP2 inhibitor with an IC50 of 2.9 μM and 5-fold selectivity over SHP1 
[148]
. A crystal 
structure of tautomycetin bound to the SHP2 catalytic domain revealed that the inhibitor 
 
binding mode is analogous to phosphotyrosine containing substrates with the lipophilic 
anionic head group forming the dominant interaction with the active site 
[145]
. 
 
Despite considerable efforts directed towards the development of potent and selective PTP 
inhibitors, many of the currently available compounds lack the potency, selectivity and cell 
permeability required for use in animal studies. However, recently a group from Novartis 
reported the identification of a highly specific, potent and orally bioavailable SHP2 
inhibitor that operates through an allosteric mechanism of inhibition 
[149]
. The allosteric 
SHP2 inhibitor, known as SHP099 (Compound 13; Figure 1.8. Table 1.2), was developed 
through an intricate series of screening assays which focused on the identification of small 
molecules which repressed activation of full length SHP2 by a pTyr-based IRS peptide, 
but had no inhibitory effect on the isolated catalytic domain. The crystal structure of 
SHP099 bound to full length SHP2 revealed a previously undisclosed tunnel-like binding 
site located between the catalytic, N-and C-SH2 domains. This suggested that SHP099 
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exerts its inhibitory effect by locking full length SHP2 in the auto-inhibited conformation 
and therefore exploits the natural inhibitory mechanism of the enzyme. Furthermore, 
SHP099 is sufficiently potent (KD  = 71 nM), and exhibits excellent selectivity with no 
significant activity against a broad panel of other PTPs and kinases. However, despite the 
advantageous properties of this inhibitor, concerns have been raised suggesting that the 
authors failed to explore the potential immune-stimulatory effects that might ensue as a 
result of blocking the immune-inhibitory response normally fine-tuned by uninhibited 
SHP2 
[150]
.
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Figure 1.8 Chemical structures of SHP2 inhibitors. (1) Sodium Stibogluconate. (2) 
NSC-87877. (3) NSC-117119. (4) Compound 14a. (5) SPI-112. (6) SPI-112Me. (7) 
Compound 2a. (8) PHPS1. (9) IIB08. (10) Estramustine phosphate. (11) Cryptotanshinone. 
(12) Tautomycetin. (13). SHP099. 
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Compound 
number 
Name IC50 or Ki 
(SHP2) 
Selectivity Activity 
(cell based; 
in-vivo) 
Mechanism 
(type of 
inhibition) 
1 Sodium 
stibogluconate 
100 μg/ml SHP1: 10 μg/ml 
PTP1B: 10 μg/ml 
Yes; yes Covalent 
2 NSC-87877 0.3 μM 
(PTP 
domain) 
1.3 μM 
(full length 
SHP2) 
SHP1: 1-fold 
PTP1B: 5-fold 
HePTP: 24-fold 
Others: >200-fold 
DUSP26: 17 μM 
Yes; yes Competitive 
3 NSC-117119 47 μM SHP1: 68 μM 
PTP1B: 96.7 μM 
Inactive; 
NA 
NA 
4 Compound 14a 0.8 μM SHP1: 15.4 μM 
PTP1B: 1.5 μM 
Inactive; 
NA 
NA 
5 SPI-112 1 μM SHP1: 18.3 μM 
PTP1B: 14.5 μM 
Inactive; 
NA 
NA 
6 SPI-112Me >100 μM 
(in-vitro) 
∼20 μM
 
(cell based 
assays) 
NA (see SPI-112 
data) 
Yes; NA NA 
7 Compound 2a 2.5 μM PTP1B: >40-fold NA NA 
8 PHPS1 0.7 μM SHP1: 8-fold 
PTP1B: 15-fold 
Others: 25-fold 
Yes; NA Competitive 
9 IIB08 5.5 μM SHP1: 15.7 μM 
PTP1B: 14.3 μM 
LYP: 25 μM 
FAP1: 20 μM 
CD45: 30 μM 
LMWPTP: 31 μM 
Yes; yes Reversible and 
non- 
competitive 
10 Estramustine 
phosphate 
17 μM SHP1: 40 μM 
PTP1B: 62 μM 
HePTP: 153 μM 
NA; yes Mixed 
11 Cryptotanshinone 22.5 μM SHP1: 40 μM 
PTP1B: 34 μM 
CD45: 42 μM 
LAR: 37 μM 
MEG2: 59 μM 
TCPTP: 56 μM 
Yes; NA Oxidation of 
catalytic Cys 
and alkylation 
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12 Tautomycetin 2.9 μM SHP1: 14.6 μM 
PTP1B: 41 μM 
LYP: 20 μM 
Others: >50 μM 
Yes; yes NA 
13 SHP099 0.071 μM SHP1: >100-fold Yes; yes Allosteric 
 
 
 
 
Table 1.2 Pharmacological profiles of selected SHP2 inhibitors. Pharmacological 
characterisation of SHP2 inhibitors. The IC50 value is defined as the inhibitor concentration 
eliciting a 50% reduction in enzymatic activity. The inhibitor constant, Ki, provides an 
indication of inhibitor potency and is also defined as the inhibitor concentration required to 
produce half-maximum inhibition. Although IC50 and Ki values both represent 
measurements of inhibitor potency, the conditions under which these measurements are 
obtained is fundamentally different. Whereas Ki values are measured in-vitro against 
isolated and purified enzyme, inhibitor IC50 values are recorded in-vivo where enzyme 
inhibition is measured in the presence of additional factors such as competing 
macromolecules and molecular crowding. As such, IC50  and Ki  values are not directly 
comparable, with IC50 values yielding more representative derivations of inhibitor activity 
under physiologically relevant conditions. Inhibitor selectivity refers to the property 
determined by combining the affinity of the molecule at a particular binding site. The 
activity of an inhibitor refers to the ability to inhibit a biochemical reaction by a known 
quantity (in a biochemical assay), or reverse a phenotypic characteristic if activity is 
measured in an in vivo context. The mechanism of an inhibitor refers to the type of 
enzymatic inhibition displayed by a particular molecule and specifically how the inhibitor 
interferes with the kinetics of enzyme mechanisms and substrate turnover. Such 
mechanisms include competitive, non-competitive and uncompetitive modes of inhibition. 
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1.8 Screening approaches for phosphatase inhibitor discovery 
 
1.8.1 High-throughput compound screening for phosphatase inhibitor discovery 
 
 
Although a successful approach for the development and progression of clinical agents 
when applied to alternative enzyme systems (such as the kinases family of enzymes), high- 
throughput screening efforts to develop cell-active phosphatase inhibitors with attractive 
selectivity has, until recently 
[149,  151]
, been met with comparatively modest success. In 
particular, this disproportionate success has been underscored by the high incidence of 
false positive hits emerging from phosphatase screening campaigns. Although a precise 
explanation for this observation has yet to emerge, multiple mechanisms underlying such 
phenomena have been suggested. These include: 1) the propensity for phosphatase 
inhibitors to form micelle-like aggregates that non-specifically inhibit enzyme activity 
[152]
, 
2)  the  high  reactivity of  the  nucleophilic active  site  cysteine  
[153]
,  and  3)  the  redox 
 
sensitivity of the active site cysteine leading to irreversible inactivation of phosphatase 
activity 
[154, 155]
. In addition to the technical challenges posed by the phosphatase active site 
chemistry and reactivity, phosphatases are renowned for a notable lack of obviously 
druggable surface pockets that could otherwise be exploited for inhibitor development. 
Instead, phosphatases harbour very shallow surface pockets which typically render these 
enzymes intractable to conventional high-throughput screening. This is primarily due to 
the enhanced molecular size of the compounds used in conventional high-throughput 
screens which hinders the accessibility of these compounds for binding these pockets. 
 
Despite the absence of clinically efficacious phosphatase inhibitors, a combination of 
conventional high-throughput screening coupled with fragment-based linking approaches 
have been successful in generating novel, potent and highly selective inhibitors of the 
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protein tyrosine phosphatase, PTP1B 
[156, 157]
. The development of these inhibitors greatly 
benefited from the versatility of NMR spectroscopy which proved to be particularly useful 
for enabling the detection of a diverse range of ligand affinities and thus offered greater 
sensitivity for the screening and validation of early stage compound hits against PTP1B. 
The generation of these inhibitors required HSQC NMR screening of uniformly 
15
N- 
labelled PTP1B against a 10,000 compound library with hits validated in the first instance 
by  assessment  of  chemical  shift  perturbations  in  
15
N-
1
H-resolved  HSQC  spectra. 
Previously determined NMR backbone assignments of the PTP1B protein then enabled 
chemical shift perturbations to be mapped to key residues V49, G228 and G218, all of 
which  were  located  in  and  around  the  PTP1B  catalytic  site.  Analysis  of  the  initial 
screening data revealed a phosphotyrosine mimetic with a KD of 100 μM which was 
subsequently optimized into a more potent active site ligand with a KD of 26 μM. The x- 
ray crystal structure of the optimised phosphotyrosine mimetic in complex with PTP1B 
provided a robust model of ligand binding and confirmed the molecular basis of active site 
specificity of the bound ligand. Unfortunately, the highly conserved architecture and 
chemistry of the phosphatase active site poses significant obstacles for the development of 
conventional active-site directed inhibitors. This in turn also poses a significant challenge 
for achieving the selectivity required for an efficacious clinical inhibitor. Circumventing 
these difficulties requires the development of a re-directed strategy involving the synthesis 
of bivalent inhibitors capable of forming interactions in close proximity to and outside of 
the active site cavity. The development of bivalent inhibitors offers the advantage of 
multiple contact points with a particular target of interest each possessing differential 
potency and specificity which ultimately enhances inhibitor selectivity and affinity. 
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In the same study Szczepankiewicz et al., were successful in discovering inhibitors binding 
to a secondary binding site which was achieved through the utilization of a second 
screening approach involving the selective labelling of PTP1B with 
13
C-methionine in 
order to observe chemical shift perturbations of 13C-methionine resonances in 
13
C-
1
H 
 
HSQC spectra. This screening approach was successful in identifying a ligand bound to 
this site which through optimization and iterative cycles of synthetic chemistry was 
conjugated to the initial active site ligand using a chemical linker. The final inhibitor 
exhibited impressive activity in a pNPP biochemical assay with a Ki of 20 nM, along with 
an equally impressive specificity profile against a panel of phosphatases including 
leukocyte antigen-related tyrosine phosphatase (LAR), SHP2, (protein tyrosine 
phosphatase, receptor type, C) PTPRC and calcineurin ranging from 36-fold to 10,000 fold 
selectively with a moderate two-old selectivity observed over T-cell tyrosine phosphatase 
(TCPTP). This approach established a clear paradigm for phosphatase inhibitor discovery, 
suggesting  that  the  development of  bivalent inhibitors  provides  considerable benefits 
which bolster the affinity and specificity of the final molecule. 
 
Despite the transformative nature of this strategy in the context of phosphatase drug 
discovery, the final PTP1B bivalent inhibitors developed through this approach exhibited 
poor physicochemical properties and unfavourable bioavailability, despite demonstrating 
promising selectivity 
[156]
. However, alternative approaches utilising NMR fragment-based 
screening methods and x-ray crystallography have been successful in generating PTP1B 
inhibitors with demonstrable cell activity 
[157]
. These screening approaches centred heavily 
on the use of monocarboxylic and non-carboxylic acid based fragments as the precursor 
chemotypes which were then optimised into more potent catalytic site ligands. Such 
chemotypes were purposefully selected on the basis of their low charge density in order to 
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maximise the possibility of generating a cell permeable inhibitor. The structure-guided 
modification of the catalytic site ligands and a second phosphotyrosine binding pocket 
yielded a potent and selective PTP1B inhibitor with improved cell permeability that vastly 
superseded the bivalent PTP1B inhibitors developed by the same group 
[156]
. The final 
inhibitors yielded low micromolar affinity and greater than 30-fold selectivity over related 
phosphatases, including TCPTP 
[158]
. 
 
More recently, the application of high-throughput screening has also been successfully 
applied to the discovery of allosteric phosphatase inhibitors. For the past decade the design 
of allosteric phosphatase inhibitors has held considerable appeal, primarily due to the 
frustrating technical challenges of developing selective phosphatase inhibitors targeting the 
active site. This has led to the successful development of selective allosteric inhibitors 
targeting oncogenic phosphatases Wip1 
[159]  
and Eya2 
[160]
. More recently, a team from 
 
Novartis reported the development of a potent, selective and orally bioavailable inhibitor, 
SHP099, for the protein tyrosine phosphatase SHP2, which appears to operate through an 
allosteric mechanism of inhibition. More specifically, the inhibitor exploits the unique 
auto-regulatory mechanism of SHP2 by binding to a centrally located tunnel away from 
the phosphatase active site. In the inhibitor-bound conformation, SHP2 is locked in the 
auto-inhibited state and is thus refractory to activation. The development of SHP099 was 
made possible through an intricately designed high-throughput screening strategy directed 
solely towards the development of allosteric inhibitors. A key factor influencing the design 
of this strategy centres on the observation that SHP2 is activated through the binding of 
doubly phosphorylated peptide and proteins through engagement of N-SH2 and C-SH2 
domains which triggers release of auto-inhibition and the opening of the active site to 
facilitate substrate turnover 
[80, 161]
. To discover inhibitors capable of exploiting this auto- 
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inhibitory mechanism, the Novartis researchers screened a library of 100,000 compounds 
at  a single  concentration  of 20  μM  against  full  length  SHP2  that  had  been  partially 
activated by equilibration with 0.5 μM of a bisphosphorylated IRS-1 peptide. From the 
primary screen, a total of 900 compounds were found to inhibit full length SHP2 by 30% 
or greater. These compounds were then progressed to assess inhibition in three distinct 
biochemical assays: (1) using the catalytic domain of SHP2 only, (2) assaying SHP2 
activity in the presence of partially activating concentrations of bisphosphorylated IRS-1 
peptide, and (3) assaying SHP2 activity in the presence of fully activating levels of 
bisphosphorylated IRS-1 peptide. Compounds targeting the SHP2 catalytic domain only 
were  prematurely  excluded  from  further  screening  to  identify  allosteric  inhibitors. 
Profiling of the inhibitors tested in each of these assays identified six inhibitors 
demonstrating  no  inhibition  against  the  SHP2  catalytic  domain,  moderate  inhibition 
against full length SHP2 equilibrated with 0.5 μM of a bisphosphorylated IRS-1 peptide, 
and reduced inhibition against full length SHP2 equilibrated with 5 μM of a 
bisphosphorylated IRS-1 peptide. The inhibitor displaying the most prominent inhibition 
of full length SHP2 (referred to as SHP836) was chemically optimised into the inhibitor 
SHP099 which exhibited >70-fold improvement in potency yielding a final IC50 = 71 nM. 
SHP099 also demonstrated a remarkable selectivity profile showing no detectable activity 
against a panel of 21 phosphatases and 66 kinases 
[162]
. 
 
 
1.8.2 Fragment-based screening for phosphatase inhibitor discovery 
 
 
In addition to the use of high-throughput screening for the development of phosphatase 
inhibitors, fragment-based screening approaches have also been employed to explore novel 
chemical  scaffolds  as  starting  points  for  phosphatase  inhibitor  development.  More 
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recently, fragment-based screening efforts have been utilised to develop inhibitors against 
the dual-specificity phosphatase CDC25B 
[163]
. To discover novel CDC25B inhibitors a 
diverse library of 1500 chemical fragments were screened by 
15
N-
1
H NMR HSQC at a 
single concentration of 250 μM. Profiling of the fragment hits identified a single hit 
yielding chemical shift perturbations which when mapped to the previously determined 
backbone assignments disclosed a binding site situated 15Å away from the active site. An 
x-ray crystal structure revealed the fragment binding location occupied a small pocket in 
close proximity to the CDK2 substrate binding site. The researchers also noticed a bound 
sulphate ion (from the crystallization buffer) in the same crystal structure which they 
attempted to link to the fragment hit. However, although the optimised molecule 
demonstrated inhibitory activity in a biochemical assay, the final potency was moderate 
with an IC50 = 1-2 mM. 
 
The application of fragment-based screening methods to develop selective phosphatase 
inhibitors remains a significantly underexplored area of research. Despite the obvious 
advantages  of  fragment-based  screening for  identifying novel  druggable  pockets,  the 
results of the CDC25B study suggest that large and chemically diverse libraries containing 
>1500 fragments are likely to be the minimum requirements for the screening of 
phosphatases. The low hit rates observed in fragment-based screens typically correlate 
with the druggable potential of a particular target, and in this instance underscore the 
significant  challenge  of  developing  selective  phosphatase  inhibitors  using  such  an 
approach 
[164]
. Although high-throughput screening has successfully generated cell-active 
phosphatase inhibitors, these screens have greatly benefited from intricately designed 
screening  cascades  and  innovative  chemical  linking  strategies  which  were  precisely 
tailored to exploit the selection of inhibitors with discrete modes of inhibition. 
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Figure 1.9 High throughput screening vs Fragment-based ligand discovery. High- 
throughput screening (HTS) typically involves screening large libraries of chemically 
advanced scaffolds (usually 100,000 – 1,000,000 compounds) with molecular weights in 
the range of 300 Da – 500 Da. However, fragment-based ligand discovery involves 
screening a comparatively smaller library (usually between 1,000 – 2,000 fragments) of 
low molecular weight fragments in the range of 150 Da - 250 Da. Employing fragment- 
based ligand discovery offers the advantage of screening smaller libraries due to the ability 
of fragments to sample large amounts of chemical space. 
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1.8.3 Fragment-based ligand discovery 
 
 
Fragment-based ligand discovery (FBLD) has emerged as a leading approach for 
accelerating the early progression of small molecule therapeutics into approved clinical 
agents 
[165-167]
. Over the past decade, the technique of FBLD has been routinely applied in 
both academic and industrial arenas and has provided clear strategies for stimulating the 
development of small molecule ligands, guiding structure-based drug discovery efforts, 
and  revaluating  approaches  to  high-throughput  screening  
[168-170]
.  The  fundamental 
rationale underpinning the FBLD approach is based on a number of key principles. The 
first of these principles is linked to the idea that small numbers of low molecular weight 
compounds (termed “fragments”) can sample a large population of chemical space [171]. 
The second of these principles refers to the fact that as the molecular weight of a molecule 
increases  along  with  an  increase  in  molecular  complexity,  the  likelihood  of  an 
unfavourable interaction occurring will be greatly increased 
[172]
. Thus, by virtue of their 
low molecular complexity, small molecular weight compounds such as fragments are 
inherently less selective than compounds with larger molecular weights and are therefore 
more capable of interacting with a larger number of protein targets than more conventional 
drug-sized compounds 
[173]
. The ability of small molecular fragments to sample chemical 
space efficiently also has profound implications for the size of chemical libraries for high- 
throughput   screening   cascades.   Typically,   conventional   high-throughput   screening 
cascades employ chemical libraries containing between 100,000 – 1, 000, 000 compounds, 
whereas libraries utilised for fragment-based ligand discovery contain a significantly lower 
number of molecular fragments usually in the range of 500-2000 compounds. Other than 
number  of   compounds,  the   key   difference  between   chemical  libraries   used   for 
conventional high-throughput screening and  fragment screening libraries concerns the 
53 
 
 
molecular weight of the constituent chemotypes, along with their predicted affinities. The 
compounds contained in conventional high-throughput screening libraries typically occupy 
molecular weights between 350 Da – 500 Da, with the expected affinity ranges for these 
compounds emerging from high-throughput assays ranging from the nanomolar to low 
micromolar potency. In contrast however, compounds selected for fragment library 
screening are typically low molecular weight compounds with molecular weights in the 
range of 100 Da - 300 Da with affinities ranging from micrormolar to millimolar potency 
[174]
. The third guiding principle of the FBLD approach is that despite the relatively low 
 
affinity of small molecule fragments, these chemotypes can be chemically optimised and 
expanded through iterative medicinal chemistry into more potent high affinity ligands. 
This iterative cycle of fragment evolution is greatly aided by structural insights obtained 
from x-ray crystal structures of fragments bounds to their protein targets. 
 
The low molecular weight of chemical fragments often results in low affinity binding 
interactions due to the smaller number of molecular contacts formed between the fragment 
scaffold  and  the  protein  target.  Detection  of  such  low  affinity  interactions  therefore 
requires highly sensitive and versatile screening assays in order to provide robust 
confirmation and validation of genuine fragment hits. More commonly, fragment library 
screening assays typically employ biophysical methods as the primary screening 
methodologies,  and  are  often  conducted  in  parallel  using  two  or  more  independent 
methods in order to cross validate hits and reduce false positive hit rates. The range of 
suitable biophysical methodologies for fragment library screening is vast and includes 
NMR  methods  
[175-178]
,  X-ray  crystallographic  screening  
[179,  180]
,  isothermal  titration 
 
calorimetry 
[181]
, protein thermal shift 
[182]
, affinity capillary electrophoresis 
[183]
, weak 
affinity chromatography 
[184] 
and SPR 
[185]
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1.9 Theoretical basis of experimental techniques 
 
1.9.1 Nuclear Magnetic Resonance Spectroscopy 
 
 
1.9.1.1 The physical basis of NMR spectroscopy 
 
Nuclear magnetic resonance spectroscopy is a powerful experimental tool facilitating the 
analysis of molecular structure in the solution state allowing interrogation of the 
interactions between individual atomic nuclei to probe their spatial relationships and 
dynamic propensities. In order to achieve this, NMR relies principally on exploiting the 
differential magnetic properties of certain atomic nuclei in the presence of an external 
magnetic field. 
 
In their simplest form, atomic nuclei can be imagined as miniature bar magnets with north 
and south poles aligned at opposite ends along a vertical axis. An intrinsic characteristic of 
many atomic nuclei concerns a property known as nuclear spin. This nuclear spin can be 
thought of as a localised magnetic field precessing about a central plane in a direction 
perpendicular to the vertical north-south axis. The spin of an individual nucleus precessing 
in this manner is thus referred to as a magnetic moment (or angular momentum) which, by 
convention, contains two fundamental properties: a direction and a magnitude. By virtue of 
containing these two components, nuclear spin is thus operationally defined as a vector 
quantity. In many atomic nuclei (such as 
12
C), the spins of subatomic particles (protons, 
 
neutrons and electrons) are paired in an anti-parallel fashion, such that the nucleus has no 
overall spin. However, for some atoms (such as 
1
H, 
13
C and 
15
N) the nucleus does possess 
an overall spin and is therefore a property that can be exploited in NMR experiments. The 
principles for determining the overall spin of an atomic nucleus are as follows: 
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1.   If the number of neutrons and the number of protons are both even, the nucleus will 
 
have no overall spin 
 
2.   If the sum of the number of neutrons and the number of protons is an odd number, 
 
then the nucleus will have a half-integer spin (e.g. ½) 
 
3.   If the number of neutrons and the number of protons are both odd then the nucleus 
will have an integer spin (e.g. 1, 2, 3) 
 
According to the elementary principles of quantum mechanics, a nucleus of spin I can be 
quantified as having 2I + 1 possible orientations. Therefore, in the case of nuclei with spin 
½ (such as 
1
H, 
13
C and 
15
N), quantum mechanics states that these nuclei can exist in two 
 
different energy states: + ½ and - ½. In the absence of an external magnetic field, these 
two orientations of the nuclear angular momentum will be equal in energy. However, in 
the presence of an external magnetic field the + ½ and - ½ nuclei will be differentially split 
into two different spin populations based on the orientation of the individual nuclear spins 
with respect to the external magnetic field. Those nuclei with spin + ½ aligning with the 
direction of the external magnetic field will be stabilised and thus lowered in energy. 
Conversely, those nuclei with spin - ½ which oppose the direction of the external magnetic 
field will be destabilised and thus excited to higher energy levels. In this way, the 
differential magnetic properties of + ½   and - ½ nuclei in the presence of an externally 
applied magnetic field creates an energy difference between the two nuclei populations 
which is proportional to the strength of the external magnetic field (Figure 1.10). 
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Figure 1.10 Splitting of spin ½ nuclei in an external magnetic field. According to 
quantum mechanics, a nucleus of spin I can be assigned 2I + 1 possible orientations. This 
asserts that nuclei with spin ½ (such as 
1
H, 
13
C and 
15
N) can occupy two different energy 
states: + ½ and - ½. In the absence of an external magnetic field, these two orientations of 
the nuclear angular momentum will be equal in energy. However, in the presence of an 
external magnetic field the + ½ and - ½ nuclei will be split to form two different spin 
populations. Nuclei with spin + ½ aligning with the direction of the external magnetic field 
(α state) will be stabilised and lowered in energy. Conversely, nuclei with spin - ½ which 
oppose the direction of the external magnetic field (β state) will be destabilised and 
promoted to higher energy levels. The differential magnetic properties of + ½   and - ½ 
nuclei in the presence of an externally applied magnetic field creates an energy difference 
between the two nuclei populations which is proportional to the strength of the external 
magnetic field. 
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Briefly, in order to generate an NMR signal the samples containing + ½ and - ½ nuclei 
populations in the presence of an external magnetic field are irradiated by applying a 
radiofrequency pulse with a frequency proportional to the energy difference between the 
two nuclei populations. The application of a radiofrequency pulse triggers the excitation of 
+ ½ nuclei from the lower energy state to the higher energy state occupying - ½ nuclei. 
During application of the radiofrequency pulse, the net magnetisation vector precessing 
around the Z dimension is tipped into the XY plane. The precession of the net 
magnetisation vector in the XY plane then generates an oscillatory signal which induces a 
current in the coil surrounding the NMR sample. The current is then amplified and 
measured as voltage per unit time. To correct the frequency difference between different 
nuclei populations, the absolute resonance frequencies for the nuclei in the sample (f 
(sample) are expressed relative to the absolute resonance frequency of a standard reference 
compound  (f  (reference)  such  as  tetramethylsilane  (TMS)  and  are  converted  into  a 
chemical shift (δ) in parts per million (ppm). Although absolute resonance frequencies are 
strictly dependant on the applied magnetic field, chemical shift values are independent of 
the external magnetic field strength and are therefore expressed in dimensionless units of 
ppm which provides a more manageable scale. Conversion of the absolute resonance 
frequencies of the sample (f (sample) and the reference compound (f (reference) into a 
chemical shift (δ) in parts per million (ppm) is achieved by using the following formula: 
 
 
𝛿 (���)  = 
�(������) − 
�(���������)
 
�(���������) 
× 106 
 
 
 
 
1.9.1.2 The origin of the NMR signal 
 
In order to provide a further explanation of how an NMR signal arises, it is first necessary 
to  adopt  an  alternative  conceptual  framework.  In  NMR  parlance,  this  conceptual 
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framework is commonly referred to as the vector model, and provides an important 
rationale to account for the behaviour of individual nuclei and their associated magnetic 
moments in the presence of an externally applied magnetic field. The vector model is 
outlined briefly below. 
 
As mentioned in section 1.9.1.1, individual atomic nuclei can be imagined as miniature bar 
magnets with each bar magnet having a magnetic moment which, according to the laws of 
quantum mechanics, can be aligned in any direction. However, when conducting an NMR 
experiment, rather than observing the magnetic moments of individual nuclei what we 
actually measure is the net effect of the total magnetic moments resulting from the entire 
nuclei population of the sample. 
 
When atomic nuclei are placed in an external magnetic field, the magnetic moments 
associated with each nuclei will precess around the Z-axis. The precession of the net 
magnetisation around the Z-axis arises due to a slight difference in population between the 
two nuclei energy states (termed α and β), with slightly more nuclei populating the lower 
energy α state. At equilibrium, these magnetic moments can be thought of as aligning in 
such a way that their contribution forms a net magnetic field along the direction of the 
applied magnetic field (B0). This notion is often referred to as the bulk magnetisation of 
the sample, which is commonly represented by a vector quantity known as the 
magnetisation vector (Figure 1.11). Importantly, at equilibrium, the magnetisation vector 
(which represents the bulk contribution of the magnetic moments from the entire nuclei 
population) can be imagined as aligning along the direction of the applied magnetic field 
(i.e. in the Z direction). At its core, the vector model centres on the disturbance of this 
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magnetisation vector away from equilibrium and how its direction can be manipulated 
with respect to the external magnetic field in order to generate an NMR chemical shift. 
 
At equilibrium, the vector model asserts that the net magnetisation vector precesses about 
the Z-axis at a frequency known as the Larmor frequency. The rate of this precession is 
proportional to the strength of the external magnetic field and is thus referred to as the 
Larmor precession.  At  the  Larmor frequency,  precession  of  the  magnetisation vector 
occurs in such a manner that it tilts away from the Z-axis, sweeping out a cone of 
precession that maintains a constant angle to the applied magnetic field (B0) (Figure 1.12). 
In order to detect an NMR signal, the processional motion of the bulk magnetisation vector 
must be disturbed away from equilibrium. In order to achieve this, a very small 90
ο 
radiofrequency  pulse  is  applied  along  the  x-dimension  (at  or  near  to  the  Larmor 
frequency), which results in tipping the magnetisation vector into the XY plane. The 
precession of the bulk magnetisation vector in the XY plane then induces a current in the 
coil surrounding the NMR sample. Following the end of the 90
o 
radiofrequency pulse, the 
bulk magnetisation vector returns back to equilibrium (from precession in the XY plane to 
precession around the Z-axis) with the current gradually decaying with time through 
Transverse relaxation (T2). This decrease in current induction is the NMR signal and is 
known as the Free Induction Decay (FID) (Figure 1.13). A Fourier transformation is then 
applied in order to convert the FID signal from the time domain to the frequency domain 
(Figure 1.14). 
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Figure 1.11 The vector model. At equilibrium, a sample containing a population of nuclei 
has a net magnetisation oriented along the Z-axis in the direction of an externally applied 
magnetic field. In NMR parlance, this is often referred to as the bulk magnetisation vector. 
 
 
 
 
 
 
 
Figure 1.12 The Larmor precession. At the particular frequency, the bulk magnetisation 
vector tilts away from the Z-axis where the vector sweeps out a cone of precession at a 
constant angle to the applied magnetic field. The rate of precessional motion of the bulk 
magnetisation vector about the Z-axis is directly proportional to the strength of the applied 
magnetic field and is referred to as the Larmor precession. 
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1.13 Generation of an NMR signal. Following the application of a 90
o 
radiofrequency 
pulse (at the Larmor frequency) along the X dimension, the precessing magnetisation 
vector is tipped into the XY plane. Tipping of the bulk magnetisation vector into the XY 
plane cuts through the coil and induces a current which is then amplified and recorded. For 
clarity, the coil has only been shown on one side of the x-axis. 
 
 
 
 
Figure 1.14 Fourier transformation of the Free Induction decay. Tipping of the bulk 
magnetisation vector into the XY plane cuts through the detection coil and induces a 
current which is then amplified and recorded as an oscillating signal. This oscillating 
signal is known as the free induction decay and is a phenomenon detected in all pulsed 
NMR experiments. A chemical shift (measured in frequency) is obtained by applying a 
Fourier Transformation which converts the  time domain signal of the free induction decay 
into a frequency signal which yields the resulting frequency spectrum of the NMR signal. 
Figure adapted from Keeler (Understanding NMR spectroscopy). 
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1.9.1.3 1D 
1
H-NMR 
 
The most basic experimental spectrum obtainable on an NMR spectrometer is a 1D 
1
H- 
NMR spectrum. This spectrum provides key information regarding the chemical shift 
resonances for the different proton environments in a particular molecule. These different 
proton environments are then utilised for elucidating the structure of small molecule 
chemicals and often provide a reliable method for verifying the identity of different 
chemical species when used in conjunction with complementary spectroscopic methods 
(such as infrared spectroscopy). In addition to small molecule analysis, the versatility of 
the basic 1D 
1
H-NMR experiment can also be extended to larger molecular systems, such 
as proteins, with a plethora of useful applications. For example, obtaining a 1D 
1
H-NMR 
 
spectrum enables rapid and reliable determination of whether a particular protein occupies 
a folded conformation by monitoring the dispersion of proton signals sweeping across the 
1-10 ppm range and for a small cluster of high field methyl groups at < 0.5 ppm indicative 
of a hydrophobic core of a protein. Prior to data collection, water suppression is often 
conducted to reduce the contribution of the water signal to the resulting NMR spectrum (at 
a concentration of 55 M, the water signals would dominate the entire NMR spectrum if not 
suppressed). A range of strategies have been developed that can be employed to achieve 
solvent suppression yielding good quality spectra 
[186]
. 
 
1.9.1.4 2D 
15
N-
1
H Heteronuclear Single Quantum Coherence Experiment (HSQC) 
 
The 
15
N-
1
H HSQC is a prototypical 2D NMR experiment and is commonly the first two- 
dimensional NMR experiment conducted on proteins. Whereas 1D 
1
H-NMR primarily 
concerns the detection of one NMR signal (in this case that of 
1
H), the basic output of a 2D 
NMR experiment is a contour plot correlating two NMR signals, either through bond or 
through space interactions. As such, the 
15
N-
1
H HSQC is a classical 2D NMR experiment 
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correlating 
15
N and 
1
H nuclei, and therefore should detect all NH groups present in a 
particular molecular species. 
 
Briefly,  the  
15
N-
1
H  HSQC  experiment  relies  chiefly  on  the  use  of  a  sensitivity 
enhancement method known as an Insensitive Nuclei Enhanced by Polarisation Transfer 
(INEPT), a particular radiofrequency pulse sequence which pairs sensitive nuclei (such as 
1
H) with insensitive nuclei (such as 
13
C or 
15
N) enabling the transfer of magnetisation from 
 
the sensitive nuclei to the insensitive nuclei via a mechanism known as scalar coupling. 
 
 
For large macromolecular systems such as proteins, the 
15
N-
1
H HSQC experiment is an 
inherently information-rich method and provides multiple layers of information for 
characterising the overall folds and dynamics of protein structure in solution. The output of 
a 
15
N-
1
H HSQC experiment is a spectrum derived from collecting data in two dimensions: 
1
H nuclei are collected in the direct dimension and the 
15
N nuclei are collected in the 
 
indirect  dimension.  The  spectral  resolution  of  the  data  collected  in  each  of  these 
dimensions during a 
15
N-
1
H HSQC experiment is highly dependent on the data acquisition 
time, with longer acquisition times generally leading to better resolution of the data in the 
dimension being detected. In a similar fashion, the relaxation time during a 
15
N-
1
H HSQC 
experiment provides short delay periods to allow the system to return to a steady state level 
of magnetisation. The more readily the system is able to return to steady state 
magnetisation, the greater the magnitude of magnetisation detected. 
 
Each individual peak represented in 
15
N-
1
H HSQC spectra corresponds to the backbone 
amide group of individual amino acids in the protein, and also includes the side chain 
amide  groups  present  in  Asparagine  (Asn),  Glutamine  (Gln)  and  Tryptophan  (Trp) 
residues. Proline residues are refractory to detection in 
15
N-
1
H HSQC spectra due to the 
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absence of an amide proton. In  NMR parlance, a 
15
N-
1
H HSQC experiment is often 
referred to as the “fingerprint” of a protein largely due to the unique observations that can 
be deduced from analysis of the resulting spectra. Firstly, one can assess whether a 
particular protein is folded by observing the relative dispersion of individual backbone 
amide signals. Typically, a uniform dispersion of amide signals across the spectrum is 
often a reliable indicator of a folded protein structure. In particular, proteins dominated by 
multiple secondary structure elements including helical regions and pleated sheets often 
display more evenly dispersed cross-peaks. 
 
In contrast to capturing more ordered protein states, 
15
N-
1
H HSQC spectra is also 
sufficiently sensitive for the detection of local regions of structural disorder and globally 
unfolded protein states. In particular, sharp and poorly dispersed amide peaks emerging in 
the 8.0-8.5 ppm region of the spectrum strongly correlate with amide protons present 
within disordered loop regions of protein structure that are largely exposed to solvent. In 
addition to the number and dispersion of amide peaks, the relative intensities of each of 
these peaks also conceal information pertaining to the dynamic properties of a particular 
protein. These properties typically comprise conformational equilibria, interconversions 
between monomer and multimer transitions and the aggregation state of a protein. 
 
 
1.9.1.5 Selective Optimised Flip-Angle Short-Transient-HMQC (SOFAST-HMQC) 
 
During the past decade, much effort has been invested into evolving the methodology to 
enable  fast  data  acquisition  for  multidimensional  NMR  experiments.  The  SOFAST- 
HMQC  method  was  developed  precisely  to  speed  up  data  acquisition  time  for  the 
collection of 
15
N, 
1
H or 
13
C, 
1
H HSQC spectra on commercial NMR spectrometers whilst 
preserving both spectral quality and sensitivity 
[187]
. Briefly, the SOFAST-HMQC involves 
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applying a polychromatic pulse (PC9) to selectively excite amide protons leading to an 
overall increase in the rate of 
1
H-spin lattice relaxation, allowing for very short recycle 
delays 
[188]
. 
 
1.9.1.6 Transverse Relaxation Optimised Spectroscopy (TROSY) HSQC 
 
A common technical problem when collecting NMR HSQC spectra on larger protein 
systems (i.e. proteins exceeding >20 KDa) concerns the observation of spectral overlap 
often accompanied with a reduction in spectral sensitivity. These phenomena arise 
principally as  a  result  of  the  sheer  abundance of  amide  proton  signals  and  the  fast 
relaxation properties exhibited by larger molecular species (leading to broadened 
linewidths). In order to overcome these technical difficulties, one has the option of running 
a TROSY version of a HSQC which extends the upper size limit of protein NMR to 
protein systems of < 40 KDa. In a HSQC experiment where decoupling has not been 
applied, amide protons appear as multiplets as a result of J-coupling. These different 
multiplet components each have different linewidths which arise as a result of the 
differential interactions between different relaxation mechanisms. For larger protein 
systems studied at higher magnetic field strengths, the relaxation properties are dominated 
chiefly by dipole-dipole and chemical shift anisotropy relaxation pathways. In a TROSY 
experiment, one exploits the multiplet exhibiting the slowest relaxation and therefore 
observes the one with the sharpest peak 
[189]
. 
 
 
1.9.1.7 3D 
1
H-
15
N-
13
C NMR for unambiguous backbone assignment 
 
As previously mentioned, the 
15
N-
1
H HSQC experiment is often the first heteronuclear 
experiment performed to probe protein structure in the solution state. However, in order to 
facilitate more complex analysis of protein structure, for example, by conducting 
assignments to map each of the cross-peaks in the 
15
N-
1
H HSQC spectra to a particular 
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amino acid in the protein, the 
15
N-
1
H HSQC spectrum must first be optimised in order to 
assess the feasibility of a protein for such analysis. Optimisation of 
15
N-
1
H HSQC spectra 
is typically achieved by adjusting various experimental parameters (e.g. acquisition time, 
protein concentration and buffer conditions) in order to improve both spectral quality and 
resolution. This enhancement in spectral quality and resolution is often signified by a 
uniform dispersion of backbone amide signals which is indicative of a stable and 
appropriately  folded  protein.  Once  an  optimised  
15
N-
1
H  HSQC  spectrum  has  been 
obtained, this then serves as a foundation for more complex structural analysis in the form 
of 3D NMR experiments to permit unambiguous backbone assignment. 
 
A range of experiments are available to facilitate unambiguous assignment of backbone 
amide peaks in 
15
N-
1
H spectra, each of which provide additional information regarding the 
alpha carbon (Cα), beta carbon (Cβ) as well as the carbonyl (CO) chemical shifts. However, 
these experiments require additional 
13
C-labelling enabling data to be collected in a third 
dimension. The most  commonly employed  experiments to  facilitate the  collection of 
backbone assignments, the naming of which is ordered according to magnetisation that is 
transferred sequentially from one nuclei to the other starting from the backbone amide 
proton (HN) are the HNCO, HNCACO, HNCA, HNCOCA, HNCACB and HNCOCACB. 
These experiments will be discussed in further detail below. 
 
1.9.1.7.1    HNCO and HN(CA)CO 
 
The HNCO experiment is widely known as the most sensitive of all the experiments used 
to perform backbone assignments and is often the first 3D experiment performed when 
deciphering the amenability of a protein for backbone assignment studies 
[190]
. The high 
sensitivity of this experiment arises principally as a result of the large J-coupling constant 
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between  the  carbonyl  CO  (i-1)  residue  and  the  N  (i)  residue.  During  the  HNCO 
experiment, magnetisation transfer proceeds from the 
1
H to 
15
N and then selectively to the 
carbonyl 
13
C via the 
15
N
H
-
13
CO J-coupling constant. The magnetisation is then transferred 
back  via  the  
15
N  for  detection on  
1
H.  The general output of  the  HNCO  experiment 
therefore consists of chemical shift spectra for the (i-1) carbonyl residue (CO) preceding 
the HN on which the magnetisation is finally detected (Figure 1.15A). 
 
 
The HN(CA)CO is a complementary experiment often conducted in parallel with the 
HNCO. Much like the HNCO experiment, the HN(CA)CO also yields chemical shifts of 
the preceding (i-1) carbonyl residue (CO) connected to the originally magnetised HN but 
also provides additional chemical shift information for the CO (i) residue (Figure 1.15B). 
The HN(CA)CO therefore gives two CO peaks of different intensity, with the stronger 
peak corresponding to the CO (i) and the weaker peak corresponding to the CO (i-1) 
residue. Taken together, both the HNCO and HN(CA)CO experiments provide 
corroborative information regarding the chemical shift of the preceding (i-1) carbonyl 
residue (CO) connected to the HN from which the magnetisation was initially transferred 
and thus provides a method for distinguishing between the carbonyl CO (i) and CO (i-1) 
for each NH group present in a particular protein. However, in comparison to the HNCO 
experiment the sensitivity of the chemical shift data collected from the HN(CA)CO 
experiment is significantly reduced owing to comparatively smaller J-coupling constant 
between the 
15
N
H
-
13
Cα pair. These complementary insights from both the HNCO and 
 
HN(CA)CO experiments can therefore be used for the sequential assignment of backbone 
amide groups present in a particular protein under investigation. 
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1.9.1.7.2    HNCA and HN(CO)CA 
 
In a similar manner to obtaining chemical shift data for the carbonyl CO of the peptide 
backbone via HNCO and HN(CA)CO experiments, HNCA and HN(CO)CA experiments 
can be performed in order to yield chemical shift information between the amide HN and 
the 
13Cα of both the (i) and preceding (i-1) residues of the peptide backbone. The HNCA 
experiment yields chemical shift resonances for the coupling between HN and 
13Cα of both 
 
(i) and the preceding (i-1) residues of the peptide backbone 
[191]
. However, the HN(CO)CA 
 
experiment provides chemical shift resonance information for the coupling between the 
 
15
N
H
-
13Cα pair of the preceding (i-1) residue only. Superimposing the spectra from HNCA 
and HN(CO)CA experiments enables unambiguous assignment of the 
13Cα for both (i) and 
the preceding (i-1) residues of the peptide backbone (Figures 1.15C and 1.15D). 
 
1.9.1.7.3    HNCACB and HN(CO)CACB 
 
The HNCACB experiment provides chemical shift information based on the coupling 
between HN and the Cα and Cβ of (i) and the preceding (i-1) residues of the peptide 
backbone. In contrast, the HN(CO)CACB experiment generates chemical shift information 
between the (i-1) of Cβ [192]. Superimposing HN(CO)CACB and HNCACB data provides a 
means of unambiguously identifying the (i-1) Cβ peaks within the HNCACB spectra. 
Although both HNCACB and HN(CO)CACB experiments are inherently information rich, 
they are insufficient for unambiguous assignment of peptide backbones. In order to 
accomplish unambiguous peptide backbone assignment, all of the assignment experiments 
described must be analysed together in order to increase the likelihood of establishing a 
correct assignment (Figures 1.15E and 1.15F) 
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Figure 1.15 Schematic depiction of 3D backbone assignment magnetisation transfer. 
Representation of magnetisation transfer pathways obtained from classical 3D protein 
backbone  assignment  spectra.  In  each  experiment,  two  residues  are  depicted  with 
individual atoms denoted in circles. To emulate classic NMR nomenclature, residues are 
denoted as (i) with the preceding residue to (i) denoted as (i-1). Pink circles represent 
atoms where magnetisation is transferred and data is collected indirectly. Blue circles 
represent atoms where magnetisation is transferred but no data is collected. Magnetisation 
transfer experiments for backbone assignments include: (A) HNCO (B) HN(CA)CO (C) 
HNCA (D) HN(CO)CA (E) HN(CO)CACB and (F) HNCACB. For experiments (A-D) the 
magnetisation begins on atom HN, but for experiments (E-F) the magnetisation begins at 
the Hα and Hβ for (E-F). Figure has been adapted from protein-nmr.org.uk, Higman V. 
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1.9.1.8 Saturation transfer difference NMR 
 
As well as enabling the characterisation of protein structure in the solution state, the 
versatility of NMR as an analytical tool can also be applied to probe small molecule ligand 
binding to macromolecular protein structures. Typically, the utility of NMR for the 
interrogation of protein-ligand interactions can be broadly divided into two different 
experimental approaches: protein-observed and ligand-observed methods. In each of these 
experiments, perturbation of the NMR signals of the protein (in the case of protein- 
observed experiments) or the small molecule ligand (in the case of ligand-observed 
experiments) are selectively detected to compare the free and bound states of each 
molecule. In the latter case, one of the most important ligand-observed NMR experiments 
is Saturation Transfer Difference NMR (STD NMR) which relies chiefly on the exchange 
between bound and free states of weakly binding small molecule ligands and a larger 
macromolecule (typically protein). 
 
The rationale underpinning the STD NMR experiment is based on the notion of saturation 
transfer occurring between protein-ligand interactions in solution. Due to their larger 
molecular size, protein-ligand complexes possess a slower tumbling rate in solution 
resulting in a faster rate of relaxation. Conversely, free ligands possess a faster tumbling 
rate in solution and a correspondingly slower rate of relaxation. During the formation of a 
protein-ligand complex, the association of the newly bound ligand (as part of the protein- 
ligand complex) increases the ligand relaxation rate relative to that of the free ligand. 
Consequently, the rate of ligand dissociation must be faster than the rate of relaxation of 
the protein-ligand complex otherwise relaxation occurs and the magnetisation transfer 
would be lost. In an STD experiment, saturation transfer from protein to ligand only occurs 
under conditions where the exchange rate between the free and bound ligand is fast enough 
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to accumulate a population of saturated (magnetised) ligand in solution. Importantly, the 
rate of dissociation of the protein-ligand complex must be large enough to generate 
sufficiently high concentrations of free ligand in solution, but not so large that it does not 
permit the optimal ligand residence time necessary to allow efficient saturation transfer 
from the protein to the ligand to occur 
[193]
. 
 
The execution of a typical STD experiment involves a number of steps. The first step 
involves recording an on-resonance spectrum in which the protein is selectively saturated 
by irradiating the sample with a radiofrequency pulse that contains only resonances of the 
protein (e.g. 0 ppm – 1 ppm). The second objective involves recording an off-resonance 
experiment where a reference spectrum is recorded under the same conditions as the on- 
resonance spectrum, but instead with the selective radiofrequency pulse off-resonance such 
that the frequency is set far away from any resonances present in the system. The off- 
resonance experiment thus yields a spectrum identical to the on-resonance spectrum except 
that the resonances intensities are not affected by saturation. By subtracting the on- 
resonance spectra from the off-resonance spectra, only the ligand resonances that 
experienced a saturation transfer from the protein will be observable in the difference 
spectra. The magnitude of the resulting saturation difference signals will therefore be 
inextricably linked to both the efficiency of the protein-ligand saturation transfer (which 
itself is dependent on the proximity of the ligand to the protein) and the number of protein- 
bound ligands that received saturation transfer. Non-binding ligands will receive no 
saturation transfer from the protein and thus their signals will be of an equal intensity in 
both the on-resonance and off-resonance spectra resulting in no ligand signals appearing in 
the final difference spectra 
[193] 
(Figure 1.16). 
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Figure 1.16 Saturation transfer difference NMR for the detection of ligand binding. 
The STD NMR experiment operates by exploiting the difference between bound and free 
states of weakly binding small molecule ligands to larger molecules, such as proteins. An 
on-resonance spectrum is first recorded in which the protein is selectively saturated via 
irradiation of the sample with a radiofrequency pulse that contains only resonances of the 
protein (e.g. 0 ppm – 1 ppm). An off-resonance spectrum is then recorded under the same 
conditions as the on-resonance spectrum, but with the selective radiofrequency pulse off- 
resonance such that the frequency is set far away from any resonances present in the 
system. The off-resonance experiment thus yields a spectrum identical to the on-resonance 
spectrum except that the resonance intensities are unaffected by saturation. Subtraction of 
the on-resonance spectra from the off-resonance spectra generates a difference spectrum 
where only the ligand resonances that experienced a saturation transfer from the protein 
will be observable. Figure taken from 
[194]
. 
73 
 
 
1.9.1.9 waterLOGSY 
 
 
Another common ligand-observed NMR experiment often employed for the detection of 
protein-ligand interactions is known as the waterLOGSY experiment. Like STD NMR, 
waterLOGSY involves the transfer of magnetisation via an intermolecular NOE (Nuclear 
Overhauser Effect – defined as the change in intensity of a particular resonance when the 
spin properties of another are disturbed from equilibrium) to the transiently bound ligand. 
However, in the case of waterLOGSY bulk water is irradiated and the magnetisation is 
transferred from the transiently bound water to the bound ligand. This transfer of 
magnetisation from water to the bound ligand can occur via multiple different pathways. 
These include direct transfer of magnetisation from water molecules occupying the ligand 
binding site, chemical exchange between irradiated water molecules and labile protons on 
the protein surface, and transfer of magnetisation from water molecules populating the 
protein surface via the protein-ligand complex 
[176,  195]
. In all of these mechanisms the 
 
ligands  transiently  interact  with  water  via   water-ligand  protein  or   protein-ligand 
complexes, where in both cases the rotational correlation times are slower (relative to free 
water which has faster tumbling rate) thus exhibiting a negative NOE value with water. In 
contrast, small molecule ligands that interact solely with bulk water (i.e. non-binders) will 
have a faster tumbling rate giving a positive NOE. Thus, in a waterLOGSY spectrum one 
typically observes opposite signs for free vs protein-bound ligands enabling discrimination 
between binding ligands vs non-binding ligands (Figure 1.17). 
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Figure 1.17 waterLOGSY NMR for the detection of ligand binding. In a waterLOGSY 
experiment, magnetization is transferred from the bulk water to the free ligand via the 
protein-ligand complex via an intermolecular NOE (Nuclear Overhauser Effect – defined 
as the change in intensity of a particular resonance when the spin properties of another are 
disturbed from equilibrium) to the transiently bound ligand. 
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1.9.2 Surface plasmon resonance 
 
 
The characterisation of biomolecular interactions is fundamental for unravelling the 
molecular basis of cellular processes and is essential for guiding the discovery and 
development of novel drug molecules for diverse biological targets. Surface plasmon 
resonance (SPR) has emerged as a powerful optical detection method that provides crucial 
insights into the binding parameters governing molecular interactions of central biological 
importance. 
 
The phenomenon of SPR arises when an incident beam of polarised light passing through a 
medium of high refractive index (such as a glass prism) undergoes total internal reflection 
by striking the glass slide of a sensor surface. The glass face of the sensor surface is coated 
with a thin layer of gold that directly interfaces to a buffer solution of low refractive index. 
In order to generate a resonance signal, the incident beam of polarised light is directed 
towards the glass face of the sensor surface and the internally reflected light emitted is 
detected. When the incident polarised light strikes the glass surface interface an evanescent 
wave is generated which is subsequently absorbed by the electrons present within the gold 
layer causing them to resonate. The resonating electrons (also referred to as plasmon 
waves) lead to a reduction in the intensity of the internally reflected light. Consequently, 
the resonant angle at which the reflected light shows the most significant reduction in 
intensity is a function of the refractive index of the buffer solution on the opposite side of 
the sensor surface. As such, the SPR response is exquisitely sensitive to environmental 
perturbations occurring at the sensor interface facing the buffer solution, and it is precisely 
this sensitivity of SPR that is exploited for the measurement of biomolecular interactions. 
By immobilising ligands to the sensor surface, the refractive index of the surface changes 
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by  altering  the  resonant  angle  at  which  the  polarised  light  (of  reduced  intensity)  is 
reflected. The change in refractive index caused through either the binding or dissociation 
of a particular analyte to an immobilised ligand is therefore proportional to the mass of 
analyte bound to the sensor surface. In order to monitor the progression of a binding 
interaction between an analyte and an immobilised ligand, the SPR instrument generates a 
sensorgram profile (Figure 1.18) from which important phases of the binding interaction 
(such as association, kinetics and dissociation) can be derived 
[196]
. 
 
As a biophysical technique, SPR benefits from providing a label-free approach which 
allows for direct measurement and observation of binding in real time, and spares the need 
to infer binding from indirect measurements through the displacement of a radio- or 
fluorescently-labelled ligand. In order to measure the kinetics of biomolecular interactions, 
the biosensor surface is primed for the immobilisation of a particular ligand which can be 
achieved through a myriad of different coupling approaches. Typical coupling strategies 
include covalent methods such as amine, thiol or aldehyde coupling, or non-covalent 
methods such as the employment of metal ion chelation, antibody tags or other affinity 
tags such as biotin or streptavidin. SPR biosensor assays can be employed to elucidate a 
number of parameters underlying the formation of molecular complexes. These include 
information regarding the kinetics (association ka  and dissociation rates kd), affinities at 
equilibrium (KD) and the stoichiometry of the interaction. 
77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18. Surface plasmon resonance. A schematic representation of a typical 
sensorgram profile for a surface plasmon resonance experiment. The biosensor surface is 
first primed by covalent or non-covalent immobilisation of a specific ligand. An analyte is 
then injected over the biosensor surface which leads to the formation of analyte-ligand 
interactions. This is known as the association phase of the sensorgram and is accompanied 
by a concomitant increase in the resonance signal. The analyte then dissociates from the 
immobilised ligand leading to a gradual decay in the resonance signal until it eventually 
returns back to baseline. The SPR experiment provides a quantitative description of the kon 
and koff rates of association and dissociation respectively, and enables a dissociation 
constant KD to be calculated at the steady state phase of the sensorgram curve. 
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1.9.3 Circular Dichroism Spectroscopy 
 
 
The quantification of protein secondary structure (i.e. the percentage of α-helices and β- 
sheets) and the extent of protein folding can be reliably determined by applying the 
technique of Circular Dichroism Spectroscopy. The technique of circular dichroism 
involves passing a beam of left and right-handed circularly polarised light at wavelengths 
between 190-260 nm through a protein sample of interest. During irradiation of the protein 
sample, the presence of secondary structure elements and chiral molecules leads to the 
differential absorption of left and right-handed polarised light in different directions. 
Quantification of the chirality or secondary structure characteristics of the protein can then 
be determined by the analysis of the resulting spectra. 
 
Typically, circular dichroism experiments involve recording spectra for both the protein 
sample and the control sample, with the latter containing buffer identical to that which the 
protein sample has been dialysed into. To ensure the collection of high quality data, all 
buffers subjected to circular dichroism analysis should be prepared meticulously so that 
the final buffer contains the fewest possible chemical reagents. In particular, chloride ions 
(Cl
-
) should be present either at minimal levels or ideally avoided completely in order to 
 
limit quenching of the absorption signal 
[197]
. 
 
 
After data collection, a solvent subtraction step is performed where the buffer control 
sample is subtracted from the sample containing protein. The resulting spectrum 
corresponds to an absorption spectrum representing the secondary structure elements of the 
protein sample. Once processed, the resulting spectra are usually reported as molar 
ellipticity (θ) in millidegrees (mdeg) as a function of wavelength. The data analysis is 
usually conducted using the online software package DICHROWEB 
[198]
. 
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1.9.4 Analytical Ultracentrifugation 
 
 
The biophysical technique of  analytical ultracentrifugation provides information 
concerning the homogeneity of both the mass and conformation of particles in solution. In 
order  to  achieve  this,  samples  are  placed  in  a  sample  cell  inside  an  analytical 
ultracentrifuge and are then subjected to a centrifugal force where the sedimentation 
velocity of particles in response to the centrifugal force is measured. The sedimentation 
velocity is inextricably linked to both the molecular mass and the shape (hydrodynamic 
radius) of the particles in solution. As such, analytical ultracentrifugation is therefore a 
valuable method for deciphering the homogeneity (in both mass and conformation), 
aggregation state and oligomerisation of the sample. The concentration distribution of 
individual particles in the sample is measured across the cell (as a sedimentation gradient) 
by taking an absorbance reading at a wavelength of 280 nm. The sedimentation velocity 
measurement is then used to measure the sedimentation co-efficient expressed in the units 
of Svedbergs (S). Analysis of analytical ultracentrifugation data is typically performed 
using  the  software  package  SEDFIT  
[199]    
(see  Appendix  figure  4).  In  this  work, 
 
sedimentation   velocity   experiments   will   be   conducted   in   order   to   measure   the 
concentration of the particles in the cell as a function of time in the centrifugal force 
 
1.9.5 Conclusion 
 
 
Despite once being considered as passive housekeeping enzymes, an evolving body of 
evidence is beginning to shed new light on the previously underappreciated roles of protein 
tyrosine phosphatases in human physiology and disease. As such, protein tyrosine 
phosphatases are now widely considered as a family of signalling enzymes with emerging 
therapeutic potential. 
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The cytoplasmic PTP SHP2 plays a central role in the propagation of downstream 
signalling from multiple growth factor and cytokine receptors, and was the first oncogenic 
PTP  to  be  discovered.  Dysregulation  of  SHP2  signalling  represents  a  pathological 
hallmark of developmental disorders such as Noonan and LEOPARD syndrome, and plays 
a central role in driving the oncogenic phenotypes underlying breast cancer and 
myeloproliferative disease. 
 
Owing to these roles, the potential of SHP2 as a novel oncology drug target has garnered 
significant interest over the past decade. Indeed, advances in drug development initiatives 
such as the implementation of fragment-based screening approaches have challenged 
conventional dogma by generating potent inhibitors for some of the most challenging 
classes of biological targets. The overarching aim of this thesis involves exploiting 
fragment-based screening methods to stimulate the development of SHP2 inhibitors that 
could serve either as chemical probes for interrogating the basic biology of SHP2, or lead 
to the development of inhibitors with potential therapeutic significance. 
 
In order to stimulate the discovery of novel SHP2 inhibitors, the first objective of this 
work involves the expression of 
15
N-labelled SHP2 catalytic domain and utilising 
15
N-
1
H 
protein-observed NMR spectroscopy to optimise 
15
N-
1
H HSQC spectra of SHP2 catalytic 
domain in solution. NMR backbone assignment experiments will then be conducted on the 
SHP2 catalytic domain under the optimised experimental conditions in an attempt to 
illuminate backbone assignments for amino acid residues in the phosphatase active site. 
The ligand binding behaviour of the SHP2 catalytic domain in solution will also be 
investigated by conducting titrations with the SHP2 inhibitor, NSC-87877. Chemical shift 
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perturbations observed in the presence of NSC-87877 will then be mapped to the backbone 
assignments to uncover the as yet structurally undisclosed binding mode of the NSC- 
87877 inhibitor. In addition, as a precursor to conducting fragment-based screening of 
SHP2, the second objective of this work involves conducting a thorough characterisation 
of published SHP2 inhibitors using a range of biophysical and biochemical assays in order 
to validate the biochemical activity and binding affinities of these compounds. SHP2 
inhibitors demonstrating consistent activity across all assays will then serve as positively 
validated tool compounds for use in fragment-based screening. Using the validated SHP2 
tool compounds, the third objective will involve conducting fragment-based screening of 
different SHP2 constructs (including the catalytic domain, tandem SH2 domains and full 
length SHP2) using both SPR and NMR-based (STD NMR and waterLOGSY) methods in 
order to identify fragment hits against each domain. Validation of fragment screening hits 
will then be confirmed by re-testing fragments in SPR dose-response, STD and 
waterLOGSY experiments. The final and fourth objective of this study will involve 
developing and optimising a soakable crystal system in order to facilitate structure 
determination of validated fragment hits bound to the SHP2 catalytic and with the ultimate 
goal of initiating structure-guided optimisation of these fragments through iterative 
medicinal chemistry in order to generate more potent chemical inhibitors. 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
 
 
2.1 Molecular biology 
 
2.1.1 SHP2 expression plasmids and construct design 
 
 
DNA encoding the SHP2 catalytic domain (amino acid residues 237-533) cloned into the 
pNIC28-Bsa4 vector as a Tobacco Etch Virus (TEV)-cleavable N-terminally Hisx6-tagged 
fusion protein was a kind gift provided by Dr Alastair Barr and Prof Stefan Knapp at the 
Structural  Genomics  Consortium,  University  of  Oxford.  For  the  surface  plasmon 
resonance (SPR) experiments all SHP2 constructs were purchased from Genscript, USA. 
DNA encoding the SHP2 catalytic domain (residues 237-533), tandem-SH2 domains 
(residues 4-216) and full-length SHP2 (residues 1-597) was codon-optimised for 
recombinant expression in Escherichia Coli (E. coli), chemically synthesised and inserted 
into a custom-made pET15b vector between restriction sites NdeI-XhoI (Genscript, USA). 
The DNA encoding each SHP2 construct was additionally modified to contain an N- 
terminal TEV-cleavable Hisx6  tag (MHHHHHHSSGVDLGTENLYFQS) along with a C- 
terminal  Avi-Tag
TM   
sequence  (GLNDIFEAQKIEWHE)  to  aid  biotinylation  of  each 
 
construct  following  heterologous  expression  and  protein  purification.  A  list  of  all 
constructs used in this study is provided in Table 2.1: 
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Protein construct 
 
Vector 
type 
 
Antibiotic 
resistance 
 
Affinity tag 
 
Cleavage tag 
 
  
SHP2 catalytic 
domain 
 
(aa residues 237-533) 
 
pNIC28- 
Bsa4 
 
Kanamycin 
 
N-terminal 
Hisx6 tag 
 
TEV-cleavable 
 
  
Tandem-SH2 
domain 
 
(aa residues 4-216) 
 
pNIC28- 
Bsa4 
 
Kanamycin 
 
N-terminal 
Hisx6 tag 
 
TEV-cleavable 
 
  
Full length SHP2 
 
(aa residues 1-597) 
 
pET- 
26b(+) 
 
Kanamycin 
 
C-terminal 
Hisx6 tag 
 
TEV-cleavable 
 
  
SHP2 catalytic 
domain Avi-tag
TM 
(SPR) 
 
(aa residues 237-533) 
 
pET- 
15b(+) 
 
Kanamycin 
 
N-terminal 
Hisx6 tag 
 
TEV-cleavable 
 
  
Tandem-SH2 
domain Avi-tag
TM 
(SPR) 
 
(aa residues 4-216) 
 
pET- 
15b(+) 
 
Kanamycin 
 
N-terminal 
Hisx6 tag 
 
TEV-cleavable 
 
  
Full length SHP2 
Avi-tag
TM (
SPR) 
 
(aa residues 1-597) 
 
pET- 
15b(+) 
 
Kanamycin 
 
N-terminal 
Hisx6 tag 
 
TEV-cleavable 
 
 
 
Table 2.1 SHP2 DNA constructs. The table shows the different SHP2 protein constructs 
with  corresponding  amino  acid  numbers,  as  well  as  expression  vectors,  antibiotic 
resistance markers, and affinity purification and cleavage tags for each SHP2 construct 
used in this study. Further information regarding the DNA and amino acid sequences of 
gene inserts for individual constructs can be found in the Appendix figure 2. 
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2.2 Protein expression 
 
2.2.1 Plasmid transformation into DH5α cells 
 
 
Plasmid DNA (~1 µl) at a concentration of 5-500 ng/µl was used to transform 20 µl of 
 
DH5α competent cells (Invitrogen). Competent DH5α cells were then incubated on ice for 
 
20 min at 4
o
C followed by heat shock treatment at 42
o
C for exactly 30 s. Transformed cells 
were then incubated on ice for a further 2 mins, after which 80 µl of room temperature 
Super Optimal Broth (SOC) or Lysogeny Broth (LB) was added and the cells left to 
incubate at 37
o
C with shaking at 210 rpm for 45 mins Transformed cells were plated onto 
LB agar plates supplemented with the appropriate antibiotic and left to incubate overnight 
at 37
o
C for colonies to develop. 
 
2.2.2 Isolation and amplification of SHP2 DNA constructs 
 
All DNA constructs used in this study were amplified according to the methodology 
described in the Qiagen Miniprep kit (Qiagen). SHP2 DNA constructs were transformed 
(see section 2.21 for transformation protocol) into E. coli DH5α competent cells, plated 
and then incubated overnight at 37
o
C. Bacterial colonies were then picked and used to 
inoculate 5 ml of LB then left to incubate with shaking at 220 rpm at 37
o
C overnight. 
 
Overnight bacterial cultures were then centrifuged at 8000 rpm for 3 minutes at 20
o
C in 
order to pellet cells. After centrifugation, bacterial pellets were thoroughly resuspended by 
addition of 250 µl P1 resuspension buffer and then lysed by addition of 250 µl of P2 lysis 
buffer. After 5 min, the lysate mixture was thoroughly mixed with 350 µl of buffer N3 and 
subsequently centrifuged for 10 minutes at 13,000 rpm in a table-top microfuge. The 
supernatant  was  subsequently  loaded  onto  a  QIAprep  spin  column  (Qiagen)  and 
centrifuged for 1 min after which the flow through was discarded and the column washed 
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by addition of 500 µl Buffer PB. After discarding the flowthrough, the column was washed 
with 750 μl buffer PE and then centrifuged for 1 minute to remove residual wash buffer. 
Purified DNA was eluted from the column by addition of 50 µl buffer EB (10 mM Tris- 
HCL, pH 8.5), left to stand for 1 min and then centrifuged for a further 1 min. The 
concentration of purified DNA was quantified using a Nanodrop and stored at -20
o
C. 
 
2.2.3 Large scale expression of unlabelled SHP2 catalytic domain 
 
 
The pNIC28-Bsa4.SHP2 catalytic recombinant vector DNA (SGC, University of Oxford) 
was used to transform E. coli BL21 (DE3) cells according to the transformation protocol 
described previously. After overnight incubation at 37
o
C, successful transformants 
appearing as colonies were then picked and used to inoculate 6 x 10 ml of overnight LB 
media supplemented with Kanamycin (30 µg/ml). Cultures were then left to incubate 
overnight at 37
o
C with shaking at 220 rpm. Overnight starter cultures were then used to 
inoculate 6 L LB media (20 ml overnight culture per 2 L LB media) supplemented with 
Kanamycin (30 µg/ml) and grown until an OD600 reading of 0.5 was reached after which 
point the temperature was then reduced to 18
o
C. Expression of SHP2 catalytic domain was 
 
then induced by addition of 1 mM IPTG when an OD600  reading of 0.7 was reached and 
then left to incubate for 16 hours overnight. 
 
2.2.4 Expression of 
15
N-1abelled SHP2 catalytic domain for NMR studies 
 
 
The pNIC28-Bsa4.SHP2 catalytic recombinant vector DNA (SGC, University of Oxford) 
was used to transform E. coli BL21 (DE3) cells according to the transformation protocol 
(described in 2.2.1). For production of 
15
N-labelled SHP2 catalytic domain the expression 
protocol (described in 2.2.4) was used and suitably modified only by exchanging LB 
media for M9 minimal media to enable production of 
15
N-labelled protein. A standard M9 
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nutrient mix was added to the M9 minimal media before inoculation with the bacterial 
starter cultures. 
 
2.2.5  Expression  of  
2
H-
15
N-
13
C  isotopically-labelled  SHP2  catalytic  domain  for 
backbone assignment determination 
 
For the production of 
2
H-
15
N-
13
C isotopically-labelled SHP2 catalytic domain the same 
protocols were used for transformation of SHP2 constructs in E. coli BL21 (DE3) cells 
(described in 2.2.1) and expression (described in 2.2.3) and purification (described in 2.3.3 
and 2.3.4) of 
15
N-labelled SHP2 catalytic domain were employed with slight modifications 
to enable additional labelling of the protein with 
2
H and 
13
C nuclei. Briefly, 
2
H-
15
N-
13
C 
 
isotopically-labelled SHP2 catalytic domain was expressed in 4 L E. coli BL21 (DE3) cell 
cultures supplemented with M9 nutrient mix containing 1g/l 
15
NH4Cl, 4 g/l 
2
H-
13
C-D 
glucose, 99% D2O, Kanamycin (30 μg/ml) and grown until an OD600 0.4 was reached after 
which point the temperature was then reduced to 18
o
C. Expression of 
2
H-
15
N-
13
C 
isotopically-labelled SHP2 catalytic domain was then induced by addition of 1 mM IPTG 
when an OD600 reading of 0.6 was reached and then left to incubate for 16 hours at 18
o
C 
overnight. 
 
2.2.6 Expression of SHP2 Avi-tag
TM 
SPR constructs 
 
 
Expression of Avi-tag
TM  
SPR constructs for SHP2 catalytic domain (residues 237-533), 
tandem-SH2 domains (residues 4-216) and full-length SHP2 (residues 1-597) was 
facilitated using the same protocols for transformation into DH5α cells (see section 2.2.1), 
expression (see section 2.2.3) and purification (see section 2.3) of labelled SHP2 catalytic 
domain. 
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2.3 Protein purification 
 
2.3.1 Harvesting cells by centrifugation 
 
After overnight expression at 18
o
C, BL21 (DE3) E. coli cells were harvested by 
centrifugation at 6000 rpm for 20 mins at 4
o
C (Avanti J-20XP centrifuge using a JLA 8.1 
rotor). After discarding the supernatant, cell pellets were resuspended in resuspension 
buffer containing 50 mM HEPES pH 7.5, 500 mM NaCl, 50 mM Imidazole, 0.5 mM 
 
TCEP (tris(2-carboxyethyl)phosphine) and two EDTA (ethylenediaminetetraacetic acid)- 
free protease inhibitor cocktail tablets (Roche). Resuspended cells were then stored at - 
80
o
C for further use. 
 
 
2.3.2 Mechanical homogenisation of cells 
 
 
Cells pellets were homogenised at 15,000 psi for three continuous cycles using an 
Emulsiflex C-3 (Avestin). During continuous rounds of lysis cells were incubated at 4
o
C 
on ice. Fully homogenised crude lysates were centrifuged at 25000 rpm for 45 mins at 4
o
C 
(Avanti J-25, centrifuge using a JA25.50 rotor). The supernatant was then filtered using a 
0.45 μm filter. 
 
 
2.3.3 Purification of His-tagged proteins by Ni
2+
-NTA affinity chromatography 
 
 
Purification of all unlabelled and isotopically-labelled SHP2 constructs for NMR and SPR 
studies (all of which were Hisx6-tagged) was conducted using the same method of Ni
2+
- 
NTA affinity chromatography. After passing the supernatant though a 0.2 µm syringe 
filter, Hisx6-tagged proteins were loaded onto a 5 ml His-trap column (GE Healthcare) pre- 
incubated with re-suspension buffer containing 50 mM HEPES pH 7.5, 500 mM NaCl, 50 
mM Imidazole, 0.5 mM TCEP and two EDTA-free protease inhibitor cocktail tablets 
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(Roche) and pre-washed according to manufacturer’s instructions before being purified by 
Ni
2+
-NTA affinity chromatography. His-tagged SHP2 protein was eluted using elution 
buffer containing 50 mM HEPES pH 7.5, 500 mM NaCl, 250 mM Imidazole, 0.5 mM 
TCEP and two complete EDTA-free protease inhibitor tablets (Roche). Elution fractions 
were tested for protein by addition of Bradford Reagent and those fractions containing the 
most protein were run by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) to determine purity and ascertain molecular weight in conjunction with 
known molecular weight markers (Bio-Rad). For all SHP2 constructs a further purification 
step was required using size-exclusion chromatography (see 2.3.5). 
 
2.3.4 Removal of Hisx6-tag by incubation with TEV protease 
 
 
Elution fractions containing the highest levels of Hisx6-tagged protein were pooled and 
transferred to SnakeSkin
TM 
dialysis tubing (Thermo Scientific) before overnight dialysis in 
50 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP in the presence of TEV protease 
(2 mg/ml). In all cases, a second His-clean step was employed by passing the overnight 
dialysate back through a pre-equilibrated Ni
2+
-NTA affinity column in order to remove the 
cleaved Hisx6-tag and any uncleaved protein. Pre and post-TEV cleavage samples, along 
with flow-through, wash and elution fractions were subject to SDS-PAGE analysis in 
order to validate successful cleavage. Successfully cleaved protein was most abundant in 
the wash fraction, which was then concentrated to ~ 5 ml and further purified by size- 
exclusion chromatography (see section 2.3.5). 
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2.3.5 Protein purification by size-exclusion chromatography 
 
 
His-cleaved protein was finally purified to homogeneity using an Superdex-75 26/60 size- 
exclusion column (GE Healthcare). Flow rates were set at 2.5 ml/min with a 4 ml fraction 
collection volume. Elution fractions corresponding to the highest absorbance peaks at 280 
nm were analysed by SDS-PAGE to gauge purity and fractions containing the highest 
quantities of pure protein were pooled and concentrated prior quantification of protein 
concentration. 
 
2.4 Protein biochemical analysis 
 
2.4.1 Determination of protein purity by SDS-PAGE 
 
 
Protein samples (~1-20 μl) for SDS-PAGE analysis were prepared by mixing samples with 
equal volumes of 2x Laemmlli buffer (Sigma) and samples were then loaded onto an 18- 
well pre-cast 4-12% SDS-PAGE gel (Bio-Rad). Molecular weight markers (Bio-Rad) were 
run as a reference alongside protein samples for comparison of molecular weight to known 
standards. Typically, SDS-PAGE gels were run at 180V for 45 mins in 2-(N- 
morpholino)ethanesulfonic acid (MES) SDS running buffer (Bio-Rad). All SDS gels were 
stained with Instant-blue
TM 
reagent and then left to develop while shaking for 30 mins. 
 
2.4.2 Determination of protein concentration by A280 measurement 
 
Following  size-exclusion  purification,  proteins  were  concentrated  using  an  Amicon 
Ultra
TM 
filter with a 10 KDa cut-off. Protein samples were then centrifuged at 4000 rpm 
for 10 min cycles at 4
o
C until reaching an approximate volume of ~1 ml. Determination of 
the final concentration of purified protein was facilitated by taking absorbance readings at 
a  wavelength of 280 nm using a UV spectrometer (Shimadzu UV-1700 Pharmaspec). 
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Quantification of the final protein concentration was conducted by computing the 
absorbance reading at 280 nm and the molar extinction coefficient for the protein sequence 
(obtained from ProtParam; see Table 2.2) into the Beer-Lambert equation: 
 
A = εcl 
Where A = absorbance reading measured at 280 nm, 
ε = molar extinction coefficient (M-1 cm-1) 
c = concentration (M) 
 
 
l  = path length (cm) 
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Protein construct Molar extinction coefficient (M
-1 
cm
-1
) 
 
 
 
SHP2 catalytic domain 
(aa residues 237-533) 
45380 
 
 
 
Tandem SH2 domain 
(aa residues 4-216) 
22920 
 
 
 
Full length SHP2 
(aa residues 1-597) 
72770 
 
 
SHP2 catalytic domain Avi-tag
TM 
(SPR) 
(aa residues 237-533) 
50880 
 
 
Tandem SH2 domain Avi-tag
TM 
(SPR) 
(aa residues 4-216) 
28420 
 
 
Full length SHP2 Avi-tag
TM 
(SPR) 
(aa residues 1-597) 
78270 
 
 
 
 
Table 2.2 Molar extinction coefficient values for SHP2 constructs. Molar extinction 
coefficient values were calculated using the ProtParam software and then inserted into the 
Beer-Lambert equation along with the A280 readings to determine the concentration of each 
SHP2 construct in solution. 
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2.5 Biophysical characterisation of protein structure 
 
2.5.1 Analytical Ultracentrifugation (AUC) 
 
 
Analytical ultracentrifugation (AUC) experiments were performed in collaboration with 
Rosemary  Parslow  (School  of  Biosciences).  Unlabelled  SHP2  catalytic  domain  was 
purified to homogeneity by Ni
2+
-NTA chromatography followed by size-exclusion 
chromatography and dialysed into 50 mM sodium phosphate pH 7.5, 150 mM NaCl, 0.5 
mM  TCEP,  and  50  mM  HEPES  pH  7.5,  150  mM  NaCl,  0.5  mM  TCEP.  Two 
concentrations of SHP2 catalytic domain were made up with phosphate and HEPES buffer 
to a final volume of 500 μl so that the absorbance readings at 280 nm were 0.15 and 0.35 
to ensure optimum data collection. Protein samples were centrifuged using a Beckman XL- 
1 analytical ultracentrifuge containing an An-50 Ti Analytical 8-place rotor at speeds of 
 
25000 and 40000 rpm for 20 h at 20
o
C. Data analysis was conducted using the SEDFIT 
 
software 
[200] 
(see Appendix figure 4). 
 
 
2.5.2 Secondary structure analysis using Circular Dichroism 
 
 
Samples for Circular Dichroism (CD) analysis were prepared by dialysis of unlabelled 
SHP2 catalytic domain into separate buffer solutions containing 20 mM sodium phosphate 
pH 7.5, 0.5 mM TCEP and 20 mM Tris pH 7.5 and 0.5 mM TCEP. The pH of all buffers 
was adjusted with appropriate equivalents of H2SO4 in order to reduce the presence of Cl- 
ions which would otherwise quench the CD signal. Proteins were diluted to a final 
concentration of 0.1 mg/ml in a final volume of ~300 µl before transfer to a 1 mm cuvette. 
All measurements were recorded on a JASCO-J810 spectrometer at 25
o
C in the spectral 
range of 180 nm-240 nm at 0.5 nm intervals with a 1 s scan rate at each data collection 
point giving a total of 120 scans. Final CD spectra were obtained by subtraction of the 
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buffer CD spectra from CD spectra recorded with protein. Subsequently analysis of the 
final CD spectra was achieved using the CDSSTR analysis tool from the DICHROWEB 
server 
[201]  
(see Appendix figure 4) which enabled quantification of the ratio of protein 
secondary structure elements. 
 
2.6 NMR experiments 
 
2.6.1 NMR sample preparation 
 
 
Samples for nuclear magnetic resonance (NMR) spectroscopy experiments were analysed 
using Agilent 600 MHz, 800 MHz and 900 MHz spectrometers, each of which was 
equipped with a triple resonance cryoprobe fitted with the appropriate z-axis pulse field 
gradients. Prior to data acquisition, the magnetic signal was locked on D2O to calibrate and 
stabilise the magnetic field. After locking the signal on D2O, the spectrometer was tuned to 
each nuclei channel and shimmed in order to homogenise the magnetic field prior to 
recording high resolution NMR spectra. Excitation sculpting was run on all samples to 
suppress the water signals enabling more accurate resolution and acquisition of the protein 
signals. Acquisition of the protein signals was then achieved through calculating the 90
o 
pulse, which represents the time-frame (measured in μs) of the radiofrequency pulse that 
leads to the rotation of the net magnetisation from the Z-axis to the XY plane. All NMR 
experiments and analysis were conducted in collaboration with Dr Mark Jeeves (Henry- 
Welcome NMR Building, University of Birmingham). 
 
2.6.2 One-dimensional 
1
H-NMR 
 
 
1
H NMR spectra was consistently recorded prior to conducting multidimensional 
experiments in order to confirm the presence of folded protein at the experimental 
concentration, and also to verify the chemical identity and gauge the solubility of various 
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chemical compounds. Before data acquisition, shimming functions were applied followed 
by excitation sculpting 
[202]  
to suppress water signals and allow determination of the 90
o 
pulse. Parameters used for excitation sculpting include a relaxation time of 1s, a spectral 
width of 18 ppm for 
1
H and an acquisition time of 70 ms. 
 
2.6.3 
15
N-
1
H NMR HSQC titrations with compound NSC-87877 
 
 
15
N-
1
H NMR heteronuclear single quantum coherence (HSQC) titrations with compound 
NSC-87877 were performed on a Varian INOVA 800 MHz spectrometer fitted with the 
appropriate z-axis gradients and a 4-channel cryoprobe. Sequential additions of sodium 
phosphate (pH 7.5) were added to 0.3 mM 
15
N-isotopically labelled SHP2 catalytic domain 
(dialysed into 50 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP) to final 
concentrations of 5 mM, 10 mM and 20 mM in order to gauge improvements in spectral 
quality. All HSQC spectra were recorded in the presence of a final NMR buffer containing 
50 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP, 10% (v/v) D2O, 5% (v/v) DMSO 
and 20 mM sodium phosphate to improve spectral resolution. Compound NSC-87877 was 
solubilised to a final concentration of 200 mM in 100% (v/v) D6-DMSO. 
15
N-
1
H TROSY 
HSQC spectra were recorded on 
15
N-isotopically labelled SHP2 catalytic domain (and 20 
 
mM sodium phosphate) in the presence and absence of a two-fold equivalent (0.6 mM) of 
compound NSC-87877. Analysis was conducted using CCPN analysis software (see 
Appendix figure 4) and spectra in the presence and absence of inhibitor was overlaid to 
identify residue-specific perturbations and map these to previously collected backbone 
assignments. 
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2.6.4  Triple  resonance  experiments  for  backbone  assignment  of  SHP2  catalytic 
domain 
 
NMR triple-resonance experiments for backbone assignment of the SHP2 catalytic domain 
were performed on a Bruker 900 MHz NMR spectrophotometer equipped with a triple 
resonance  cryoprobe  and  z-axis  pulse  field  gradients.  Backbone  assignments  were 
collected by running TROSY versions of HNCO, HNCACO, HNCA, HN(CO)CA, 
HNCACB, HN(CO)CACB experiments 
[203] 
along with 
15
N-
1
H HSQC on 0.5 mM 
2
H-
15
N- 
13
C-labelled SHP2 catalytic domain in a final NMR buffer containing 50 mM sodium 
 
phosphate pH 7.5, 150 mM NaCl, 0.5 mM TCEP and 10% (v/v) D2O. 25% non-uniform 
sampling was applied during data collection across 3D planes for all assignment 
experiments. For the 
15
N dimension, 64 planes were collected across all assignment 
experiments. A total of 64 planes were also collected for the carbonyl (CO) and alpha 
carbon (CA) dimensions corresponding to HNCO, HN(CA)CO, HNCA and HN(CO)CA 
experiments, as well as 96 planes collected for the alpha carbon (CA) and beta carbon 
(CB) corresponding to HNCACB and HNCOCACB experiments. Backbone pulse 
sequences were obtained from VNMRJ Biopack. Triple resonance data was processed with 
NMRPipe (see Appendix figure 4) and analysed using CCPN (see Appendix figure 4) 
analysis in collaboration with Dr Mark Jeeves (Henry-Welcome NMR facility, University 
of Birmingham). 
 
2.6.5 STD-NMR validation of NSC-87877 inhibitor binding 
 
 
All STD-NMR spectra were acquired on a Varian 600 MHz spectrometer with z-axis pulse 
field gradients and a triple-channel cryogenic probe. Samples containing 100 μM NSC- 
87877 and 5 μM unlabelled SHP2 catalytic domain were prepared in glass champagne 
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vials in buffer containing 50 mM d-Tris pH 7.5, 100 mM NaCl, 0.5 mM TCEP, 5% (v/v) 
DMSO and 20% (v/v) D2O to a final volume of 50 μl. Data was analysed in Topspin 3.1. 
 
 
 
 
 
2.7 Enzymatic activity assays 
 
2.7.1 pNPP activity assay 
 
The phosphatase activity of SHP2 catalytic domain was assessed using the 
spectophotometric p-nitrophenyl phosphate (pNPP) assay. Initial reactions to determine 
the Km  of pNPP for SHP2 were conducted at 25
o
C in 50 mM HEPES pH 7.5, 150 mM 
NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), and 0.5 mM tris(2- 
carboxyethyl)phosphine (TCEP). Enzymatic reactions were initiated with addition of 100 
nM SHP2 to assay mixtures containing 0, 1, 2.5, 5, 10, 20, 30, 40, 50 mM pNPP substrate 
 
(~0.5Km-10Km) in final reaction volumes of 100 μl. Phosphatase activity for each pNPP 
concentration was assayed at time points 0, 2, 4, 6, 8, 10, 12 min and was subsequently 
arrested with 50 µl of 5M NaOH. Activity measurements for each substrate concentration 
were corrected for non-enzymatic hydrolysis by subtracting the control at time point 0 in 
the absence of enzyme. The amount of p-nitrophenol product generated from each reaction 
was measured by absorbance at 405 nm using a Bio-Rad iMark
TM 
microplate reader. 
Absorbance readings were plotted against pNPP concentration for each time point and 
initial rates in Abs min
-1  
were converted into µM min
-1  
by using the molar extinction 
coefficient 18,000 M
-1  
cm
-1
. Michaelis-Menten curves were generated using Sigma plot 
 
12.0 by fitting data to a rectangular hyperbola enabling derivation of enzymatic parameters 
 
Km and Vmax. 
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2.7.2 Inhibitor activity assays 
 
 
Inhibition of SHP2 phosphatase activity was assessed using the spectrophotometric pNPP 
assay in the presence of SHP2 inhibitors IIB08 and NSC-87877 and was conducted using 
the same experimental protocol and assay parameters as described in 2.7.1. Compound 
IIB08 was tested at concentrations of 0 µM, 5 µM and 10 µM, and compound NSC-87877 
at concentrations of 0 µM, 0.5 µM, 1.0 µM and 2.0 µM in final reaction volumes of 100 
µl. In addition, inhibitor assays were repeated in the presence of BSA (0.1 mg/ml) and 
Tween 20 in order to eliminate non-specific and aggregation-driven mechanisms of 
inhibition. Michaelis Menten curves were generated using Sigmaplot 12.0 by non-linear 
regression analysis by fitting to a rectangular hyperbola enabling derivation of enzymatic 
parameters Km and Vmax and determination of the mode of inhibition. Values for the 
inhibitor constant Ki were derived by fitting the inhibitor curves to a rectangular hyperbola 
modified for competitive and non-competitive inhibition. 
 
2.8 SHP2 fragment screening 
 
2.8.1 Preparation of fragment library 
 
 
A 433-compound fragment library of sufficient diversity was compiled from a selection of 
commercially available chemical fragments (Maybridge and Sigma). Fragments were 
selected on the basis of physicochemical properties including molecular weight (typically 
between 110 - 250 g mol
-1
), predicted solubility in water (2 mM), suitability for the 
proposed screening strategy, chemical tractability, appropriate functionality for synthesis, 
diversity of chemical scaffolds and general applicability to a wide array of target classes. 
Compounds were prepared as 200 mM stocks in 100% (v/v) DMSO in a dark moisture- 
free cabinet. Prior to screening, 1D 
1
H-NMR analysis was conducted on all compounds to 
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confirm structural integrity and verify chemical identity. Mass spectrometry was also 
orthogonally employed in order to resolve ambiguities in compound validation. 
 
 
 
 
 
2.8.2 Biotinylation of SHP2 Avi-tag
TM 
constructs for SPR 
 
 
Purified Avi-tagged SHP2 constructs were buffer exchanged into biotinylation reaction 
buffer consisting of 100 mM Tris pH 7.5, 20 mM NaCl, 5 mM MgCl2. Avi-tagged SHP2 
constructs were then incubated for 2  hours at  30
o
C in a reaction mixture containing 
 
25 x protease inhibitor cocktail (PIC; Roche), 100 mM ATP, 100 µM  Biotin and 2 mg/ml 
BirA ligase enzyme. Biotinylated SHP2 constructs were further purified by size exclusion 
chromatography (Superdex-75 10/300 GL column; GE Healthcare) to remove excess free 
biotin. Elution fractions from size-exclusion chromatography were concentrated (see 2.4.1) 
and the final concentration calculated by measuring absorbance at A280 (see 2.4.2). 
 
 
 
 
 
2.8.3 Western blotting analysis 
 
 
Western blots of purified biotinylated SHP2 catalytic domain, tandem SH2 domain and 
full length SHP2 were conducted in order to determine whether biotinylation of protein 
constructs was successful. Protein samples (2 μl) were mixed with equal volumes of 2x 
Laemelli buffer (Sigma) and run by SDS-PAGE (see 2.4.1) alongside control protein 
CamKID at 180V for 45 mins. The SDS gel was then washed for 5-10 mins with western 
blot buffer consisting of 1 x Tris-buffered saline and Tween 20 (TBST) to remove residual 
gel running buffer and was subsequently transferred to a polyinylidene fluoride (PVDF) 
and nitrocellulose membrane as part of a Trans-Blot® Turbo™ Mini PVDF Transfer Pack 
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(Bio-Rad). Transfer was conducted using a Trans-Blot® Turbo™ blotter set at 180 V for 7 
 
mins (Bio-Rad) and after successful transfer the nitrocellulose membrane was washed in 
 
3%  (w/v)  BSA  for  1  hour,  followed  by  incubation  with  streptavidin-horse  radish 
peroxidase (HRP) antibody (1:20,000 fold dilution) for a further 1 hour at room 
temperature. After antibody incubation, the nitrocellulose membrane was washed with 1 x 
TBST for 3 x 10 min washes to remove residual antibody and developed with a 50:50 ratio 
of ECL (enhanced chemiluminescence solution) solution using the ChemiDoc system 
(Bio-Rad). 
 
2.8.4 Fragment screening by SPR 
 
 
A Biacore T200 instrument (GE Healthcare) was used to conduct all SPR fragment-based 
screening experiments. Biotinylated SHP2 catalytic domain, tandem SH2 domains and 
wild-type full length SHP2 proteins were each immobilised on a Series S SA streptavidin- 
coated sensor chip using standard methodology and reagents (GE Healthcare handbook). 
SHP2 catalytic domain was immobilised on flow cell 2 with the tandem SH2 domains and 
wild-type full length SHP2 immobilised to flow cells 3 and 4, respectively. Flow cell 1 
was left unmodified and used as a reference control channel. SHP2 catalytic domain, 
tandem SH2 domains and wild type full length SHP2 were prepared as 1 μM, 1.5 μM, and 
3.0 μM respectively in buffer containing 10 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM 
TCEP and then immobilised to a Series S SA streptavidin-coated sensor chip over a 10 
min period with a set immobilisation level of 10000 RU. Final immobilisation levels were 
7900 RU, 7875 RU and 7600 RU, for the SHP2 catalytic, tandem SH2 domains and wild- 
type full length SHP2, respectively. A 433-compound Maybridge/Sigma library was then 
screened to identify active fragments binding to each SHP2 construct. Prior to running the 
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fragment screen all compounds were solubilised in 100% (v/v) D6-DMSO to a final 
concentration of 200 mM. Compound stocks at 200 mM were initially diluted to 40 mM in 
100%  (v/v)  D6-DMSO  before  further  dilution  to  a  final  screening  concentration  of 
 
200 µM. Fragment screening experiments were performed at 25
o
C with assay running 
buffers consisting of phosphate and non-phosphate buffer conditions. For non-phosphate 
buffer conditions, fragments were prepared in 10 mM HEPES pH 7.5, 150 mM NaCl, 
0.05% (v/v) Tween 20 (Sigma) and 0.5 mM TCEP. In phosphate buffer, fragments were 
prepared in 1.05 x PBS (GE Healthcare) pH 7.5, 0.05% (v/v) Tween 20 (Sigma) and 0.5 
mM TCEP. 
 
For each screening run, fragments were injected over the sensor chip surface at a final 
concentration of 200 μM with a contact time of 30s and a flow rate of 30 μl/min. The 
SHP2 catalytic domain inhibitor NSC-87877 at an initial stock concentration of 200 mM 
in 100% (v/v) D6-DMSO was then subsequently diluted using both phosphate and HEPES 
running buffers to a running concentration of 100 μM. Compound NSC-87877 was then 
injected every 46 cycles and run as a positive control throughout the screening assay to 
gauge protein stability as a measurement of ligand binding throughout the duration of the 
assay. Before running the fragment screens, a DMSO (dimethyl sulfoxide) solvent 
correction curve was prepared with either phosphate or 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid (HEPES) fragment dilution buffer spanning a DMSO 
concentration range between 4.5-5.8% (v/v), corresponding to concentrations above and 
below the 5% (v/v) final DMSO concentration used in the screening assay. Biacore 2000 
evaluation software was then used for the analysis of each screening dataset. Screening 
data for all experiments was corrected for DMSO responses by applying the solvent 
correction  to  all  samples  in  the  screen  to  analyse  the  extent  to  which  the  DMSO 
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concentration of the fragments matched the DMSO concentration in the running buffer. 
Observable discrepancies or DMSO mismatches between samples and running buffers 
above or below the solvent correction parameters were eliminated from the screen and re- 
tested. Screening data was then normalised according to compound molecular weights and 
then corrected for signals from the running buffer. Final responses for fragment hits were 
generated by subtraction of the signals generated from protein-immobilised flow-cells 
from signals obtained from the unmodified reference surface. 
 
Fragment hits were then selected for by interrogation and inspection of final sensorgram 
profiles (subtracted from the blank reference cell). Responses showing a classical on/off 
“table-top” binding profile that gave responses at or greater than the 3 RU cut-off were 
validated as hits. Validated hits from the primary screen were then tested by dose-response 
SPR experiments in order to derive appropriate binding affinities. 
 
Fragments  hits  recorded  against  the  SHP2  catalytic  domain  by  SPR  screening  were 
selected for further analysis in dose-response experiments by SPR. Fragments active in 
dose-response experiments were repurchased as singletons (Maybridge) and prepared as 
200 mM stock solutions in 100% (v/v) D6-DMSO. Singleton stock solutions were then 
prepared as 10 mM stock solutions in 5% (v/v) DMSO by dilution in buffer containing 10 
mM HEPES pH 7.5, 150 mM NaCl, 0.05% (v/v) Tween 20 and 0.5 mM TCEP. Dose- 
response experiments were then conducted in running buffer containing 10 mM HEPES 
pH 7.5, 150 mM NaCl, 0.05% (v/v) Tween 20, 0.5 mM TCEP and 5% (v/v) DMSO. 
Biotinylated SHP2 catalytic and full length SHP2 were immobilised to saturation yielding 
final responses of 7900 RU and 6870 RU, respectively, using the same concentrations and 
immobilisation parameters as previously described. Fragments were injected with a total 
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contact time of 30 s at a concentration range of 0.64 mM - 10 mM (1:5 serial dilution 
series from 10 mM starting concentration) using a flow rate of 30 μl/min. The positive 
control compound NSC-87877 (Merck) was also tested using a 30 s contact time and 30 
μl/min flow rate at 0.0064 μM-100 μM (1:5 serial dilution series from 100 μM) in order to 
confirm protein stability and assess the reproducibility of the results. Biacore 2000 
evaluation software was used to confirm fragments showing dose-response binding and 
validate fragment binding affinities. Dose-response binding data for each fragment dilution 
series  was  corrected  for  DMSO  mismatch  and  apparent  fragment  affinities  were 
determined by fitting to a 1:1 protein-ligand binding stoichiometry. The maximum binding 
capacity of the surface (Rmax) based on the level of protein immobilisation was calculated 
for each fragment hit and the sensorgrams interrogated for binding profiles to discriminate 
between specific and non-specific binding. 
 
 
 
 
 
2.8.5 Fragment screening by STD-NMR and waterLOGSY 
 
 
Fragment screening by STD (saturation transfer difference)-NMR and water-ligand 
observed via gradient spectroscopy (waterLOGSY) was conducted in collaboration with 
Dr Mark Jeeves (Henry-Welcome NMR building, University of Birmingham) using the 
same fragment library used for SPR screening. Out of the 433 fragments only 384 were 
screened with 49 fragments discarded due to solubility issues. The 384 fragments were 
screened in cocktails of 4 and each mixture added to 5 µM of unlabelled SHP2 catalytic 
domain, tandem SH2 domains and full length SHP2. Screening of the fragment cocktails 
was  conducted  using  STD-NMR  and  waterLOGSY  using  two  separate  screening 
conditions for each measurement in final NMR buffers containing 50 mM d-Tris pH 7.5, 
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150 mM NaCl, 0.5 mM TCEP, 20% D2O, 5% (v/v) D6-DMSO and 20 mM sodium 
phosphate pH 7.5, 150 mM NaCl, 0.5 mM TCEP, 20% (v/v) D2O, 5% (v/v) D6-DMSO to 
compare fragment hit rates in phosphate and HEPES buffer conditions. The final 
concentration of each fragment in the cocktails was 500 μM. Samples were mixed in 
champagne vials and subsequently transferred into 1.7 mm NMR tubes using a Gilson GX- 
271  liquid  handler.  STD-NMR  and  waterLOGSY  measurements  were  acquired  on  a 
Bruker 600 MHz spectrometer at 298 K equipped with a cryoprobe, the appropriate z-axis 
pulse field gradients and an autosampler. For STD data acquisition, irradiation frequency 
parameters were - 0.5 ppm for on resonance spectra and 25 ppm for off resonance spectra, 
with the power set to 5 mw 
[193]
. The acquisition time used for both STD and waterLOGSY 
experiments was 1.7s. For STD experiments a saturation time of 3s was used, whereas a 
mixing time of 1.5s was used for all waterLOGSY experiments. Final protein 
concentrations of 5 µM and ligand concentrations of 500 µM were used throughout both 
STD and waterLOGSY experiments. The number of scans used in both STD 
[193]  
and 
waterLOGSY 
[176] 
experiments was 128. STD and waterLOGSY data were both analysed 
 
using TOPSPIN version 3.2 by comparing experimental STD spectra for each fragment 
cocktail with 
1
H-NMR spectra for the individual compounds. Fragments showing an 
inversion of the waterLOGSY signal were validated as hits. Fragment hits in STD spectra 
were deciphered and subsequently deconvoluted in sample mixtures showing positive STD 
resonances. 
 
2.8.7 Thermal shift assays for buffer stability 
 
 
Thermofluor
TM 
assays were conducted to determine optimal buffer conditions of the SHP2 
catalytic domain as a precursor to crystal screening. A 2 μl aliquot of SYPRO orange 
104  
 
fluorescent dye (20x stock) was added to the protein (20 μM) and then a further 2 μl of the 
protein:dye mix was added to a 96-well buffer screen (48 μl in each well). Thermal 
stability measurements for the protein in each buffer condition were obtained by recording 
the assay in an RT-Mx3005P PCR machine (Stratagene). Melting curves were recorded at 
temperatures between 25
o
C-90
o
C and fluorescence readings were obtained at excitation 
and emission wavelengths of 490 nm 560 nm, respectively. 
 
 
 
 
 
2.9 X-ray crystallography 
 
2.9.1 Crystallisation screening 
 
 
Prior to setting up crystallisation trials, SHP2 catalytic domain was expressed and purified 
to >95% homogeneity as determined by SDS-PAGE analysis according to methods 
previously  described  in  2.2.1,  2.3.1  and  2.4.1.  Small-scale  crystallisation  trials  were 
initially set up using a Mosquito nanolitre crystallisation robot (TTP Labtech). This 
involved mixing 100 nl of protein with an equivalent 100 nl volume of crystallisation 
buffer in a series of 96-well plates. Conditions yielding promising crystal hits were then 
progressed and optimised on a larger scale by adjusting precipitant concentration, protein 
concentration, the ratio of protein to crystallisation buffer in the drop, and the total drop 
volume. Large scale optimisation using 24-well plates (Cloverleaf) led to growth of 
diffraction-quality crystals of the SHP2 catalytic domain in conditions containing 8%-9% 
PEG 3350, 25 mM sodium malate pH 7.5 with 3 μl crystal drops containing 1 μl protein to 
2 μl crystallisation buffer. All crystallisation trials were conducted at 5
o
C with crystal 
 
growth occurring after 3 days. 
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2.9.2 X-ray data collection and processing 
 
 
Prior to X-ray data collection, crystals grown at 8 mg/ml protein concentration in 
crystallisation buffer containing 8%-9% PEG 3350 and 25 mM sodium malate pH 7.5 
were soaked in a cryoprotectant mixture containing 25% ethylene glycol before being 
immediately flash frozen in liquid nitrogen. Crystals flash frozen in liquid nitrogen were 
then mounted and cooled at 100 K under a nitrogen gas cryostream. X-ray diffraction data 
was collected to a resolution of 3.1 Å on an in-house MicroMax 007HF X-ray source 
(Rigaku) using a Saturn CCD detector (X-ray facility, School of Biosciences, University of 
Birmingham) and processed by Dr Fiyaz Mohammed (Institute of Cancer and Genomic 
Sciences, University of Birmingham). The initial diffraction data was then integrated, 
scaled and merged using programs of the XDS suite. Molecular replacement was used to 
obtain missing phase information using the PHENIX program suite 
[204]  
(see Appendix 
 
figure 4). 
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CHAPTER 3: STRUCTURAL ANALYSIS OF SHP2 INHIBITOR 
BINDING BY NMR SPECTROSCOPY 
 
 
 
 
3.1 Experimental aims 
 
To assist the development of more efficacious inhibitors and enable further understanding 
of the ligand binding behaviour of the SHP2 catalytic domain in the solution state, the aim 
of this chapter was to utilise 
15
N-
1
H protein-observed NMR spectroscopy to provide the 
first structural evidence for the binding mode of the previously identified SHP2 inhibitor, 
NSC-87877. To do this it was necessary to perform 
1
H-
15
N-
13
C amide backbone 
assignments. More broadly, utilising an NMR-based approach the aim was to explore 
ligand-binding to the SHP2 catalytic domain under physiologically relevant conditions and 
use these insights to determine the optimal conditions for conferring protein stability as a 
precursor to fragment-based compound library screening and inhibitor development. 
 
The work described in this chapter has built upon previous and unpublished data generated 
by Dr Timothy Knowles (School of Biosciences, University of Birmingham) and Dr Mark 
Jeeves  (Henry  Welcome-NMR  Building,  University  of  Birmingham),  whose  work 
provided an 80% completion of the backbone resonance assignments of the SHP2 catalytic 
domain in the solution state. Mapping of these assignments to the crystal structure of the 
SHP2  catalytic domain (PDB: 3B7O) 
[38]   
revealed a noticeable stretch of unassigned 
 
regions correlating with amino acid residues located directly in the phosphatase active site. 
In particular, those residues residing in the dynamic phosphate binding loop (P-loop), a 
core component of the conserved protein tyrosine phosphatase (PTP) catalytic motif, 
exhibited the longest stretch of continuous unassigned resonances. Indeed, several NMR 
assignment studies on related protein tyrosine phosphatases 
[205-207]  
have reported similar 
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observations of missing assignments owing to the inherent conformational dynamics and 
structural plasticity of active site loop regions, which serve as critical determinants for 
governing substrate recognition and accessibility of phosphopeptide ligands to the 
phosphatase active site. As a crucial structural component of SHP2 ligand recognition, it 
was deemed prudent to concentrate on attempting to resolve the missing key assignments 
surrounding the catalytic pocket. Defining a more completely assigned active site would 
thus enable rapid and accurate prediction of active-site directed inhibitors and fragments 
binding to the SHP2 catalytic domain in the solution state. As such, the first aim of this 
chapter was to therefore expand the current assignment coverage by increasing the 
deuteration levels of the protein sample to improve data quality and thus yield further 
resolution of amide backbone resonance assignments of unassigned residues lining the 
SHP2 catalytic pocket. 
 
As a precursor to fragment based library screening to enable the discovery of novel small 
molecule inhibitors targeting SHP2, the second aim of this chapter was to characterise the 
structural integrity and solution behaviour of SHP2 catalytic domain in phosphate and 
HEPES buffer conditions and verify perturbations of these phenomena in the presence and 
absence of the SHP2 inhibitor, NSC-87877. In obtaining such information, our intention 
was to characterise the ligand binding behaviour of SHP2 catalytic domain with a putative 
inhibitor to validate 
15
N-
1
H HSQC NMR spectroscopy as a viable method for mapping and 
 
interrogation of inhibitor and fragment binding modes in solution. This approach provides 
complementary insights into the optimal buffer conditions for small- molecule screening to 
ensure targeting of a stable, correctly folded and physiologically-relevant protein 
conformation. 
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As a final objective, to further explore the ligand binding capabilities of SHP2 in solution, 
the backbone amide assignments of the SHP2 catalytic domain derived from triple 
resonance  NMR  experiments  were  utilised  to  map  the  binding  mode  of  inhibitor 
NSC87877 and uncover structural and dynamic aspects of inhibitor interactions with the 
SHP2 catalytic domain that would be directly applicable to the objective of developing 
novel SHP2 inhibitors. More specifically, binding of the NSC87877 inhibitor may serve to 
stabilise the active site loop motions in a more rigid conformation allowing additional 
assignments in these regions of protein structure to be determined, in particular those of 
the amino acid residues lining the catalytic pocket. This would provide the first 
experimental validation of SHP2 inhibitor binding by NMR spectroscopy and illuminate 
key amino acid residues that are directly or indirectly perturbed upon interaction with 
NSC-87877 and the SHP2 catalytic domain. 
 
3.2 Results 
 
In order to guide the development of novel SHP2 inhibitors, the first aim of this chapter of 
work was to expand the total assignment coverage of the SHP2 catalytic domain by 
increasing the levels of protein deuteration in an attempt to resolve the previously 
unassignable residues lining the phosphatase active site. Unfortunately, the restrictions of 
15
N-
1
H  protein-observed  NMR  spectroscopy to  the  study  of  proteins  with  molecular 
 
weights <40 kDa prohibited collection of backbone assignments for the 72 kDa full length 
SHP2 protein. To circumvent this problem, concerted efforts by past and current members 
of Professor Michael Overduin’s laboratory have culminated in the assignment of the 
individual domains of SHP2 which collectively comprise all of the structured domains in 
the full length protein. 
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These efforts have led to the sequential backbone resonance assignments of the n-SH2, c- 
SH2, tan-SH2 (n-SH2 and c-SH2 domain together) and catalytic domain of SHP2. In 
particular, 80% of the backbone amide resonances of the SHP2 catalytic domain have been 
assigned (from the unpublished work of Dr Timothy Knowles, University of Birmingham). 
These contributions have elevated our understanding of the structure and dynamics of 
SHP2 in solution and offer a robust platform for interrogating ligand binding to SHP2 
using  NMR   spectroscopy.  This   platform  allows   the   characterisation  of   inhibitor 
interactions with individual domains, and can be exploited for the development of SHP2 
inhibitors with novel modes of inhibition. 
 
3.2.1 Expression and purification of 
2
H-
15
N-
13
C-labelled SHP2 catalytic domain 
 
 
Prior  to  conducting  triple  resonance  experiments  in  an  attempt  to  further  resolve 
unassigned regions of SHP2 catalytic domain, a uniformly-labelled sample of 
2
H-
15
N-
13
C 
SHP2 catalytic domain was grown in 99% D2O using M9 minimal media supplemented 
with  deuterated  glucose  to  increase  deuterium-labelling of  the  protein  to  ~85%  (see 
method described in 2.2.5). These conditions were selected and optimised based on 
previous conditions which used M9 media supplemented with 
13
C-labelled glucose to 
generate a triple-labelled protein sample yielding 80% of backbone amide assignments of 
the SHP2 catalytic domain (data collected by Dr Timothy Knowles). After obtaining 
purified protein to ~95% homogeneity, as judged by SDS PAGE analysis (Figures 3.1 & 
3.2), 
2
H-
15
N-
13
C-labelled SHP2 catalytic domain was incubated with TEV protease to 
 
facilitate removal of the His-tag. Analysis of the SDS gel (Figure 3.1B) suggests that 
cleaved protein elutes predominantly in the wash fraction with negligible levels of 
detectable protein in the flow-through fraction. Despite the SDS gel indicating a clear mass 
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difference (an unquantified observation that appears consistent with the removal of a 2.6 
 
KDa Hisx6  tag and linker region) between uncleaved and cleaved protein (Figure 3.1B, 
lanes 2 and 3, respectively), the virtually undetectable levels of cleaved protein in the 
flow-through  fraction  were  initially surprising.  However,  the  total  volume  of  pooled 
protein collected from the initial purification step (which formed the overnight TEV- 
treated dialysate) was ~ 6 ml suggesting that the majority of the cleaved protein species 
may have still been loaded onto the 5 ml HisTrap column which had only passed through 
one column volume. A subsequent wash step with 25 ml wash buffer (5 column volumes) 
proved sufficient to recover the residual cleaved protein that had yet to elute (Figure 3.1B, 
lane 5). Thereafter, the recovered cleaved protein was concentrated and dialysed into a 
final NMR buffer containing 50 mM sodium phosphate, 150 mM NaCl, 0.5 mM TCEP. 
The final protein concentration was 0.52 mM which was subsequently diluted to 0.5 mM 
for collection of NMR backbone assignments. 
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Figure 3.1 Affinity purification and SDS-PAGE analysis of  
2
H-
15
N-
13
C – labelled 
SHP2 catalytic domain. A. From left to right: molecular weight markers (M), supernatant 
(S), flow-through from soluble lysate fraction (FT), wash (W), elution fractions (E1-E12). 
Arrowhead indicates overexpression of SHP2 catalytic domain. B. Pooled 1.5 ml elution 
fractions obtained from affinity purification using a 5 ml HisTrap affinity column (E5- 
E12) pre and post-incubation with TEV protease (2 mg/ml). From left to right: pooled 
elution fractions pre-TEV incubation (PC), pooled elution fractions post-TEV incubation 
(C),  flow-through  collected  from  TEV-treated  overnight  dialysate  (FT),  wash  (W). 
Analysis of the molecular weight differences between pre and post-TEV incubation 
fractions indicate the successful removal of Hisx6-tag + linker region. The wash fraction 
containing TEV-cleaved protein was further purified to homogeneity by size-exclusion 
chromatography. 
112  
 
 
Figure  3.2  Purification  of  
2
H-
15
N-
13
C-labelled  SHP2  catalytic  domain  by  size 
exclusion chromatography. A. Analysis of purified 
2
H-
15
N-
13
C–labelled SHP2 catalytic 
domain by SDS-PAGE and size-exclusion chromatography. TEV-cleaved protein in the 
wash fraction was concentrated and further purified by size-exclusion chromatography. A. 
Size exclusion chromatogram showing elution of 
2
H-
15
N-
13
C–labelled SHP2 catalytic 
domain as a single dominant peak indicating the presence of a monomeric species in 
solution. B. From left to right: molecular weight markers (M), elution fractions from size- 
exclusion chromatography run (E1-E6). 
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3.2.2 
15
N-
1
H TROSY HSQC of SHP2 catalytic domain in the presence of HEPES 
 
 
To determine the solution conditions that would yield optimal resolution of backbone 
amide resonances, and to provide a direct comparison of spectra quality under different 
solution conditions, we recorded 
15
N-
1
H TROSY HSQC spectra of 
15
N-labelled SHP2 
catalytic domain in the presence of both HEPES and phosphate buffer conditions at the 
same protein concentration of 0.5 mM. In conditions containing 50 mM HEPES, 150 mM 
NaCl and 0.5 mM TCEP, only approximately 10% of the expected amide signals in the 
15
N-
1
H TROSY HSQC spectra were observed (Figure 3.3A). 
 
 
3.2.3 
15
N-
1
H TROSY HSQC of SHP2 catalytic domain in the presence of phosphate 
 
 
In contrast to HSQC spectra recorded in HEPES, 
15
N-
1
H TROSY HSQC spectra of the 
SHP2 catalytic domain recorded in the presence of 50 mM phosphate generated spectra of 
excellent quality with the “fingerprint” of the protein giving good dispersion of backbone 
amide signals (Figure 3.3B). Importantly, there were no detectable signs of peak clustering 
in the central region of the spectrum or any other characteristic hallmarks of protein 
denaturation or unfolding under the experimental conditions tested indicating that SHP2 
catalytic domain existed as an appropriately folded species in phosphate buffer conditions. 
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Figure 3.3. 
15
N-
1
H TROSY HSQC spectra of 
15
N-labelled SHP2 catalytic domain 
recorded in the presence of HEPES and phosphate buffer conditions. A. 
15
N-
1
H 
TROSY HSQC spectra of 
15
N-labelled SHP2 catalytic domain recorded in 50 mM HEPES 
pH 7.5, 150 mM NaCl, 0.5 mM TCEP (turquoise). The recorded spectra yielded a 
significant reduction in the expected number of backbone amide signals. The marked lack 
of spectral resolution suggests that under HEPES buffer conditions, SHP2 catalytic domain 
exhibits prominent structural and conformational plasticity. B. Comparative 
15
N-
1
H NMR 
HSQC  spectra  of  
15
N-labelled  SHP2  catalytic  domain  recorded  in  50  mM  sodium 
phosphate buffer (purple). The recorded spectra yielded an even dispersion of backbone 
amide signals with vast improvement in peak resolution. This indicates that the presence of 
phosphate imparts structural and conformational stabilisation of SHP2 catalytic domain 
under these conditions. 
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3.2.4 Refinement of sequential backbone assignments of the SHP2 catalytic domain 
 
 
Expression of 
2
H-
15
N-
13
C-labelled SHP2 catalytic domain in M9 minimal media 
supplemented with deuterated glucose was conducted in an attempt to increase deuterium- 
labelling which serves to reduce the relaxation properties of 
13
C and 
15
N nuclei (through 
suppressing spin diffusion) and optimise data collection by improving signal to noise. 
TROSY versions of HNCA, HNCOCA, HNCACB, HNCOCAB, HNCO and HNCACO 
experiments were conducted in order to facilitate sequential amide backbone assignments 
on uniformly 
2
H-
15
N-
13
C-labelled protein 
[203]
. The backbone assignments were conducted 
in the presence of 50 mM NaP, 150 mM NaCl and 0.5 mM TCEP, which were identical to 
the conditions used for collection of the previous assignment dataset (unpublished data 
collected from Dr Tim Knowles) and known to yield a well dispersed fingerprint of the 
SHP2 catalytic domain with excellent spectral resolution of backbone amide signals. 
Picking of amide peaks was initially conducted on 
15
N-
1
H TROSY HSQC spectra with the 
sequential backbone assignments completed using the CCPN-NMR Analysis software 
package (see Appendix figure 4). Once completed, the assigned amide peaks in the new 
dataset were overlaid onto the previous dataset in order to validate the previous set of 
assignments. From the previous dataset (unpublished data collected by Dr Tim Knowles), 
approximately 80%  of  amide backbone assignments (corresponding to  ~212  assigned 
amide peaks from a predicted total of 274). Analysis of this dataset (recorded on ~70% 
deuterated protein) with the newly collected assignment data recorded on ~90% deuterated 
protein enabled positive validation of 198 of the previously determined backbone amide 
assignments, along with the emergence of approximately 10 additional amide peaks which 
arose  presumably  as  a  result  of  increased  deuterium-labelling  and  thus  improved 
relaxation.  Unfortunately,  of  the  10  additional  amide  peaks  obtained  none  of  these 
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resonances were assignable perhaps due to low peak intensity. The remaining 20% of 
unassigned amide resonances are likely due to internal dynamics in the protein leading to 
broadened linewidths. Unsurprisingly, many of these missing assignments correlate with 
residues located in exposed loop regions of protein structure. Despite the unsuccessful 
attempts  to  obtain  additional  assignments,  enhancing  the  level  of  deuterated  protein 
enabled refinement of the previous assignment dataset by altering 14 of these assignments 
with the correct and less ambiguous resonances. 
 
3.2.5 SHP2 catalytic domain is folded in the presence of phosphate 
 
 
To further interrogate the effect of phosphate on the solution conformation of SHP2 
catalytic domain and to provide orthogonal confirmation of a correctly and relevantly 
folded protein conformation under these conditions, circular dichroism (CD) analysis of 
SHP2 catalytic domain was conducted in the presence and absence of Tris and phosphate 
buffers  to  probe  any  differences  in  secondary  structure  integrity  in  both  conditions. 
Interestingly, despite significant differences in chemical shift dispersion in 
15
N-
1
H TROSY 
 
HSQC spectra in the presence of HEPES and phosphate buffer (Figures 3.3A and 3.3B, 
respectively), circular dichroism analysis revealed that SHP2 catalytic domain exists in a 
folded conformation in the presence of 50 mM Tris pH 7.5 and 50 mM sodium phosphate 
pH 7.5. Furthermore, negative CD traces were observed at 222 nm and 208 nm and 
positive traces observed at 193 nm confirming a predominantly α-helical protein fold 
(Figure 3.4). Although the geometry of individual α-helices and β-sheets are structurally 
unperturbed in both conditions (as evidenced by close similarities in the ratios of the 
different secondary structure elements calculated in DICHROWEB), the difference in CD 
traces in both the presence and absence of phosphate suggest that phosphate is likely 
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acting by imparting stabilisation of the overall protein fold in solution. This observation is 
supported  by  the  marked  disparities  in  backbone  amide  signal  dispersion  in  
15
N-
1
H 
TROSY  HSQC  spectra  for  SHP2  catalytic  domain  in  the  presence  and  absence  of 
phosphate (Figure 3.3A and 3.3B), and suggests that the phosphate-dependent stabilisation 
of SHP2 folding may be representative of a more physiologically relevant conformational 
state of the protein. Furthermore, the calculated values quantifying the ratio of individual 
secondary structure elements of the SHP2 catalytic domain in both Tris and HEPES buffer 
conditions are highly consistent with those reported for the crystal structure of the SHP2 
catalytic domain (PDB: 4B7O) 
[38]
. Indeed, the crystal structure of the SHP2 catalytic 
domain reports a 31% helical content in addition to a 19% β-sheet content, both of which 
are highly corroborative with the values reported in Figure 3.4 calculated from 
DICHROWEB secondary structure analysis. 
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Figure 3.4. Circular dichroism (CD) analysis of unlabelled SHP2 catalytic domain in 
the presence of phosphate and non-phosphate buffers. Comparative CD spectra of 
unlabelled SHP2 catalytic domain (0.1 mg/ml) were recorded both in the presence of Tris 
buffer pH 7.5 (blue) and sodium phosphate buffer pH 7.5 (red). Negative CD traces 
recorded for SHP2 catalytic domain at 222 nm and 208 nm, and positive traces recorded at 
193 nm suggest a predominantly α-helical protein secondary structure. The contrasting 
spectral profiles recorded for each buffer condition despite testing at the same protein 
concentration indicate a difference in the overall protein fold, which provides further 
evidence of differential stabilisation of the protein in each buffer condition. Buffer 
subtracted CD traces for SHP2 catalytic domain in the presence of both Tris and phosphate 
buffer conditions were subsequently analysed using the DICHROWEB server in order to 
quantify the ratio of secondary structure elements. 
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Figure 3.5. Methodology of sequential NMR backbone resonance assignments of the 
SHP2 catalytic domain. Strip plots of a HNCA experiment showing overlapping of i and 
i-1 residues. 
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Figure 3.6. Refinement of NMR backbone resonance assignments for SHP2 catalytic 
domain by  enhanced deuteration. A.  
15
N-
1
H TROSY HSQC  of  
2
H-
15
N-
13
C-labelled 
SHP2 catalytic domain grown in 99% D2O and recorded in 50 mM sodium phosphate pH 
7.5, 150 mM NaCl, 0.5 mM TCEP. Previous backbone assignments determined by Dr Tim 
Knowles were re-analysed, confirmed and refined using a secondary assignment dataset 
reported in this study. B. Mapping of the refined NMR backbone resonance assignments to 
the crystal structure of SHP2 catalytic domain (PDB code: 3B7O). Regions in grey 
correspond to assigned regions of protein structure. Regions in red correspond to regions 
of protein structure that remain unassigned. Arrows indicate the assignment state for the 
conserved PTP catalytic motifs, including the phosphate binding loop (P-loop) and WPD 
loop. 
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3.2.6 SHP2 catalytic domain exists as a monomeric species in the presence of HEPES 
 
 
After confirming that the SHP2 catalytic domain existed in a folded conformation in the 
presence and absence of phosphate, the next aim was to eliminate the possibility that 
differences in the backbone amide signal dispersion in 
15
N-
1
H TROSY HSQC spectra were 
a result of aggregation of SHP2 catalytic domain in solution. Since the primary objective 
of this chapter of work was to utilise 
15
N-
1
H NMR spectroscopy to unravel the structural 
mechanisms and dynamic insights into SHP2 inhibitor binding as well as characterise the 
most appropriate conditions permitting interrogation of inhibitor binding, the next aim was 
to  ensure  that  the  phosphate-dependant  enhancement  of  signal  resolution  in  
15
N-
1
H 
TROSY HSQC spectra was being recorded on a single monomeric species and that the 
presence of phosphate was not inducing protein aggregation or multimerisation events that 
may act to perturb ligand binding. Furthermore, an additional aim was to confirm that the 
poor 
15
N-
1
H TROSY HSQC spectra recorded in HEPES is due to conformational exchange 
within the protein and not a result of protein aggregation. 
 
In order to investigate whether the presence of phosphate was alleviating possible 
aggregation of SHP2 observed in HEPES buffer conditions and elucidate the predominant 
oligomerisation state of SHP2 in solution, analytical ultracentrifugation (AUC) was 
conducted on SHP2 catalytic domain in both the presence of HEPES and phosphate buffer. 
Testing SHP2 catalytic domain at two separate concentrations (A280 = ~0.5 and 0.9 AU) in 
both phosphate and HEPES buffer conditions revealed the presence of a stable and 
dominant monomeric species in solution with an apparent molecular mass of 34 KDa 
which is consistent with the expected molecular mass of 34 kDa predicted using ProtParam 
(Figure  3.7).  This  observation  was  also  independently  confirmed  by  size-exclusion 
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chromatography during purification of SHP2 catalytic domain in both phosphate and 
HEPES buffer where examination of the elution profiles confirmed that SHP2 catalytic 
domain eluted with a single monomeric peak and existed as a monomeric species in both 
the presence and absence of phosphate (Figure 3.8). Although calibration of the size- 
exclusion column with a range of proteins with known molecular weight was not 
conducted,  SDS  gels  of  SHP2  catalytic  domain  (Figure  3.2B)  along  with  AUC 
experiments reveal an apparent molecular weight of 34.0 KDa which is identical to the 
expected molecular weight of the monomer of 34.3 KDa predicted from the protein 
sequence using the ProtParam program (see Appendix figure 4). 
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Figure 3.7. Analytical ultracentrifugation of SHP2 catalytic domain in HEPES and 
sodium phosphate buffer conditions. A) AUC of SHP2 catalytic domain (Abs280 = ~0.5 
AU) in 50 mM HEPES pH 7.5 and 50 mM sodium phosphate 7.5 reveals a homogenous 
population of monomeric species with an apparent molecular mass of 34.0 KDa which is 
very close to the expected molecular mass of 34.3 KDa predicted from the protein 
sequence. B) AUC of SHP2 catalytic domain (Abs280 = ~0.9 AU in 50 mM HEPES pH 7.5 
and 50 mM phosphate pH 7.5 similarly reveals a homogenous population of monomeric 
species with an identical molecular mass. No higher order aggregates or oligomeric species 
were observed. 
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Figure 3.8. Analysis of SHP2 catalytic domain by size-exclusion chromatography in 
both  HEPES  and  phosphate  buffer  conditions.  A.  Purification  of  SHP2  catalytic 
domain by size-exclusion chromatography in the presence of buffer containing 50 mM 
HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP. B. Purification of SHP2 catalytic domain 
by size-exclusion chromatography in the presence of buffer containing 50 mM sodium 
phosphate pH 7.5, 150 mM NaCl, 0.5 mM TCEP. SHP2 catalytic domain elutes as a single 
dominant peak in both HEPES (red) and phosphate (blue) buffer indicating the presence of 
a single monomeric species. 
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3.2.7 Sequential titration of 
15
N-labelled SHP2 catalytic domain with phosphate 
 
 
After confirming that SHP2 catalytic domain was appropriately folded and present as a 
stable monomeric species in the presence of phosphate and HEPES buffer, the next aim 
was to verify whether the folded conformation of SHP2 catalytic domain was structurally 
perturbed in the presence of a SHP2-specific inhibitor and whether it was possible to map 
chemical shift perturbations induced through inhibitor binding under these experimental 
conditions.  Preliminary  experiments  conducted  by  titrating  promiscuous  phosphate 
inhibitors sodium orthovanadate (an irreversible phosphatase inhibitor) 
[208] 
and glycerol-2- 
 
phosphate with 
15
N-labelled SHP2 catalytic domain and recording 
15
N-
1
H TROSY HSQC 
spectra revealed no obvious indications of inhibitor binding to SHP2 catalytic domain in 
the presence of phosphate (data not shown), despite sodium orthovanadate being a well 
characterised phosphatase inhibitor with nanomolar binding affinity. These experiments 
were also repeated with the validated salicylic acid-based SHP2 inhibitor IIBO8 
[143]
, but 
no  chemical  shift  perturbations  or  alternative  binding  phenomena  were  observed  to 
indicate an interaction between the inhibitor and the SHP2 catalytic domain, despite the 
addition of a 5-fold molar excess of inhibitor relative to protein. This observable lack of 
inhibitor binding  was  therefore  attributed to  the  compromised solubility of  IIB08  in 
solution combined with the high phosphate concentrations necessary for optimal 
15
N-
1
H 
HSQC spectral resolution. 
 
The initial observations pertaining to a lack of inhibitor binding therefore motivated a 
search for  an  alternative SHP2  tool compound with improved solubility for  which a 
binding site could be elucidated by mapping chemical shift perturbations in 
15
N-
1
H HSQC 
NMR spectra causing previously collected backbone assignments for the SHP2 catalytic 
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domain. After a thorough investigation of the literature the commercially available 
disulphonic acid-based  inhibitor NSC-87877  was  identified  as  a  promising candidate 
which exhibited an IC50 of 0.3 µM in a biochemical pNPP assay. Furthermore, a 
combination of in-silico modelling and mutagenesis studies suggest that NSC-87877 is an 
active site-directed inhibitor of the SHP2 catalytic domain, but structural evidence 
confirming the proposed mode of inhibition has remained elusive 
[136]
. 
 
Earlier observations regarding the lack of inhibitor binding by 
15
N-
1
H NMR spectroscopy 
led to the hypothesis that in the presence of 50 mM phosphate concentration the 
phosphatase active site was saturated resulting in conditions that actively disfavour rather 
than promote the binding of active site-targeting inhibitors and leading to an improve 
backbone  amide  signal  resolution  in  
15
N-
1
H  HSQC  spectra.  This  is  consistent  with 
previous observations where attempts to observe inhibitor binding were unsuccessful for 
sodium  orthovanadate  and  compound  IIB08,  both  of  which  are  validated  inhibitors 
targeting the phosphatase active site. 
 
After reasoning that the high phosphate concentration could be acting to occlude the SHP2 
active site and therefore perturb inhibitor binding, as a precursor to conducting 
15
N-
1
H 
HSQC titrations against SHP2 catalytic domain with compound NSC-87877, it was 
suggested  that  employing  a  sequential  phosphate  titration  against  
15
N-labelled  SHP2 
protein in 50 mM HEPES pH 7.5 was a necessary step in order to determine the optimum 
phosphate concentration that yielded sufficient 
15
N-
1
H HSQC spectral resolution but also 
maximised the possibility of observing inhibitor binding by outcompeting the active site- 
bound phosphate. Increasing equivalents of sodium phosphate buffer (pH 7.5) to final 
concentrations of 10  mM and 20  mM were then added and then a series of  
15
N-
1
H 
127  
SOFAST-HMQC experiments of 
15
N-labelled SHP2 catalytic domain were recorded in the 
absence of compound NSC-87877 in order to gauge whether backbone amide signals were 
sufficiently  resolved  and  that  conditions  were  conducive  for  inhibitor  NSC-87877 
titrations (Figure 3.11). 
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Figure 3.9. 
15
N-
1
H SOFAST-HMQC NMR spectra of 
15
N-labelled SHP2 catalytic 
domain in the presence of 10 mM and 20 mM sodium phosphate pH 7.5. A) Titration 
of 
15
N-labelled SHP2 catalytic domain in 50 mM HEPES buffer pH 7.5 with 10 mM 
sodium phosphate buffer pH 7.5. Despite showing a clear improvement in spectral 
resolution, 
15
N-
1
H SO-FAST HMQC spectra recorded in 10 mM phosphate show 
insufficient resolution of backbone amide resonance signals for inhibitor titrations. B) 
Secondary sequential titration of 15N-labelled SHP2 catalytic domain with an additional 
equivalent of 10 mM sodium phosphate buffer pH 7.5 yielding a final concentration of 20 
mM sodium phosphate. Titration of an additional equivalent of sodium phosphate pH 7.5 
to a final concentration of 20 mM yields marked improvement in spectral resolution that 
was deemed conducive for inhibitor titrations. 
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Although 
15
N-
1
H SOFAST-HMQC spectra recorded in 10 mM phosphate provided minor 
improvements in backbone amide signal resolution (Figure 3.9A), the observed 
improvement in spectral resolution was deemed insufficient for chemical shift perturbation 
analysis. However, increasing the phosphate concentration to 20 mM yielded sufficient 
improvement in spectral resolution to enable chemical shift mapping with peak dispersion 
comparable to the 
15
N-
1
H TROSY HSQC spectra recorded in the presence of 50 mM 
phosphate (Figure 3.3B). Despite observing improvements in spectral resolution at a 
phosphate concentration of 20 mM, 
15
N-
1
H SOFAST-HMQC spectra yielded noticeable 
broad linewidths owing to the relatively large molecular weight of the SHP2 catalytic 
domain, which typically occupies the upper molecular weight limit for the study of protein 
structures by protein-observed NMR methods. To address the caveat of broad linewidths 
and achieve overall enhancement of spectral resolution and sensitivity, 
15
N-
1
H TROSY 
spectra for 
15
N-labelled SHP2 catalytic domain were recorded at a phosphate concentration 
 
of 20 mM. The resulting 
15
N-
1
H TROSY HSQC experiment yielded spectra of excellent 
resolution with sufficiently dispersed backbone amide peaks (Figure 3.10). The marked 
improvement in spectral quality and clarity enabled the employment of titrations of 
15
N- 
labelled SHP2 catalytic domain with inhibitor NSC-87877 to probe inhibitor binding by 
monitoring perturbations of backbone resonances in the presence and absence of inhibitor. 
130  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. 
15
N-
1
H TROSY HSQC NMR spectra of 
15
N-labelled SHP2 catalytic 
domain in the presence of 20 mM sodium phosphate pH 7.5. 
15
N-
1
H TROSY HSQC 
experiments on 
15
N-labelled SHP2 yielded reduced line broadening and marked 
improvement in overall spectral resolution and sensitivity. This enabled conditions that 
were conducive for NSC-87877 inhibitor titrations. 
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3.2.8 Titration of 
15
N-labelled SHP2 catalytic domain with compound NSC87877 
 
 
Addition of a 2-fold equivalent of NSC-87877 (600 µM) relative to the concentration of 
 
15
N-labelled SHP2 catalytic domain (300 µM) in the presence of 20 mM sodium phosphate 
pH 7.5 revealed no obvious indications of compound precipitation or insolubility and the 
compound appeared highly soluble in 5% (vol/vol) DMSO compared to the previously 
tested IIB08 inhibitor. Overlaying 
15
N-
1
H TROSY HSQC spectra of 
15
N-labelled SHP2 
catalytic domain recorded in 20 mM sodium phosphate pH 7.5 in the presence and absence 
of inhibitor NSC-87877 revealed no observable chemical shift perturbations of backbone 
amide signals. However, closer inspection of 
15
N-
1
H TROSY HSQC spectra revealed an 
unexpected disappearance of particular amide resonances upon addition of the NSC-87877 
inhibitor, which initially suggested an intermediate exchange mechanism of inhibitor 
binding. At this point, an alternative but equally plausible explanation for this observation 
was also considered, suggesting that addition of the NSC-87877 inhibitor reintroduces 
some of the intermediate exchange dynamics into the SHP2 catalytic domain through 
liberation of bound phosphate. After confirming the disappearance of a total of five peaks 
upon addition of NSC-87877, the identity of these peaks was verified by mapping to the 
corresponding resonance assignments in an attempt to generate the first structural evidence 
of the binding mode of NSC-87877 to the SHP2 catalytic domain (Figure 3.11A) 
Interestingly, all five of the disappearing peaks exhibited assignable backbone resonances 
which corresponded to residues Y279, N281, T357, T468 and T507.  Mapping these 
residues to the crystal structure of the SHP2 catalytic domain (PDB: 3B7O) revealed that 
all of these residues are located in and around the active site cavity of SHP2 catalytic 
domain, confirming a possible active site-directed mechanism of inhibition (Figure 3.11B) 
132  
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Titration of 
15
N-labelled SHP2 catalytic domain with inhibitor NSC- 
87877. A. Overlay of 
15
N-
1
H TROSY HSQC spectra of 300 µM 
15
N-labelled SHP2 
catalytic domain in the presence (light blue) and absence (red) of 600 µM NSC-87877. 
Backbone resonances of assigned residues Y279, N281, T357, T468 and T507 for 
disappearing peaks have been magnified for clarity, along with control peaks K378* and 
A452*. B. Surface representation of SHP2 catalytic domain highlighting disappearing 
peaks upon addition of NSC-87877 (red) and the catalytic cysteine 459 (orange). Perturbed 
residue T468 is not shown as residue is buried in the interior of the protein and proved 
difficult to project using a surface representation of the SHP2 catalytic domain. 
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3.3 Discussion 
 
In order to assist the discovery and development of more efficacious SHP2 inhibitors  and 
characterise the ligandable potential of the SHP2 catalytic domain under solution 
conditions, triple-resonance NMR methods were employed in conjunction with 
15
N-
1
H 
TROSY HSQC experiments in an attempt to assign previously unresolvable backbone 
resonances in the active site loop regions of SHP2 catalytic domain, enabling exploitation 
of structural and dynamic mechanisms of SHP2 inhibitor binding as a precursor to 
fragment-based ligand discovery. 
 
NMR spectroscopy provides an indispensable tool for the characterisation of molecular 
structure  and  offers  powerful  structural  and  dynamic  insights  into  protein-ligand 
recognition events in the solution state. The acquisition of structural information by NMR- 
based methods typically begins with elucidation of resonance assignments for each 
backbone amide group in a particular protein target which can then be utilised for rapid 
determination of inhibitor binding to active and regulatory sites on the protein. This allows 
for molecular interactions and conformational flexibilities of macromolecular structures to 
be characterised under physiological conditions and at levels of resolution sufficient for 
confirming small-molecule binding to a given target and guiding inhibitor development as 
part of NMR-based ligand discovery campaigns. 
 
Prior to commencing this work, the elucidation of a previous set resonance assignments 
revealed an approximate 80% coverage of backbone amide signals for the SHP2 catalytic 
domain (unpublished data generated and analysed by Dr Tim Knowles and Dr Mark 
Jeeves). Interestingly, further interrogation of the assignment data identified approximately 
20% of the observed resonances were still unassignable despite increasing deuterium- 
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labelling and, after mapping to the crystal structure of SHP2 (PDB: 3B7O), these were 
found  to  be  predominantly  situated  in  the  dynamic  loop  regions  comprising  the 
phosphatase active site. These regions that exhibit a lack of assignable resonances can be 
rationalised by considering multiple explanations, which include the intrinsic flexibility 
and structural plasticity of the phosphatase active site loop regions leading to rapid 
interconversion between multiple conformational ensembles, and chemical exchange 
mechanisms operating in the phosphatase active site leading to perturbations in signal 
intensity. 
 
In order to circumvent these obstacles and attempt to resolve the hitherto uncharacterised 
backbone resonances for residues lining the active site loops of SHP2, the level of protein 
deuteration was increased by supplementing M9 minimal growth media with deuterated 
glucose.  This  was  in  contrast  to  the  methodology  used  for  sample  preparation  for 
collection of the previous assignment dataset (recorded by Dr Tim Knowles) which used 
13
C-labelled glucose. For the SHP2 catalytic domain which comprises a molecular weight 
 
of 36 kDa, it was suggested that enhancement of protein deuteration could yield a 
favourable strategy for resolving backbone resonances associated with the dynamic and 
catalytic components of SHP2 structure. Typically, in order to overcome the difficulties 
associated  with  NMR  data  collection  on  larger  protein  structures  (i.e.  for  proteins 
exceeding a molecular weight >20 kDa), deuterium-labelling is commonly employed to 
improve signal-to-noise by suppressing spin diffusion and reducing the overall relaxation 
properties of 
13
C and 
15
N-labelled nuclei 
[209]
. Unfortunately, despite continued attempts, 
 
efforts to obtain any additional assignments of the SHP2 catalytic domain were 
unsuccessful, with the majority of the active site loop assignments remaining largely 
unassigned. However, the new triple resonance dataset recorded on >90% deuterium- 
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labelled protein was successfully utilised in order to refine the initial round of assignments. 
This enabled the correction and reassignment of around 20 previously unclear and 
ambiguous backbone resonances. 
 
Despite unsuccessful attempts in gaining additional assignments in the phosphatase active 
site by enhancing protein perdeuteration, difficulties associated with assigning flexible 
regions of protein structure is not an uncommon occurrence and has been reported by 
previous phosphatase NMR assignment studies, particularly those conducted on PRL-3. 
For example, determination of the NMR-solution structure of PRL-3 revealed that despite 
possessing overall similar folds to PTEN and PAC-1, the loop regions comprising the 
respective active sites all exhibit significant structural plasticity 
[205]
. The variation in 
 
conformational flexibility of phosphatase active site loops has been suggested to arise from 
the difference in side chain distances between residues Cys 104, Arg 110 (both in the PTP 
catalytic signature motif HCXXGXXR) and Asp 72 in PRL-3 which in comparison to the 
corresponding residues in PTEN are separated by a greater distance. This has been 
suggested to arise largely from the key position of the Asp residue which serves as the 
general acid in the conserved catalytic mechanism of all phosphatases. The extent of 
conformational flexibility exhibited by active site loop regions across the phosphatase 
superfamily has been similarly confirmed by high throughput crystallography studies 
reporting significant conformational propensities of loop regions from a comprehensive 
analysis of 25 phosphatase crystal structures 
[38]
. 
 
 
A necessary prerequisite before initiating NMR-based ligand discovery is ensuring the 
macromolecular target of interest has undergone robust characterisation in solution in 
order  to  determine  optimum  conditions  for  preserving  protein  folding,  stability  and 
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catalytic integrity. This also includes a thorough evaluation of structural and dynamic 
perturbations of the target in the presence of putative ligands or inhibitors. Collectively, 
these preliminary measures ensure that validated hits emerging from NMR-based small 
molecule screening assays are binding to a physiologically relevant and stable form of the 
protein, rather than preferentially binding to an unfolded or oligomerised state of the 
target. In this way, as a precursor to small molecule screening a primary objective was to 
elucidate the optimum screening conditions under which SHP2 catalytic domain would 
exhibit the relevant folding and stability representative of physiological conditions. Indeed, 
attempts to characterise the preferred solution conditions for optimal stability of the SHP2 
catalytic domain raised interesting questions concerning the role of phosphate in stabilising 
the structure of SHP2 catalytic domain, as evidenced by the marked differences in amide 
signal resolution in protein-observed NMR experiments conducted in the presence and 
absence of phosphate. In parallel with observations from AUC confirming that SHP2 
catalytic domain existed as a stable monomeric species in the presence and absence of 
phosphate, 
15
N-
1
H HSQC spectra independently confirmed that the presence of phosphate 
 
induced a more conformationally stable protein structure. For the purposes of NMR 
assignment determination and the use of assigned backbone resonances to characterise 
ligand binding sites, these experiments could only be conducted in the presence of 
phosphate due to the greater resolution and dispersion of the amide signals in comparison 
to the profoundly unresolved spectra recorded in the absence of phosphate. Indeed, our 
initial attempts to map chemical shift perturbations by 
15
N-
1
H TROSY HSQC experiments 
 
in the presence and absence of SHP2 inhibitors sodium orthovanadate and IIB08 revealed 
a surprising lack of inhibitor binding. In the case of compound IIB08, overlaying 
15
N-
1
H 
TROSY HSQC spectra in the presence and absence of inhibitor revealed no observable 
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evidence of ligand binding despite a thorough assessment of backbone resonances for 
chemical shift perturbations or line broadening. However, a likely explanation underlying 
the lack of IIB08 inhibitor binding concerns the poor solubility of the inhibitor which may 
have been exacerbated by the requirement for the high inhibitor concentrations (>300 µM) 
necessary for protein-observed NMR HSQC experiments. Aside from problems associated 
with compound solubility, it was strongly suspected the large molar excess of phosphate 
required for  sufficient resolution of  backbone amide signals posed  additional 
complications for observing ligand binding. This is especially true given that the reported 
KD of 5.5 μM for compound IIB08 
[143] 
compared with a KD of approximately 10-20 mM 
 
for phosphate should easily enable compound IIB08 to outcompete the presence of active 
site bound phosphate. However, this is not true if the binding of phosphate in the active 
site is significantly tighter than the binding of phosphate acting to stabilise and rigidify the 
overall protein conformation. Although concentrations of phosphate exceeding 20 mM 
contribute favourably to the structural and dynamic stabilisation of SHP2 in solution, such 
conditions are also likely to disfavour inhibitor binding through occlusion and saturation of 
the phosphatase active site. Despite the likely probability that abrogation of inhibitor 
binding is a direct result of phosphate-mediated occlusion of the active site, we strongly 
suspect that the presence of phosphate may also be acting to stabilise the conformational 
dynamics of SHP2 through binding to multiple different sites on the protein. This is 
supported by previous experiments where addition of increasing equivalents of the active 
site directed inhibitor IIB08 (to a final concentration of 2 mM) to 
15
N-labelled SHP2 
 
catalytic domain in the absence of phosphate causes minor improvements in peak recovery 
(presumably through stabilisation of the active site) but is not sufficient to fully reproduce 
the effects recorded in phosphate which yields excellent dispersion of amide resonance 
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signals in 
15
N-
1
H TROSY HSQC spectra. This leads us to hypothesise that the presence of 
phosphate could be driving stabilisation of the SHP2 catalytic domain through binding to 
multiple different sites on the protein which collectively lead to a more favourable 
conformational ensemble in solution. This would allow for greater stability, folding and 
resolution of the signature amide signals needed for determination of backbone 
assignments. 
 
Our hypothesis asserting that the vast molar excess of phosphate necessary for full 
resolution of the backbone amide signals acts to occlude the phosphatase active site posed 
significant obstacles for characterising the ligand binding behaviour of the SHP2 catalytic 
domain in solution. Indeed, this was a particularly striking observation, especially given 
that  both  sodium  orthovanadate  and  IIB08  have  both  been  reported  to  target  the 
phosphatase active site. Although repeated attempts to map the binding site of inhibitor 
IIB08 by 
15
N-
1
H HSQC NMR were unsuccessful, we extended our assessment of SHP2 
 
ligandability by 
15
N-
1
H HSQC methods by partially mapping the previously undetermined 
binding mode of the more potent SHP2 inhibitor, NSC-87877. 
 
As backbone amide resonances are exquisitely sensitive to perturbations in the local 
chemical environment, the utility of protein-observed NMR spectroscopy provides a rapid 
method for examining the interactions in solution between small-molecule compounds and 
15
N-labelled  SHP2  catalytic  domain  by  monitoring  chemical  shift  perturbations  of 
 
backbone amide resonances present in 
15
N-
1
H TROSY HSQC spectra. 
 
 
Although compound NSC-87877  displayed  comparatively greater  solubility compared 
with inhibitor IIB08, efforts to directly map progressive chemical shift perturbations to 
observe  the  exchange  dynamics  of  NSC-87877  binding  were  largely  unsuccessful. 
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Interestingly however, overlaying of 
15
N-labelled SHP2 
15
N-
1
H TROSY HSQC spectra in 
the presence and absence of a 2-fold excess of NSC-87877 inhibitor (600 µM) relative to 
protein concentration (300 µM) resulted in noticeable disappearance of several backbone 
amide resonances. The specific changes occurring in HSQC spectra upon addition of a 
bound ligand (i.e. chemical shift perturbations or line broadening) are governed by the 
exchange rates between bound and unbound species relative to the difference in chemical 
shift between bound and unbound states. A progressive decrease in signal intensity or 
complete disappearance of a resonance signal implies that the exchange rate between the 
bound and unbound species is in an intermediate exchange regime with respect to the 
NMR timescale of the experiment, or that we have reverted to a localised intermediate 
exchange mechanism within the protein seen in the absence of phosphate. In our case, it 
would therefore be reasonable to suggest that the interaction between compound NSC- 
87877 and SHP2 catalytic domain is obeying intermediate exchange dynamics, resulting in 
complete disappearance of specific resonance signals. 
 
As mentioned previously, chemical shift mapping analysis of disappearing peaks to the 
assigned backbone resonances uncovered a total of five amino acid residues in close 
proximity to and in the vicinity of the phosphatase active site. These residues include 
Y279, N281, T357, T468 and T507 (T468 not shown as due to lack of visibility in the 
surface representation model of SHP2 catalytic domain). Interestingly, although the 
interaction of NSC-87877 with SHP2 catalytic domain lacks the robust structural evidence 
required for  unravelling precise modes of  inhibitor binding,  in-silico docking studies 
predict that the B-ring sulphonic acid moiety of inhibitor NSC-87877 forms hydrogen 
bonds with the backbone amide group of Arg 465 
[136] 
(Figure 3.12B) – a highly conserved 
 
residue in the PTP signature motif located at the base of the phosphatase catalytic cleft 
[21]
. 
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Furthermore, the A-ring sulphonic acid moiety was predicted to form hydrogen bonds with 
the side chain NH3 group of K280 and the side chain NH2 group of N281. Both K280 and 
N281 are non-conserved PTP residues located adjacent to the key phosphotyrosine 
recognition loop 
[136]
. Indeed, studies investigating the role of residues K280 and N281 in 
determining NSC-87877 inhibitor sensitivity found that SHP2 K280V and K280R/N281D 
mutants show an approximate 3-fold reduction in biochemical activity in a pNPP assay, 
with IC50 values of 1.1 and 1.0 µM for SHP2V280 and SHP2 K280R/N281D, respectively, 
compared to the 0.3 µM IC50 determined for wild-type SHP2. Although no chemical shift 
perturbations or  peak disappearance for  backbone resonance signals corresponding to 
K280 were observed, perturbed residues were mapping to Y279 and N281 upon NSC- 
87877 addition suggesting that residue N281 and either Y279 and/or K280 form key 
interactions with the A-ring sulphonic acid group of inhibitor NSC-87877. This provides 
the first structural validation in support of NSC-87877 binding in which N281 is suggested 
to play a key role in anchoring the disulphonic acid moiety to the phosphatase active site. 
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Figure  3.12  Comparison  of  inhibitor  NSC-87877  binding  to  the  SHP2  catalytic 
domain by 
15
N-
1
H HSQC NMR spectroscopy vs in-silico analysis of the NSC-87877 
binding mode. A. Mapping of assigned residues to the crystal structure of SHP2 that 
showed perturbation upon addition of NSC-87877 as recorded by 
15
N-
1
H HSQC NMR 
spectroscopy. Interestingly, upon inhibitor NSC-87877 binding, perturbed residues Y279 
and N281 reported in 
15
N-
1
H TROSY HSQC NMR spectra corroborate with predicted 
residues K280 and N281, reported from in-silico and mutational studies suggesting that 
these residues are important for recognition of the A-ring sulphonic acid moiety of NSC- 
87877. Furthermore, perturbed residues T357 and T507, although not highlighted in the in- 
silico model of NSC-87877 binding to SHP2 catalytic domain, may form interactions with 
the sulphonate and hydroxyl moieties either side of the B-ring sulphonic acid moiety. 
Although not highlighted on the surface representation of SHP2 catalytic domain, due to 
deep burial in the core of the SHP2 catalytic domain, residues T468 may also play an 
additional role by forming an interaction with the B-ring sulphonic acid moiety of NSC- 
87877 in conjunction with Arg 465. B. In-silico analysis of NSC-87877 binding reported 
by Chen et.al 
[136] 
predicting key hydrogen bond interactions between residues K280, N281 
of the A-ring sulphonic acid moiety and between R465 of the B-ring sulphonic acid moiety 
of inhibitor NSC-87877. 
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The complete disappearance of chemical shift resonances upon addition of NSC-87877 in 
this manner is therefore likely driven by structural rearrangement of the SHP2 catalytic 
domain in response to NSC-87877 binding, generating a more conformationally mobile 
species. These experimental observations have led us to hypothesise that the disappearance 
of backbone resonance signals arises from the displacement of active site-bound phosphate 
upon NSC-87877 binding. Furthermore, we propose that binding of NSC-87877 alone is 
not sufficient to mimic the stabilising contribution of phosphate and thus upon phosphate 
displacement leads to transient structural flexibility in SHP2 catalytic domain which is 
manifested by a complete and unrecoverable loss of specific backbone resonance signals. 
Backbone resonance signals for which we observe a complete loss of peak intensity are 
therefore likely to correspond to residues occupying dynamically perturbed regions of 
protein structure that are greatly influenced by the stabilising effect of phosphate and the 
structural perturbations that occur when phosphate is displaced upon compound NSC- 
87877 binding. Similar intermediate ligand exchange mechanisms have also been 
highlighted by other NMR-based studies focussing on inhibitor-binding to HIV-1 protease 
[210]
.
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3.4 Conclusion 
 
In  conclusion,  the  work  presented  in  this  chapter  offers  insights  into  the  molecular 
structure and conformational dynamics of the SHP2 phosphatase domain under solution 
conditions, and in the broad context of NMR-based drug discovery provides a robust and 
informative platform for probing small molecule inhibitor interactions with catalytic sites, 
or novel allosteric pockets and regulatory sites that may be of key relevance to guiding 
more potent SHP2 inhibitor development. As such, in the context of this work, compiling a 
near complete map of the peptide backbone assignments of SHP2 catalytic domain would 
serve as an excellent prelude for validating hits from fragment-based screening that allows 
us to interrogate the binding locations of fragments through mapping chemical shift 
perturbations which serve to illuminate novel allosteric binding sites. 
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CHAPTER 4: BIOPHYSICAL AND BIOCHEMICAL VALIDATION 
OF SHP2 TOOL COMPOUNDS 
 
 
 
 
 
4.1 Experimental aims 
 
After exploring the solution behaviour of SHP2 catalytic domain in the presence of 
phosphate and non-phosphate buffer conditions, it was clear that phosphate plays a key 
role in stabilising the overall conformational dynamics of the SHP2 catalytic domain. 
Biophysical  characterisation  of  SHP2  structure  in  solution,  including  AUC  and  CD 
analysis combined with size-exclusion chromatography suggested that the protein also 
exists as a stable, folded and monomeric species in HEPES buffer and in the absence of 
phosphate, despite yielding poorly resolved 
15
N-
1
H HSQC spectra in HEPES. 
 
To further explore the interactions of SHP2 ligands with the SHP2 catalytic domain and 
provide orthogonal validation of SHP2-ligand binding by alternative methods, a robust 
panel of biophysical and biochemical assays, was used to complement fragment-based 
screening. The aim was to characterise the biochemical activities and binding affinities of 
previously reported SHP2 inhibitors, PHPS1, IIB08 and NSC-87877. Although similar 
biochemical characterisation of SHP2 inhibitors has previously reported, corroborative 
biophysical evidence confirming the affinities of these interactions with the SHP2 catalytic 
domain has remained surprisingly elusive. 
 
To interrogate and validate the binding interactions of inhibitors PHPS1, IIB08 and NSC- 
 
87877 with the SHP2 catalytic domain, the biophysical assay panel included ligand- 
observed NMR experiments (STD and waterLOGSY) and SPR. This was accompanied by 
an assessment of the effect of these inhibitors on the biochemical activity of SHP2 using a 
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pNPP   activity  assay.   Together,  this   approach  enabled  direct  observation   of   the 
performance of each inhibitor in each of these assays and permitted selection of the most 
active inhibitors as validated chemical tools for fragment-based screening. The more 
robustly validated SHP2  tool  compounds emerging  from  these  assays  could  then  be 
utilised as positive control ligands to authenticate fragment-based screening assays, 
providing robust confirmation of positive hit matter for further optimisation, which might 
otherwise prove difficult in the absence of a validated control compound. 
 
4.2 Results 
 
In order to validate and profile the activity of known SHP2 inhibitors as a precursor to 
fragment-based screening, we surveyed the scientific literature and identified a number of 
suitable candidates for evaluation across a panel of biophysical and biochemical assays, 
including NMR (STD-NMR and waterLOGSY), SPR and enzyme inhibition assays. 
Inhibitors selected for validation included compounds PHPS1 
[140]
, IIB08 
[143]  
and NSC- 
87877 
[136] 
(Figure 4.1), all of which were shortlisted based on their previous disclosure as 
 
specific inhibitors of the SHP2 catalytic domain. These tool compounds have all been 
reported to possess similar binding mechanisms with differential levels of evidence 
supporting an active-site targeted interaction with the SHP2 catalytic domain. More 
specifically, compound IIB08 represents the only inhibitor for which an active-site binding 
mode has been experimentally validated by a co-crystal structure with the SHP2 catalytic 
domain. While in-silico modelling and enzymatic-inhibition assays have predicted active- 
site binding modes of interaction for compounds PHPS1 
[140]  
and NSC-87877 
[136]  
the 
 
availability of similarly robust structural evidence supporting these mechanisms remain 
elusive. 
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Figure 4.1 Chemical structures of literature reported SHP2 inhibitors PHPS1, IIB08 
and NSC-87877. A) Chemical structure of compound PHPS1. B) Chemical structure of 
IIB08. C) Chemical structure of NSC-87877. The inhibitor constants derived from 
biochemical activity assay measurements are reported as 0.7 μM (PHPS1), 5.5 μM (IIB08) 
and 0.3 μM. 
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4.2.1 
15
N-
1
H NMR HSQC titrations of SHP2 inhibitors PHPS1 and IIB08 
 
 
Having previously observed evidence of a putative interaction between compound NSC- 
 
87877 and 
15
N-labelled SHP2 catalytic domain by 
15
N-
1
H HSQC NMR (Chapter 3), it was 
deemed necessary to perform similar 
15
N-
1
H TROSY HSQC titration experiments to see 
whether it was possible to observe binding of inhibitors PHPS1 and IIB08 by directly 
probing  backbone  
15
N-
1
H  backbone  amide  perturbations  in  recorded  
15
N-
1
H  TROSY 
HSQC spectra in the presence and absence of each inhibitor. A thorough survey of the 
literature revealed that no previous attempts had been made to validate the interaction of 
compounds PHPS1 and IIB08 with the SHP2 catalytic domain by protein-observed NMR 
methods. However, unfortunately, despite repeated attempts to improve compound 
solubility, the relative insolubility of these compounds at the high concentrations required 
for 
15
N-
1
H NMR HSQC experiments in 5% (v/v) DMSO meant that we were unable to 
map any chemical shift perturbations to confirm the binding of these compounds by 
protein-observed NMR. 
 
4.2.2 SPR characterisation of inhibitor binding to SHP2 catalytic domain 
 
 
To further validate the interactions of these inhibitors with SHP2 catalytic domain, SPR 
was utilised to enable direct observation of inhibitor binding in real time, and quantify the 
binding affinities for the interactions of inhibitors PHPS1, IIB08 and NSC-87877 with the 
SHP2  catalytic domain. In  corroborative fashion to  observations made in  the  
15
N-
1
H 
HSQC NMR experiments, the lack of solubility of PHPS1 in 5% (v/v) DMSO made it 
increasingly difficult to measure binding affinities for the interaction with the SHP2 
catalytic domain by SPR. However, we were successful in deriving binding affinities for 
compound NSC-87877 and compound IIB08. Compound NSC-878777 was tested across 
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an 8-point 5-fold dilution series from 100 µM to the lowest concentration of 0.0064 µM 
and IIB08 across an 8-point 2-fold dilution series from 250 µM to the lowest concentration 
of 3.9 µM. In order to derive an appropriate KD value for compound NSC-87877 and 
compound IIB08 binding to SHP2 catalytic domain, the resulting binding profiles were 
fitted to a simple 1:1 Langmuir binding model   (using the Biacore evaluation software) 
[211]
. Importantly, fitting the data to this model involves two fundamental assumptions. 
Firstly, the analyte (compounds NSC-87877 and IIB08) must be homogenous and bind 
with a 1:1 stoichiometry with the immobilised ligand (i.e. form a monovalent interaction). 
The same is also true regarding the ligand which is also assumed to be homogenous. The 
second important consideration of the Langmuir model is the assumption that all binding 
events are independent. 
 
 
Derivation of the KD for the binding interactions between inhibitors NSC-87877 and 
compound IIB08 binding to SHP2 catalytic domain was then obtained by non-linear curve 
fitting of the data to the Langmuir equation: 
 
 
 
 
��eq = 
[�]𝑅𝑚��𝑥
 
[�]+�𝐷 
 
 
 
Where Req  is the response (measured in RU) obtained from binding measured at 
equilibrium (i.e. the steady state phase of the binding interaction), Rmax  is the maximum 
response (measured in RU) recorded at saturating concentrations of ligand, [L] is the free 
ligand concentration, and the KD is the dissociation constant of the binding interaction 
measured at equilibrium. 
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Fitting of the NSC-87877 binding data to the Langmuir model generated a KD  value of 
 
3 μM (with the error in KD being +/- 0.3 μM) and, to our knowledge, represented the first 
attempt to  characterise the  binding of  NSC-87877  to  SHP2  using SPR  (Figure 4.2). 
Specific binding of compound NSC-87877 to the SHP2 catalytic domain was further 
confirmed by derivation of an Rmax  (equivalent to the maximum binding capacity of the 
surface based on the amount of protein immobilised) value which after fitting the data 
proved to be just underneath the theoretical Rmax based on the protein immobilisation level. 
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Figure 4.2 SPR characterisation of compound NSC-87877 binding to SHP2 catalytic 
domain. A. An SPR concentration-response curve showing a dose-dependent interaction 
between compound NSC-87877 and immobilised SHP2 catalytic domain. A 100 μM stock 
solution of compound NSC-87877 was serially diluted with SPR running buffer across a 5- 
fold dilution series to give a concentration range of 0.0064 μM – 100 μM. Saturation of the 
signal response can be observed at 100 μM concentration. The figure inset represents a 
standard ligand binding curve demonstrating saturation binding behaviour. The Rmax can be 
calculated from the asymptote of the curve, and the KD  is defined as the ligand 
concentration giving half Rmax. The KD is measured at equilibrium using the data points at 
the end of the binding plateau. B. Real-time observation of the increase in signal response 
upon addition of increasing concentrations of NSC-87877 inhibitor. The return of the 
response  signal  to  baseline  after  each  inhibitor  binding  event  indicates  a  specific 
interaction devoid of aggregation. All response curves were solvent-corrected, and 
subtracted from the blank (non-immobilised) reference cell and buffer. 
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Although derivation and quantification of a binding affinity was possible for compound 
IIB08 (KD  = 3 µM when fitted to a 1:1 Langmuir binding model), closer analysis of the 
binding profiles suggested that the effects observed were analogous to a compound 
exhibiting a non-specific binding profile (Figure 4.3). This is supported by the lack of 
dose-dependent binding in response to increasing concentrations of inhibitor which should 
lead to the eventual saturation of the signal as all protein sites on the SPR chip gradually 
become occupied. The relatively unstable response signal which shows a period of signal 
loss before inhibitor dissociation also indicates that the response signal shown is unlikely 
to be that of a true protein-ligand interaction. This suggests that the increase in response 
signal is likely to have arisen as a result of compound aggregation which gives a change in 
mass and thus refractive index at the surface. The most feasible explanation for this 
phenomenon is therefore a result of non-specific binding of compound IIB08 which 
accumulates on the SPR sensor chip surface, yielding a false-positive result. 
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Figure 4.3 SPR characterisation of non-specific binding of inhibitor IIB08 to the 
SHP2 catalytic domain. A. SPR concentration-response curve showing the non-specific 
interaction between compound IIB08 and immobilised SHP2 catalytic domain. A 100 μM 
stock solution of compound IIB08 was serially diluted with SPR running buffer across a 
two-fold dilution series to give a concentration range of 3.9 μM – 250 μM. B) The real- 
time observation of an increase in signal response upon addition of increasing 
concentrations   of   IIB08   inhibitor   suggests   an   aggregation-driving   mechanism   of 
compound binding. The slow duration of the response signal in returning to baseline after 
each binding event provides further evidence of a non-specific interaction. All response 
curves were solvent-corrected, and subtracted from the blank (non-immobilised) reference 
cell. 
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4.2.3 Validation of compound NSC-87877 binding by STD-NMR 
 
 
After confirming binding of compound NSC-87877 and observing non-specific binding of 
compound IIB08 by SPR, it was deemed necessary to proceed by investigating whether 
similar observations were reproducible by orthogonal ligand-observed NMR-methods, 
including STD-NMR and waterLOGSY. Prior to running ligand-observed NMR 
experiments, 1H-NMR spectra was collected for compounds IIB08 and NSC-87877 to 
assess compound integrity and probe solubility. 
1
H-NMR spectra recorded for compound 
 
NSC-87877 enabled successful assignment of the 10 predicted aromatic proton signals (the 
exchangeable protons associated with the two sulphonic acid groups and the sole hydroxyl 
group are assumed to be exchanging very rapidly with the bulk water and were not 
observed). Assignment of the individual proton environments present in compound IIB08 
proved extremely challenging due to poor spectra quality which was attributed to a lack of 
compound solubility. In order to confirm this observation, further interrogation by 
1
H- 
 
NMR, using a compound with high solubility at known concentrations as an internal 
control, revealed that the solubility limit of IIB08 was around 50 µM in 5% DMSO (data 
not shown). Interestingly, this also supported initial observations of suspected compound 
insolubility in the SPR assays, which generated bi-phasic binding profiles comprising a 
phase of initial specific binding, followed by progressive non-specific binding as the 
compound concentration exceeded 50 µM. 
 
To  finalise  the  biophysical  validation  of  compounds  IIB08  and  NSC-87877,  the 
interactions between inhibitors NSC-87877 and IIB08 with the SHP2 catalytic domain 
were assessed using ligand-observed methods STD-NMR and waterLOGSY. Interestingly, 
no observable enhancement of the STD signal or inversion of the waterLOGSY signal was 
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apparent to confirm an interaction between compound IIB08 and the SHP2 catalytic 
domain. This was unsurprising as accurate assignment of protein-bound ligand signals is 
only possible from well resolved 
1
H-NMR spectra for the specific ligand of interest. For 
compound NSC-87877, a very weak STD signal was observed confirming a binding 
interaction with the SHP2 catalytic domain (Figure 4.4). Surprisingly, despite the 
observation of a positive hit for compound NSC-87877 by STD-NMR, we were unable to 
observe a signal inversion in the waterLOGSY spectra to confirm NSC-87877 binding to 
SHP2 catalytic domain, despite numerous attempts at optimising mixing time parameters 
to aid waterLOGSY signal resolution. The weak STD spectra and absence of observable 
waterLOGSY signals were reasoned to be a likely consequence of the preferential 
sensitivity of these techniques for detection of weak (often mM to high μM) affinity 
interactions. This is particularly true in light of the KD  value determined for compound 
NSC-87877, which at 3 µM affinity would have a low off-rate relative to the time-frame of 
the STD-experiment, suggesting a possible explanation underlying the weakly observed 
STD signal for NSC-87877 binding to the SHP2 catalytic domain. 
155  
 
 
 
 
 
 
Figure 4.4 Interaction of inhibitor NSC-87877 with the SHP2 catalytic domain by 
STD-NMR. Initial 
1
H-NMR spectra was recorded on compound NSC-87877 (100 μM in 
5% DMSO) to confirm compound identify and account for all proton environments in the 
molecule (blue). STD experiments to elucidate an interaction between the SHP2 catalytic 
domain and compound NSC-87877 were conducted by recording off-resonance (at 25 
ppm, without protein saturation) and on-resonance (via selective saturation of the protein 
at -0.5 ppm) spectra for SHP2 catalytic domain (5 μM) in the presence of compound NSC- 
87877 (100 μM). The red spectra represents the difference spectra obtained by subtracting 
the on-resonance spectra from the off-resonance spectra enabling identification of the 
NSC-87877 compound signals receiving saturation transfer from binding to the SHP2 
catalytic  domain.  The  green  spectra  represent  the  difference  spectra  recorded  for 
compound NSC-877877 only (in the absence of SHP2 catalytic domain) which was used 
as the control experiment. The broken line indicates saturation transfer in the difference 
spectra containing both SHP2 catalytic domain and compound NSC-87877 (red), but not 
in the difference spectra recorded for compound NSC-87877 only (green). 
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4.2.4 Phosphatase activity assays in the presence of SHP2 inhibitors 
 
 
As a final assessment of the activities of SHP2 inhibitors IIB08 and NSC-87877, analysis 
of inhibitory activity was investigated by examining the effect of compounds IIB08 and 
NSC-87877 on the inhibition of SHP2-catalysed hydrolysis of p-nitrophenyl phosphate 
(pNPP) using an in-vitro enzymatic assay. This provided a basis for confirming the 
biochemical activity of these compounds as well as observing whether the modes of 
inhibition corroborated with previously reported literature findings. Prior to evaluation of 
compounds IIB08 and NSC-87877 activity in the biochemical assay, preliminary 
experiments were conducted to assay the basal phosphatase activity of SHP2 catalytic 
domain (at a final concentration of 100 nM) in the absence of inhibitor allowing the 
derivation of a Km value for the pNPP substrate. Indeed, after several rounds of assay 
optimisation, values for the Km of the pNPP substrate for the SHP2 catalytic domain were 
calculated to be 5.1 mM (Figure 4.5A), 4.9 mM (in the presence of BSA; Figure 4.5B) and 
5.2 mM (in the presence of Tween 20; Figure 4.5C) all of which are in close agreement 
with  Km    values  ranging  between  0.5-10  mM  reported  from  independent  kinetic 
experiments on multiple phosphatases 
[212-215]
. 
 
 
To determine the mode of inhibition for  compounds IIB08  and NSC87877,  inhibitor 
assays were repeated in the presence of at least two fixed concentrations of each inhibitor 
ranging from 0.2-5-fold the apparent Km value of pNPP. Analysis of the activity data 
(Sigmaplot 12.0) enabled subsequent derivation of the Michaelis-Menten parameters Km 
and Vmax values. Consistently similar Km values of 5.1 mM, 5.0 mM and 5.3 mM recorded 
in  the  presence  of  inhibitor  IIB08,  along  with  a  reduction  in  the  Vmax   values  from 
0.062  μM/min-1,  0.051  μM/min-1   and  0.038  μM/min-1   at  0  μM,  5  μM  and  10  μM 
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concentrations of IIB08 indicate a non-competitive mode of inhibition which corroborates 
with previously reported modes of inhibition for this compound using a similar assay 
[143]
. 
In the case of inhibitor NSC-87877, a noticeable increase in the Km  values from 5.1 μM, 
8.6 μM, 11.4 μM and 13.7 μM were observed as a function of increasing inhibitor 
concentrations at 0 μM, 0.5 μM, 1.0 μM, 2.0 μM, which were also accompanied by a 
constant Vmax value of 0.062-0.065 μM/min
-1 
indicating a competitive mode of inhibition. 
The  observed  mode  of  inhibitor  action  for  NSC-87877  was  also  akin  to  previous 
 
observations reporting a similar mechanism of inhibition 
[136]
. Furthermore, derivation of 
inhibitor constant (Ki) values (by fitting of the curves to a modified form of the Michaelis- 
Menten equation accounting for the presence of competitive and non-competitive inhibitor 
action) of 6.2 µM and 2.7 µM for the presence of compounds IIB08 (Figure 4.5A) and 
NSC-87877 (Figure 4.6A) respectively, were also in close agreement with the literature 
values of 5.5 µM and 0.3 µM previously reported for these compounds 
[136, 143].
 
 
To evaluate whether the inhibitory effects observed were a result of specific as opposed to 
non-specific inhibition of SHP2 catalytic domain, activity measurements were repeated 
using the same experimental parameters in the presence and absence of BSA (0.1 mg/ml), 
to observe whether this had any significant effect on the inhibition constant Ki. Analysis of 
the activity data for compounds IIB08 and NSC-87877 confirmed no significant difference 
between the inhibitor constants (6.2 µM for inhibitor IIB08 (Figure 4.5B), and 2.7 µM for 
inhibitor NSC-87877 (Figure 4.6B) when comparing measurements recorded in presence 
and absence of BSA, suggesting that inhibition of SHP2 phosphatase activity by inhibitors 
IIB08 and NSC-87877 is likely to be occurring through a specific rather than non-specific 
interaction. To  address  the  possibility of  aggregation-based mechanisms of  inhibition 
which  based  on  previous  observations  were  suggested  to  underlie  the  behaviour  of 
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compound IIB08 in the SPR assay, the inhibition assays for compounds IIB08 and NSC- 
 
87877 were repeated in the presence of the detergent Tween 20. As such,  no significant 
difference in the inhibitor constant Ki  (5.9 µM for inhibitor IIB08 (Figure 4.5C) and 2.5 
µM for inhibitor NSC-87877 (Figure 4.6C) was observed when compared with previous 
 
assays conducted under detergent-free conditions, suggesting that inhibition of SHP2- 
catalysed hydrolysis of pNPP is occurring through specific inhibition as opposed to 
inhibition driven by aggregation-based mechanisms. 
 
A summary of the overall performance of inhibitors PHPS1 , IIB08 and NSC-87877 across 
the assay panel are summarised in Table 4.1, and the statistics from Sigmaplot analysis 
summarised in Table 4.2. 
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Figure 4.5 Non-competitive inhibition of SHP2-catalysed pNPP hydrolysis by 
compound IIB08. Inhibition of SHP2 catalytic activity was recorded at IIB08 
concentrations of 0 µM, 5 µM and 10 µM at pNPP concentrations of 0-50 mM (0.5 Km-10 
Km) and a final enzyme concentration of 100 nM. A) Inhibition of SHP2 catalytic activity 
in the presence 0 µM, 5 µM and 10 µM concentrations of compound IIB08 only. B) 
Inhibition of SHP2 catalytic activity with 0 µM, 5 µM and 10 µM concentrations of 
compound IIB08 in the presence of BSA (0.1 mg/ml). C) Inhibition of SHP2 catalytic 
activity with compound IIB08 in the presence of Tween-20 detergent (0.05%). All assays 
investigating the inhibitory activity of compound IIB08 were initiated with SHP2 catalytic 
domain at a final concentration of 100 nM. 
160  
 
 
 
 
 
 
 
Figure 4.6 Competitive inhibition of SHP2-catalysed pNPP hydrolysis by compound 
NSC-87877. Inhibition of SHP2 catalytic activity was recorded at NSC-87877 
concentrations of 0 µM, 0.5 µM, 1.0 µM and 2.0 µM at pNPP concentrations of 0-50 mM 
(0.5 Km-10 Km) and a final enzyme concentration of 100 nM. A) Inhibition of SHP2 
catalytic activity with 0 µM, 0.5 µM, 1.0 µM and 2.0 µM concentrations of compound 
NSC-87877 only. B) Inhibition of SHP2 catalytic activity with 0 µM, 0.5 µM, 1.0 µM and 
2.0 µM compound NSC-87877 in the presence of BSA (0.1 mg/ml). C) Inhibition of SHP2 
catalytic activity with compound NSC-87877 in the presence of Tween-20 detergent 
(0.05%). All assays investigating the inhibitory activity of compound NSC-87877 were 
initiated with SHP2 catalytic domain at a final concentration of 100 nM. 
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 V..,.x(I.IM 
min·1) 
K..,pNPP 
(mM) 
 
) 
R2 t-value p-value 
pNPPonly 0.062 5.1 37.2 0.983 2.8 0.039 
11808 (51.1M) 0.051 5.0 30.6 0.981 2.6 0.041 
11808 (10 !JM) 0.038 5.3 22.8 0.989 2.9 0.038 
 
 
 
 
 
 
 
Figure 4.5A statistics: 
 
 
K""'(s·1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.58  statistics: 
 
 
 Vmax (IJM 
min·1) 
KmpNPP 
(mM) 
Kcat (s·1) R2 t-value p-value 
pNPP+ 8SA 0.063 4.9 37.8 0.972 2.7 0.042 
11808 (51JM) +8SA 0.054 5.0 32.4 0.981 2.8 0.040 
11808 (10 !JM) + 8SA 0.041 5.1 24.6 0.962 2.7 0.038 
 
 
 
 
 
Figure 4.5C statistics: 
 
 
 Vmax (IJM 
min·1) 
KmpNPP 
(mM) 
Kcat (s·1) R2 t-value p-value 
pNPP + Tween 20 0.068 5.2 40.8 0.964 2.1 0.035 
11808 (5 !JM) +Tween 20 0.052 4.9 31.2 0.978 2.2 0.037 
11808 (10 !JM) + Tween 20 0.039 5.1 23.4 0.983 2.4 0.031 
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Figure 4.6A statistics: 
 
 
 Vmax (liM 
min·1) 
KmpNPP 
(mM) 
Kcat (s·1) R2 t-value p-value 
pNPPonly 0.065 5.1 39.0 0.962 2.3 0.041 
NSC-87877 (0.5 11M) 0.064 8.6 38.4 0.984 2.6 0.031 
NSC-87877 (111M) 0.062 11.4 37.2 0.953 2.7 0.036 
NSC-87877 (2 11M) 0.062 13.7 37.2 0.626 2.2 0.030 
 
 
 
Figure 4.68 statistics: 
 
 
 Vmax (liM 
min·1) 
KmpNPP 
(mM) 
Kcat (s·1) R2 t-value p-value 
pNPP+ BSA 0.066 5.4 39.6 0.986 2.5 0.034 
NSC-87877 (0.5 11M) + BSA 0.063 9.1 37.8 0.981 2.0 0.039 
NSC-87877 (111M) + BSA 0.063 12.2 37.8 0.945 2.2 0.032 
NSC-87877 (2 11M) + BSA 0.061 14.7 36.6 0.974 2.4 0.037 
 
 
 
 
Figure 4.6C statistics: 
 
 
 Vmax (liM 
min·1) 
KmpNPP 
(mM) 
Kcat (s·1) R2 t-value p-value 
pNPP + Tween 20 0.072 5.6 43.2 0.973 2.9 0.028 
NSC-87877 (0.5 11M)+ 
Tween20 
0.069 8.8 41.4 0.979 2.4 0.032 
NSC-87877 (111M) + 0.068 12.4 40.8 0.981 2.6 0.035 
Tween20  
NSC-87877 (2 11M) + 
Tween20 
0.068 15.1 40.8 0.969 2.1 0.039 
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Table 4.1 Determination of Michaelis-Menten and statistical parameters from non- 
linear regression analysis of SHP2 catalytic activity in the presence and absence of 
inhibitors IIB08 and NSC-87877. Enzyme kinetic and statistical parameters for SHP2 
activity were determined from individual curves showing SHP2 activity in the presence of 
pNPP as well as in the presence of inhibitors IIB08 and NSC-87877. These parameters 
were also determined for repeats of these experiments conducted in the presence and 
absence of BSA and Tween 20. The apparent values for the inhibitor constants (Ki) for 
IIB08 and NSC-87877 have also been derived and then compared with the expected values 
previously reported in the scientific literature. Vmax values for individual experiments 
indicate the maximum velocity of the enzyme-catalysed reaction occurring at saturating 
concentrations  of  substrate.  The  Km   values  represent  the  concentration  of  substrate 
required to give half maximum velocity (1/2Vmax) of the enzyme-catalysed reaction. The 
Kcat of an enzyme is often referred to as the turnover number and is a measurement of the 
catalytic efficiency of the enzyme which signifies the number of substrate molecules 
turned over into product per enzyme per second. The inhibitory constant or Ki is the 
inhibitor concentration required to produce half maximum inhibition and serves as a 
measure of inhibitor potency. Statistical parameters derived from non-linear regression 
fitting of the individual curves in Sigmaplot have been provided for the highest 
concentration of inhibitors IIB08 and NSC87877 measured in the presence and absence of 
BSA and Tween 20. The R
2  
value represents the coefficient of determination; the closer 
the values of R
2 
to 1 the greater the accuracy of the fitted curve. The t value corresponds to 
how  accurately the parameters (e.g.  Vmax   and  Km)  predict the values of  the reaction 
velocity (Vo); the larger the t value the more the value of Vo depends upon the parameters 
of Km   and Vmax.  The p-value represents the probability of the Km  and Vmax values 
incorrectly predicting the values of Vo. The p value should be <0.05. 
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KD (µM) Ki (µM) 
Compound 2D-NMR SPR STD- 
NMR 
waterLOGSY Enzyme 
assay 
PHPS1 (1) No binding No binding No 
binding 
No binding Not 
tested 
IIB08 (2) No binding Ambiguous No 
binding 
No binding 3 µM 
NSC-87877 (3) Binding* 2 µM Binding Binding 0.5 µM 
 
 
 
 
 
Table 4.2. Summary of biophysical and biochemical assay profiling of SHP2 inhibitor 
compounds PHPS1, IIB08 and NSC-87877. Compound PHPS1 was found to be highly 
insoluble in 5% (v/v) DMSO and thus attempts to detect an interaction with the SHP2 
catalytic domain by NMR and SPR proved unsuccessful. Although more soluble than 
compound PHPS1, IIB08 also demonstrated poor solubility at concentrations above 50 µM 
in 5% (v/v) DMSO. As such, interactions between IIB08 and SHP2 catalytic domain were 
not observed by NMR when tested in both STD and waterLOGSY experiments. Although 
initially promising, SPR characterisation of compound IIB08 interaction with SHP2 
catalytic domain was later suggested to be non-specific due to aggregation at concentration 
of 50 µM and above. Compound NSC-87877 exhibited consistent activity across the panel 
of assays and thus was used as a validated positive control to authenticate future screening 
assays. 
165  
 
4.3 Discussion 
 
As a precursor to fragment-based ligand discovery to accelerate the development of more 
selective and potent SHP2 chemical probes, a series of robust biophysical and enzyme 
inhibition assays were developed and optimised to examine the binding affinities and 
biochemical activities of three previously reported SHP2 inhibitors, PHPS1, IIB08 and 
NSC-87877. Although tested in preliminary screening measurements, we decided to 
prematurely exclude inhibitor PHPS1 from further studies midway through our 
investigation owing to a profound lack of compound solubility. As such, this compound 
was deemed unsuitable for use as an assay-validating chemical tool. 
 
Prior to engaging in fragment-based screening of SHP2, it was deemed necessary to invest 
efforts in profiling the activities of previously reported SHP2 chemical probes across our 
panel of relevant screening assays to determine the utility of these probes as potential tool 
compounds for hit validation in fragment screening. The cascade of small-molecule 
screening assays included protein and ligand-observed NMR spectroscopy, SPR, and 
enzymatic activity assays, all of which enabled determination and confirmation of binding 
interactions, affinities and inhibitory mechanisms of action. 
 
Compounds NSC-87877 and IIB08 were initially selected for investigation on the basis of 
their literature precedent as validated and commercially available SHP2 inhibitors 
[136, 143]
. 
The initial identification of compound NSC-87877 emerged through screening of the 
National Cancer Institute (NCI) Diversity chemical library and validation of inhibitory 
activity was confirmed in enzymatic pNPP assays with a reported IC50 of 0.3 µM against 
SHP2 along with cross-inhibition of the closest SHP2 homologue, SHP1, with a similar 
potency. In addition to characterising inhibition using biochemical assays, the deployment 
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of  molecular docking analysis in  combination with mutagenesis studies suggested an 
active-site directed mode of SHP2 inhibition, validation of which has yet to be confirmed 
experimentally 
[136]
. Conversely, compound IIB08 was identified by employing a unique 
combinatorial library approach which utilised an indole salicylic acid core as an initial 
chemotype to accelerate the search for novel bivalent inhibitors of SHP2. In a pNPP 
biochemical assay, compound IIB08 gave an IC50 of 5.5 µM and a modest threefold 
selectivity profile over close phosphatase homologs SHP1 and PTP1B. Subsequent kinetic 
analysis also revealed compound IIB08 exhibited reversible non-competitive inhibitor 
kinetics. These kinetic observations were accompanied by promising inhibitory activity in 
a cell-based assay where compound IIB08 demonstrated effective repression of EGF- 
triggered activation of ERK1/2 leading to sustained hyper- proliferation of haematopoietic 
progenitors in response to GM-CSF cytokine signalling 
[143]
. Observations of the inhibitory 
effects of compound IIB08 have also successfully translated into in-vivo studies resulting 
in abrogation of xenograft tumour growth in mouse models of non-small cell lung 
carcinoma 
[142]
. Despite compelling evidence for the inhibitory potential of these 
compounds in enzymatic and cell-based assays, the biophysical evidence confirming 
binding modes, affinities and kinetic parameters for inhibitor interactions with the SHP2 
catalytic domain remains surprisingly underexplored. To address this imbalance, a range of 
biophysical  assays  were  deployed  to  directly characterise inhibitor interactions in  an 
attempt to validate compounds IIB08 and NSC-87877 as authentic and biophysically- 
active chemical tools which could be harnessed as positive control compounds during 
fragment-based screening of SHP2. 
 
Interrogation  of  binding  interactions between  compounds IIB08  and  NSC-87877  and 
 
SHP2 catalytic domain were first conducted by 
15
N-
1
H HSQC NMR spectroscopy. Despite 
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the unique sensitivity of this method for mapping inhibitor binding sites through 
perturbations in backbone amide signals, the poor solubility of IIB08 at the high 
concentrations required for inhibitor binding obfuscated any attempts to observe inhibitor 
binding. Although titration of inhibitor NSC-87877 against 
15
N-labelled SHP2 catalytic 
domain yielded an absence of observable chemical shift perturbations, putative residues 
involved in this interaction (described in Chapter 3) were already identified providing 
support for a pre-existing in-silico model of NSC-87877 binding 
[136]
. 
 
In conjunction with protein-observed NMR methods, the biophysical assay cascade also 
exploited the use of SPR to provide orthogonal evaluation and direct observation of 
compound IIB08 and NSC-87877 binding to the SHP2 catalytic domain. This enabled 
derivation and confirmation of KD  values of 2 µM for compound NSC-87877 and 3 µM 
for IIB08 interactions with the SHP2 catalytic domain. Inspection of the raw SPR data for 
compound NSC-87877 binding to SHP2 catalytic domain revealed a binding profile 
indicative of a specific and reversible binding interaction. However, although initial 
observations suggested a specific interaction between compound IIB08 and SHP2 catalytic 
domain, closer analysis of the response versus time data (Figure 4.3B) suggested that the 
binding profiles observed may not be truly representative of a specific binding interaction. 
This is supported by the absence of true saturation of the response signal as a function of 
increasing inhibitor concentration. Instead, the change in response signal was observed to 
increase by the same increment each time as a function of the inhibitor concentration 
indicating an aggregation-based mechanism of interaction. This suggests that compound 
IIB08 may be acting in a bi-phasic manner where, initially, a specific interaction is 
observed between compound IIB08 and the catalytic domain of SHP2 at compound 
concentrations below 50 µM. However, as the concentration of IIB08 exceeds 100 µM, the 
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SPR curve displays a linear increase in response characteristic of an aggregation-driven 
interaction. The use of IIB08 as a tool compound is severely compromised by its limited 
solubility and any results of its inhibitory properties must therefore be treated with caution. 
 
To finalise the characterisation of compound IIB08 and NSC-87877, inhibitor constants 
were determined for each inhibitor using enzymatic assay based on the spectrophotometric 
detection of p-nitrophenol production as a result of SHP2-catalysed hydrolysis of pNPP. In 
this assay, compounds IIB08 and NSC-87877 gave Ki values of 6.2 µM and 2.8 µM 
respectively, both of which are in close general agreement with the previously reported 
literature values of 5.5 µM and 3 µM for these compounds. Analysis of the inhibitory 
mechanism revealed that compounds IIB08 and NSC-87877 demonstrate non-competitive 
and competitive inhibitor kinetics respectively, which corroborate with previously reported 
modes of inhibition for these compounds 
[136, 143]
. Furthermore, repeating the inhibition 
 
assays for compounds IIB08 and NSC-87877 in the presence of BSA (0.1 mg/ml) revealed 
no significant difference in kinetic parameters for SHP2 activity compared to inhibitor 
assays conducted in the absence of BSA suggesting that inhibition of SHP2-catalysed 
hydrolysis of pNPP occurred as a result of specific inhibition as opposed to non-specific 
promiscuous inhibition of BSA. This confirmed, at least mechanistically, that compounds 
IIB08 and NSC-87877 appeared to be operating through specific rather than non-specific 
inhibitor mechanisms of action in the pNPP biochemical assay. Interestingly, analysis of 
compound IIB08 behaviour across the spectrum of binding assays not only highlighted 
issues relating to compound solubility, but also raised concerns regarding the possibility of 
aggregation-based mechanisms of inhibition, which was postulated as a potential 
mechanism underlying the behaviour of this compound in the SPR assay. It has been well 
documented that at micromolar concentrations, many small molecules have the propensity 
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to self-assemble into micelle-like aggregates capable of driving promiscuous and non- 
specific inhibition of enzymes and proteins 
[152, 216]
. Attenuation of inhibition under 
detergent-rich conditions is therefore a key hallmark of aggregation-based mechanisms of 
inhibition 
[217, 218]
. As such, repeating the inhibition assays for compounds IIB08 and NSC- 
87877 in the presence of the detergent Tween 20 confirmed that there was no significant 
difference in the values derived for the inhibitor constant Ki  compared with previous 
assays conducted under detergent-free conditions, suggesting that inhibition of SHP2- 
catalysed hydrolysis of pNPP is occurring through specific inhibition as opposed to 
inhibition driven by aggregation-based mechanisms. 
 
Despite extensive characterisation of NSC-87877 activity in enzymatic assays and cell 
culture reported in previous studies 
[219] 
the availability of structural evidence in support of 
a competitive mode of inhibition remains elusive. In contrast, the previously reported co- 
crystal structure of IIB08 in complex with SHP2 catalytic domain revealed that IIB08 
binds preferentially to the phosphatase active site supporting a competitive inhibitor 
mechanism of action. 
 
4.4 Conclusions 
 
The binding interactions and biochemical activities of previously reported SHP2 inhibitors 
IIB08  and  NSC-87877  were  characterised  and  their  performance  compared  across  a 
cascade of relevant and robust biophysical and biochemical assays, including 2D-NMR, 
STD-NMR, waterLOGSY, SPR and enzymatic assays. These observations have confirmed 
that inhibitor NSC-87877 demonstrates consistent activity across all assays, and appears to 
be a validated SHP2 inhibitor which can be exploited for use as a positive control 
compound in  fragment-based  screening.  Although  attempts  to  characterise compound 
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IIB08 as a non-competitive inhibitor of SHP2 were successful in the biochemical assay, 
the observation of an active-site binding mode from a previously determined co-crystal 
structure of this compound in complex with the SHP2 catalytic domain is intriguing, 
especially given the absence of inhibitor contacts outside the active site cavity. Overall 
therefore, it is still unclear whether the observed effects are a result of true inhibition or a 
false positive driven by compound aggregation in the NMR and SPR assays. Therefore, the 
inability of  IIB08  to  manifest activity consistently across  the  NMR  and  SPR  assays 
suggest that, for the purposes of this investigation, it was intractable for use as a validated 
chemical probe. 
171  
 
CHAPTER 5: FRAGMENT-BASED SCREENING OF SHP2 BY NMR 
AND SPR 
 
 
 
 
 
5.1 Experimental aims 
 
In Chapter 3, protein-observed NMR spectroscopy was employed to interrogate ligand 
binding to the SHP2 catalytic domain under physiologically-relevant conditions, yielding 
novel insights into the structural basis of ligand interactions in the solution. In Chapter 4, a 
range of biophysical and biochemical assays were conducted in order to validate the 
binding affinities and biochemical activities of previously reported SHP2 inhibitors, 
providing a robust evaluation of the suitability of these ligands for use as positive controls 
in fragment-based screening of SHP2. The utility of validated chemical tools with 
demonstrable binding interactions was a necessary prerequisite for enabling validation of 
our  screening  approach  and  ensured  that  the  SPR  and  NMR-based  assays  used  for 
fragment screening were sufficiently configured for optimal hit detection. 
 
The over-arching aim of this chapter was to utilise SPR and NMR-based approaches to 
screen a 433-compound fragment library with a diverse range of chemical fragments 
(Figure 5.1; see Appendix figures 3a and 3b for extended table highlighting the chemical 
identities of all 433 fragments) against the SHP2 catalytic domain, Tandem-SH2 domains 
and full length SHP2, in order to identify fragment hits that could serve as chemical 
starting points for the development of more potent SHP2 inhibitors. 
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Figure  5.1  Chemical  composition  of  fragment library.  A  433-compound  fragment 
library was assembled from a mixture of fragments deriving from the Maybridge and 
Sigma fragment collections. The fragment scaffolds were selected according to a checklist 
of pre-determined selection critieria. Such criteria included physical properties, such as 
low molecular weight (110 Da - 250 Da) and solubility in water (2 mM), chemical 
tractability  ensuring  fragment  contain  appropriate  functional  groupss  for  synthesis, 
diversity of chemistry, optimal purity and stability, and applicability to a range of target 
classes. 
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5.2 Results 
 
Prior to implementing a fragment-based screening strategy to accelerate the development 
of  novel  SHP2  inhibitors,  a  433-compound  fragment  library  of  sufficient  chemical 
diversity (Figure 5.1) was compiled from a selection of commercially available chemical 
fragments from the Maybridge and Sigma collection. Individual fragments were selected 
on the basis of physiochemical properties including molecular weight (typically between 
110 Da - 250 Da), predicted solubility in water (2 mM), suitability for the proposed 
screening strategy, chemical tractability, appropriate functionality for synthesis, diversity 
of chemical scaffolds and general applicability to a wide array of target classes. All 
compounds were dissolved in 100% D6-DMSO to generate stock solutions at a final 
concentration of 200 mM. Compounds were diluted to 1 mM in 5% D6-DMSO and were 
subjected to  
1
H-NMR  quality control  analysis  before  screening  to  confirm  structural 
 
integrity and verify chemical identity. Mass spectrometry on selected compounds was also 
performed to resolve any ambiguities in compound validation. The preparation of the 
fragment stocks and quality control measures were conducted by previous project students 
Leanne Davies and Mussa Qureshy prior to starting this PhD project. 
 
5.2.1 Expression and purification SHP2 expression constructs for SPR 
 
 
In order to facilitate fragment-library screening of SHP2 using SPR, a series of expression 
constructs  comprising SHP2  catalytic  domain  (residues  247-521)  (Figure  5.2),  SHP2 
Tandem SH2 domain (residues 6-216) (Figure 5.3), and wild type full-length SHP2 + C- 
terminal tail (residues 1-598) (Figure 5.4) were designed and engineered to contain a C- 
terminal Avi-tag
TM   
sequence  (GLNDIFEAQKIEWHE) to  aid  in-vitro biotinylation of 
SHP2 for SPR immobilisation. All constructs were purposely engineered with the Avi- 
174  
tag
TM  
at the C-terminus in order to avoid the N-terminal Hisx6-tag and to preserve the 
native dynamics and allosteric inhibitory mechanisms in the full length construct that 
might otherwise be compromised by immobilisation via the N-terminus. All SPR Avi- 
tag
TM 
expression constructs were codon-optimised for heterologous expression in E. coli, 
cloned into appropriate expression vectors and expressed and purified as described in 
Materials and methods (see section 2.2.6). 
175  
 
 
 
 
 
 
 
 
 
Figure 5.2. Expression and purification of the SHP2 catalytic domain Avi-tag
TM 
construct.  A.  Purification  of  SHP2  catalytic  domain  by  Ni
2+-
NTA  affinity 
chromatography. From left to right: molecular weight markers (M), supernatant (S), 
flowthrough (FT), wash (W), elution fractions (E1-E9). B. Purification of SHP2 catalytic 
domain by size-exclusion chromatography. From left to right: molecular weight markers 
(M), elution fractions (E1-E5). 
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Figure 5.3. Expression and purification of SHP2 Tan-SH2 domain Avi-tag
TM 
construct. A. Purification of SHP2 Tan-SH2 domain by Ni
2+
-NTA affinity 
chromatography. From left to right: molecular weight markers (M), supernatant (S), wash 
(W), elution fractions (E1-E10). B. Purification of SHP2 Tan-SH2 domain by size- 
exclusion chromatography. From left to right: molecular weight markers (M),  elution 
fractions (E1-E16). 
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Figure 5.4. Expression and purification of full length SHP2 Avi-tag
TM  
construct. A. 
Purification  of  full  length  SHP2  Avi-tag
TM   
construct  by  Ni
2+
-NTA  affinity 
chromatography.  Arrowhead  indicates  full  length  SHP2  eluting  from  the  Ni
2+
-NTA 
column wit Ah molecular weight of approximately 68 KDa. From left to right: molecular 
weight markers (M), pellet (P), flowthrough (FT), wash (W), elution fractions (E1-E13). 
B. Purification of full length SHP2 by size-exclusion chromatography. From left to right: 
molecular weight markers (M), pooled and concentrated elution fractions of pure full 
length SHP2 from size exclusion chromatography. 
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5.2.2 Biotinylation of SHP2 catalytic, Tan-SH2 and full length SHP2 constructs 
 
 
As a precursor to initiating fragment-screening of SHP2 catalytic, Tan-SH2 and full length 
SHP2 by SPR, an appropriate strategy was devised for generating biotinylated forms of 
each these constructs, in order to achieve protein immobilisation to the Biacore sensor chip 
surface via biotinylation of the C-terminal Avi-tag
TM
. Preliminary experiments suggested 
that a single screening run of the entire 433-compound fragment library (with all fragments 
run as singletons) would take approximately three days for completion. Thus, adopting a 
strategy using biotinylated protein coupled to a streptavidin coated sensor chip surface 
ensured optimum stability and protein immobilisation throughout the entire duration of 
each individual screening run. As a precursor to protein immobilisation to the SPR sensor 
chip surface, each SHP2 construct was incubated with BirA ligase from E coli, which 
catalyses the ATP-dependant covalent attachment of free biotin 
[220] 
to lysine residues 
present within the biotin recognition sequence GLNDIFEAQKIEWHE. After 
experimenting with a range of biotin concentrations and incubation times, it was observed 
that incubation of the biotinylation reaction for 2 hours at a constant temperature of 30
o
C 
along  with  a  two-fold  molar  excess  of  biotin  relative  to  protein  concentration  was 
sufficient to achieve detectable biotinylation of all SHP2 Avi-tag
TM 
constructs. Throughout 
all experiments both temperature and buffer conditions (supplemented with MgCl2 to 
provide an essential source of Mg
2+ 
as a cofactor for aiding BirA catalysis) were kept 
constant. After employing size-exclusion chromatography to purify biotinylated protein 
and facilitate the removal of excess biotin, western blotting analysis was used to confirm 
the presence of biotinylated species (Figure 5.5). 
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Figure 5.5. Western blot analysis of biotinylated SHP2 catalytic domain, Tan-SH2 
domain and full length SHP2. Confirmation of successful biotinylation of SHP2-Avi- 
tag
TM 
constructs was judged relative to biotinylated CamK1D control protein. From left to 
right: molecular weight markers (M), biotinylated SHP2 catalytic domain-Avi-tag
TM
, 
biotinylated Tan-SH2 domain-Avi-tag
TM
, biotinylated full-length SHP2-Avi-tag
TM 
and 
biotinylated CamK1D-Avi-tag
TM 
(positive control). 
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Although precise quantification of biotinylation levels for each species was not measured, 
successful biotinylation was determined by comparison against a control sample of 
biotinylated CamK1D protein (molecular weight = 38 KDa), which revealed successful but 
differential levels of biotinylation for the SHP2-Avi-tag
TM 
construct. Since all reaction 
conditions   were   conducted   using   the   same   incubation   times,   ATP   and   biotin 
concentrations, the observation of differential levels of biotinylation could be rationalised 
by the relative accessibility of the C-terminal Avi-tag
TM 
sequence for ligation by the BirA 
ligase enzyme. This was particularly pertinent for the full length SHP2 Avi-tag
TM 
construct 
 
which resulted in the highest level of biotinylation relative to the control protein CamK1D. 
This was suspected to have arisen due to location of the Avi-tag
TM 
which, being tethered to 
the end of the disordered SHP2 C-terminal tail would provide greater accessibility to BirA 
enzyme in solution to facilitate the biotinylation reaction. The same justification can also 
be applied to both the SHP2 catalytic and Tan-SH2-Avi-tag
TM  
constructs, each of which 
showed comparatively less biotinylation compared with the full length SHP2 Avi-tag
TM
 
 
construct. For similar reasons, it was suggested that the lack of accessibility of the Avi- 
tag
TM 
as a result of being tethered to the more globular SHP2 catalytic and tan-SH2 
domains, may have sterically hindered BirA ligase recognition of the Avi-tag
TM 
sequence, 
leading to  less  efficient  biotinylation. After  confirming successful  biotinylation, each 
SHP2-Avi-tag
TM  
construct was immobilised to the streptavidin-coated SPR sensor chip 
surface following several rounds of optimisation. 
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The optimum immobilisation level for each SHP2 construct for fragment screening was 
decided based on a molecular weight of 150 Da, which represents the average molecular 
weight calculated for all 433 compounds present in the fragment library. The average 
molecular weight (analyte MW) was then used in conjunction with the molecular weight of 
each SHP2 construct (ligand MW) to calculate the maximum theoretical response value 
(Rmax) based on a protein immobilisation level of 8,000 RU for each construct (Equation 
1). For a small molecule fragment (molecular weight - 150 Da) binding to a protein 
(molecular weight – 34,000 Da) immobilised to a level yielding 8,000 RU, the maximum 
expected response would be 35 RU. 
 
Equation 1: 
 
 
𝑅��� (𝑅��) 
= 
(������� 𝑀 ) (������� 𝑀 ) × 𝑖����𝑖�𝑖��� �𝑖���� ������ (𝑅��) 
 
 
 
 
 
The final protein concentrations were 1 µM, 1.5 µM and 3 µM for SHP2 catalytic domain, 
Tan-SH2 domain and full length SHP2 which each gave immobilisation levels of 7900 
RU, 7875 RU and 7600 RU, respectively, compared to the response expected response of 
 
8000 RU for each SHP2 construct. 
 
 
5.2.3 Fragment-library screening by SPR 
 
 
After confirming successful biotinylation levels for each SHP2 construct and ensuring 
sufficient levels of biotinylated protein had been immobilised to the streptavidin-coated 
sensor chip surface, a library of 433-fragments from the Maybridge-Sigma selection (see 
2.8.1 and Appendix figures 3a and 3b) was screened by SPR to order to identify active 
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fragments that bound to SHP2 catalytic domain, Tan-SH2 domain and wild-type full 
length SHP2. The buffer screening conditions were devised based on earlier findings (as 
described in chapters 3 and 4) demonstrating that the SHP2 catalytic domain exists as a 
stable,  monomeric  and  appropriately  folded  conformation  in  the  presence  of  both 
phosphate and HEPES buffer conditions. These observations suggested that implementing 
a screening strategy employing both HEPES and phosphate buffer conditions would allow 
screening of SHP2 under two separate conditions both of which support structural integrity 
and functional phosphatase activity despite differing in their physiological relevance. 
Incorporating both screening conditions would also provide an interesting comparative 
dataset for assessing the difference in fragment hit rates between phosphate and non- 
phosphate buffer conditions, providing informative insights into future screening strategies 
for an emerging target class that remain largely unexplored for their drug discovery 
potential. 
 
Each SPR fragment screen was completed in five separate experimental runs lasting a total 
of three days. The entire 433 fragments were screened at single concentrations of 50 µM 
and 200 µM in both HEPES and phosphate buffer conditions, with each screening run 
lasting for a total of three days. Each screen was conducted against C-terminally 
biotinylated SHP2 catalytic, Tan-SH2 and full length SHP2 Avi-tag
TM 
constructs 
immobilised on a streptavidin-coated Series SA Biacore sensor chip to levels of ~7900, 
7875 and 7600 RUs respectively. In order to assess the stability of SHP2 catalytic domain 
throughout the duration of the screening assay, the positive control compound NSC-87877 
was injected at a concentration of 100 µM. Unfortunately, there were no small molecule 
inhibitors available for probing the stability of Tan-SH2 domains throughout the SPR 
screening assay. The same was also true for wild-type full length SHP2, however the 
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recent discovery of allosteric inhibitor SHP099 as the first reported inhibitor of full length 
SHP2 could have been exploited for use as a stability probe in these assays had earlier 
development been possible 
[149] 
. 
 
The data from all SPR screening runs were processed as described in the Material and 
Methods (see section 2.8.4). Deconvolution of fragment hit matter was determined by 
setting a cut-off level of 3 RU according to previously published methods 
[221]
. The 
sensorgram profiles for suspected hits at or above this cut-off were then interrogated 
individually for overall shape to identify specific binders and eliminate non-specific 
fragment hits (Figure 5.6). 
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Figure 5.6. Interrogation of SPR sensorgram profiles from fragment-based screening 
of the SHP2 catalytic domain to discriminate between specific versus non-specific and 
non-binding fragments. A) Classic “table-top” profile of a fragment hit demonstrating 
fast  on/off  kinetics  indicative  of  specific  fragment  binding.  B)  Super-stoichiometric 
binding phenomena indicative of non-specific fragment binding. C) Sensorgram profile of 
a non-binding fragment showing negligible change in response. 
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5.2.4 Identification of active fragment hits against SHP2 catalytic domain by SPR 
 
 
Unfortunately, preliminary attempts to identify fragment hits against SHP2 catalytic, tan- 
SH2 and full length SHP2 domains when screening at a single fragment concentration of 
50 µM in both phosphate and HEPES buffer conditions (data not shown) were 
unsuccessful. Owing to the lack of fragment hits at 50 µM concentration, the fragment 
screening concentration was increased to 200 µM to increase the possibility of identifying 
active fragment hits against each domain. Indeed, screening at a single fragment 
concentration of 200 µM enabled identification of a total of 11 active fragments against the 
SHP2 catalytic domain in HEPES buffer (Figure 5.7), with each hit confirmed through 
rigorous inspection of individual sensorgram profiles. Interestingly, a repeat of the same 
433 fragment screen in phosphate buffer revealed 6 active fragments against the SHP2 
catalytic domain (data not shown), 2 of which were also identified as part of the 11 
fragment hits originally identified in the HEPES buffer screen. Despite increasing the 
fragment screening concentration to 200 µM, identification of fragment hits against the 
Tan-SH2 domains in both HEPES and phosphate buffer conditions was still unsuccessful, 
exemplifying  the  challenges  associated  with  the  development  of  chemical  tools  for 
selective modulation of SH2 domain function. Equally, a similar but unexpectedly low 
fragment hit rate was also observed for the full length SHP2 domain, with only 5 fragment 
hits recorded in phosphate and none in HEPES buffer conditions when screening at a 
single fragment concentration of 200 µM (data not shown). This suggested that future 
assay protocols for SPR screening of Tan-SH2 and wild type full length SHP2 domains 
may benefit from screening single fragment concentrations at  or  exceeding 0.5  mM. 
Results showing the number of fragment hits recorded against SHP2 catalytic domain, 
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Tan-SH2 and full length SHP2 in each buffer screening condition are summarised in Table 
 
5.1. 
 
 
 
 
SPR STD waterLOGSY 
 
 
SHP2 construct 
 
HEPES 
 
NaP 
 
Both 
 
d-Tris 
 
NaP 
 
Both 
 
d-Tris 
 
NaP 
  
Both 
SHP2 cat 11 6 2* 27 14 2* 24 14  2* 
Tan-SH2 2 2 0 9 10 0 13 15  0 
FL SHP2 0 5 0 3 4 0 6 8  0 
SHP2 cat + Tan- 
SH2 
13 8 0 39 23 2 14 18  0 
Tan-SH2 + FL 
SHP2 
2 7 0 2 7 0 22 17  0 
SHP2 cat + FL 
SHP2 
11 11 0 6 9 0 14 16  0 
 
 
 
Table 5.1 Analysis of fragment screening cascade showing the number of hits 
identified against the SHP2 catalytic, Tan-SH2 and full length SHP2 constructs by 
SPR, STD and waterLOGSY in the presence of HEPES and phosphate buffer 
conditions. Fragment hits recorded for SPR and NMR-based screening of SHP2 catalytic 
domain (SHP2 cat), tandem SH2 domain (Tan-SH2) and full length SHP2 (FL SHP2) in 
HEPES and phosphate buffer conditions. Fragments confirmed as hits in both screening 
conditions by the same technique are also included. *denotes two cross-validated fragment 
hits against the SHP2 catalytic domain by STD and waterLOGSY in both HEPES and NaP 
buffer   conditions   (for   SPR)   and   d-Tris   and   NaP   buffer   conditions   (STD   and 
waterLOGSY). Cross-validated hits for the SHP2 catalytic domain were then progressed to 
SPR dose-response experiments for further validation. 
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Figure 5.7. SPR screening of a 433-compound fragment library against the SHP2 
catalytic domain in HEPES buffer conditions. Fragment hits were determined based on 
interrogation of individual sensorgram profiles giving responses at or above the 3 RU cut- 
off threshold. Fragments were screened as singletons at a single concentration of 200 uM 
in 5% DMSO. All 433 fragments were screened as singletons by dividing fragments into 5 
separate screening runs. Figures A-E represent 5 individual screening runs for a single 433 
fragment library screen. Labels correspond to chemical vendors from which the fragments 
were originally purchased. A - Maybridge I, B - Maybridge II, C - Maybridge III, D - 
Maybridge IV, E - Sigma I. Fragments demonstrating “table-top” sensorgram profiles were 
classified as hits. Fragments hits for each screen are circled in blue. 
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5.2.5 Fragment library screening by STD-NMR and waterLOGSY 
 
 
As an orthogonal screening method both STD-NMR and waterLOGSY were used to 
counter screen the 433 compound fragment library in order to observe cross-validation of 
fragment hits highlighted in the primary SPR screen. These ligand-observed NMR 
techniques  operate  through  directly  monitoring  the  changes  in  ligand  resonances  in 
solution thus avoiding the need for protein immobilisation which could perturb native 
conformational dynamics and allosteric inhibitory mechanisms. For STD-NMR and 
waterLOGSY, 384 fragments from the original 433-compound library (49 fragments were 
excluded due to poor solubility) was screened in cocktails of 4 with each fragment present 
at a single concentration of 500 µM. The high fragment concentration (compared with the 
200 μM concentration used in the previous SPR screens) was employed to ensure all 
ligand resonances were resolvable enabling accurate fragment hit determination. In 
comparison to the SPR screens, STD identified 27 initial fragment hits for the SHP2 
catalytic domain in d-Tris buffer conditions giving a hit rate of 7%, compared to the same 
screen in phosphate which yielded 14 initial fragment hits and an overall hit rate of 3.6%. 
In contrast to the SPR screens, 9 fragment hits were confirmed by STD against the Tan- 
SH2 domain in d-Tris and 10 fragment hits in phosphate buffer conditions. waterLOGSY 
experiments identified a total of 24 fragment hits against the SHP2 catalytic domain in d- 
Tris buffer conditions giving a hit rate of 6.2%, compared with 14 fragment hits identified 
in phosphate buffer conditions giving a hit rate of 3.6%. For the Tan-SH2 domain,a total of 
13 fragment hits were identified by waterLOGSY giving a hit rate of 3.3%, whereas 
screening of the Tan-SH2 domain in phosphate identified a total of 15 fragment hits 
against by waterLOGSY giving a fragment hit rate of 3.9%. 
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After completing SPR and NMR-based fragment screens against the SHP2 catalytic, Tan- 
SH2 and full length SHP2 domains, initial analysis of the SPR and NMR fragment 
screening data for the SHP2 catalytic domain revealed an unexpected and surprising lack 
of cross-validated hits, with only one fragment showing activity in both assay screens. In 
the interests of time and in line with project objectives, it was decided that further work 
would concentrate on providing further validation and characterization of SHP2 catalytic 
domain fragment hits from the SPR screen as chemical starting points for further 
optimization. 
 
5.2.6 SPR dose-response analysis of fragment binding against SHP2 catalytic domain 
 
 
To identify false-positive hits among the 11 fragment hits identified from initial SPR 
screening in HEPES buffer, these fragments were tested against the SHP2 catalytic domain 
in dose- response using concentration ranges from 6.4 µM-10 mM in 5-fold dilution steps. 
Of the 11 fragment hits identified by SPR screening, we identified the 2 active fragments 
1A9 and 4B1 both of which displayed dose-response behaviour against the SPR catalytic 
domain typical of specific binding. The remaining 9 fragments were excluded from further 
analysis due to a combination of non-specific promiscuous binding, concentration- 
dependent aggregation, superstoichiometric binding (>3-fold ratio of ligand to protein), or 
weak binding which generated insufficient signal responses. After identifying fragment 
hits 1A9 and 4B1, both of these fragments were then repurchased and rescreened as 
singletons in order to independently confirm dose-response activity against the SHP2 
catalytic domain and gauge the reproducibility of the dose-response results. In order to 
monitor the stability of the SHP2 catalytic domain and ensure dose-dependent responses of 
fragments were measured against active protein, dose-response analysis of NSC-87877 
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was assessed alongside the active fragments as a positive control compound. Indeed, NSC- 
 
87877 bound with the expected affinity and kinetics (previously reported in chapter 4) 
suggesting  that  SHP2  catalytic  domain  was  active  on  the  SPR  sensor  chip  surface. 
Analysis of the dose-response curves reconfirmed that repurchased fragments 1A9 and 
4B1 bound in a concentration-dependent fashion enabling the derivation of binding 
affinities for each fragment by fitting to a 1:1 ligand: protein stoichiometry. Fragment 1A9 
was observed to bind SHP2 catalytic domain with a KD of 960 µM (and with an error in 
KD +/- 96 µM; Figure 5.8) and fragment 4B1 bound with a KD of 2 mM (with an error in 
KD of 0.2 mM; Figure 5.9). 
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Figure 5.8. SPR dose-response analysis for fragment 1A9 binding to SHP2 catalytic 
domain. Five-fold serial dilutions of fragment 1A9 were tested across an eight point series 
in the concentration range of 0.64 μM - 10 mM and responses were fitted to the Langmuir 
model assuming a 1:1 protein: ligand binding stoichiometry. A KD for the binding 
interaction was determined as 960 µM. 
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Figure 5.9. SPR dose-response analysis for fragment 4B1 binding to SHP2 catalytic 
domain. Five-fold serial dilutions of fragment 4B1 were tested across an eight point series 
in the concentration range of 0.64 μM - 10 mM and responses were fitted to a Langmuir 
model assuming a 1:1 protein: ligand binding stoichiometry. A KD for the binding 
interaction was determined as 2 mM. 
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5.2.7 SPR dose-response analysis for fragment binding to full length SHP2 
 
After  confirming the  activity of  fragments 1A9  and  4B1  against  the  SHP2  catalytic 
domain, a similar dose-response analysis of these fragments was then performed against 
full length SHP2. Under basal conditions, full length SHP2 exists in an auto-inhibited 
conformation whereby the N-SH2 domain conformationally occludes the active site 
[80]
. 
Given the purposeful engineering of the Avi-tag
TM 
at the C-terminal tail of the full length 
 
SHP2 SPR construct, it was assumed that the native auto-inhibited state would be the 
predominant conformational state of the protein immobilized on the SPR sensor chip 
surface. Thus, the next aim was to investigate whether fragments 1A9 and 4B1 both 
reproduced the same binding profile when binding to conformationally occluded catalytic 
domain compared with the previously binding profiles recorded against the open catalytic 
domain. This would yield insights into the binding location of each fragment and permit 
further exploration of novel fragment binding modes at unique pockets positioned at the 
interface between the N-SH2 domain and the catalytic domain of the full length SHP2 
protein.  Testing  fragments  1A9  and  4B1  in  dose-response  against  full  length  SHP2 
(Figures 5.10 and 5.11) did not recapitulate binding profiles comparable with fragments 
binding  to  the  open  catalytic  domain,  suggesting  that  fragment  binding  is  disrupted 
through N-SH2 domain-mediated occlusion of the phosphatase active site. Furthermore, 
the most likely explanation underlying the sensorgram profiles obtained for fragment 1A9 
and 4B1 binding to full length SHP2 is that full length SHP2 occupies a mixed population 
of open and closed states on the SPR sensor chip. This suggests that the binding profiles 
obtained may represent an average of the fragment binding to both open and 
conformationally occluded full length SHP2. 
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Figure 5.10. SPR dose-response analysis for fragment 1A9 binding to full length 
SHP2. Five-fold serial dilutions of fragment 1A9 were tested across an eight point series 
in the concentration range of 0.64 μM - 10 mM and responses were fitted to a Langmuir 
model assuming a 1:1 protein: ligand binding stoichiometry. Although an apparent KD was 
calculated as 1.2 mM, the response vs time sensorgram does not recapitulate the fragment 
binding profiles recorded previously for the open SHP2 domain. The fragment-binding 
profiles obtained suggest that the N-SH2 domain of SHP2 conformationally occludes the 
active site to perturb optimal fragment binding. Furthermore, the binding profile suggest 
that there is likely to be a mixed population of open and closed full length SHP2 
immobilised on the chip, with the resulting sensorgram profile representing an average of 
the fragment binding response to both conformationally open and closed forms of full 
length SHP2., 
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Figure 5.11. SPR dose-response analysis for fragment 4B1 binding to full length 
SHP2. Five-fold serial dilutions of fragment 4B1 were tested across an eight point series in 
the concentration range of 0.64 μM - 10 mM and responses were fitted to a Langmuir 
model assuming a 1:1 protein: ligand binding stoichiometry. Although an apparent KD was 
calculated as  2.5  mM,  the  binding  response  was  insufficient  to  reach  a  steady state 
meaning an accurate KD value could not be derived. A similar profile for the binding 
response compared to that recorded for fragment 1A9 is consistent with the idea that the 
obtained sensorgram binding profiles represent an average of fragment binding to a mixed 
population of both conformationally open and occluded full length SHP2. 
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5.2.8 Cross validation of fragment binding by STD-NMR and waterLOGSY 
 
 
To provide corroborative evidence for the dose-dependent binding of fragments 1A9 and 
 
4B1  to  the  SHP2  catalytic  domain  by  SPR  and  provide  further  validation  of  these 
fragments as chemical starting points for further development of inhibitors targeting the 
SHP2 catalytic domain, the repurchased fragments were retested in isolation by STD- 
NMR and waterLOGSY experiments. Although both the STD-NMR and waterLOGSY 
experiments gave  particularly weak  ligand  signals  during the  initial  fragment  library 
screen, for the repurchased singletons of these fragments, the emergence of clear positive 
STD signals in alignment with chemical shifts recorded in 
1
H NMR spectra were observed 
 
for both fragments 1A9 (Figure 5.12A) and fragment 4B1 (Figure 5.13A) in the subtracted 
STD spectra, indicative of a binding interaction between fragments 1A9 and 4B1 and the 
SHP2 catalytic domain. Similar observations were also recorded in waterLOGSY spectra, 
with an inversion of the waterLOGSY signal upon addition of both fragment 1A9 (Figure 
5.12B) and fragment 4B1 (Figure 5.13B) consistent with an interaction of these fragments 
with the SHP2 catalytic domain. 
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Figure 5.12 Interaction of fragment 1A9 with the SHP2 catalytic domain by STD- 
NMR  and  waterLOGSY.  A.  STD  spectra  of  fragment  1A9  interaction  with  SHP2 
catalytic domain, as shown by STD signals in substracted spectra (red). B. waterLOGSY 
spectra of fragment 1A9 interaction with SHP2 catalytic domain, as shown by inversion of 
waterLOGSY signal (red) 
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Figure  5.13 Interaction of fragment 4Bl  with  the  SHP2  catalytic  domain  by STD- 
NMR  and  waterLOGSY. A  STD  spectra  of  fragment  4B1  interaction  with  SHP2 
catalytic  domain, as shown  by STD signals in subtracted  spectra (red).  B. waterLOGSY 
spectra of fragment 1A9 interaction with SHP2 catalytic domain, as shown by inversion of 
waterLOGSY signals (red). 
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5.3 Discussion 
 
Screening a 433-compound fragment library has enabled the successful identification of 
two chemically diverse fragment scaffolds which show orthogonal activity against the 
SHP2  catalytic  domain  by  SPR,  STD-NMR  and  waterLOGSY  in  HEPES  buffer 
conditions. Alongside the SHP2 catalytic domain, the overall strategy also included 
screening of the Tan-SH2 domains and wild-type full length SHP2 protein in an attempt to 
identify fragments exploiting novel allosteric binding sites. Unfortunately, however, due to 
experimental time constraints further validation of fragment hits against the Tan-SH2 
domain and full length SHP2 protein was not possible. Thus, efforts were focused on 
validation and characterization of hit matter solely for the SHP2 catalytic domain. 
 
The primary screening assays for SPR and NMR-based (STD-NMR and waterLOGSY) 
fragment screening of the SHP2 catalytic domain were conducted in both HEPES and 
phosphate buffer conditions. This was decided based on preliminary findings reported in 
Chapter 3 which suggested that the presence of phosphate was necessary for stabilization 
of the overall structure of SHP2 enabling greater resolution of backbone amide signals in 
solution  (as  demonstrated  by  
15
N-
1
H  TROSY  HSQC  studies  on  
15
N-labelled  SHP2 
 
catalytic domain). Although the presence of phosphate may prohibit the binding of active- 
site directed fragments, it was hypothesized that the additional stabilization provided by 
phosphate enriched-screening conditions may expose novel and previously unexploited 
pockets for fragment binding allowing characterization and exploitation of novel binding 
sites for SHP2 inhibitor development. However, when comparing the SPR and NMR 
screening results in HEPES which exhibited 2.5% and 7% fragment hit rates respectively 
against  the  SHP2  catalytic  domain,  the  identical  screen  of  SHP2  catalytic  domain 
conducted in the presence of phosphate buffer exhibited 1.3% and 3.2% fragment hit rates 
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for the SPR and NMR screens, suggesting that the presence of phosphate in the screening 
buffer has no significant effect on fragment hit rates for the SHP2 catalytic domain or the 
type of fragments (in terms of particular chemical scaffolds) that bind for the SHP2 
catalytic domain. Since screening phosphatases by fragment-based methods remains a 
highly underexplored discipline, it is not yet clear whether this observation is specific for 
screening studies involving SHP2 alone or whether such an approach can be applied more 
generically to guide future fragment-based screening efforts against other phosphatase 
targets 
 
The 2.5% fragment hit rate (11 fragment hits from a total of 433 fragments screened) 
obtained from SPR screening of the SHP2 catalytic domain at a single fragment 
concentration of 200 μM recorded in HEPES buffer is low compared to hit rates generally 
observed for fragment-based screening efforts, which typically yield hit rates between 3- 
10%   
[222]
. However, fragment hit rates are dependent on a variety of factors, the most 
 
important of which include the size and diversity of the fragment library, and have also 
been suggested as a useful metric for the assessment of the druggable potential of a 
particular target 
[223]
. Indeed, despite the relatively underexplored area of phosphatase drug 
discovery, the notion of fragment hit rates correlating with the overall druggability of a 
particular target is supported by recently reported fragment screening efforts against 
phosphatases.  For  example, screening an  in-house  library of  1500-chemically diverse 
fragments against the phosphatase CDC25B by 
15
N-
1
H NMR spectroscopy identified a 
 
total of 1 fragment hit, giving a hit rate of 0.05% 
[163]
 Compared with other fragment 
 
libraries, the 433 compound fragment library used in this work is significantly smaller, 
with many commercially and industrially developed libraries containing in the range of 
1000-3000 fragments 
[164] 
. Thus, the relatively small size of the fragment screening library 
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combined with the renounced and poor druggability of phosphatases are both key factors 
underlying the relatively low hit rate of 2.5%. 
 
From the SPR screening assay, a total of 11 fragment hits were recorded from the screen 
conducted in HEPES buffer, which after dose-response analysis was reduced to 2 active 
fragments, 1A9 and 4B1. Interestingly, the parallel SPR screen conducted in phosphate 
buffer recorded a total of 6 fragment hits, of which 4 fragments overlapped with the 11 hits 
against the SHP2 catalytic domain recorded in HEPES. Of these 4 overlapping hits, the 
validated  fragment  1A9  bound  in  both  HEPES  and  phosphate  screening  conditions, 
whereas fragment 4B1 was identified only in the HEPES screen. Although further studies 
are necessary in order to validate the binding locations of these fragment hits, abrogation 
of fragment 4B1 binding in the presence of phosphate could be suggestive of a binding site 
located in SHP2 active site. In contrast, fragment 1A9 binding was independent of the 
buffer screening condition suggesting that a putative binding site for this fragment could 
be either the SHP2 active site or an alternative binding location distinct from the 
phosphatase active site. Multiple experimental methods can be utilized for the validation of 
fragment binding locations. These include, but are not exclusive to X-ray crystallography 
[224]
, 2D-NMR 
[225]  
and STD-competition experiments, all of which offer complementary 
 
but differing levels of information regarding fragment binding sites. Unfortunately, as 
documented  in  Chapter  3,  the  high  phosphate  concentrations  required  for  optimal 
resolution of 
15
N-
1
H amide signals poses challenges for mapping inhibitor binding sites by 
2D-NMR methods. For this reason, it was deemed that the weak binding affinities of 
 
fragments 1A9 and 4B1 (as determined by SPR) coupled with the high fragment 
concentrations required for binding site mapping would compromise fragment solubility 
and thus be insufficient to overcome the saturating levels of phosphate occluding the SHP2 
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active site. In contrast, although STD-fragment competition experiments were attempted 
towards the latter part of this study, time constraints meant that it was not possible to 
optimize  the   experimental  parameters  to   a   degree   that   enabled   observations   of 
displacement of fragment 1A9 and 4B1 binding in the presence of the NSC-87877 
competitor  ligand.  Indeed,  STD-fragment  competition  assays  have  been  routinely 
employed with great success as part of kinase drug discovery drug initiatives, which have 
greatly benefited from the use of the potent active-site competitor ligand strausporine 
[226]
. 
 
Despite preliminary attempts to identify the binding locations of these fragments, 
confirmation of fragment 1A9 and 4B1 binding was observed by dose-response analysis 
which revealed both fragments bound with affinities of 960 µM and 2 mM against the 
SHP2 catalytic domain, respectively. Indeed, the weak affinities of these fragments explain 
why it was not possible to observe these fragment hits when conducting the preliminary 
fragment library screens at a single concentration of 50 µM. Interestingly, despite 
identifying fragments 1A9 and 4B1 as initial hits in the SPR screen, these fragments were 
missed as hits in the orthogonal STD and waterLOGSY screens. Furthermore, when 
comparing the level of cross-validation between fragment hits recorded by SPR, STD- 
NMR and waterLOGSY, surprisingly only one fragment hit out of a total of 433 fragments 
was  confirmed  as  a  successful  hit  using  all  three  methods.  It  was  only  through 
repurchasing of the 11 SPR fragment hits as singletons and the subsequent retesting of 
fragments 1A9 and 4B1 in dose-response experiments that provided confirmation of the 
orthogonal activity of these fragments by STD-NMR and waterLOGSY. Although the lack 
of cross-validated hits against the SHP2 catalytic domain from the SPR and NMR-based 
screens was initially surprising, similar observations have also been reported using SPR 
and NMR-based fragment screening methodologies for alternative protein target classes. 
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For example, fragment screening campaigns conducted against the HIV-1 integrase core 
domain have reported similar observations revealing an unexpected lack of hit cross- 
validation when utilizing SPR and STD-NMR as primary screening tools 
[227]
. In that 
study, Wielens et al. conducted two independent fragment screens using 500 compound 
fragment libraries selected from the Maybridge collection, both of which showed only 
10% variation in chemical context and shared 455 identical fragments. The two screening 
cascades utilized different screening methodologies for the initial detection of fragment 
hits; one fragment library was screened using SPR, and the other library screened using 
STD-NMR. Interestingly, despite screening virtually identical fragment libraries, the 
analysis revealed very little cross-correlation between fragment hits using these methods. 
The authors posited the differences in experimental conditions used in each screening 
cascade as a possible explanation underlying this observation, citing differences in pH (pH 
7.5 in SPR screen versus pH 8.5 used in the STD-NMR screen), DMSO concentration (5% 
(v/v) DMSO used in SPR screen versus 1.5% (v/v) DMSO used in STD-NMR screen), salt 
concentration (150 mM NaCl in SPR screen versus 50 mM in STD-NMR screen) and 
fragment concentration (0.5 mM in SPR screen vs 1 mM in STD-NMR screen) between 
the  two  screens  as  possible  factors  contributing  to  the  lack  of  hit  cross-validation. 
However, rescreening the initial hits from the primary screens at the same pH revealed no 
significant differences in hit overlap between the two screens. This led the authors to 
suggest that the lack of observable hit overlap between the two screens was primarily a 
result of the difference in hit selection criteria rather than differences in screening 
conditions. For example, in the STD-NMR screen the authors selected even fragments 
giving weak STD signals in order to enrich the pool of novel fragment chemotypes for 
further evolution and medicinal chemistry optimisation. However, in the SPR screen, the 
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authors incorporated a cut-off value for hit determination which prioritized the selection of 
fragment hits at or above the calculated cut-off value 
[227].
 
 
The observations reported by Wielens et al. form an explanatory framework which can be 
used to interpret the results from fragment-based screening of SHP2 described in this 
chapter. In a similar manner, an underlying explanation for the lack of cross-validated 
fragments  hits  observed  during  SHP2  screening  is  likely  a  result  of  the  different 
sensitivities  of  NMR  and  SPR-based  screening  methods.  Furthermore,  screening  at 
different fragment concentrations by SPR (0.2 mM) and STD-NMR and waterLOGSY (0.5 
mM) encourages selection of two different fragment populations where higher affinity 
fragments are preferentially selected as hits by SPR (and are often overlooked as hits in the 
STD-NMR and waterLOGSY screens due to weaker signals), and lower affinity fragments 
that fall under the SPR cut-off are detected by the STD-NMR and waterLOGSY screens. 
 
5.4 Conclusion 
 
Utilizing  SPR  and  NMR-based  fragment  screening  methods  (STD-NMR  and 
waterLOGSY) has enabled the identification of novel and chemically distinct fragments hit 
against the SHP2 catalytic domain which now serve as starting points for further validation 
and characterization. More specifically, fragment screening assays combined with further 
validation of fragment hits enabled deconvolution of hit matter from 433 fragments to 
confirm fragments 1A9 and 4B1 as dose-response active fragments against the SHP2 
catalytic domain, which bind with affinities of 960 µM and 2 mM respectively. Similar 
dose-response analysis of these fragments against conformationally occluded full length 
SHP2 was unable to reproduce the sensorgram binding curves comparable with similar 
dose-response  analysis  against  the  open  catalytic  domain.  The  explanation  for  this 
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phenomenon  is likely to be a result of a mixed population of open and closed full length 
SHP2  immobilised  on  the  SPR  chip,  suggesting  that  the  fragment  binding  profiles 
recorded represent an average of fragment binding to two different populations of 
conformationally open and occluded forms of full length SHP2. 
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CHAPTER 6: DETERMINING A LIGAND SOAKABLE CRYSTAL 
FORM OF THE SHP2 CATALYTIC DOMAIN 
 
 
 
 
 
6.1 Experimental aims 
 
Fragment-based library screening of the SHP2 catalytic domain by SPR and NMR-based 
methods enabled the successful identification of chemically distinct fragments 1A9 and 
4B1 with binding affinities of 960 µM and 2 mM for the SHP2 catalytic domain, 
respectively (Chapter 5). These validated fragment hits now serve as novel chemical 
starting points for optimisation and development of more potent SHP2 inhibitors. To aid 
the iterative evolution of these fragments into more potent and selective inhibitors, our aim 
was to determine the x-ray crystal structures of these fragments in complex with the SHP2 
catalytic domain to provide experimental validation of fragment binding modes and utilise 
this structural information to guide the medicinal chemistry-driven expansion and 
progression of these fragments into more potent lead inhibitors. In order to facilitate this 
structure-guided approach, the over-arching aim of this was to optimise and develop a 
sufficiently robust and soakable crystal form of the SHP2 catalytic domain that was 
amenable for fragment-soaking and structure determination. 
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6.2 Results 
 
The progression and evolution of validated fragment hits to facilitate the development of 
drug-like inhibitors is greatly accelerated by x-ray crystallographic structure determination 
of fragments bound to the corresponding protein target. Such high resolution structural 
information provides experimental validation of fragment binding modes, can illuminate 
novel and previously undisclosed druggable pockets and enables structure-guided 
elaboration of fragments through an iterative cycle of medicinal chemistry optimisation to 
evolve weak  affinity fragment starting points into more potent lead inhibitors. In  an 
attempt to optimise fragments 1A9 and 4B1 into more potent drug-like inhibitors of the 
SHP2 catalytic domain, it was necessary to devise a robust and soakable crystal system 
that would allow experimental validation of fragment binding modes as a precursor to 
medicinal chemistry optimisation. Due to the high concentration of phosphate required, 
which would inevitably result in saturation of the SHP2 active site, the use of 
15
N-
1
H 
 
HSQC NMR and observation of chemical shift perturbations was deemed an intractable 
approach for characterising fragment binding modes. The less physiologically relevant but 
higher resolution method of x-ray crystallography was therefore pursued in an attempt to 
crystallise an open and unoccluded form of the SHP2 catalytic domain that was amenable 
to fragment-soaking and permitted determination of fragment-bound crystal structures to 
resolutions sufficient for driving medicinal chemistry optimisation. 
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6.2.1 Expression and purification of SHP2 catalytic domain 
 
 
Purification of recombinant human SHP2 catalytic domain (residues 247-534) was 
facilitated by a two-step method of Ni
2+
-NTA and size-exclusion chromatography (as 
described in Materials and methods) which yielded sufficient quantities of stable, 
homogenous and TEV-cleaved protein for structural analysis at a final concentration of 41 
mg/ml (Figure 6.1). 
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Figure 6.1. Expression and purification of unlabelled SHP2 catalytic domain for 
crystallisation. A) Purification of unlabelled SHP2 catalytic domain by Ni
2+-
NTA affinity 
chromatography from 6L BL21 (DE3) cells. From left to right: Molecular markers (M), 
supernatant  (S),  flow-through  (FT),  Wash  (W),  Elution  fractions  1-12  (E1-E12).  B) 
Cleavage of Hisx6-tag pre- and post-incubation with TEV protease. From left to right: 
Molecular markers (M), pooled protein fractions prior to incubation with TEV protease 
(pre-TEV), pooled protein fractions after overnight dialysis and incubation with TEV- 
protease (post-TEV). C) Size-exclusion chromatography of His-cleaved SHP2 catalytic 
domain. SHP2 catalytic domain elutes as a single peak indicating the presence of a stable 
monomeric species. D) Purified fractions of His-cleaved SHP2 catalytic domain by size- 
exclusion chromatography. 
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Rather fortuitously, the expression construct of the SHP2 catalytic domain used for this 
investigation (donated as a kind gift by the SGC, University of Oxford) had been 
crystallised previously to 1.8 Å resolution and the co-ordinates and crystallisation 
conditions deposited in the protein databank under PDB code 3B7O 
[38]
. Unfortunately, 
despite employing an extensive crystal screening strategy, preliminary attempts to identify 
alternative crystallisation conditions for the SHP2 catalytic domain were unsuccessful. 
Owing to the lack of success in the search for alternative crystallisation conditions, it was 
decided  that  the  next  strategy  would  involve  exploiting  the  known  crystallisation 
conditions used for structure determination of SHP2 catalytic domain (PDB code: 3B7O) 
and  using  these  crystallisation  conditions  as  a  starting  point  for  further  crystal 
optimisation. In parallel to this objective, the secondary aim was to explore the tractability 
of this crystal system by assessing whether crystals generated from these conditions were 
sufficiently robust (tolerant to DMSO concentrations typically not exceeding 10%) and 
soakable (crystallise in an open form with an accessible binding site). Both crystal 
robustness and soakability (amongst other criteria to be discussed throughout this chapter) 
are the key criteria when assessing crystal suitability for fragment soaking 
[224]
. 
 
6.2.2 Thermal shift assays to determine optimal buffer stability 
 
 
Prior to setting up crystal trials we considered it prudent to assess the thermal stability of 
the SHP2 catalytic domain across a range of buffer conditions in order to identify the most 
stable buffer condition giving maximal protein stability. This we reasoned would yield a 
more homogenous population of stable protein in solution encouraging more efficient 
protein packing during crystallisation and leading to a more ordered crystal lattice. In order 
to assess thermal stability we utilised the Thermofluor
TM 
system to assay the stability of 
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SHP2 catalytic domain across a range of different buffer conditions. The Thermofluor
TM 
assay relies primarily on the changes in fluorescent properties of the hydrophobic dye 
SYPRO Orange which recognises and binds to hydrophobic patches of protein structure. 
Since hydrophobic regions of protein structure are typically localised to the core of most 
proteins (which is shielded from solvent exposure), an increase in fluorescence signal is 
often observed upon gradual increases in temperature. This drives protein unfolding 
ultimately  leading  to  the  exposure  of  hydrophobic  patches  and  an  increase  in  the 
propensity of dye binding 
[228]
. In this way, buffer conditions giving fluorescent signals at 
the highest melting temperature correlate with optimum protein stability. The thermal 
stability assay therefore involved assessment of protein stability by recording thermal 
melting curves of protein unfolding for the SHP2 catalytic domain over 96 different buffer 
conditions. The experimental method for this assay is described in Materials and Methods. 
Analysis of the 96 thermal melt curves (data not shown) identified 50 mM HEPES pH 7.5 
as the buffer condition producing the greatest fluorescence signals at higher temperature 
indicating that this condition was most conducive to optimum thermal stability. Therefore, 
prior to setting up crystallisation trials of SHP2 catalytic domain, SHP2 catalytic domain 
was dialysed into buffer containing 50 mM HEPES pH 7.5, 150 mM NaCl and 10 mM 
DTT. 
 
6.2.3 Overview of X-ray crystallography 
 
 
X-ray crystallography is a widely used technique for determining the atomic resolution 
structures of protein molecules at the molecular level. The insights obtained from X-ray 
structure analysis can be utilised for the assignment of protein function, to aid 
understanding of substrate and inhibitor interactions with target proteins to unravel enzyme 
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mechanisms and accelerate drug development, and can also be used to probe the functional 
consequences of protein catalysis in different biological systems. Although X-ray 
crystallography has several caveats, namely that crystal structures exhibit static 
representations of protein structure rendering them unable to account for the dynamic 
flexibilities of protein molecules essential for driving catalysis, the resulting structures are 
often generated to an unprecedented level of accuracy. The process of protein structure 
determination by X-ray crystallography is a multi-step process, all of which will be 
summarised in forthcoming sections. 
 
6.2.3.1 Protein crystallisation theory 
 
 
The primary and most fundamental requirement of protein structure determination by 
X-ray crystallography is the generation of highly-ordered, diffraction-quality crystals. This 
process typically involves an iterative cycle of optimisation and refinement and relies on 
the identification of crystallisation conditions yielding crystals of appropriate size and 
morphology for X-ray diffraction. In order to drive protein crystallisation, the overall aim 
is to create conditions which reduce protein interactions with the solvent whilst 
simultaneously maximising protein-protein interactions. To encourage protein-protein 
interaction   leading   to   crystal   formation,   the   protein   solution   needs   to   reach   a 
supersaturated state which increases the probability of protein self-association. The overall 
process of protein crystallisation can be broadly separated into three distinct but related 
stages. These stages include crystal nucleation, growth and termination, and the sequential 
order of these processes underlies the growth of all crystals. The first stage of crystal 
nucleation refers to the early stages of crystal growth and often results in the formation of 
small microcrystal aggregates or “nuclei”, each of which can act as a seeding site to 
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encourage new crystal growth. The perpetual growth of the crystal is then driven by the 
recruitment of multiple protein molecules to sites of nucleation, which over time may 
result in larger and morphologically distinct crystals suitable for X-ray diffraction analysis. 
The final stage of the crystallisation process involves termination, where crystal growth is 
arrested often due to the limiting availability of protein molecules, growth defects, or the 
presence of contaminants which impede further crystallisation. 
 
In order to achieve the super-saturated protein states required for crystallisation, conditions 
must  be  appropriately  configured  in  order  to  reduce  protein  solubility.  The  protein 
solubility is influenced by a multitude of different factors which include pH, ionic strength 
and the presence of precipitants. In particular, pH and the protein isoelectric point (pI) are 
key parameters for determining the solubility of all proteins, with pH values closest to the 
isoelectric point (pI) representing conditions where protein solubility will be at its lowest. 
As such, for any given protein, the optimal crystallisation conditions will therefore be a 
combination of pH, ionic strength and precipitant concentration sufficient to compromise 
protein solubility and minimise protein-solvent interactions while simultaneously driving 
the unfavourable self-association of proteins to yield a diffraction-quality crystal. 
 
6.2.3.2 Protein crystallisation by vapour diffusion 
 
 
The  generation  of  protein  crystals  using  the  vapour  diffusion  method  is  the  most 
commonly employed technique in protein crystallisation, and typically involves two 
primarily different approaches known as hanging drop and sitting drop methods. The use 
of one or both of these approaches in combination allows multiple different crystallisation 
conditions to be screened in parallel, with the ultimate aim of identifying initial screening 
conditions as a starting point for further optimisation of crystal growth. Methodologically, 
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both hanging drop and sitting drop approaches involve mixing equal volumes of protein 
solution with crystallisation buffer (usually precipitant plus additives) and then leaving this 
solution to incubate at 5
o
C or 25
o
C for crystallisation to occur. For the hanging drop 
method, crystallisation is usually conducted by mixing protein and crystallisation solutions 
onto the surface of a cover slip and then inverting the cover slip over a reservoir solution 
containing the corresponding crystallisation screening condition. For the sitting drop 
method, individual wells or sitting bridges are used to suspend the crystallisation drop 
above the reservoir solution. Despite differences in methodology, the thermodynamic 
principles underlying protein crystallisation by hanging and siting drop vapour diffusion 
are fundamentally similar. The underlying catalyst for driving crystal growth originates 
from the difference in precipitant concentration between the crystallisation drop and the 
reservoir solution. More specifically, the lower precipitant concentration in the crystal drop 
compared with the precipitant concentration of the reservoir solution causes the diffusion 
of water from the drop by vapour diffusion establishing an equilibrium between the drop 
and the solution. The diffusion of water from the crystallisation drop leads to a gradual 
increase in protein concentration which is eventually sufficient to reach the supersaturated 
state required for optimal crystallisation. After reaching a supersaturated state, the number 
of protein-protein interactions vastly supersede the number of protein-solvent interactions 
leading to the unfavourable self-association of protein molecules which acts as the trigger 
for early stage nucleation and crystal growth, or precipitation. The precipitation of protein 
in the crystallisation drop is primarily driven by the non-specific interaction between 
protein molecules which is insufficient to support crystal growth. 
 
The preliminary stages of initial crystal screening are typically conducted using a 96-well 
plate format and benefit from the utilisation of a variety of commercially available sparse 
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matrix screens. Setting up individual screening conditions in this manner often involves 
nanolitre drop sizes set up in an automated fashion using a mosquito crystallisation robot, 
which  allows  screening  to  be  performed  on  a  larger  scale  and  across  multiple 
crystallisation  conditions  with  relatively  low  protein  consumption.  The  individual 
screening conditions are then left for crystallisation to occur which depending on the type 
of protein can typically take between 1-14 days. The buffer conditions yielding initial hits 
are then selected for further optimisation, with optimisation of initial hits typically 
involving adjustments to the protein concentration, buffer conditions, precipitant 
concentration or the buffer pH. 
 
After optimising initial hit conditions to generate crystals of suitable size and morphology, 
crystals are then subjected to x-ray diffraction analysis to aid structure determination. 
However, prior to exposure to the x-ray beam crystals must be immersed in a suitable 
cryoprotectant solution in order to minimise damage induced by high energy x-ray 
radiation. The  cryoprotectant, which  acts  by  forming  a  protective barrier  around  the 
protein crystal, additionally serves to prevent ice crystal formation around the crystals 
which can lead to the unwanted and spurious inclusion of diffractions patterns and 
interference with data processing. The composition of the cryoprotectant solution usually 
consists of the reservoir solution from which the crystal was grown combined with 
additional PEG, glycerol or ethylene glycol, with the exact composition tailored to the 
precise recipe of the mother liquor. After development of an appropriate cryoprotection 
strategy, protein crystals are immersed in the cryoprotection solution before being flash 
frozen in liquid nitrogen ready for x-ray diffraction analysis. 
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6.2.3.3 X-ray diffraction and data collection 
 
 
To  facilitate  x-ray  data  collection,  protein  crystals  previously  flash  frozen  in  liquid 
nitrogen must first be mounted in a nylon loop to ensure that the crystal position coincides 
with the direct path of the x-ray beam. Once mounted, the crystal is maintained at a 
constant temperature by a cryostream of nitrogen gas which also serves to preserve crystal 
integrity. The mounted crystal is then rotated periodically through a number of defined 
angles and bombarded with a beam of high intensity x-rays which interact at different 
orientations of the crystal in order to record a complete dataset. The high energy x-ray 
beam collides with the protein crystal and interacts with electrons in the protein molecules 
inducing oscillations which re-emit the x-rays as discrete beams. This generates a unique 
diffraction pattern on an x-ray detector which, following data processing and analysis, 
facilitates protein structure determination. 
 
6.2.3.4 X-ray data processing 
 
 
The first objective of processing x-ray diffraction data as a precursor to structure 
determination involves defining the unit cell parameters and space group characteristics of 
the protein crystal. The unit cell is fundamentally defined as the simplest repeating 
structural unit of the crystal and therefore is an essential metric for measuring the degree of 
internal order and regularity. The unit cell parameters for any given crystal are divided into 
seven distinct categories, with each unit cell dimension defined by three cell lengths (a, b 
and  c)  and  three  corresponding  angle  assignments  (α  β,  γ).  Each  of  these  unit  cell 
categories exhibited by a crystal imposes a defined set of constraints on these length and 
angles. Therefore, in order to proceed with structure determination, the unit cell parameters 
of the crystal must be derived experimentally by calculating the distances between the 
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spots recorded in X-ray diffraction pattern. In conjunction with defining the unit cell 
parameters, the crystal space group must also be defined which provides a description of 
the precise arrangement of the protein molecules in the unit cell of the crystal. 
 
Determination of the unit cell parameters from an x-ray diffraction pattern relies on 
exploiting the fundamental properties of x-rays exhibited by all wave forms. These 
properties include the amplitude, frequency and phase of the wave, all of which are 
essential prerequisites for protein structure determination. After completing an x-ray 
diffraction experiment, the frequency of the wave can be calculated from the wavelength 
of the x-ray beam, and the wave amplitude can be routinely established during data 
processing through measurement of the individual spot intensities and converting these to 
amplitude. However, the crucial phase information of the wave is not obtained during data 
collection and therefore has to be determined independently through further 
experimentation. This notion describing the absence of phase information is commonly 
referred to by protein crystallographers as “The phase problem”. 
 
6.2.3.5 Obtaining Phase Information 
 
 
To drive the process of structure determination, multiple experimental approaches have 
been developed to extract the necessary phase information from diffracted x-rays recorded 
on  the diffraction pattern. The most commonly employed of these approaches is the 
method of molecular replacement, which involves obtaining the missing phase information 
from  a  known  structural  homologue.  In  summary,  the  methodology  underpinning 
molecular replacement relies on the utilisation of phase models generated from the known 
structural homologue and superimposition of these phases onto the unknown structure. The 
success of molecular replacement is thus entirely dependent on the degree of corroboration 
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between the sequence identities of the known structural homologue and the unknown 
structure. In most cases, higher levels of corroborative sequence identities correlate with 
greater superimposition and generate a more accurate prediction of phase information for 
the unknown structure. Once the structures of the known homologue and the unknown 
target protein have been superimposed, the resulting phase information can then be 
harnessed to provide a near complete derivation of the structure. 
 
Although the method of molecular replacement has been used for many years to 
successfully exploit a multitude of protein structures, the employment of such an approach 
is not universally applicable to all protein structures. For example, proteins exhibiting 
novel domain architectures or unique folds for which phase information is unavailable 
(due to the absence of structural homologues) must derive the necessary phase information 
experimentally. One of the most commonly used techniques for determining phase 
information experimentally is known as Multiple Isomorphous Replacement (MIR), which 
relies on the soaking of protein crystals in a solution containing heavy metal atoms. The 
theoretical basis of MIR relies on the fact that heavy metal atoms are electron rich and 
therefore possess higher atomic scattering factors. This intrinsic property of heavy metal 
atoms is manifested in the production of x-ray diffraction patterns of altered intensity 
compared with non-heavy metal soaked versions of the same crystal. The difference in 
intensities of the emitted x-ray beams is sufficient to derive the experimental phase 
information crucial for structure determination. Heavy metal atoms typically used for 
crystal soaking as part of MIR include platinum, gold and iodine which all react with 
histidine and methionine residues, and metals from the lanthanide and actinide series 
which are reactive towards glutamic acid and aspartic acid residues. In order for MIR to 
work  successfully,  the  heavy-atom  soaked  crystals  must  retain  the  same  unit  cell 
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dimensions as the native non-soaked crystals. Since x-ray diffraction data is collected on 
the heavy atom-soaked crystals and then subtracted from the x-ray diffraction patterns 
obtained from native crystals, any perturbations or alterations in the unit cell dimensions of 
the heavy-atom soaked crystals will result in inaccurate determination of the heavy atom 
positions and thus incorrect determination of the experimental phases. In order to provide 
independent confirmation of phase information, orthogonal heavy-atom soaking 
experiments are usually conducted with a second heavy metal atom. Contrary to molecular 
replacement approaches for obtaining phase information, MIR provides a useful approach 
for the experimental determination of phase information for novel protein structures, 
however these experiments are often time consuming are soaking experiments are not 
always successful. 
 
A third approach often employed to derive experimental phase information is known as 
multi-wavelength  anomalous  diffraction  (MAD).  Briefly,  this  method  operates  by 
recording anomalous diffraction measurements at different x-ray energies where the 
anomalous scattering factors of heavy metal atoms significantly differ from one another. 
The larger changes in anomalous scattering factors are typically observed near the 
absorption edges and thus provide useful information regarding the derivation of 
experimental phases to aid structure determination. Implementation of MAD is usually 
facilitated by incorporation of selenium through the expression of seleno-methionine- 
labelled proteins which are crystallised, bombarded with high intensity x-rays and the x- 
ray diffraction data processed in order to determine the experimental phase information. 
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6.2.3.6 Model building and structure refinement 
 
 
Experimental determination of the phase characteristics of electron waves combined with 
the corresponding amplitude enables the first round of model building by calculation of 
electron density maps. The electron density maps define the distribution boundaries of the 
electron clouds around each individual atom in the protein structure. These electron clouds 
are then used as a template and are then interpreted by substitution of a set of atomic co- 
ordinates in order to fit and build the backbone and side chains of specific amino acid 
residues.  Once  a  preliminary structure  has  been  built,  the  model  then  undergoes  an 
iterative cycle of refinement using a series of computer programmes in order to produce 
the best possible fit of the experimental phases to the electron density maps. Higher 
resolution crystal structures will generate clearer electron density maps where the atomic 
co-ordinates can be fitted with greater accuracy. 
 
6.2.4 Crystallisation of SHP2 catalytic domain by malate screening 
 
 
A detailed survey of the crystallisation literature for SHP2 catalytic domain was conducted 
prior to setting up crystal trials. This identified the initial conditions supporting the 
crystallisation of the same SHP2 catalytic domain construct used in this investigation as 
20% (v/v) PEG 3350, 150 mM sodium malate pH 7.5 at 298 K using sitting drop vapour 
diffusion 
[38]
. Under these conditions, a single malate ion was observed as the primary 
occupant of the phosphatase active site, presumably acting as a key mediator for 
maintaining an open and accessible crystal form, with the WPD loop in the open 
conformation. Although representative of an open crystal form, the structure raised initial 
concerns over the presence of the bound malate ion, which was deemed likely to 
compromise the soakability of open crystals grown under these conditions. Furthermore, at 
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a concentration of 150 mM, the substantial molar excess of malate would be at saturating 
concentrations and thus outcompeting bound malate with low affinity fragments would 
pose a significant challenge for determining fragment-bound structures and may prove 
ultimately prohibitive to fragments binding in the same location. 
 
Unfortunately, attempts to elucidate the binding affinity of malate for the SHP2 catalytic 
domain by SPR were unsuccessful. However, it was suggested that optimisation of the 
crystallisation conditions with lower malate concentrations may aid the generation of apo- 
crystals required for fragment soaking experiments. In addition, the decision to proceed 
with optimising crystallisation conditions at lower malate concentrations was also 
motivated  by  unsuccessful  attempts  to  replicate  the  growth  of  SHP2  crystals  under 
literature reported conditions of 20% (v/v) PEG 3350, 150 mM sodium malate pH 7.5 
(Figure 6.2A) that were morphologically amenable for x-ray diffraction studies. 
 
Hence, to investigate whether growth of SHP2 catalytic crystals was feasible at lower 
malate concentrations and explore the effect of this phenomenon on crystal size and 
morphology, a malate screening strategy was  employed at different concentrations of 
SHP2 catalytic domain (17 mg/ml, 25 mg/ml and 34 mg/ml) using a malate concentration 
gradient from the highest concentration of 150 mM to the lowest concentration of 10 mM. 
This strategy enabled screening over a range of malate concentrations, including 
concentrations below 150 mM malate reported in the original conditions, and provided a 
rapid assessment of whether these conditions were amenable for producing crystals of 
appropriate morphology for x-ray diffraction. As a further consideration, it was reasoned 
that any reduction in malate concentration may also aid in generating the large supply of 
apo-crystals necessary for fragment soaking experiments. Finally, when considering the 
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putative importance of the malate ion for holding the active site in an open conformation, 
an additional area of uncertainty centred on the consequences that reducing the malate 
concentration may have on the WPD loop conformation and thus the overall accessibility 
of the phosphatase active site for fragment soaking. 
 
The  results  from  the  small-scale  malate  crystallisation  screens  suggested  that  it  was 
possible to achieve ubiquitous micro-crystal growth of SHP2 catalytic crystals across all 
malate concentrations and at protein concentrations of 17 mg/ml, 25 mg/ml and 34 mg/ml. 
Notably, clear improvements in crystal size and morphology were observed in drops 
containing 75 mM sodium malate pH 7.5 concentrations and above, across all protein 
concentrations screened. In an attempt to optimise crystal growth, large scale  sitting and 
hanging drop crystallisation trials were set up with conditions containing protein 
concentrations of 17 mg/ml, 25 mg/ml and 34 mg/ml at malate concentrations of 75 mM, 
100 mM, 125 mM and 150 mM. Unfortunately, despite scaling up drop sizes from 200 nl 
(100 nl protein: 100 nl precipitant used in the initial screens) to 4 µl (2 µl protein: 2 µl 
precipitant),  no  clear  improvement  in  crystal  size  and  morphology  was  observed. 
However, closer inspection of crystal conditions containing 75 mM sodium malate pH 7.5 
at the lowest protein concentration of 17 mg/ml (Figure 6.2B) revealed that there were 
minor improvements in the size and morphology of crystals grown in this condition. 
 
Despite observing this improvement in crystal growth, the abundance of crystal growth in 
each drop suggested that a reduction in the number of nucleation sites in each drop was a 
worthwhile strategy for further optimisation of crystal morphology. 
 
However, reducing the protein and precipitant concentration by setting up crystallisation 
conditions containing 14 mg/ml - 17 mg/ml protein and 15%-20% (v/v) PEG 3350 only 
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resulted in minor improvement in crystal morphology and micro-crystal growth (Figure 
 
6.2C). This suggested a more drastic adjustment of the crystallisation conditions were 
necessary in order to achieve sufficient reduction in the levels of nucleation and 
optimisation of crystal morphology. 
 
6.2.5 Optimisation of SHP2 catalytic domain crystal morphology 
 
 
To further optimise crystal morphology large-scale crystal screens were set up at lower 
protein, malate and precipitant concentrations in order to reduce the number of nucleation 
sites and achieve crystal morphologies representative of diffraction-quality crystals. 
Interestingly, screening at reduced protein concentrations of 8 mg/ml and 10 mg/ml using 
malate concentrations of 10 mM and 25 mM and a PEG 3350 concentration range of 
7.5%-10% (v/v) produced significantly better crystal morphology compared to results 
obtained from previous crystal trials. In particular, large scale optimisation of these 
conditions resulted in distinct morphological improvement of crystals grown under 
conditions containing 8 mg/ml protein concentration at 8% (v/v) PEG 3350 with 10 mM 
and 25 mM sodium malate pH 7.5 in the crystallisation buffer (Figure 6.2D). 
 
6.2.6 Crystallisation of SHP2 catalytic domain in the presence of DMSO 
 
 
To explore whether crystals exhibited the robust properties required for fragment soaking 
studies and confirm whether crystal integrity was preserved in the presence of DMSO, 
crystals were grown under the optimised condition containing 8 mg/ml protein 
concentration, 10 mM and 25 mM sodium malate pH 7.5, 8% (v/v) PEG 3350, in the 
presence of 5% (v/v) DMSO. Strikingly, despite the addition of 5% (v/v) DMSO these 
conditions yielded crystals with excellent morphology with no obvious defects in crystal 
appearance and integrity, suggesting that crystals grown under these conditions exhibited 
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DMSO tolerance and could be produced under the optimised crystal conditions in both the 
presence and absence of 5% (v/v) DMSO. The ability of these crystals to withstand harsh 
crystallisation conditions containing 5% (v/v) DMSO was also reassuring suggesting that 
crystal integrity would likely be preserved during fragment soaking experiments conducted 
at high DMSO concentrations. 
 
After an iterative cycle of crystal optimisation and assessing crystal growth across a range 
of conditions, a number of crystals were identified from a large scale screen of the 
optimised crystal condition containing 8 mg/ml protein concentration in conditions 
containing 8%-9% (v/v) PEG 3350, 25 mM sodium malate pH 7.5 grown in the presence 
and absence of 5% (v/v) DMSO, with drop sizes of 1 µl: 2 µl and 1 µl to 3 µl protein: 
precipitant respectively. These crystals were selected for x-ray diffraction analysis on the 
basis of size and depth with larger crystals exhibiting straighter edges used as the 
predominant criterion for optimum morphology (Figure 6.2E). 
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Figure 6.2. Small and large-scale optimisation of SHP2 catalytic domain crystals. A) 
Small scale microcrystals of SHP2 catalytic domain grown in conditions containing 25 
mg/ml protein concentration, 20% (v/v) PEG 3350, 150 mM sodium malate pH 7.5, with 
100 nl: 100 nl protein: precipitant set up using a Mosquito robot. B) Small scale growth of 
SHP2 catalytic domain crystals in conditions containing 20% (v/v) PEG 3350, 75 mM 
sodium malate pH 7.5 set up at protein concentrations of 17 mg/ml. C) Reduction of 
crystal nucleation sites by setting up conditions at reduced protein and precipitant 
concentrations containing 14 mg/ml-17 mg/ml protein and 15%-20% (v/v) PEG 3350 only 
resulted in minor improvement in crystal morphology and micro-crystal growth. D) Large 
scale optimisation of crystallisation conditions containing 8 mg/ml protein concentration in 
a crystallisation buffer containing 25 mM sodium malate pH 7.5 and a PEG 3350 
concentration range of 7.5%-10%. These conditions generated diffraction-quality crystals 
which were subsequently used to derive the structure of the SHP2 catalytic domain in the 
apo-conformation. E) Large scale optimisation of DMSO-tolerant SHP2 catalytic domain 
crystals grown at a protein concentration of 8 mg/ml and under crystallisation conditions 
containing 8%-9% (v/v) PEG 3350 and 25 mM sodium malate pH 7.5, grown in the 
presence of 5% (v/v) DMSO. 
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6.2.7 Data collection and processing 
 
 
X-ray diffraction experiments were performed as described in Material and Methods (see 
section 2.9). Briefly, prior to x-ray data collection, crystals grown at 8 mg/ml protein 
concentration in crystallisation buffer containing 8% (v/v) PEG 3350 and 25 mM sodium 
malate pH 7.5 were soaked in a cryoprotectant mixture containing 25% (v/v) ethylene 
glycol as previously described 
[38]
. After cryoprotection, crystals were then mounted and 
cooled at 100 K under a nitrogen gas cryostream. X-ray diffraction data was collected to a 
resolution of 3.1 Å (Figure 6.3) by Dr Fiyaz Mohammed on an in-house MicroMax 007HF 
X-ray source (Rigaku) using a Saturn CCD detector (X-ray facility, School of Biosciences, 
University of Birmingham). The initial data collected was auto indexed with XDS and 
revealed that the SHP2 catalytic domain crystallised in the orthorhombic space group P21 
with unit cell parameters a = 48.7 Å, b = 130.2 Å, c = 48.9 Å, α = 90o, β= 109.6o and γ = 
90
o
. The raw X-ray diffraction data was then integrated, scaled and merged using programs 
 
of the XDS suite. The relevant data processing statistics are displayed in table 6.1. 
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Space Group P21 
 
Unit Cell Length (Å) a= 48.7 Å, b = 130.2 Å, c = 48.9 Å 
 
Unit Cell Angles (
O
) α = 90o, β= 109.6o, γ = 90o 
 
Resolution range (Å) 65-3.1 
 
Total Reflections 147143 (13248) 
 
Unique Reflections 10352 (929) 
 
Completeness (%) 98.5 (97.7) 
 
Rsym (%) 15.9 (60.9) 
 
Rfree (%) 20.2 
 
I/σ (I) 20.99 (5.6) 
 
Multiplicity 1.37 (14.27) 
 
 
 
 
Table 6.1 Data processing statistics for structure determination of SHP2 catalytic 
domain. X-ray data processing statistics for structure determination of SHP2 catalytic 
domain were obtained by integrating, scaling and merging using XDS. Numbers in 
parentheses represent data from the highest resolution shell. 
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Figure 6.3 X-ray diffraction pattern of SHP2 catalytic domain. A 0.5
o  
oscillation 
image of the SHP2 catalytic domain crystal recorded on an in house Micro-Max 007HF 
rotating  anode  X-ray  generator  (Rigaku).  The  crystal  generated  an  X-ray  diffraction 
pattern to a resolution of 3.1Å. 
231  
 
6.2.8 Structure determination using molecular replacement 
 
 
In order to obtain the necessary phase information for structure determination of the SHP2 
catalytic domain, the method of molecular replacement was employed using MOLREP and 
utilising the previously determined malate-bound structure of the SHP2 catalytic domain 
(PDB: 3B7O) as the primary search model. The criteria for selection of a suitable search 
model was based solely on the very high degree of sequence identity (100%) exhibited by 
the experimentally derived SHP2 structure and 3B7O, both of which were constructs of 
identical sequence. Unsurprisingly, the outputs from molecular replacement calculations 
yielded unambiguous solutions for the translation and rotation functions (Tables 6.2, 6.3 
and 6.4) consistent with the SHP2 catalytic domain crystallising as a dimer with two 
copies in the asymmetric unit. After an initial round of refinement, the R-factors of the 
resulting model were reduced from 0.523 to 0.328 (Table 6.4). 
232  
 
Peak number α β γ Rf/θ 
1 5.00 68.59 240.39 12.38 
2 266.27 13.49 336.51 12.38 
3 0.00 66.98 230.82 4.97 
4 124.28 33.31 207.25 4.17 
5 329.83 54.55 164.47 4.14 
 
 
Table 6.2 Rotation function statistics for structure determination of SHP2 catalytic 
domain using molecular replacement. The table shows the outputs from molecular 
replacement which contains the 5 highest solutions for the rotation function peaks using 
structure 3B7O as the primary search model. The correct solutions for the rotation function 
peaks are highlighted in red, which were determined by the increase in Rf/θ score. 
 
 
 
Peak number TX TY TZ RFcnt R factor 
1 0.201 0.00 0.159 21.52 0.478 
 
2 
 
0.352 
 
0.00 
 
0.252 
 
18.95 
 
0.488 
 
3 
0.207 0.00 0.156 2.95 0.550 
 
4 
0.463 0.00 0.465 2.79 0.561 
 
5 
0.317 0.00 0.364 2.38 0.557 
 
 
Table  6.3  Translation  function  statistics  for  SHP2  catalytic  domain  (PDB  code 
3B7O). The table shows the 5 highest translation function solutions determined using the 
rotation function angles derived from Table 6.2. The correct solutions for the translation 
function peaks are determined by a progressive decrease in the R factor value. 
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Peak number TX TY TZ RFcnt R factor 
1 0.352 0.238 0.752 31.22 0.368 
2 0.209 0.355 0.155 1.22 0.525 
3 0.768 0.804 0.849 2.81 0.524 
4 0.342 0.700 0.960 3.51 0.525 
5 0.124 0.817 0.720 3.11 0.523 
 
 
 
 
Table 6.4 Translation function statistics for SHP2catapo. The table shows the 5 highest 
translation function peaks after fixing the search model structure (PDB:  3B7O). The 
correct solutions are highlighted in red which are determined by a progressive decrease in 
the R factor value. 
 
 
 
After calculation and interpretation of the relevant statistical outputs, the molecular 
replacement solution was further validated by assessment of the calculated electron density 
maps. Unsurprisingly, the identical sequences for the SHP2 catalytic domain and the 
search model 3B7O generated clear and unambiguous electron density allowing the 
structure determination with a single round of refinement. Typically, fitting of the 
experimentally determined structure to the calculated electron density maps is followed by 
iterative cycles of model building and structure refinement in order to generate the final 
refinement and stereochemical restraints necessary for complete structure determination. 
However, for the purposes of this investigation, further cycles of model building and 
refinement were deemed unnecessary as a single round of refinement was sufficient to 
confirm  the  structure,  given  the  already  available  structure  of  3B7O  with  identical 
sequence. 
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6.2.9 Fragment and inhibitor soaking of SHP2 catalytic domain crystals 
 
 
In addition, the crystal of the SHP2 catalytic domain solved to 3.1Å was soaked in a 
cryoprotectant solution containing the SHP2 catalytic domain inhibitor NSC-87877. 
Unfortunately, we were unable to identify any clear electron density to unambiguously 
define the binding site of this inhibitor. Similar efforts to derive fragment-bound structures 
of the SHP2 catalytic domain also resulted in similar outcomes with no observable electron 
density detected in the final refined structure. 
 
6.2.10 Structural analysis of the SHP2 catalytic domain crystal structure 
 
 
In the absence of further structural refinement the experimentally derived crystal structure 
of the SHP2 catalytic domain (Figure 6.4) is expected to be comparable to previously 
determined structures solved in both malate-bound (PDB: 3B7O) and auto-inhibited (PDB: 
2SHP) conformations. However, the lower resolution of this structure compared with the 
malate-bound structure (which was refined to a final resolution of 1.8 Å) prohibits further 
discussion regarding the presence or absence of bound ligands or crystallisation artefacts, 
and greatly limits the conclusions that can be drawn regarding whether the catalytic site is 
in an open or closed conformation. 
 
Structurally, the architecture of the SHP2 catalytic domain comprises a total of 8 α helices 
and 13 β strands which is topologically identical to structure 3B7O, but is structurally 
different from 2SHP which features an additional β strand and α helix corresponding to N- 
terminal amino acid residues 221-234 which are truncated from the 3B7O construct. Ten 
of the thirteen β strands group to form a large β sheet dominated by a combination of 
parallel and anti-parallel architecture which encloses the isolated helix αE. Helices αB, αF, 
αG, αH, αI and αJ cluster together on the opposite face of the dominant β sheet. The 
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signature catalytic motif containing the sequence [I/V]HCXAGXXR[S/T]G (where X 
denotes any amino acid) which harbours the catalytically conserved nucleophilic cysteine 
amongst other key functional groups required for phosphate recognition are located in 
sheet βM, helix αG and the intermittent loop region connecting these two elements. The 
catalytic motif in conjunction with the essential WPD loop (the latter formed from the loop 
region extending from sheet βL and terminating at the start of helix αF) form a catalytic 
groove at the base of the phosphate binding pocket. 
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Figure 6.4. Crystal structure of the SHP2 catalytic domain. The experimentally 
determined crystal structure of the SHP2 catalytic domain was solved by molecular 
replacement using the homologue structure 3B7O. Assignment of individual secondary 
structure motifs  comprising the  mixed  α/β  architecture  was  based  on  the  previously 
reported sequence alignments of the SHP2 catalytic domain 
[80]
. 
237  
 
6.2.11 Crystal structure of the SHP2 catalytic domain dimer 
 
 
Since two molecules of SHP2 catalytic domain were found to occupy the asymmetric unit 
(Figure 6.5), the experimentally derived crystal structure of the SHP2 catalytic domain 
initially raised the question of whether the dimeric interface captured during crystallisation 
was a physiologically representative state of the SHP2 catalytic domain or merely an 
artefact of crystal packing. Interestingly, a similar dimeric interaction in the asymmetric 
unit was also observed during crystallisation of the SHP2 catalytic domain in the auto- 
inhibited conformation (PDB: 2SHP). Therefore, to confirm the physiological relevance of 
the dimer, the residues stabilising the dimer interface of both SHP2catapo and 2SHP were 
analysed in further detail to observe whether these were conserved across both structures. 
If dimerization of SHP2 was functionally significant, then one might expect residues 
governing this interaction to have been conserved throughout evolution to support the 
signalling capabilities of SHP2. Indeed, analysis of the residues occupying the dimer 
interface  of  the  SHP2  catalytic  domain  reveal  that  the  majority  of  the  stabilising 
interactions form between the loop region of beta sheet βK of molecule A with the 
corresponding loop region of beta sheet βF of molecule B. Additional stabilising 
interactions are also predicted between the loop region of beta sheet βK from molecule A 
and the helix of beta sheet βF of molecule B, and the loop region of alpha helix αF in 
molecule A with the loop regions of beta sheets βL and βE in molecule B (Table 6.5). 
Similar analysis of the dimeric interface stabilising the crystal structure of 2SHP (Figure 
6.6) also revealed that the majority of the residues lining the dimer interface are located in 
the loop region of beta sheets βJ and βL in molecule A and the loop region of beta sheet βF 
in molecule B. In particular, the loop region of beta sheet βF was also identified as a key 
interaction  motif  stabilising  the  dimer  interface.  Despite  a  commonality  between 
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interaction motifs predicted to stabilise the dimer interface reported in the experimentally 
derived crystal structure of SHP2 and auto-inhibited crystal structure of the SHP2 catalytic 
domain, the evidence gathered in this study does not support the physiological relevance of 
this dimeric interaction. In particular, the low resolution of the experimentally derived 
crystal structure of the SHP2 catalytic domain suggest that these predictions regarding the 
residue  contacts  between  the  dimer  interface  must  be  treated  with  caution.  Further 
evidence against the notion of a physiologically relevant dimer of the SHP2 catalytic 
domain reported in this study includes size-exclusion chromatography, which revealed that 
the SHP2 catalytic domain elutes with a single dominant peak indicative of a dominant 
monomeric species, and that this observation is identical in both physiologically relevant 
phosphatase buffer conditions as well as and non-physiologically relevant HEPES buffer 
conditions. This is also supported by AUC data which demonstrates that SHP2 also exists 
as a predominantly monomeric species in solution, in both phosphate and HEPES buffer 
conditions (see section 3.2.6). 
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Figure 6.5 Crystal structure of the SHP2catapo dimer. The experimentally determined 
crystal structure of SHP2 was observed to contain two molecules in the asymmetric unit 
(molecule A and molecule B). 
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Table 6.5 Residues involved in stabilisation of the SHP2 catalytic domain dimer 
interface. The majority of the residues occupying the interface are located in the loop 
region (L) of beta sheet βK of molecule A with the corresponding loop region (L) of beta 
sheet βF of molecule B. Additional residues include the loop region of alpha helix αF in 
molecule A with the beta sheets of βL and βE. Distances between the interacting side 
chains of these residues are also included. 
241  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Crystal structure of the auto-inhibited SHP2 catalytic domain dimer from 
full length SHP2 (PDB: 2SHP). Structure determination of auto-inhibited full length 
SHP2 observed two copies of each molecule in the asymmetric unit, molecule A and 
molecule B. 
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Table 6.6 Residues involved in stabilisation of the auto-inhibited SHP2 catalytic 
domain dimer interface. The key residues occupying the dimer interface are located in 
the loop region (L) of beta sheet βJ of molecule A with loop region (L) of beta sheet βF of 
molecule B, and loop region (L) of beta sheet βL on molecule A with loop region (L) of 
beta  sheet  βF.  Distances  between  interacting  side  chains  of  these  residues  are  also 
included. 
 
 
 
6.2.12 Superimposition of SHP2 catalytic domain with PDB structures 3B7O and 
 
2SHP 
 
 
In order to confirm whether the experimentally derived structure of the SHP2 catalytic 
domain was structurally similar or exhibited any structural perturbations compared with 
the previously determined malate-bound (PDB: 3B7O) and auto-inhibited conformations 
of the SHP2 catalytic domain (PDB: 2SHP), all three molecules were superimposed and 
the Root Means Square Deviation (RMSD)  calculated (Figure 6.7).  As  predicted, an 
RMSD of 0.17 Å was calculated for the experimentally derived SHP2 crystal structure and 
the malate-bound SHP2 catalytic domain (PDB:3B7O), suggesting that these molecules 
possess very high structural similarity. However, the RMSD values for superimposition of 
2SHP onto SHP2 catalytic domain yielded a value of 3.8 Å, which was likely a result of 
the profoundly distorted N-terminal helix in 2SHP which extends into the C-SH2 and N- 
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SH2 domains of SHP2 to form the entire full length SHP2 protein. The distorted helix 
geometry is therefore likely to resemble a physiologically relevant conformation as 
positioning of this helix is crucial for orienting the tan-SH2 domain in the correct position 
to mediate occlusion of the catalytic pocket and maintain the integrity of the auto-inhibited 
state. 
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Figure 6.7 Overlay of superimposed structures of the experimentally derived crystal 
structure of SHP2 with PDB structures 3B7O and 2SHP. Crystal structures of SHP2 
catalytic domain (red), 3B7O (orange) and 2SHP (blue) were all superimposed to enable 
RMSD calculations. Superimposition of SHP2catalytic domain and 3B7O both gave an 
RMSD value of 0.17 Å, signifying a high degree of structural similarity. The RMSD value 
for 2SHP superimposed to SHP2 catalytic domain and 3B7O was 3.8 Å, presumably 
owing to the distorted helix geometry which extends to the tan-SH2 domain of SHP2 and 
functions by maintaining the integrity of the auto-inhibited state of the full length SHP2 
protein. 
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6.2.13 WPD loop conformation in the SHP2 catalytic domain crystal structure 
 
 
Although a crystal structure of the SHP2 catalytic domain was solved to a resolution of 
 
3.1Å, no definitive conclusions can be drawn regarding the presence of bound malate 
despite crystals being grown in conditions containing high malate concentrations. Given 
this information, we were intrigued to observe the conformational state of the critical 
phosphatase  WPD  loop  in  the  experimentally  derived  crystal  structure  of  SHP2.  In 
addition to playing a central role in the phosphatase catalytic mechanism, the WPD loop is 
a critical regulator of substrate access and therefore acts as a gateway by governing the 
accessibility of the phosphatase active site to a variety of phosphopeptide ligands 
[33]
. The 
 
malate bound structure of SHP2 catalytic domain (PDB: 3B7O) reports the WPD loop in 
an open and accessible conformation, suggesting that the presence of the malate ion is 
acting to support an open conformation of the active site. Initially, although the objective 
was to generate a structure of the SHP2catalytic domain in the absence of bound malate, it 
was unclear whether generating a structure of this kind would destabilise the WPD loop 
thus leading to a closed and inaccessible active site. However, analysis of the electron 
density map for the WPD loop region (Figure 6.8B) suggests that, in the absence of bound 
malate, the WPD loop appears to occupy an open conformation with the W423 side chain 
extending below the plane of the catalytic cleft mimicking the W423 side chain 
conformation observed in the malate bound structure of the SHP2 catalytic domain (Figure 
6.8). This position of the W423 side chain is in stark contrast to the conformation observed 
in the auto-inhibited structure 2SHP (Figure 6.8A, blue) where the upwards protrusion of 
the W423 side chain is sufficient to occlude the catalytic pocket. However, as previously 
mentioned, the low  resolution of this structure compared to the malate-bound crystal 
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structure   of   SHP2   (PDB:   3B70)  is   insufficient   to   conclusively   define   both   the 
conformational state of the WPD loop and the presence or absence of a bound malate ion. 
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Figure 6.8. Comparison of the WPD loop conformation in SHP2 catalytic domain, 
3B7O and 2SHP. A. Overlay of the crystal structures of SHP2 catalytic domain (red), 
3B7O  (orange)  and  2SHP  (blue).  WPD  loop  conformations  (highlighted  as  sticks) 
highlight the position of the W423 side chain as critical determinant for governing open 
and closed conformations of the phosphatase catalytic cleft. The catalytic cysteine is 
highlighted in  yellow. B. Electron density of  the critical W423 residue in the SHP2 
catalytic domain structure suggests that the W423 side chain conformation may mimic the 
equivalent  conformation  of  the  identical  W423  residues  observed  in  structure  3B7O 
leading to an open and accessible catalytic cleft. However, the limitation of a lower 
resolution structure prohibits any definitive conclusions from being drawn regarding the 
precise conformation of the WPD loop. 
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6.3 Discussion 
 
Fragment-based ligand discovery relies on the robust validation of initial fragment hits to 
accelerate the development of hit matter into potent and selective lead molecules. The 
evolution of lead inhibitors requires a robust model of fragments binding to the target of 
interest, insights of which are provided by x-ray crystallography. This enables progressive 
and iterative expansion of the fragment through multiple cycles of medicinal chemistry, 
ultimately leading to the development of more potent inhibitors.  Following a fragment- 
based library screen of the SHP2 domain, which identified fragments 1A9 and 4B1 as 
active and validated fragment hits, the overarching aim of this chapter was to explore and 
optimise a known set of crystallisation conditions for the SHP2 catalytic domain to aid the 
development of an appropriate crystal form that was amenable to fragment-soaking. The 
appropriate crystal form could then be utilised to determine the crystal structures of 
fragments 1A9 and 4B1 bound to the SHP2 catalytic domain and drive optimisation and 
expansion of these fragment into more potent inhibitors of the SHP2 catalytic domain. 
 
In order to develop an appropriate crystal form of the SHP2 catalytic domain, an initial set 
of conditions were used as a starting point for further optimisation. These crystallisation 
conditions contained 20% (v/v) PEG 3350 and 150 mM sodium malate pH 7.5, and had 
previously led to the derivation of the first crystal structure of the SHP2 catalytic domain 
in an open and accessible conformation [38].  Interestingly, the crystal structure reported 
by Barr, et al. revealed the SHP2 catalytic domain in complex with a bound malate ion, 
which was presumably acting as a key mediator for stabilisation of the active site in an 
open conformation. Although an open and accessible active site is necessary for fragment- 
soaking, the presence of the bound malate ion as a crystallisation artefact would be 
prohibitive to fragments binding in the same location. Furthermore, malate concentrations 
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of 150 mM (reported in the initial crystallisation conditions) would also serve to 
outcompete fragments binding to the active site. In order to generate a crystal form devoid 
of bound malate, a number of crystal conditions were screened across a malate 
concentration range spanning 10 mM to 150 mM, the latter malate concentration being the 
condition that resulted in the successful crystallisation of the malate-bound open 
conformation of the SHP2 catalytic domain. After several rounds of optimisation, final 
conditions of 8 mg/ml SHP2 catalytic domain, 8%-9% (v/v) PEG and 25 mM malate was 
sufficient for the generation of diffraction-quality crystals. Interestingly, crystals of similar 
morphology also grew under the same conditions supplemented with 5% (v/v) DMSO. 
Although these crystals did not diffract, crystal growth in conditions supplemented with 
5% (v/v) DMSO suggest that crystals exhibited sufficient DMSO tolerance and thus would 
be  capable  of  withstanding  the  high  DMSO  concentrations  necessary  for  soaking 
fragments 1A9 and 4B1 into crystals of the SHP2 catalytic domain. 
 
Despite exploring a  range of  different soaking conditions, including different 
concentrations of fragments 1A9 and 4B1 in the final soak, there was no clear electron 
density confirming the presence of a bound fragment or inhibitor to the SHP2 catalytic 
domain to validate the soakability of the crystal system. Although electron density for 
fragments and inhibitors was not observed in fragment and ligand-soaked crystals, 
additional  factors  may  be  responsible  for  the  lack  of  crystal  soakability.  The  most 
important of these factors which underlies the soakability of all crystal systems is the 
presence (or absence) of an open and accessible solvent channel in the crystal leading to an 
unobstructed binding site. Although there is no clear method for detecting the presence of 
crystal solvent channels, crystals with high levels of symmetry and open lattice structures 
generally correlate with excellent levels of soakability 
[224]
. To overcome the problem of 
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crystal soakability, extensive engineering of the protein construct or utilisation of a 
surrogate form of the protein with high sequence homology have been typically employed 
in fragment-based screening campaigns to generate more tractable crystal systems 
[229]
. 
 
Interestingly, despite the availability of multiple inhibitor-bound structures of the SHP2 
catalytic domain 
[143, 148, 230]
, all of these have been successfully generated by the use of co- 
crystallisation as opposed to soaking strategies. Indeed, co-crystallisation strategies for 
structure determination of protein-ligand complexes possess several advantages over 
fragment and ligand-based soaking methods. For example, co-crystallisation typically 
generates a more accurate representation of native ligand binding modes as incubation of 
the protein and ligand under solution conditions enables a greater range of dynamic and 
conformational binding equilibria to be sampled, compared with the relatively static 
dynamics of a crystal structure. 
 
Despite unsuccessful attempts to generate structures of fragments 1A9 and 4B1 bound to 
the SHP2 catalytic domain, crystal screening enabled the determination of the structure of 
the  SHP2  catalytic  domain  crystallised  using  an  alternative  set  of  crystallisation 
conditions. However, the low resolution of the final crystallisation structure coupled with 
only a single round of structural refinement prohibit drawing definitive conclusions 
regarding the presence or absence of bound ligands. The same degree of caution must also 
be utilised in the interpretation of the crystal dimer and the residue contacts governing the 
dimeric interface. 
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6.4 Conclusion 
 
After conducting a fragment-based library screen against the SHP2  catalytic domain, 
which identified fragments 1A9 and 4B1 as validated fragment hits, the work conducted in 
this chapter centred on the exploration and optimisation of a known set of crystallisation 
conditions to generate an alternative crystal form of the SHP2 catalytic domain amenable 
for structure determination of the SHP2 catalytic domain bound with fragment 1A9 and 
4B1. Unfortunately, although efforts to derive fragment-bound structures were 
unsuccessful, a crystal structure of the SHP2 catalytic domain was solved with a single 
round of refinement to a resolution of 3.1Å. Although the structural features of this 
structure  were  comparable  with  the  malate-bound  structure  3B7O,  any  conclusion 
regarding the presence of bound malate must be treated with caution. 
 
Despite the amenability of phosphatase enzymes to fragment-based ligand discovery, the 
inherent challenges associated with the development of selective phosphatase inhibitors 
have meant that soakable crystal structures for phosphatases have been a relatively 
underexplored area of research. With fragment-based screening now widely established as 
a powerful tool for identifying novel binding sites and ligandable pockets, particularly in 
the context of more challenging target classes, future applications of fragment-based drug 
discovery may lead to a surge in the pipeline of soakable phosphatase crystal structures to 
facilitate structure-based discovery efforts against this notoriously challenging class of 
enzymes. 
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Appendix 
 
Figure 1a – vector map of pNIC-Bsa4 
 
 
 
 
 
 
 
 
 
The pNIC28-Bsa4 vector was a kind gift from Dr Alastair Barr and Professor Stefan 
Knapp at the Structural Genomics Consortium, University of Oxford. The pNIC28-Bsa4 
vector is a pET expression system containing a Hisx6  affinity tag as part of a 22 amimo- 
acid linker which harbours a TEV protease cleavage site.   The pNIC28-Bsa4 vector 
possesses a Kanamycin resistance gene and gene expression is under the control of a T7 
promoter system. 
276  
 
Appendix figure 1b – vector map of pET15b 
 
 
 
 
 
 
 
The pET-15b vector carries an N-terminal Hisx6 tag sequence immediately followed by a 
thrombin site and three cloning sites, and is under the control of a T7 promoter. 
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Appendix figure 1c – vector map of pET-26b(+) 
 
 
 
 
 
pET-26b(+) carries an N-terminal pelB signal sequence (which acts as a periplasmic 
localisation signal) and also contains a non-cleavable C-terminal Hisx6 tag 
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Appendix figure 2 – SHP2 DNA constructs 
 
 
 
 
Summary of SHP2 constructs used in this study: 
 
 
 
 
Protein construct Vector 
 
 
 
1.   SHP2 catalytic 
domain 
(aa residues 237-533) 
pNIC28-Bsa4 
 
 
 
2.   SHP2 Tandem SH2 
domain 
(aa residues 4-216) 
pNIC28-Bsa4 
 
 
 
3.   Full length SHP2 
(aa residues 1-597) 
pET-26b(+) 
 
 
 
4.   SHP2 catalytic 
domain (SPR) 
(aa residues 237-533) 
pET-15b(+) 
 
 
 
5.   SHP2 Tandem SH2 
domain (SPR) 
(aa residues 4-216) 
pET-15b(+) 
 
 
 
6.   Full length SHP2 
(SPR) 
(aa residues 1-597) 
pET-15b(+) 
 
 
 
 
DNA sequences for each of these constructs including the SHP2 gene insertion and 
corresponding cloning sites are provided below. 
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Shp2 catalytic domain 
 
 
Vector: pNIC-Bsa4 
 
Shp2 catalytic domain, N-terminal Hisx6 tag (plus cleavage site and 
linker region) 
 
Protein sequence 
 
MGHHHHHHSSGVDLGTENLYFQ*SMAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKN 
RYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWR 
MVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQG 
NTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDIL 
IDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRI 
 
MGHHHHHHSSGVDLGTENLYFQ* - denotes TEV-cleavable Hisx6 tag 
 
DNA sequence 
 
Cloning site: NdeI – XhoI 
 
5’CCATGG 
 
atgggccatcatcatcatcatcatagcagcggcgtggatctgggcaccgaaaacctgtat 
tttcagagcatggcggaaaccaccgataaagtgaaacagggcttttgggaagaatttgaa 
accctgcagcagcaggaatgcaaactgctgtatagccgcaaagaaggccagcgccaggaa 
aacaaaaacaaaaaccgctataaaaacattctgccgtttgatcatacccgcgtggtgctg 
catgatggcgatccgaacgaaccggtgagcgattatattaacgcgaacattattatgccg 
gaatttgaaaccaaatgcaacaacagcaaaccgaaaaaaagctatattgcgacccagggc 
tgcctgcagaacaccgtgaacgatttttggcgcatggtgtttcaggaaaacagccgcgtg 
attgtgatgaccaccaaagaagtggaacgcggcaaaagcaaatgcgtgaaatattggccg 
gatgaatatgcgctgaaagaatatggcgtgatgcgcgtgcgcaacgtgaaagaaagcgcg 
gcgcatgattataccctgcgcgaactgaaactgagcaaagtgggccagggcaacaccgaa 
cgcaccgtgtggcagtatcattttcgcacctggccggatcatggcgtgccgagcgatccg 
ggcggcgtgctggattttctggaagaagtgcatcataaacaggaaagcattatggatgcg 
ggcccggtggtggtgcattgcagcgcgggcattggccgcaccggcacctttattgtgatt 
gatattctgattgatattattcgcgaaaaaggcgtggattgcgatattgatgtgccgaaa 
accattcagatggtgcgcagccagcgcagcggcatggtgcagaccgaagcgcagtatcgc 
tttatttatatggcggtgcagcattatattgaaaccctgcagcgccgcatt 
 
3’ CTCGAG 
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Tandem SH2 domain 
 
 
Vector: pNIC-Bsa4 
 
Tandem SH2 domain, N-terminal Hisx6 tag (plus cleavage site and 
linker region) 
 
Protein sequence 
 
MHHHHHHSSGVDLGTENLYFQ*SMRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSV 
RRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSE 
RWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQ 
ELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPL 
 
MGHHHHHHSSGVDLGTENLYFQ* - denotes TEV-cleavable Hisx6 tag 
 
DNA sequence 
 
Cloning site: NdeI – XhoI 
 
5’CCATGG 
 
atgcatcatcatcatcatcatagcagcggcgtggatctgggcaccgaaaacctgtatttt 
cagagcatgcgccgctggtttcatccgaacattaccggcgtggaagcggaaaacctgctg 
ctgacccgcggcgtggatggcagctttctggcgcgcccgagcaaaagcaacccgggcgat 
tttaccctgagcgtgcgccgcaacggcgcggtgacccatattaaaattcagaacaccggc 
gattattatgatctgtatggcggcgaaaaatttgcgaccctggcggaactggtgcagtat 
tatatggaacatcatggccagctgaaagaaaaaaacggcgatgtgattgaactgaaatat 
ccgctgaactgcgcggatccgaccagcgaacgctggtttcatggccatctgagcggcaaa 
gaagcggaaaaactgctgaccgaaaaaggcaaacatggcagctttctggtgcgcgaaagc 
cagagccatccgggcgattttgtgctgagcgtgcgcaccggcgatgataaaggcgaaagc 
aacgatggcaaaagcaaagtgacccatgtgatgattcgctgccaggaactgaaatatgat 
gtgggcggcggcgaacgctttgatagcctgaccgatctggtggaacattataaaaaaaac 
ccgatggtggaaaccctgggcaccgtgctgcagctgaaacagccgctg 
 
3’ CTCGAG 
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Full length SHP2 
 
 
Vector: pET-26B(+) 
 
Full length SHP2, non-cleavable C-terminal Hisx6 tag (pre-cloned 
into pET-26B(+) 
 
 
 
Protein sequence 
 
MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLY 
GGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKH 
GSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYK 
KNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYS 
RKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIAT 
QGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDY 
TLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAG 
IGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRR 
IEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPPCAEMREDSARVYENVGLMQQQKSFR 
 
DNA sequence 
 
Cloning site: NdeI – XhoI 
 
5’CCATGG 
 
atgaccagccgccgctggtttcatccgaacattaccggcgtggaagcggaaaacctgctgctgacc 
cgcggcgtggatggcagctttctggcgcgcccgagcaaaagcaacccgggcgattttaccctgagc 
gtgcgccgcaacggcgcggtgacccatattaaaattcagaacaccggcgattattatgatctgtat 
ggcggcgaaaaatttgcgaccctggcggaactggtgcagtattatatggaacatcatggccagctg 
aaagaaaaaaacggcgatgtgattgaactgaaatatccgctgaactgcgcggatccgaccagcgaa 
cgctggtttcatggccatctgagcggcaaagaagcggaaaaactgctgaccgaaaaaggcaaacat 
ggcagctttctggtgcgcgaaagccagagccatccgggcgattttgtgctgagcgtgcgcaccggc 
gatgataaaggcgaaagcaacgatggcaaaagcaaagtgacccatgtgatgattcgctgccaggaa 
ctgaaatatgatgtgggcggcggcgaacgctttgatagcctgaccgatctggtggaacattataaa 
aaaaacccgatggtggaaaccctgggcaccgtgctgcagctgaaacagccgctgaacaccacccgc 
attaacgcggcggaaattgaaagccgcgtgcgcgaactgagcaaactggcggaaaccaccgataaa 
gtgaaacagggcttttgggaagaatttgaaaccctgcagcagcaggaatgcaaactgctgtatagc 
cgcaaagaaggccagcgccaggaaaacaaaaacaaaaaccgctataaaaacattctgccgtttgat 
catacccgcgtggtgctgcatgatggcgatccgaacgaaccggtgagcgattatattaacgcgaac 
attattatgccggaatttgaaaccaaatgcaacaacagcaaaccgaaaaaaagctatattgcgacc 
cagggctgcctgcagaacaccgtgaacgatttttggcgcatggtgtttcaggaaaacagccgcgtg 
attgtgatgaccaccaaagaagtggaacgcggcaaaagcaaatgcgtgaaatattggccggatgaa 
tatgcgctgaaagaatatggcgtgatgcgcgtgcgcaacgtgaaagaaagcgcggcgcatgattat 
accctgcgcgaactgaaactgagcaaagtgggccagggcaacaccgaacgcaccgtgtggcagtat 
cattttcgcacctggccggatcatggcgtgccgagcgatccgggcggcgtgctggattttctggaa 
gaagtgcatcataaacaggaaagcattatggatgcgggcccggtggtggtgcattgcagcgcgggc 
attggccgcaccggcacctttattgtgattgatattctgattgatattattcgcgaaaaaggcgtg 
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gattgcgatattgatgtgccgaaaaccattcagatggtgcgcagccagcgcagcggcatggtgcag 
accgaagcgcagtatcgctttatttatatggcggtgcagcattatattgaaaccctgcagcgccgc 
attgaagaagaacagaaaagcaaacgcaaaggccatgaatataccaacattaaatatagcctggcg 
gatcagaccagcggcgatcagagcccgctgccgccgtgcaccccgaccccgccgtgcgcggaaatg 
cgcgaagatagcgcgcgcgtgtatgaaaacgtgggcctgatgcagcagcagaaaagctttcgc 
 
3’ CTCGAG 
 
 
 
 
Shp2 catalytic domain (SPR) 
 
 
Vector: pET-15b(+) 
 
Shp2 catalytic domain, N-terminal Hisx6 tag (plus cleavage site and 
linker region) and C-terminal (Avi-Tag) biotinylation sequence 
 
Protein sequence 
 
MGHHHHHHSSGVDLGTENLYFQ*SMAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKN 
RYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWR 
MVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQG 
NTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDIL 
IDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETLQRRIGLNDIFEAQKIE 
WHE* 
 
MGHHHHHHSSGVDLGTENLYFQ* - denotes TEV-cleavable Hisx6 tag 
 
GLNDIFEAQKIEWHE* - denotes C-terminal Avi-tag biotinylation 
sequence 
 
DNA sequence 
 
Cloning site: NdeI – XhoI 
 
5’CCATGG 
 
ccatgggccatcatcatcatcatcatagcagcggcgtggatctgggcaccgaaaacctgtattttc 
agagcatggcggaaaccaccgataaagtgaaacagggcttttgggaagaatttgaaaccctgcagc 
agcaggaatgcaaactgctgtatagccgcaaagaaggccagcgccaggaaaacaaaaacaaaaacc 
gctataaaaacattctgccgtttgatcatacccgcgtggtgctgcatgatggcgatccgaacgaac 
cggtgagcgattatattaacgcgaacattattatgccggaatttgaaaccaaatgcaacaacagca 
aaccgaaaaaaagctatattgcgacccagggctgcctgcagaacaccgtgaacgatttttggcgca 
tggtgtttcaggaaaacagccgcgtgattgtgatgaccaccaaagaagtggaacgcggcaaaagca 
aatgcgtgaaatattggccggatgaatatgcgctgaaagaatatggcgtgatgcgcgtgcgcaacg 
tgaaagaaagcgcggcgcatgattataccctgcgcgaactgaaactgagcaaagtgggccagggca 
acaccgaacgcaccgtgtggcagtatcattttcgcacctggccggatcatggcgtgccgagcgatc 
cgggcggcgtgctggattttctggaagaagtgcatcataaacaggaaagcattatggatgcgggcc 
cggtggtggtgcattgcagcgcgggcattggccgcaccggcacctttattgtgattgatattctga 
ttgatattattcgcgaaaaaggcgtggattgcgatattgatgtgccgaaaaccattcagatggtgc 
gcagccagcgcagcggcatggtgcagaccgaagcgcagtatcgctttatttatatggcggtgcagc 
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attatattgaaaccctgcagcgccgcattggcctgaacgatatttttgaagcgcagaaaattgaat 
ggcatgaataa 
 
3’ CTCGAG 
 
Tan-SH2 domain (SPR) 
 
 
Vector: pET-15b(+) 
 
Tan-SH2 domain, N terminal Hisx6 tag (plus cleavage site and linker 
region) and C-terminal (Avi-Tag) biotinylation sequence 
 
Protein sequence 
 
MHHHHHHSSGVDLGTENLYFQ*MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLS 
VRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSE 
RWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQE 
LKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLGLNDIFEAQKIEWHE* 
 
MGHHHHHHSSGVDLGTENLYFQ* - denotes TEV-cleavable Hisx6 tag 
 
GLNDIFEAQKIEWHE* - denotes C-terminal Avi-tag biotinylation 
sequence 
 
DNA sequence 
 
Cloning site: NdeI – XhoI 
 
5’CCATGG 
 
GGCCATCACCATCACCATCACTCATCGGGCGTTGACCTGGGCACCGAAAATCTGTACTTCCAAATG 
ACCTCGCGTCGTTGGTTCCACCCGAACATTACCGGTGTCGAAGCAGAAAATCTGCTGCTGACGCGT 
GGTGTGGATGGCAGTTTTCTGGCTCGCCCGAGCAAATCTAACCCGGGTGACTTCACCCTGTCCGTT 
CGTCGCAACGGCGCGGTCACCCATATTAAAATCCAGAATACGGGCGATTATTACGACCTGTATGGC 
GGTGAAAAATTTGCGACCCTGGCCGAACTGGTGCAGTATTACATGGAACATCACGGTCAACTGAAA 
GAGAAAAACGGCGATGTTATTGAACTGAAATACCCGCTGAATTGCGCGGACCCGACCAGCGAACGT 
TGGTTTCATGGCCACCTGTCTGGCAAAGAAGCCGAAAAACTGCTGACGGAAAAAGGTAAACATGGC 
AGCTTTCTGGTGCGTGAAAGTCAGTCCCACCCGGGTGATTTCGTGCTGTCTGTTCGCACCGGTGAT 
GACAAAGGCGAATCAAACGATGGCAAATCGAAAGTCACGCATGTGATGATCCGTTGTCAAGAACTG 
AAATATGATGTTGGCGGTGGCGAACGCTTTGATAGCCTGACCGACCTGGTCGAACACTACAAGAAA 
AACCCGATGGTGGAAACCCTGGGTACGGTTCTGCAACTGAAACAACCGCTGGGCCTGAATGACATC 
TTTGAAGCACAGAAAATTGAATGGCACGAATGA 
 
3’ CTCGAG 
 
 
 
 
 
 
Full length SHP2(SPR) 
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Vector: pET-15b(+) 
 
Full length SHP2, N-terminal Hisx6 tag (plus cleavage site and 
linker region) and C terminal (Avi-Tag) biotinylation sequence 
 
Protein sequence 
 
MHHHHHHSSGVDLGTENLYFQ*MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLS 
VRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSE 
RWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQE 
LKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDK 
VKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINAN 
IIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDE 
YALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQALLQGNTERTVWQYHFRTWPDHGVPSDPGGVL 
DFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRS 
GMVQTEAQYRFIYMAVQHYIETLQRRIEEEQKSKRKGHEYTNIKYSLADQTSGDQSPLPPCTPTPP 
CAEMREDSARVYENVGLMQQQKSFRGLNDIFEAQKIEWHE 
 
MGHHHHHHSSGVDLGTENLYFQ* - denotes TEV-cleavable Hisx6 tag 
 
GLNDIFEAQKIEWHE* - denotes C-terminal Avi-tag biotinylation 
sequence 
 
DNA sequence 
 
Cloning site: NdeI – XhoI 
 
5’CCATGG 
 
atgcatcatcatcatcatcatagcagcggcgtggatctgggcaccgaaaacctgtattttcagatg 
accagccgccgctggtttcatccgaacattaccggcgtggaagcggaaaacctgctgctgacccgc 
ggcgtggatggcagctttctggcgcgcccgagcaaaagcaacccgggcgattttaccctgagcgtg 
cgccgcaacggcgcggtgacccatattaaaattcagaacaccggcgattattatgatctgtatggc 
ggcgaaaaatttgcgaccctggcggaactggtgcagtattatatggaacatcatggccagctgaaa 
gaaaaaaacggcgatgtgattgaactgaaatatccgctgaactgcgcggatccgaccagcgaacgc 
tggtttcatggccatctgagcggcaaagaagcggaaaaactgctgaccgaaaaaggcaaacatggc 
agctttctggtgcgcgaaagccagagccatccgggcgattttgtgctgagcgtgcgcaccggcgat 
gataaaggcgaaagcaacgatggcaaaagcaaagtgacccatgtgatgattcgctgccaggaactg 
aaatatgatgtgggcggcggcgaacgctttgatagcctgaccgatctggtggaacattataaaaaa 
aacccgatggtggaaaccctgggcaccgtgctgcagctgaaacagccgctgaacaccacccgcatt 
aacgcggcggaaattgaaagccgcgtgcgcgaactgagcaaactggcggaaaccaccgataaagtg 
aaacagggcttttgggaagaatttgaaaccctgcagcagcaggaatgcaaactgctgtatagccgc 
aaagaaggccagcgccaggaaaacaaaaacaaaaaccgctataaaaacattctgccgtttgatcat 
acccgcgtggtgctgcatgatggcgatccgaacgaaccggtgagcgattatattaacgcgaacatt 
attatgccggaatttgaaaccaaatgcaacaacagcaaaccgaaaaaaagctatattgcgacccag 
ggctgcctgcagaacaccgtgaacgatttttggcgcatggtgtttcaggaaaacagccgcgtgatt 
gtgatgaccaccaaagaagtggaacgcggcaaaagcaaatgcgtgaaatattggccggatgaatat 
gcgctgaaagaatatggcgtgatgcgcgtgcgcaacgtgaaagaaagcgcggcgcatgattatacc 
ctgcgcgaactgaaactgagcaaagtgggccaggcgctgctgcagggcaacaccgaacgcaccgtg 
tggcagtatcattttcgcacctggccggatcatggcgtgccgagcgatccgggcggcgtgctggat 
tttctggaagaagtgcatcataaacaggaaagcattatggatgcgggcccggtggtggtgcattgc 
agcgcgggcattggccgcaccggcacctttattgtgattgatattctgattgatattattcgcgaa 
285 
 
 
aaaggcgtggattgcgatattgatgtgccgaaaaccattcagatggtgcgcagccagcgcagcggc 
atggtgcagaccgaagcgcagtatcgctttatttatatggcggtgcagcattatattgaaaccctg 
cagcgccgcattgaagaagaacagaaaagcaaacgcaaaggccatgaatataccaacattaaatat 
agcctggcggatcagaccagcggcgatcagagcccgctgccgccgtgcaccccgaccccgccgtgc 
gcggaaatgcgcgaagatagcgcgcgcgtgtatgaaaacgtgggcctgatgcagcagcagaaaagc 
tttcgcggcctgaacgatatttttgaagcgcagaaaattgaatggcatga 
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Appendix figure 3a: Maybridge Fragment Library Collection 
 
 
 
CHEMICAL NAME SMIILES BARCODE 
2-ethyl-4-methyl-1H-imidazole CCc1[nH]cc(n1)C  
0103512998 
4-methylquinolin-2-ol CC1=CC(=NC2=C1C=CC=C2)O  
0103512997 
[(5-methoxy-1H-indol-3- 
yl)methyl]dimethylamine 
COC1=CC2=C([NH]C=C2CN(C) 
C)C=C1 
 
0103512996 
7-methyl-1H-indole CC1=C2[NH]C=CC2=CC=C1  
0103512995 
2-(pyridin-3-yl)acetic acid hydrochloride Cl.OC(=O)CC1=CC=CN=C1  
0103512994 
1-benzylpiperidin-3-ol hydrochloride Cl.OC1CCCN(C1)CC2=CC=CC= 
C2 
 
0103512993 
4-(1H-imidazol-1-yl)phenol OC1=CC=C(C=C1)[N]2C=CN=C 
2 
 
0103512992 
3-phenyl-1H-pyrazole c1ccc(cc1)c2cc[nH]n2  
0103512991 
6-chloro-1,3-benzoxazol-2-ol OC1=NC2=C(O1)C=C(Cl)C=C2  
0103512990 
3-methyl-2,3-dihydro-1,3-benzoxazole-2- 
thione 
CN1C(=S)OC2=C1C=CC=C2  
0103512989 
1H-indazol-5-amine Nc1ccc2c(c1)cn[nH]2  
0103512119 
methyl 1H-indole-3-carboxylate COC(=O)c1c[nH]c2c1cccc2  
0103512120 
2-methylfuran-3-carboxylic acid Cc1c(cco1)C(=O)O  
0103512975 
2-methyl-1H-indol-5-amine Cc1cc2cc(ccc2[nH]1)N  
0103512976 
1,3-benzothiazol-2-ol c1ccc2c(c1)nc(s2)O  
0103512977 
ethyl 2-amino-4-(4-fluorophenyl)thiophene-3- 
carboxylate 
CCOC(=O)c1c(N)scc1- 
c1ccc(F)cc1 
 
0103512978 
1-[4-(trifluoromethyl)pyrimidin-2- 
yl]piperidin-4-ol 
OC1CCN(CC1)C2=NC(=CC=N2 
)C(F)(F)F 
 
0103512979 
4-(2-methyl-1,3-thiazol-4-yl)aniline Cc1nc(cs1)-c1ccc(N)cc1  
0103512980 
2-amino-5-phenylfuran-3-carbonitrile NC1=C(C=C(O1)C2=CC=CC=C 
2)C#N 
 
0103512981 
8-methyl-1,2,3,4-tetrahydroquinoline Cc1cccc2CCCNc12  
0103512982 
4-(morpholin-4-yl)aniline c1cc(ccc1N)N2CCOCC2  
0103512983 
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2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5- 
dione 
O=C1CNC(=O)C2=CC=CC=C2 
N1 
 
0103512984 
2-(morpholin-4-yl)aniline NC1=C(C=CC=C1)N2CCOCC2  
0103512985 
5-amino-1-phenyl-1H-pyrazole-4- 
carboxamide 
c1ccc(cc1)n2c(c(cn2)C(=O)N)N  
0103512986 
3-(2-methoxyphenyl)propanoic acid COc1ccccc1CCC(=O)[O-]  
0103512974 
1-phenyl-1,2,3,6-tetrahydropyridazine-3,6- 
dione 
O=c1ccc(=O)n([nH]1)c1ccccc1  
0103512973 
5-amino-2-(1H-pyrrol-1-yl)benzonitrile c1ccn(c1)c2ccc(cc2C#N)N  
0103512972 
5-methyl-2-phenyl-2H-1,2,3-triazole-4- 
carboxamide 
Cc1c(nn(n1)c2ccccc2)C(=O)N  
0103512971 
3-chloro-4-fluorobenzamide c1cc(c(cc1C(=O)N)Cl)F  
0103512970 
6-(2,6-dichlorophenoxy)pyridin-3-amine c1cc(c(c(c1)Cl)Oc2ccc(cn2)N)Cl  
0103512969 
2-(piperidin-1-yl)benzamide c1ccc(c(c1)C(=O)N)N2CCCCC2  
0103512968 
5-fluoroquinazolin-4-ol OC1=NC=NC2=C1C(=CC=C2)F  
0103512967 
N-(4-propylphenyl)acetamide CCCC1=CC=C(C=C1)NC(=O)C  
0103512966 
6-methyl-1,3-benzothiazol-2-amine Cc1ccc2c(c1)sc(n2)N  
0103512965 
6-chloro-1,3-benzothiazol-2-amine c1cc2c(cc1Cl)sc(n2)N  
0103512964 
3,5-dichlorobenzene-1-sulfonamide c1c(cc(cc1Cl)Cl)S(=O)(=O)N  
0103512963 
2-aminoquinazolin-4-ol c1ccc2c(c1)c(=O)[nH]c(n2)N  
0103512951 
6-methyl-1,2,3,4-tetrahydropyridazin-3-one CC1=NNC(=O)CC1  
0103512952 
6-methyl-2-phenyl-1,2,3,4- 
tetrahydropyridazin-3-one 
CC1=NN(C(=O)CC1)C2=CC=C 
C=C2 
 
0103512953 
2-methylquinolin-6-amine Cc1ccc2cc(ccc2n1)N  
0103512954 
2-chlorobenzamide NC(=O)c1ccccc1Cl  
0103512955 
1-methyl-3-(trifluoromethyl)-4,5-dihydro-1H- 
pyrazol-5-one 
CN1C(=O)CC(=N1)C(F)(F)F  
0103512956 
thiophene-2-carboxamide NC(=O)c1cccs1  
0103512957 
3,5-dimethylpyrazin-2-amine Cc1cnc(c(n1)C)N  
0103512958 
2-(2,4-difluorophenoxy)pyridin-3-amine c1cc(c(nc1)Oc2ccc(cc2F)F)N  
0103512959 
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3-(benzyloxy)pyridin-2-amine c1ccc(cc1)COc2cccnc2N  
0103512960 
4-(4-chlorophenyl)piperidin-4-ol c1cc(ccc1C2(CC[NH2+]CC2)O) 
Cl 
 
0103512102 
4-methyl-3-phenyl-2,5-dihydro-1H-pyrrol-2- 
one 
CC1=C(C(=O)NC1)c2ccccc2  
0103512962 
methyl isoquinoline-3-carboxylate COC(=O)c1cc2ccccc2cn1  
0103512950 
pyridine-2,3-diamine Nc1ncccc1N  
0103512949 
isoquinolin-3-amine c1ccc2c[nH+]c(cc2c1)N  
0103512948 
phenyl(pyridin-2-yl)methanamine 
dihydrochloride 
c1ccc(cc1)[C@H](c2ccccn2)[NH 
3+] 
 
0103512947 
5-phenyl-1H-pyrazol-3-ol C1C(=NNC1=O)C2=CC=CC=C2  
0103512946 
5-methyl-4H,7H-[1,2,4]triazolo[1,5- 
a]pyrimidin-7-one 
Cc1cc(n2c(n1)ncn2)[O-]  
0103512945 
6-phenylpyridazin-3-ol c1ccc(cc1)c2ccc(=O)[nH]n2  
0103512944 
quinolin-2-amine c1ccc2c(c1)ccc(n2)N  
0103512943 
1-phenyl-1,2,3,4-tetrahydroisoquinolin-3-one c1ccc(cc1)[C@@H]2c3ccccc3CC 
(=O)N2 
 
0103512942 
1-[2-(1H-imidazol-5-yl)ethyl]pyrrolidine-2,5- 
dione 
c1c([nH]c[nH+]1)CCN2C(=O)C 
CC2=O 
 
0103512941 
2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one Cc1cc(=O)n2ccccc2n1  
0103512940 
methyl 2-(5-methyl-2-phenyl-1,3-thiazol-4- 
yl)acetate 
CC1=C(N=C(S1)C2=CC=CC=C2 
)CC(=O)OC 
 
0103512939 
3-phenyl-1,2,4-thiadiazol-5-amine Nc1nc(ns1)-c1ccccc1  
0103512927 
4-(2-methoxyphenyl)piperidine COc1ccccc1C2CC[NH2+]CC2  
0103512928 
3-methyl-1-phenyl-1H-pyrazol-5-amine Cc1cc(n(n1)c2ccccc2)N  
0103512929 
2-(1H-indol-3-yl)ethan-1-ol c1ccc2c(c1)c(c[nH]2)CCO  
0103512930 
2,3-dihydro-1H-indole-2-carboxylic acid c1ccc2c(c1)C[CH](N2)C(=O)[O-]  
0103512931 
(5-chloro-1-benzothiophen-3-yl)methanol c1cc2c(cc1Cl)c(cs2)CO  
0103512932 
(5-methyl-3-phenyl-1,2-oxazol-4-yl)methanol Cc1c(c(no1)c2ccccc2)CO  
0103512933 
[5-(pyridin-2-yl)thiophen-2-yl]methanol OCC1=CC=C(S1)C2=CC=CC=N 
2 
 
0103512934 
[5-(pyridin-2-yl)thiophen-2-yl]methanamine 
dihydrochloride 
Cl.Cl.NCc1ccc(s1)-c1ccccn1  
0103512935 
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pyrazin-2-ylmethanol c1cnc(cn1)CO  
0103512936 
quinolin-6-ylmethanol c1cc2cc(ccc2nc1)CO  
0103512937 
quinoline-4-carboxylic acid c1ccc2c(c1)c(ccn2)C(=O)[O-]  
0103512938 
thieno[2,3-b]pyridin-2-ylmethanol c1cc2cc(sc2nc1)CO  
0103512926 
methyl(thieno[2,3-b]pyridin-2- 
ylmethyl)ck)amine 
CNCc1cc2cccnc2s1  
0103512925 
(dimethyl-1,3-thiazol-5-yl)methanol Cc1c(sc(n1)C)CO  
0103512924 
1,3-benzothiazol-6-amine c1cc2c(cc1N)scn2  
0103512923 
1,3-benzothiazol-2-ylmethanol c1ccc2c(c1)nc(s2)CO  
0103512922 
1,3-benzothiazol-2-ylmethanamine 
hydrochloride 
c1ccc2c(c1)nc(s2)C[NH3+]  
0103512921 
methyl[(1-methyl-1H-indazol-3- 
yl)methyl]amine 
 
CNCC1=N[N](C)C2=CC=CC=C 
12 
 
0103512919 
1-benzofuran-2-ylmethanol OCc1cc2c(o1)cccc2  
0103512918 
1-benzofuran-5-ylmethanol c1cc2c(cco2)cc1CO  
0103512917 
1-benzofuran-5-amine NC1=CC2=C(OC=C2)C=C1  
0103512916 
1,3-thiazol-2-ylmethanol c1csc(n1)CO  
0103512915 
(5-phenyl-1,3-oxazol-4-yl)methanol c1ccc(cc1)c2c(nco2)CO  
0103512903 
quinoxalin-6-amine c1cc2c(cc1N)nccn2  
0103512904 
(4-benzylmorpholin-2-yl)methanol c1ccc(cc1)CN2CCO[CH](C2)CO  
0103512905 
(4-benzylmorpholin-2-yl)methanamine c1ccc(cc1)CN2CCO[CH](C2)C[ 
NH3+] 
 
0103512906 
(1,5-dimethyl-1H-pyrazol-3-yl)methanol Cc1cc(nn1C)CO  
0103512907 
1H-indole-3-carboxylic acid c1ccc2c(c1)c(c[nH]2)C(=O)[O-]  
0103512908 
1H-indole-2-carboxylic acid c1ccc2c(c1)cc([nH]2)C(=O)[O-]  
0103512909 
[2-(pyridin-3-yl)-1,3-thiazol-4-yl]methanol c1ccc2c(c1)cc([nH]2)C(=O)[O-]  
0103512910 
(5-methyl-1-phenyl-1H-pyrazol-4-yl)methanol Cc1c(cnn1c2ccccc2)CO  
0103512911 
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[4-(morpholin-4-yl)phenyl]methanol c1cc(ccc1CO)N2CCOCC2  
0103512912 
2-phenyl-1,3-thiazole-4-carboxylic acid c1ccc(cc1)c2nc(cs2)C(=O)[O-]  
0103512913 
(2-phenyl-1,3-thiazol-4-yl)methanol c1ccc(cc1)c2nc(cs2)CO  
0103512914 
(2-phenyl-1,3-thiazol-4-yl)methanamine c1ccc(cc1)c2nc(cs2)C[NH3+]  
0103512105 
[4-(1H-pyrazol-1-yl)phenyl]methanol OCc1ccc(cc1)n1cccn1  
0103512106 
[4-(1H-imidazol-1-yl)phenyl]methanol OCc1ccc(cc1)n1cncc1  
0103512708 
[3-(2-methyl-1,3-thiazol-4-yl)phenyl]methanol OCc1cccc(c1)c1csc(n1)C  
0103512707 
methyl([3-(2-methyl-1,3-thiazol-4- 
yl)phenyl]methyl)amine 
CNCc1cccc(c1)c1csc(n1)C  
0103512706 
6-phenoxypyridin-3-amine Nc1ccc(nc1)Oc1ccccc1  
0103512705 
4-methyl-2-phenylpyrimidine-5-carboxylic 
acid 
CC1=NC(=NC=C1C(O)=O)C2= 
CC=CC=C2 
 
0103512704 
(4-methyl-2-phenylpyrimidin-5-yl)methanol CC1=NC(=NC=C1CO)C2=CC=C 
C=C2 
 
0103512703 
(3-methyl-5-phenyl-1,2-oxazol-4-yl)methanol OCc1c(C)noc1c1ccccc1  
0103512702 
(1-methyl-1H-imidazol-2-yl)methanol OCc1nccn1C  
0103512701 
6-phenylpyridine-3-carboxylic acid OC(=O)C1=CC=C(N=C1)C2=CC 
=CC=C2 
 
0103512700 
(6-phenylpyridin-3-yl)methanol OCc1ccc(nc1)-c1ccccc1  
0103512117 
6-phenylpyridine-3-carbonitrile N#Cc1ccc(nc1)-c1ccccc1  
0103512687 
(2-methylimidazo[1,2-a]pyridin-3-yl)methanol Cc1nc2ccccn2c1CO  
0103512688 
[3-(1H-pyrrol-1-yl)thiophen-2-yl]methanol OCc1sccc1-n1cccc1  
0103512689 
(1,3-dimethyl-1H-thieno[2,3-c]pyrazol-5- 
yl)methanol 
Cc1nn(C)c2sc(CO)cc12  
0103512690 
[5-(thiophen-2-yl)-1,2-oxazol-3-yl]methanol OCc1cc(on1)-c1cccs1  
0103512691 
methyl[(1-methyl-1H-imidazol-5- 
yl)methyl]amine 
CNCc1cncn1C  
0103512692 
(1-benzyl-1H-imidazol-2-yl)methanol OCc1nccn1Cc1ccccc1  
0103512693 
2,3-dihydro-1-benzofuran-2-ylmethanol OCC1Cc2ccccc2O1  
0103512694 
2,3-dihydro-1-benzofuran-2-ylmethanamine 
hydrochloride 
Cl.NCC1Cc2ccccc2O1  
0103512695 
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5-phenylpyridine-3-carboxylic acid OC(=O)c1cncc(c1)-c1ccccc1  
0103512696 
[2-(morpholin-4-yl)phenyl]methanol OCc1ccccc1N1CCOCC1  
0103512697 
2-(1H-pyrazol-1-yl)benzonitrile N#Cc1ccccc1-n1cccn1  
0103512698 
1-phenyl-1H-pyrazole-5-carboxylic acid OC(=O)c1ccnn1-c1ccccc1  
0103512686 
[4-(1H-pyrrol-1-yl)phenyl]methanol OCc1ccc(cc1)-n1cccc1  
0103512685 
[4-(1H-pyrrol-1-yl)phenyl]methanamine NCc1ccc(cc1)-n1cccc1  
0103512091 
3,4-dihydro-2H-1-benzopyran-3-ylmethanol OCC1COc2ccccc2C1  
0103512683 
(dimethyl-1,3-oxazol-4-yl)methanol Cc1nc(CO)c(C)o1  
0103512682 
(1-methyl-5-phenyl-1H-pyrazol-4-yl)methanol Cn1ncc(CO)c1-c1ccccc1  
0103512681 
(2-methylquinolin-6-yl)methanol Cc1ccc2cc(CO)ccc2n1  
0103512680 
1H-indol-4-ylmethanol OCc1cccc2[nH]ccc12  
0103512679 
methyl[(4-methyl-2-phenyl-1,3-thiazol-5- 
yl)methyl]amine 
CNCc1sc(nc1C)-c1ccccc1  
0103512678 
3,4-dihydro-2H-1,4-benzoxazin-2-ylmethanol OCC1CNc2ccccc2O1  
0103512677 
(5-phenyl-1,2-oxazol-3-yl)methanol OCc1cc(on1)-c1ccccc1  
0103512676 
4-methylthiophene-2-carboxamide Cc1csc(c1)C(N)=O  
0103512675 
imidazo[1,2-a]pyridin-2-ylmethanol OCc1cn2ccccc2n1  
0103512663 
3-(2-methylpyrimidin-4-yl)aniline Cc1nccc(n1)-c1cccc(N)c1  
0103512664 
imidazo[2,1-b][1,3]thiazol-6-ylmethanol OCc1cn2ccsc2n1  
0103512665 
3-(1H-imidazol-1-yl)benzonitrile N#Cc1cccc(c1)-n1ccnc1  
0103512666 
2-(1H-imidazol-1-yl)aniline Nc1ccccc1-n1ccnc1  
0103512667 
imidazo[1,2-a]pyridin-6-ylmethanol OCc1ccc2nccn2c1  
0103512668 
(imidazo[1,2-a]pyridin-6- 
ylmethyl)(methyl)amine 
CNCc1ccc2nccn2c1  
0103512669 
[3-(morpholin-4-yl)phenyl]methanol OCc1cccc(c1)N1CCOCC1  
0103512670 
methyl([3-(piperidin-1- 
yl)phenyl]methyl)amine 
CNCc1cccc(c1)N1CCCCC1  
0103512671 
292 
 
 
[2-(1H-pyrrol-1-yl)phenyl]methanol OCc1ccccc1-n1cccc1  
0103512672 
[4-(pyridin-4-yl)phenyl]methanol OCc1ccc(cc1)-c1ccncc1  
0103512673 
[3-(pyridin-4-yl)phenyl]methanol OCc1cccc(c1)-c1ccncc1  
0103512674 
3-(pyridin-4-yl)aniline Nc1cccc(c1)-c1ccncc1  
0103512662 
methyl([3-(pyridin-4-yl)phenyl]methyl)amine CNCc1cccc(c1)-c1ccncc1  
0103512661 
[2-(4-methylpiperazin-1-yl)phenyl]methanol CN1CCN(CC1)c1ccccc1CO  
0103512660 
2-(4-methylpiperazin-1-yl)aniline CN1CCN(CC1)c1ccccc1N  
0103512659 
methyl([3-(1,3-thiazol-2- 
yl)phenyl]methyl)amine 
CNCc1cccc(c1)-c1nccs1  
0103512658 
3-(piperidin-1-yl)pyridine-2-carbonitrile N#Cc1ncccc1N1CCCCC1  
0103512657 
[3-(pyrrolidin-1-yl)phenyl]methanol OCc1cccc(c1)N1CCCC1  
0103512656 
methyl([3-(pyridin-3-yl)phenyl]methyl)amine CNCc1cccc(c1)-c1cccnc1  
0103512655 
[4-(pyridin-3-yl)phenyl]methanol OCc1ccc(cc1)-c1cccnc1  
0103512654 
[3-(morpholin-4-ylmethyl)phenyl]methanol OCc1cccc(CN2CCOCC2)c1  
0103512653 
methyl([3-(morpholin-4- 
ylmethyl)phenyl]methyl)amine 
CNCc1cccc(CN2CCOCC2)c1  
0103512652 
methyl([4-(1,3-thiazol-2- 
yl)phenyl]methyl)amine 
CNCc1ccc(cc1)-c1nccs1  
0103512651 
[4-(2-methyl-1,3-thiazol-4-yl)phenyl]methanol Cc1nc(cs1)-c1ccc(CO)cc1  
0103512639 
2-(1-benzofuran-3-yl)ethan-1-ol OCCc1coc2ccccc12  
0103512640 
methyl(4-methyl-4H-thieno[3,2-b]pyrrol-5- 
ylmethyl)amine hydrochloride 
Cl.CNCc1cc2sccc2n1C  
0103512641 
[4-(pyridin-2-yl)phenyl]methanol OCc1ccc(cc1)-c1ccccn1  
0103512642 
methyl([4-(pyridin-2-yl)phenyl]methyl)amine CNCc1ccc(cc1)-c1ccccn1  
0103512643 
[3-(pyrimidin-5-yl)phenyl]methanol OCc1cccc(c1)-c1cncnc1  
0103512644 
(2-methyl-4-phenyl-1,3-thiazol-5-yl)methanol Cc1nc(c(CO)s1)-c1ccccc1  
0103512645 
[3-(1H-imidazol-1-ylmethyl)phenyl]methanol OCc1cccc(Cn2ccnc2)c1  
0103512646 
[4-(1H-imidazol-1-ylmethyl)phenyl]methanol OCc1ccc(Cn2ccnc2)cc1  
0103512647 
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[2-(pyrrolidin-1-yl)pyridin-3-yl]methanamine NCc1cccnc1N1CCCC1  
0103512648 
[5-(thiophen-2-yl)-1H-pyrazol-3-yl]methanol OCc1cc([nH]n1)-c1cccs1  
0103512649 
(1-methyl-1H-indol-6-yl)methanol Cn1ccc2ccc(CO)cc12  
0103512650 
[4-(pyrimidin-5-yl)phenyl]methanol OCc1ccc(cc1)-c1cncnc1  
0103512638 
(2-methyl-2H-indazol-3-yl)methanol Cn1nc2ccccc2c1CO  
0103512637 
methyl([2-(pyrrolidin-1- 
yl)phenyl]methyl)amine 
CNCc1ccccc1N1CCCC1  
0103512636 
2-(piperazin-1-yl)aniline Nc1ccccc1N1CCNCC1  
0103512635 
[4-(piperidin-1-ylmethyl)phenyl]methanol OCc1ccc(CN2CCCCC2)cc1  
0103512634 
(4-[(4-methylpiperazin-1- 
yl)methyl]phenyl)methanol 
CN1CCN(Cc2ccc(CO)cc2)CC1  
0103512633 
1H-1,3-benzodiazol-5-ylmethanol OCc1ccc2[nH]cnc2c1  
0103512632 
(1-methyl-5-phenyl-1H-pyrazol-3-yl)methanol Cn1nc(CO)cc1-c1ccccc1  
0103512631 
(1-methyl-5-phenyl-1H-pyrazol-3- 
yl)methanamine 
Cn1nc(CN)cc1-c1ccccc1  
0103512630 
(1-methyl-3-phenyl-1H-pyrazol-5-yl)methanol Cn1nc(cc1CO)-c1ccccc1  
0103512629 
methyl[(1-methyl-3-phenyl-1H-pyrazol-5- 
yl)methyl]amine 
CNCc1cc(nn1C)-c1ccccc1  
0103512628 
[1-methyl-5-(thiophen-2-yl)-1H-pyrazol-3- 
yl]methanol 
Cn1nc(CO)cc1-c1cccs1  
0103512627 
[1-methyl-3-(thiophen-2-yl)-1H-pyrazol-5- 
yl]methanol 
Cn1nc(cc1CO)-c1cccs1  
0103512090 
(2-[(4-methylpiperazin-1- 
yl)methyl]phenyl)methanol 
CN1CCN(Cc2ccccc2CO)CC1  
0103512616 
(3,5-dimethyl-1-phenyl-1H-pyrazol-4- 
yl)methanol 
Cc1nn(c(C)c1CO)-c1ccccc1  
0103512617 
[2-(morpholin-4-ylmethyl)phenyl]methanol OCc1ccccc1CN1CCOCC1  
0103512618 
2-(morpholin-4-ylmethyl)aniline Nc1ccccc1CN1CCOCC1  
0103512619 
2-(morpholin-4-ylmethyl)benzonitrile N#Cc1ccccc1CN1CCOCC1  
0103512620 
[4-(pyridin-2-yloxy)phenyl]methanol OCc1ccc(Oc2ccccn2)cc1  
0103512621 
4-(pyridin-2-yloxy)benzonitrile N#Cc1ccc(Oc2ccccn2)cc1  
0103512622 
5-methyl-2-phenylfuran-3-carboxylic acid Cc1cc(C(O)=O)c(o1)-c1ccccc1  
0103512623 
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(2-phenoxyphenyl)methanol OCc1ccccc1Oc1ccccc1  
0103512624 
methyl[(2-phenoxyphenyl)methyl]amine CNCc1ccccc1Oc1ccccc1  
0103512625 
[3-(pyridin-2-yloxy)phenyl]methanol OCc1cccc(Oc2ccccn2)c1  
0103512626 
[2-(piperidin-1-yl)pyridin-4-yl]methanol OCc1ccnc(c1)N1CCCCC1  
0103512118 
methyl([2-(piperidin-1-yl)pyridin-4- 
yl]methyl)amine 
C[NH2+]Cc1ccnc(c1)N2CCCCC 
2 
 
0103512901 
[2-(pyrrolidin-1-yl)pyridin-4-yl]methanol c1c[nH+]c(cc1CO)N2CCCC2  
0103512900 
(2-[2- 
(dimethylamino)ethoxy]phenyl)methanol 
CN(C)CCOc1ccccc1CO  
0103512899 
(4-[2- 
(dimethylamino)ethoxy]phenyl)methanol 
C[NH+](C)CCOc1ccc(cc1)CO  
0103512898 
(4-phenoxyphenyl)methanol c1ccc(cc1)Oc2ccc(cc2)CO  
0103512897 
methyl[(4-phenoxyphenyl)methyl]amine C[NH2+]Cc1ccc(cc1)Oc2ccccc2  
0103512896 
2-methyl-1,3-benzothiazol-6-amine Cc1nc2ccc(cc2s1)N  
0103512895 
[6-(thiophen-2-yl)pyridin-3-yl]methanol OCc1ccc(nc1)-c1cccs1  
0103512894 
[4-(pyrrolidin-1-ylmethyl)phenyl]methanol OCc1ccc(CN2CCCC2)cc1  
0103512893 
3-(pyrrolidin-1-ylmethyl)aniline c1cc(cc(c1)N)C[NH+]2CCCC2  
0103512892 
[4-(1H-pyrazol-1-ylmethyl)phenyl]methanol OCc1ccc(Cn2cccn2)cc1  
0103512124 
methyl([4-(1H-pyrazol-1- 
ylmethyl)phenyl]methyl)amine 
CNCc1ccc(Cn2cccn2)cc1  
0103512879 
methyl[(3-phenoxyphenyl)methyl]amine C[NH2+]Cc1cccc(c1)Oc2ccccc2  
0103512880 
methyl([2-(morpholin-4-yl)-5- 
(trifluoromethyl)phenyl]methyl)amine 
CNCc1cc(ccc1N1CCOCC1)C(F)( 
F)F 
 
0103512881 
[2-(phenoxymethyl)phenyl]methanamine c1ccc(cc1)OCc2ccccc2C[NH3+]  
0103512882 
2H,3H,4H-pyrido[3,2-b][1,4]oxazine C1COc2cccnc2N1  
0103512883 
3-(1H-pyrrol-1-yl)pyridine c1ccn(c1)-c1cccnc1  
0103512884 
5-methyl-3-phenyl-1,2-oxazole-4- 
carboxamide 
Cc1c(c(no1)c2ccccc2)C(=O)N  
0103512885 
3-(1H-pyrrol-1-ylmethyl)pyridine C(c1cccnc1)n1cccc1  
0103512886 
2-(1H-pyrrol-1-ylmethyl)pyridine C(c1ccccn1)n1cccc1  
0103512887 
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4-phenyl-1,2,3-thiadiazole-5-carboxamide c1ccc(cc1)c2c(snn2)C(=O)N  
0103512888 
3-methylpyridin-2-ol Cc1ccc[nH]c1=O  
0103512889 
4-[(4-fluorophenyl)carbonyl]piperidine 
hydrochloride 
c1cc(ccc1C(=O)C2CC[NH2+]CC 
2)F 
 
0103512890 
2,4-difluorobenzene-1-sulfonamide NS(=O)(=O)c1ccc(F)cc1F  
0103512878 
4-(dimethyl-1,2-oxazole-4- 
sulfonyl)morpholine 
Cc1c(c(on1)C)S(=O)(=O)N2CCO 
CC2 
 
0103512877 
3,5-dimethyl-4-(pyrrolidine-1-sulfonyl)-1,2- 
oxazole 
Cc1noc(C)c1S(=O)(=O)N1CCCC 
1 
 
0103512122 
2-methyl-3-(1H-pyrazol-5-yl)pyrazine Cc1c(nccn1)c2ccn[nH]2  
0103512875 
4-[(2-methyl-1,3-thiazol-4- 
yl)methoxy]benzonitrile 
Cc1nc(COc2ccc(cc2)C#N)cs1  
0103512874 
4-benzyl-1,4-thiomorpholine-1,1-dione c1ccc(cc1)CN2CCS(=O)(=O)CC 
2 
 
0103512873 
N-[4-(propan-2-yl)phenyl]acetamide CC(C)c1ccc(cc1)NC(=O)C  
0103512872 
1-methyl-1H-pyrazol-3-amine Cn1ccc(n1)N  
0103512871 
5-methylthieno[2,3-d]pyrimidin-4-ol Cc1csc2c1c(=O)[nH]cn2  
0103512870 
1-methyl-1H-pyrazol-5-amine Cn1c(ccn1)N  
0103512869 
3-(trifluoromethyl)-1H-pyrazole FC(F)(F)c1cc[nH]n1  
0103512868 
2-[5-(trifluoromethyl)pyridin-2- 
yl]oxyacetonitrile 
c1cc(ncc1C(F)(F)F)OCC#N  
0103512867 
4-fluoro-1H-indazol-3-ol Fc1cccc2[nH][nH]c(=O)c12  
0103512855 
4-methyl-N-[2-(2-oxoimidazolidin-1- 
yl)ethyl]benzamide 
Cc1ccc(cc1)C(=O)NCCN2CCNC 
2=O 
 
0103512856 
1-benzylpiperidin-4-ol c1ccc(cc1)C[NH+]2CCC(CC2)O  
0103512857 
1-benzyl-1H-imidazol-2-ol O=c1[nH]ccn1Cc1ccccc1  
0103512858 
3-phenyl-1H-1,2,4-triazol-5-ol c1ccc(cc1)c2[nH]c(=O)[nH]n2  
0103512859 
5-phenyl-1H-pyrazol-3-amine c1ccc(cc1)c2cc(n[nH]2)N  
0103512860 
2,5-dimethyl-4H,7H-pyrazolo[1,5- 
a]pyrimidin-7-one 
Cc1cc2[nH]c(C)cc(=O)n2n1  
0103512861 
5-(thiophen-2-yl)-1H-pyrazol-3-amine c1cc(sc1)c2cc([nH]n2)N  
0103512862 
3-methyl-1,2-oxazol-5-amine Cc1cc(N)on1  
0103512863 
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1-methanesulfonyl-4-methylbenzene Cc1ccc(cc1)S(=O)(=O)C  
0103512864 
1-methyl-3-phenyl-1H-pyrazol-5-amine Cn1c(cc(n1)c2ccccc2)N  
0103512865 
3-(4-chlorophenyl)-1H-pyrazol-5-amine c1cc(ccc1c2cc(n[nH]2)N)Cl  
0103512866 
4-(benzenesulfonyl)thiophen-3-amine Nc1cscc1S(=O)(=O)c1ccccc1  
0103512854 
3-(4-bromophenyl)-1-methyl-1H-pyrazole Cn1ccc(n1)c2ccc(cc2)Br  
0103512853 
5-(pyridin-2-yl)thiophene-2-carboxamide c1ccnc(c1)c2ccc(s2)C(=O)N  
0103513202 
1-(2,3-dihydro-1H-indol-1-yl)ethan-1-one CC(=O)N1CCc2c1cccc2  
0103512851 
(1,4-dimethylpiperazin-2-yl)methanol C[NH+]1CCN(C[C@H]1CO)C  
0103512850 
benzyl 3-oxopiperazine-1-carboxylate c1ccc(cc1)COC(=O)N2CCNC(= 
O)C2 
 
0103512849 
1-benzyl-1H-imidazole c1ccc(cc1)Cn2ccnc2  
0103512848 
piperidin-4-ylmethanol OCC1CCNCC1  
0103512847 
2-(methyl[2-(trifluoromethyl)quinolin-4- 
yl]amino)ethan-1-ol 
CN(CCO)c1cc(nc2ccccc12)C(F)( 
F)F 
 
0103512846 
6-methyl-4-(piperazin-1-yl)-2- 
(trifluoromethyl)quinoline 
Cc1ccc2c(c1)c(cc([nH+]2)C(F)(F 
)F)N3CC[NH2+]CC3 
 
0103512845 
5-methyl-1,2-benzothiazole-3-carboxamide CC1=CC2=C(C=C1)SN=C2C(=O 
)N 
 
0103512844 
(1-benzylpiperidin-4-yl)methanol c1ccc(cc1)C[NH+]2CCC(CC2)C 
O 
 
0103512843 
2-(pyridin-3-yl)ethan-1-ol OCCc1cccnc1  
0103512831 
2-(4-benzylpiperazin-1-yl)ethan-1-amine c1ccc(cc1)C[NH+]2CCN(CC2)C 
C[NH3+] 
 
0103512832 
7-chloro-4-(piperazin-1-yl)quinoline c1cc2c(ccnc2cc1Cl)N3CC[NH2+] 
CC3 
 
0103512833 
2,2-dimethyl-N-(pyridin-4-yl)propanamide CC(C)(C)C(=O)Nc1ccncc1  
0103512834 
1,2-benzoxazol-3-amine c1ccc2c(c1)c(no2)N  
0103512835 
3,5-dimethyl-1-phenyl-1H-pyrazole-4- 
carboxylic acid 
Cc1c(c(n(n1)c2ccccc2)C)C(=O)[ 
O-] 
 
0103512836 
[1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4- 
yl]methanol 
Cc1c(cnn1c2ccc(cc2)F)CO  
0103512837 
2,3-dihydro-1H-indol-2-ylmethanol OCC1Cc2ccccc2N1  
0103512838 
[2-(piperidin-1-yl)pyridin-3-yl]methanol c1cc(c([nH+]c1)N2CCCCC2)CO  
0103512839 
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3-[(pyrrolidin-1-yl)carbonyl]piperidine C1CCN(C1)C(=O)[C@@H]2CC 
C[NH2+]C2 
 
0103512840 
4-[(pyrrolidin-1-yl)carbonyl]piperidine C1CCN(C1)C(=O)C2CC[NH2+] 
CC2 
 
0103512841 
[2-(3-chlorophenyl)-1,3-thiazol-4- 
yl]methanamine hydrochloride 
Cl.NCc1csc(n1)-c1cccc(Cl)c1  
0103512842 
5-phenyl-1,2,4-thiadiazol-3-amine Nc1nsc(n1)-c1ccccc1  
0103512830 
[6-(piperidin-1-yl)pyridin-3-yl]methanol c1cc([nH+]cc1CO)N2CCCCC2  
0103512829 
3,4-dihydro-2H-1-benzopyran-2-ylmethanol c1ccc2c(c1)CC[C@H](O2)CO  
0103512828 
(6-aminopyridin-3-yl)methanol c1cc(ncc1CO)N  
0103512827 
1-(dimethyl-1,3-thiazole-5-sulfonyl)piperidine Cc1nc(C)c(s1)S(=O)(=O)N1CCC 
CC1 
 
0103512826 
1-([5-methyl-2-(trifluoromethyl)furan-3- 
yl]carbonyl)piperidine 
Cc1cc(C(=O)N2CCCCC2)c(o1)C 
(F)(F)F 
 
0103512825 
4-(furan-2-sulfonyl)morpholine O=S(=O)(N1CCOCC1)c1ccco1  
0103512824 
1-[(furan-3-yl)carbonyl]-4-methylpiperazine CN1CCN(CC1)C(=O)c1ccoc1  
0103512823 
4-[(1-methyl-1H-pyrrol-2- 
yl)carbonyl]morpholine 
Cn1cccc1C(=O)N1CCOCC1  
0103512822 
1-(1-methyl-1H-imidazole-4- 
sulfonyl)piperidine 
Cn1cnc(c1)S(=O)(=O)N1CCCCC 
1 
 
0103512821 
5-[(pyrrolidin-1-yl)carbonyl]-1,2-oxazole O=C(N1CCCC1)c1ccno1  
0103512820 
N,N-dimethylquinoxaline-6-carboxamide CN(C)C(=O)c1ccc2nccnc2c1  
0103512819 
4-[(1,3-dimethyl-1H-pyrazol-5- 
yl)carbonyl]morpholine 
Cc1cc(C(=O)N2CCOCC2)n(C)n1  
0103512807 
N,1,5-trimethyl-1H-pyrazole-3-carboxamide CNC(=O)c1cc(C)n(C)n1  
0103512808 
4-(thiophene-2-sulfonyl)morpholine O=S(=O)(N1CCOCC1)c1cccs1  
0103512809 
N,N-dimethylthiophene-3-sulfonamide CN(C)S(=O)(=O)c1ccsc1  
0103512810 
2,2-dimethyl-2,3-dihydro-1-benzofuran-7- 
carboxamide 
CC1(C)Cc2cccc(C(N)=O)c2O1  
0103512811 
N,N-dimethyloxane-4-carboxamide CN(C)C(=O)C1CCOCC1  
0103512812 
1-[(oxan-4-yl)carbonyl]piperidine O=C(C1CCOCC1)N1CCCCC1  
0103512813 
1-methyl-1H-pyrazole-3-carboxamide Cn1ccc(n1)C(N)=O  
0103512814 
N-methyl-2-(oxan-4-yloxy)benzamide CNC(=O)c1ccccc1OC1CCOCC1  
0103512815 
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5-chloro-N,1-dimethyl-1H-pyrazole-4- 
carboxamide 
CNC(=O)c1cnn(C)c1Cl  
0103512816 
N,N,1,2-tetramethyl-1H-imidazole-4- 
sulfonamide 
CN(C)S(=O)(=O)c1cn(C)c(C)n1  
0103512817 
1-[(3-fluorobenzene)sulfonyl]pyrrolidine Fc1cccc(c1)S(=O)(=O)N1CCCC1  
0103512818 
2,2,6,6-tetramethyl-N-(2- 
methylphenyl)piperidin-4-amine 
Cc1ccccc1NC2CC([NH2+]C(C2) 
(C)C)(C)C 
 
0103512096 
5-acetyl-2,3,4,5-tetrahydro-1H-1,5- 
benzodiazepin-2-one 
CC(=O)N1CCC(=O)Nc2c1cccc2  
0103512094 
1-(4-phenylpiperazin-1-yl)ethan-1-one CC(=O)N1CCN(CC1)c2ccccc2  
0103513284 
2-phenyl-2,3,4,5-tetrahydro-1,4-benzoxazepin- 
5-one 
O=C1NCC(Oc2ccccc12)c1ccccc1  
0103513283 
3-(2-methyl-1,3-thiazol-4-yl)pyridine Cc1nc(cs1)-c1cccnc1  
0103513282 
3-phenyl-2,5-dihydro-1,2-oxazol-5-one O=C1CC(=NO1)c1ccccc1 |c:3|  
0103513281 
1,2-benzoxazol-3-ol Oc1noc2ccccc12  
0103513280 
6-chloro-1,2-benzoxazol-3-ol c1cc2c(cc1Cl)onc2[O-]  
0103513279 
4-phenyl-1,3-thiazol-2-ol c1ccc(cc1)c2csc(=O)[nH]2  
0103513278 
4-(trifluoromethyl)-1H,2H-pyrrolo[1,2- 
d][1,2,4]triazin-1-one 
Oc1nnc(n2cccc12)C(F)(F)F  
0103512095 
5-methyl-N-(pyridin-3-ylmethyl)-1,2-oxazol- 
3-amine 
Cc1cc(NCc2cccnc2)no1  
0103512099 
4-phenyl-3-(pyridin-3-yl)-4,5-dihydro-1,2,4- 
oxadiazol-5-one 
c1ccc(cc1)n2c(noc2=O)c3cccnc3  
0103512101 
6-phenyl-1,2,3,4-tetrahydropyridazin-3-one c1ccc(cc1)C2=NNC(=O)CC2  
0103513263 
3-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-6- 
amine 
Nc1ccc2nnc(-c3ccccc3)n2n1  
0103513264 
6-methylidene-4-[(4-methylphenyl)methyl]- 
1,2,3,6-tetrahydropyridazin-3-one 
Cc1ccc(cc1)Cc2cc(n[nH]c2=O)C  
0103513265 
1-[4-(1H-indol-3-yl)piperidin-1-yl]ethan-1- 
one 
CC(=O)N1CCC(CC1)c2c[nH]c3c 
2cccc3 
 
0103513266 
2-methyl-4-(piperazin-1-yl)quinoline Cc1cc(c2ccccc2[nH+]1)N3CC[N 
H2+]CC3 
 
0103513267 
5-phenyl-1,3,4-thiadiazol-2-amine c1ccc(cc1)c2nnc(s2)N  
0103513268 
5-bromopyrimidin-2-amine c1c(cnc(n1)N)Br  
0103513269 
6-fluoro-1,3-benzothiazol-2-amine c1cc2c(cc1F)sc(n2)N  
0103513270 
5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin- 
2-one 
c1ccc(cc1)C2=NCC(=O)Nc3c2cc 
cc3 
 
0103513271 
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3-methylcinnolin-5-amine Cc1cc2c(cccc2nn1)N  
0103513272 
3-methyl-5-phenylpyridazine Cc1cc(cnn1)-c1ccccc1  
0103513273 
2,3-dihydro-1,4-benzodioxine-6-sulfonamide NS(=O)(=O)c1ccc2OCCOc2c1  
0103513274 
(6-methylpyridin-2-yl)methanol Cc1cccc(n1)CO  
0103513262 
2-methyl-6-phenylpyrimidin-4-ol Cc1[nH]c(=O)cc(n1)c2ccccc2  
0103513261 
6-methyl-2-phenylpyrimidin-4-ol Cc1cc(=O)[nH]c(n1)c2ccccc2  
0103513260 
phthalazine-1,4-diol c1ccc2c(c1)c(=O)[nH]nc2[O-]  
0103513259 
2-(2-fluorophenyl)-1,3-thiazolidin-4-one Fc1ccccc1C1NC(=O)CS1  
0103513258 
[(4-fluorophenyl)methyl]urea c1cc(ccc1CNC(=O)N)F  
0103513257 
1H-indole c1cc2ccccc2[nH]1  
0103513256 
5-methyl-1,2-oxazol-3-amine Cc1cc(N)no1  
0103513255 
dimethyl-1,2-oxazol-5-amine Cc1c(noc1N)C  
0103513254 
5-amino-2-phenyl-2,3-dihydro-1H-pyrazol-3- 
one 
c1ccc(cc1)N2C(=O)CC(=N2)N  
0103513253 
1-benzylpiperidin-4-amine c1ccc(cc1)CN2CCC(CC2)[NH3+ 
] 
 
0103513252 
1H-1,3-benzodiazol-2-ol c1ccc2c(c1)[nH]c(=O)[nH]2  
0103513251 
5-methylpyridin-2-amine Cc1ccc([nH+]c1)N  
0103513239 
pyridin-4-amine c1c[nH+]ccc1N  
0103513240 
5-methyl-1,3,4-thiadiazol-2-amine Cc1nnc(N)s1  
0103513241 
1,3-dimethylimidazolidin-2-one CN1CCN(C1=O)C  
0103513242 
2-methylbenzene-1-sulfonamide Cc1ccccc1S(=O)(=O)N  
0103513243 
2-(4-hydroxyphenyl)acetamide c1cc(ccc1CC(=O)N)O  
0103513244 
2-phenyl-1H-imidazole-4-carboxylic acid c1ccc(cc1)c2[nH]cc(n2)C(=O)[O- 
] 
 
0103513245 
5-(4-methylphenyl)-1,3-oxazole Cc1ccc(cc1)c2cnco2  
0103513246 
4-(1,3-oxazol-5-yl)pyridine c1ncc(o1)-c1ccncc1  
0103513247 
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3-(1,3-oxazol-5-yl)aniline c1cc(cc(c1)N)c2cnco2  
0103513248 
2-(4-methylphenyl)-1,3,4-oxadiazole Cc1ccc(cc1)c2nnco2  
0103513249 
5-(4-methylphenyl)-1,2,4-thiadiazole Cc1ccc(cc1)c2ncns2  
0103513250 
2-(1H-pyrazol-3-yl)pyridine c1cc(n[nH]1)-c1ccccn1  
0103513238 
3,5-dimethyl-1-phenyl-1H-pyrazole-4- 
carboxamide 
Cc1c(c(n(n1)c2ccccc2)C)C(=O)N  
0103513237 
5-phenyl-1,3-oxazole c1ccc(cc1)c2cnco2  
0103513236 
4-[(2,6-difluorobenzene)sulfonyl]morpholine c1cc(c(c(c1)F)S(=O)(=O)N2CCO 
CC2)F 
 
0103513235 
4-phenyl-1H-imidazole c1ccc(cc1)c2cnc[nH]2  
0103513234 
5-fluoroquinazolin-4-amine c1cc2c(c(c1)F)c(ncn2)N  
0103513233 
ethyl 2,5-dimethyl-1H-pyrrole-3-carboxylate CCOC(=O)c1cc([nH]c1C)C  
0103513232 
N-(4-fluoro-1-methyl-1H-indazol-3- 
yl)propanamide 
CCC(=O)Nc1nn(C)c2cccc(F)c12  
0103513231 
2-hydroxy-6-methylpyridine-3-carbonitrile Cc1ccc(C#N)c(=O)[nH]1  
0103513230 
6-methoxypyridine-3-carbonitrile COc1ccc(cn1)C#N  
0103513229 
3-benzyl-2H,3H-[1,3]oxazolo[4,5-b]pyridin-2- 
one 
c1ccc(cc1)Cn2c3c(cccn3)oc2=O  
0103513228 
(2-methoxyphenyl)thiourea COc1ccccc1NC(N)=S  
0103513227 
2-methoxypyridin-3-amine COc1c(cccn1)N  
0103513215 
N-methyl-[1,3]thiazolo[5,4-b]pyridin-2-amine CNc1nc2cccnc2s1  
0103513216 
3,4-dimethylbenzamide Cc1ccc(cc1C)C(=O)N  
0103513217 
methyl(pyridin-3-ylmethyl)amine C[NH2+]Cc1cccnc1  
0103513218 
N-(pyridin-3-ylmethyl)acetamide CC(=O)NCc1cccnc1 0103513219 
1-methyl-1H-imidazole-4-sulfonamide Cn1cc(nc1)S(=O)(=O)N  
0103513220 
4-phenylquinazolin-2-ol c1ccc(cc1)c2c3ccccc3nc(=O)[nH] 
2 
 
0103513221 
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Appendix Figure 3b: Sigma Fragment Library Collection 
 
 
 
CHEMICAL NAME  SMILES BARCODE 
pyridine-2-carboxamide NC(=O)C1=NC=CC=C1 
 
103559462 
[2-(3-chlorophenyl)-1,3-thiazol-4- 
yl]methanol 
 
O=C1COc2cccnc2N1 
 
B00050367 
5-(4-fluorophenyl)-1,2-oxazol-3-amine 
 
Nc1cc(on1)-c1ccc(F)cc1 
 
103559461 
1-[(furan-2-yl)carbonyl]piperazine 
 
O=C(N1CCNCC1)c1ccco1 
 
103559460 
4-phenyl-1,2,4-triazolidine-3,5-dione 
 
O=c1[nH][nH]c(=O)n1-c1ccccc1 
 
103559459 
5-phenyl-1H-pyrazole-4-carboxylic acid 
 
OC(=O)c1cn[nH]c1-c1ccccc1 
 
103559458 
2H,4H-pyrido[3,2-b][1,4]oxazin-3-one 
 
O=C1COc2cccnc2N1 
 
103559457 
isoquinolin-1-ol 
 
C1=CC=C2C(=C1)C=CNC2=O 
 
103559456 
pyrimidine-2,4-diamine 
 
C1=CN=C(N=C1N)N 
 
103559455 
3-phenyl-1H-pyrazole-5-carboxylic acid C1=CC=C(C=C1)C2=NNC(=C2)C 
(=O)O 
 
103559454 
6-chloro-2-N-ethyl-1,3,5-triazine-2,4- 
diamine 
 
CCNc1nc(N)nc(Cl)n1 
 
103559453 
5-chloro-1,3-benzoxazol-2-amine 
 
C1=CC2=C(C=C1Cl)N=C(O2)N 
 
103559452 
4-benzylpiperazin-2-one C1CN(CC(=O)N1)CC2=CC=CC= 
C2 
 
103559451 
5-chloro-2-methyl-1,3-benzoxazole 
 
Cc1nc2cc(Cl)ccc2o1 
 
103559439 
quinolin-2-ol 
 
C1=CC=C2C(=C1)C=CC(=O)N2 
 
103559440 
5,5-dimethyl-1,3-oxazolidine-2,4-dione 
 
CC1(C)OC(=O)NC1=O 
 
103559441 
6-methyl-9H-purine 
 
CC1=C2C(=NC=N1)N=CN2 
 
103559442 
N-methylpyridin-2-amine 
 
CNc1ccccn1 
 
 
103559443 
1H-pyrazolo[3,4-d]pyrimidin-4-ol 
 
C1=C2C(=NC=NC2=O)NN1 
 
103559444 
5-chloro-1H-1,3-benzodiazole 
 
Clc1ccc2[nH]cnc2c1 
 
103559445 
1,3-benzoxazol-2-ol 
 
Oc1nc2ccccc2o1 
 
103559446 
1H-indazole-3-carboxylic acid C1=CC=C2C(=C1)C(=NN2)C(=O) 
O 
 
103559447 
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5-bromopyrimidin-2-ol 
 
C1=CC(=O)NC=C1Br 
 
103559448 
3-phenyl-1,2-oxazol-5-amine Nc1cc(no1)-c1ccccc1 
 
103559449 
phthalazin-1-ol 
 
Oc1nncc2ccccc12 
 
103559450 
1H-pyrazolo[3,4-d]pyrimidin-4-amine 
 
C1=NNC2=C1C(=NC=N2)N 
 
103559438 
6-phenyl-1,3,5-triazine-2,4-diamine C1=CC=C(C=C1)C2=NC(=NC(=N 
2)N)N 
 
103559437 
5-chloropyridin-2-ol 
 
Oc1ccc(Cl)cn1 
 
103559436 
3-chloro-1H-indazole 
 
ClC1=N[NH]C2=C1C=CC=C2 
 
103559435 
N-benzylpyridin-2-amine C1=CC=C(C=C1)CNC2=CC=CC= 
N2 
 
103559434 
quinazolin-4-ol 
 
C1=CC=C2C(=C1)C(=O)N=CN2 
 
103559433 
quinoline-3-carboxylic acid C1=CC=C2C(=C1)C=C(C=N2)C(= 
O)O 
 
103559432 
benzoic acid amine N.OC(=O)c1ccccc1 
 
103559431 
4-methyl-2-phenyl-1H-imidazole 
 
CC1=CN=C(N1)C2=CC=CC=C2 
 
103559430 
3,4-dihydro-2H-1,4-benzoxazin-3-one 
 
C1C(=O)NC2=CC=CC=C2O1 
 
103559429 
quinoxalin-2-ol 
 
C1=CC=C2C(=C1)NC(=O)C=N2 
 
103559428 
1H-1,3-benzodiazole-5-carboxylic acid 
 
[O-]C(=O)c1ccc2[nH]cnc2c1 
 
103559427 
N-ethylpyridine-3-carboxamide 
 
CCNC(=O)C1=CC=CN=C1 
 
103559415 
2-methylquinoline-4-carboxamide CC1=NC2=CC=CC=C2C(=C1)C(= 
O)N 
 
103559416 
N-(2-methyl-1,3-benzoxazol-5-yl)acetamide CC1=NC2=C(O1)C=CC(=C2)NC( 
=O)C 
 
103559417 
N,1-diethyl-2-methyl-1H-1,3-benzodiazole- 
5-sulfonamide 
CCNS(=O)(=O)c1ccc2n(CC)c(C)n 
c2c1 
 
103559418 
5-methyl-3-phenyl-1H-pyrazole-4- 
carboxamide 
CC1=C(C(=NN1)C2=CC=CC=C2) 
C(=O)N 
 
103559419 
1-ethyl-5-methanesulfonyl-2-methyl-1H-1,3- 
benzodiazole 
CCN1C(=NC2=C1C=CC(=C2)S(= 
O)(=O)C)C 
 
103559420 
3-cyclohexyl-1-(pyridin-3-ylmethyl)urea C1CCC(CC1)NC(=O)NCC2=CN= 
CC=C2 
 
103559421 
N-(pyrimidin-2-yl)acetamide 
 
CC(=O)NC1=NC=CC=N1 
 
103559422 
1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5- 
ol 
 
Cc1cc(O)n(n1)-c1ccc(F)cc1 
 
103559423 
5-(4-methylphenyl)-1,2-oxazole 
 
CC1=CC=C(C=C1)C2=CC=NO2 
 
103559424 
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7,8-dimethyl-2,3,4,5-tetrahydro-1H-1,5- 
benzodiazepin-2-one 
 
Cc1cc2NCCC(=O)Nc2cc1C 
 
103559425 
N-(pyridin-2-yl)acetamide 
 
CC(=O)NC1=CC=CC=N1 
 
103559426 
6-aminopyridine-3-sulfonamide 
 
C1=CC(=NC=C1S(=O)(=O)N)N 
 
103514126 
6-bromo-2-methylpyrazolo[1,5-a]pyrimidine 
 
CC1=NN2C=C(C=NC2=C1)Br 
 
103514066 
2-hydroxy-1-propyl-1H-1,3-benzodiazole-5- 
sulfonamide 
CCCn2c(O)nc1cc(S(N)(=O)=O)ccc 
12 
 
103513586 
6-bromo-[1,2,4]triazolo[1,5-a]pyrimidine 
 
C1=C(C=NC2=NC=NN21)Br 
 
103513658 
2-methyl-4-phenyl-1,3-thiazole-5-carboxylic 
acid 
CC1=NC(=C(S1)C(=O)O)C2=CC= 
CC=C2 
 
103513634 
1,2-benzoxazol-3-ylmethanesulfonamide C1=CC=C2C(=C1)C(=NO2)CS(= 
O)(=O)N 
 
103514114 
5-(2-chlorophenyl)-1H-1,2,4-triazole C1=CC=C(C(=C1)C2=NC=NN2)C 
l 
 
103513611 
N-methyl-3,4-dihydro-2H-1,4-benzoxazine- 
2-carboxamide 
 
CNC(=O)C1CNC2=CC=CC=C2O1 
 
103513646 
N-(pyridin-2-ylmethyl)acetamide 
hydrochloride 
 
CC(=O)NCC1=CC=CC=N1.Cl 
 
103514103 
2-(benzyloxy)-6-chloropyrazine C1=CC=C(C=C1)COC2=CN=CC( 
=N2)Cl 
 
103514102 
pyrido[2,3-d]pyrimidin-4-ol C1=CC2=C(NC=NC2=O)N=C1 103514078 
6-fluoro-1,2,3,4-tetrahydroquinolin-2-one FC1=CC2=C(NC(=O)CC2)C=C1 103514150 
2-chloro-5-phenyl-1,3,4-thiadiazole C1=CC=C(C=C1)C2=NN=C(S2)Cl 103512073 
1-(propane-1-sulfonyl)pyrrolidine-2- 
carboxylic acid (note chiral) 
CCCS(=O)(=O)N1CCC[C@H]1C( 
O)=O 
 
103513647 
1-phenyl-1H-pyrazol-3-ol C1=CC=C(C=C1)N2C=CC(=O)N2 103513623 
1-(4-chlorophenyl)-1H-1,2,3,4-tetrazole Clc1ccc(cc1)-n1cnnn1 103512060 
1-benzyl-3-methyl-1H-pyrazol-5-amine CC1=NN(C(=C1)N)CC2=CC=CC 
=C2 
 
103514055 
3,6-dimethyl-1-benzofuran-2-carboxylic acid CC1=CC2=C(C=C1)C(=C(O2)C(= 
O)O)C 
 
103513610 
2-amino-1,3-benzothiazole-6-sulfonamide C1=CC2=C(C=C1S(=O)(=O)N)SC 
(=N2)N 
 
103513622 
5-methyl-7-phenyl-4H,5H,6H,7H- 
[1,2,4]triazolo[1,5-a]pyrimidine 
CC1CC(N2C(=N1)N=CN2)C3=CC 
=CC=C3 
 
103514127 
3-amino-1-6,2-benzothiazole-1,1-dione NC1=N[S](=O)(=O)C2=C1C=CC= 
C2 
 
103514090 
3-ethyl-4-oxo-3,4-dihydrophthalazine-1- 
carboxylic acid 
CCN1C(=O)C2=CC=CC=C2C(=N 
1)C(=O)O 
 
103513575 
3,6-dimethyl-[1,2]oxazolo[5,4-b]pyridine-4- 
carboxylic acid 
 
Cc1noc2nc(C)cc(C(O)=O)c12 
 
103513598 
1,3,6-trimethyl-1H-pyrazolo[3,4-b]pyridine- 
4-carboxylic acid 
CC1=NC2=C(C(=NN2C)C)C(=C1) 
C(=O)O 
 
103514079 
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1-[(4-fluorophenyl)methyl]-1H-pyrazol-4- 
amine 
 
Nc1cnn(Cc2ccc(F)cc2)c1 
 
103513599 
[5-(4-chlorophenyl)-1,2,4-oxadiazol-3- 
yl]methanamine 
C1=CC(=CC=C1C2=NC(=NO2)C 
N)Cl 
 
103514067 
1-(3-phenyl-2H,4H,5H,6H,7H-pyrazolo[4,3- 
c]pyridin-5-yl)propan-1-one 
CCC(=O)N1CCc2n[nH]c(c2C1)- 
c1ccccc1 
 
103514091 
1-[(4-methylphenyl)methyl]-1H-1,2,4- 
triazol-3-amine 
 
Cc1ccc(Cn2cnc(N)n2)cc1 
 
103513587 
2-(piperidin-1-ylmethylidene)- 
1H,2H,3H,4H-thieno[3,2-d]pyrimidin-4-one 
O=C1NC(CN2CCCCC2)NC3=C1S 
C=C3 
 
103514138 
3-methyl-4-phenyl-1,2-oxazol-5-amine  
CC1=NOC(=C1C2=CC=CC=C2)N 
 
50476863 
[2-(3-chlorophenyl)-1,3-thiazol-4- 
yl]methanol 
 
OCc1csc(n1)c1cccc(c1)Cl 
 
B00050367 
 
 
 
Appendix figures 3a and 3b. A tabulated version of the entire 433-Maybridge-Sigma 
fragment  screening  library  used  in  this  study.  Chemical  vendors,  chemical  names, 
SMILES (Simplified Molecular Input Line Entry System – a notation used in organic 
chemistry to depict chemical structures and information) and barcodes have been provided 
for each individual fragment to enable ease of location. 
305 
 
 
Appendix figure 4 – Software/programs used routinely throughout this study 
 
 
 
Software/program Use Reference Websource 
NMRPipe Processing NMR 
spectra 
F. Delaglio et 
al. 1995 
https://spin.niddk.n 
ih.gov/NMRPipe/ 
PDB Visualising protein 
crystal structures 
H.M. Berman 
et al. 2000 
http://www.rcsb.or 
g/pdb/home/home. 
do 
Sedfit Analysis of AUC 
data 
P Schuck et al. 
2000[199, 200] 
http://analyticalultr 
acentrifugation.co 
m/default.htm 
Protparam Calculating protein 
molecular weight, 
protein 
concentrations and 
determination of 
protein pIs 
E Gasteiger et 
al. 2005 
http://web.expasy.o 
rg/protparam/ 
CCPN Analysis of NMR 
spectra 
WF Vranken et 
al. 2005 
http://www.ccpn.ac 
.uk/ 
VNMRJ Guide for use of 
NMR spectrometers 
and experimental 
selection 
- http://openvnmrj.or 
g/ 
CDSSTR Analysis of CD data Sreerama and 
Woody, 2000 
http://dichroweb.cr 
yst.bbk.ac.uk/html/ 
home.shtml 
Biacore Analysis of SPR data - https://www.biacor 
e.com/lifesciences/i 
ndex.html 
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